Quinoline-derived amide modulators of vanilloid VR1 receptor

ABSTRACT

This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to quinoline-derived amides that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional PatentApplication No. 60/444,442, filed Feb. 3, 2003, which is hereby fullyincorporated herein by reference.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0002] The research and development of the invention described below wasnot federally sponsored.

BACKGROUND OF THE INVENTION

[0003] This invention is directed to novel vanilloid receptor VR1ligands. More particularly, this invention relates to novelquinoline-derived amides that are potent antagonists or agonists of VR1and exhibit activity in animal models of hyperalgesia and colitis, andare useful for the treatment and prevention of pain conditions in humansincluding arthritis, and for the treatment of irritable-bowel syndromeand associated conditions.

[0004] Noxious chemical, thermal and mechanical stimuli exciteperipheral nerve endings of small diameter sensory neurons (nociceptors)in sensory ganglia (e. g., dorsal root, nodose and trigeminal ganglia)and initiate signals that are perceived as pain. These neurons arecrucial for the detection of harmful or potentially harmful stimuli(heat) and tissue damage (local tissue acidosis and/or stretch) thatarise from changes in the extracellular space during inflammatory orischaemic conditions (Wall, P. D., and Melzack, R., Textbook of Pain,1994, New York: Churchill Livingstone). Nociceptors transduce noxiousstimuli into membrane depolarization that triggers action potential,conducts the action potential from the sensory sites to the synapses inthe CNS, and conversion of action potentials invokes a perception ofpain, discomfort, and appropriate mechanical/physical protectivereflexes. At the molecular level, nociception is carried out by ionchannels or receptors. Plant derived vanilloid compounds (capsaicin andits ultrapotent analog, resiniferatoxin, etc.) are known to selectivelydepolarize nociceptors and elicit sensations of burning pain—thesensation that is typically obtained by hot chili peppers. Therefore,capsaicin mimics the action of physiological/endogenous stimuli thatactivates the “nociceptive pathway”. Recent advances in pain biologyhave identified receptors for vanilloids, protons (i.e., acidicsolutions), and for heat. Because nociceptors are involved with unwantedpain and inflammatory conditions in human beings and animals, modulationof their nociceptive pathway is important in palliative and othertherapies.

[0005] U.S. Pat. No. 4,786,644 discloses 1-aryl-3-quinoline carboxamidesas analgesics and antiinflammatory agents. This patent, however, doesnot disclose or suggest the compounds, compositions or methods of thepresent invention.

[0006] Thus, there is a need for potent modulators of VR, and inparticular, for novel quinoline-derived amides that exhibit potentbinding affinity for the human and rat VR1 ion channel. There is also aneed for novel quinoline-derived amides that act as potent functionalantagonists and/or agonists of the human and rat VR1 ion channel.Finally, there is a need for novel quinoline-derived amides that bindwith high affinity to VR1 and also act as potent functional antagonistsof the human and rat VR1 ion channel.

SUMMARY OF THE INVENTION

[0007] The present invention is directed to a compound of Formula (I):

[0008] wherein:

[0009] R¹ is a substituent independently selected from the groupconsisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionallysubstituted with one or more substituents independently selected fromthe group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy;C₁₋₈alkanyloxy optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl;C₁₋₈alkanylthio optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy;nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino;C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl;C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl;C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;wherein the heteroatom contained in the quinoline ring of Formula (I) isoptionally substituted with an oxo substituent;

[0010] m is 0, 1 or 2;

[0011] R² is hydrogen or C₁₋₈alkanyl;

[0012] L is a direct bond or C₁₋₄alkyldiyl optionally substituted with asubstituent selected from the group consisting of C₁₋₈alkanyl,C₃₋₈cycloalkanyl and phenyl optionally substituted with one to threesubstituents independently selected from the group consisting ofC₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl,fluorinated alkanyloxy, amino, di(C₁₋₃)alkanylamino, andC₁₋₃alkanylamino;

[0013] R³ is selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl and cyclohexyl;

[0014] R⁴ is independently selected from the group consisting ofC₁₋₁₂alkanyl, C₄₋₈alkanyloxy, C₃₋₈cycloalkanyloxy, C₁₋₈alkanylamino,C₃₋₈cycloalkanylamino, C₃₋₁₄ cyclic heteroalkanyl, C₁₋₆fluorinatedalkanyl, and —N(R⁵)(R⁶); or when n is 2 or 3, optionally two R⁴substituents taken together form a C₃₋₁₄ cyclic heteroalkyl or C₃₋₁₄cyclic alkanyl;

[0015] R⁵ is hydrogen, C₁₋₁₆alkyl, alkanylcarbonyl or arylcarbonyl;

[0016] R₆ is C₄₋₁₆ alkyl, alkanylcarbonyl, C₁₋₃alkyl substituted with asubstituent selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl, and furyl, or arylcarbonyl; or optionally R⁶ andone of R⁴ taken together form a saturated or partially unsaturatedcyclic heteroalkyl or a heteroaryl; or R⁵ and R⁶ optionally takentogether form a bridged or non-bridged cyclic heteroalkanyl, whereinsaid heteroalkanyl is optionally substituted with C₁₋₆alkanylcarbonyl;

[0017] wherein the alkanyls in any of the foregoing alkanyl-containingsubstituents of R⁴, R⁵ or R⁶ are optionally and independentlysubstituted with pyrrolyl, pyridyl, furyl, thienyl, phenyl, furyl,C₁₋₄alkylpyrrolyl, C₁₋₄alkylpyridyl, C₁₋₄alkylthienyl, C₁₋₄alkylphenyl,or C₁₋₄alkylfuryl;

[0018] n is 1, 2 or 3;

[0019] Z is O or S; and

[0020] enantiomers, diastereomers, tautomers, solvates, andpharmaceutically acceptable salts thereof.

[0021] In another embodiment, the present invention is directed to acompound of Formula (I) wherein:

[0022] R¹ is a substituent independently selected from the groupconsisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionallysubstituted with one or more substituents independently selected fromthe group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy;C₁₋₈alkanyloxy optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl;C₁₋₈alkanylthio optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy;nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino;C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl;C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl;C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;wherein the heteroatom contained in the quinoline ring of Formula (I) isoptionally substituted with an oxo substituent;

[0023] m is 0, 1 or 2;

[0024] R² is hydrogen or C₁₋₈alkanyl;

[0025] L is a C₁₋₄alkyldiyl optionally substituted with a substituentselected from the group consisting of C₁₋₈alkanyl, C₃₋₈cycloalkanyl andphenyl optionally substituted with one to three substituentsindependently selected from the group consisting of C₁₋₈alkanyl,halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, fluorinatedalkanyloxy, amino, di(C₁₋₃)alkanylamino, and C₁₋₃alkanylamino;

[0026] R³ is selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl and cyclohexyl;

[0027] R⁴ is independently selected from the group consisting ofC₁₋₁₂alkanyl, C₄₋₈alkanyloxy, C₃₋₈cycloalkanyloxy, C₁₋₈alkanylamino,C₃₋₈cycloalkanylamino, C₃₋₁₄ cyclic heteroalkanyl, C₁₋₆ fluorinatedalkanyl, and —N(R⁵)(R⁶); or when n is 2 or 3, optionally twoR⁴substituents taken together form a C₃₋₁₄ cyclic heteroalkyl or C₃₋₁₄cyclic alkanyl;

[0028] R⁵ is hydrogen, C₁₋₁₆alkyl, alkanylcarbonyl or arylcarbonyl;

[0029] R₆ is C₄₋₁₆ alkyl, alkanylcarbonyl, C₁₋₃alkyl substituted with asubstituent selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl, and furyl, or arylcarbonyl; or optionally R⁶ andone of R⁴ taken together form a saturated or partially unsaturatedcyclic heteroalkyl or a heteroaryl; or R⁵ and R⁶ optionally takentogether form a bridged or non-bridged cyclic heteroalkanyl, whereinsaid heteroalkanyl is optionally substituted with C₁₋₆alkanylcarbonyl;

[0030] wherein the alkanyls in any of the foregoing alkanyl-containingsubstituents of R⁴, R⁵ or R⁶ are optionally and independentlysubstituted with pyrrolyl, pyridyl, furyl, thienyl, phenyl, furyl,C₁₋₄alkylpyrrolyl, C₁₋₄alkylpyridyl, C₁₋₄alkylthienyl, C₁₋₄alkylphenyl,or C₁₋₄alkylfuryl;

[0031] n is 1, 2 or 3;

[0032] Z is O or S; and

[0033] enantiomers, diastereomers, tautomers, solvates, andpharmaceutically acceptable salts thereof.

[0034] In another embodiment, the present invention is directed to acompound of Formula (I) wherein:

[0035] R¹ is a substituent independently selected from the groupconsisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionallysubstituted with one or more substituents independently selected fromthe group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy;C₁₋₈alkanyloxy optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl;C₁₋₈alkanylthio optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy;nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino;C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl;C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl;C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;wherein the heteroatom contained in the quinoline ring of Formula (I) isoptionally substituted with an oxo substituent;

[0036] m is 0, 1 or 2;

[0037] R² is hydrogen or C₁₋₈alkanyl;

[0038] L is a direct bond or C₁₋₄alkyldiyl optionally substituted with asubstituent selected from the group consisting of C₁₋₈alkanyl,C₃₋₈cycloalkanyl and phenyl optionally substituted with one to threesubstituents independently selected from the group consisting ofC₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl,fluorinated alkanyloxy, amino, di(C₁₋₃)alkanylamino, andC₁₋₃alkanylamino;

[0039] R³ is selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl and cyclohexyl;

[0040] R⁴ is independently selected from the group consisting ofC₁₋₁₂alkanyl, C₁₋₈alkanyloxy, C₃₋₈cycloalkanyloxy, C₁₋₈alkanylamino,C₃₋₈cycloalkanylamino, C₃₋₁₄ cyclic heteroalkanyl, C₁₋₆fluorinatedalkanyl and —N(R⁵)(R⁶); or when n is 2 or 3, optionally two R⁴substituents taken together form a C₃₋₁₄ cyclic heteroalkyl or C₃₋₁₄cyclic alkanyl;

[0041] R⁵ is hydrogen, C₁₋₁₆alkyl, alkanylcarbonyl or arylcarbonyl;

[0042] R₆ is C₄₋₁₆ alkyl, alkanylcarbonyl, C₁₋₃alkyl substituted with asubstituent selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl, and furyl, or arylcarbonyl; or optionally R⁶ andone of R⁴ taken together form a saturated or partially unsaturatedcyclic heteroalkyl or a heteroaryl; or R⁵ and R⁶ optionally takentogether form a bridged or non-bridged cyclic heteroalkanyl, whereinsaid heteroalkanyl is optionally substituted with C₁₋₆alkanylcarbonyl;

[0043] wherein the alkanyls in any of the foregoing alkanyl-containingsubstituents of R⁴, R⁵ or R⁶ are optionally and independentlysubstituted with pyrrolyl, pyridyl, furyl, thienyl, phenyl, furyl,C₁₋₄alkylpyrrolyl, C₁₋₄alkylpyridyl, C₁₋₄alkylthienyl, C₁₋₄alkylphenyl,or C₁₋₄alkylfuryl;

[0044] n is 2 or 3;

[0045] Z is O or S; and

[0046] enantiomers, diastereomers, tautomers, solvates, andpharmaceutically acceptable salts thereof.

[0047] In another embodiment, the present invention is directed to acompound of Formula (I) wherein:

[0048] R¹ is a substituent independently selected from the groupconsisting of hydroxy; halogen; C₁₋₈alkanyl optionally substituted withone or more substituents independently selected from the groupconsisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy;C₁₋₈alkanyloxy optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl;C₁₋₈alkanylthio optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy;nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino;C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl;C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl;C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;wherein the heteroatom contained in the quinoline ring of Formula (I) isoptionally substituted with an oxo substituent;

[0049] m is 1 or 2;

[0050] R² is hydrogen or C₁₋₈alkanyl;

[0051] L is a direct bond or C₁₋₄alkyldiyl optionally substituted with asubstituent selected from the group consisting of C₁₋₈alkanyl,C₃₋₈cycloalkanyl and phenyl optionally substituted with one to threesubstituents independently selected from the group consisting ofC₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl,fluorinated alkanyloxy, amino, di(C₁₋₃)alkanylamino, andC₁₋₃alkanylamino;

[0052] R³ is selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl and cyclohexyl;

[0053] R⁴ is independently selected from the group consisting ofC₁₋₈alkanyl, C₁₋₈alkanyloxy, C₃₋₈cycloalkanyloxy, C₁₋₈alkanylamino,C₃₋₈cycloalkanylamino, C₃₋₁₄ cyclic heteroalkanyl, C₁₋₆ fluorinatedalkyl, and —N(R⁵)(R⁶); or when n is 2 or 3, optionally two R⁴substituents taken together form a C₃₋₁₄ cyclic heteroalkyl or C₃₋₁₄cyclic alkanyl;

[0054] R⁵ is hydrogen, C₁₋₁₆alkyl, alkanylcarbonyl or arylcarbonyl;

[0055] R₆ is C₄₋₁₆ alkyl, alkanylcarbonyl, C₁₋₃alkyl substituted with asubstituent selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl, and furyl, or arylcarbonyl; or optionally R⁶ andone of R⁴ taken together form a saturated or partially unsaturatedcyclic heteroalkyl or a heteroaryl; or R⁵ and R⁶ optionally takentogether form a bridged or non-bridged cyclic heteroalkanyl, whereinsaid heteroalkanyl is optionally substituted with C₁₋₆alkanylcarbonyl;

[0056] wherein the alkanyls in any of the foregoing alkanyl-containingsubstituents of R⁴, R⁵ or R⁶ are optionally and independentlysubstituted with pyrrolyl, pyridyl, furyl, thienyl, phenyl, furyl,C₁₋₄alkylpyrrolyl, C₁₋₄alkylpyridyl, C₁₋₄alkylthienyl, C₁₋₄alkylphenyl,or C₁₋₄alkylfuryl;

[0057] n is 1, 2 or 3;

[0058] Z is O or S; and

[0059] enantiomers, diastereomers, tautomers, solvates, andpharmaceutically acceptable salts thereof.

[0060] In another embodiment, the present invention is directed to acompound of Formula (I) wherein:

[0061] R¹ is a substituent independently selected from the groupconsisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionallysubstituted with one or more substituents independently selected fromthe group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy;C₁₋₈alkanyloxy optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl;C₁₋₈alkanylthio optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy;nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino;C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl;C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl;C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;wherein the heteroatom contained in the quinoline ring of Formula (I) isoptionally substituted with an oxo substituent;

[0062] m is 0, 1 or 2;

[0063] R² is hydrogen or C₁₋₈alkanyl;

[0064] L is ethen-1,2-diyl;

[0065] R³ is selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl and cyclohexyl;

[0066] R⁴ is independently selected from the group consisting ofC₁₋₁₂alkanyl, C₄₋₈alkanyloxy, C₃₋₈cycloalkanyloxy, C₁₋₈alkanylamino,C₃₋₈cycloalkanylamino, C₃₋₁₄ cyclic heteroalkanyl, C₁₋₆fluorinatedalkanyl, halogen, and —N(R⁵)(R⁶); or when n is 2 or 3, optionally two R⁴substituents taken together form a C₃₋₁₄ cyclic heteroalkyl or C₃₋₁₄cyclic alkanyl;

[0067] R⁵ is hydrogen, C₁₋₁₆alkyl, alkanylcarbonyl or arylcarbonyl;

[0068] R₆ is C₄₋₁₆ alkyl, alkanylcarbonyl, C₁₋₃alkyl substituted with asubstituent selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl, and furyl, or arylcarbonyl; or optionally R⁶ andone of R⁴ taken together form a saturated or partially unsaturatedcyclic heteroalkyl or a heteroaryl; or R⁵ and R⁶ optionally takentogether form a bridged or non-bridged cyclic heteroalkanyl, whereinsaid heteroalkanyl is optionally substituted with C₁₋₆alkanylcarbonyl;

[0069] wherein the alkanyls in any of the foregoing alkanyl-containingsubstituents of R⁴, R⁵ or R⁶ are optionally and independentlysubstituted with pyrrolyl, pyridyl, furyl, thienyl, phenyl, furyl,C₁₋₄alkylpyrrolyl, C₁₋₄alkylpyridyl, C₁₋₄alkylthienyl, C₁₋₄alkylphenyl,or C₁₋₄alkylfuryl;

[0070] n is 1, 2 or 3;

[0071] Z is O or S; and

[0072] enantiomers, diastereomers, tautomers, solvates, andpharmaceutically acceptable salts thereof.

[0073] The present invention is also directed to a compound of Formula(I) wherein:

[0074] R¹ is a substituent independently selected from the groupconsisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionallysubstituted with one or more substituents independently selected fromthe group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy;C₁₋₈alkanyloxy optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl;C₁₋₈alkanylthio optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy;nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino;C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl;C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl;C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;wherein the heteroatom contained in the quinoline ring of Formula (I) isoptionally substituted with an oxo substituent;

[0075] m is 0, 1 or 2;

[0076] R² is hydrogen or C₁₋₈alkanyl;

[0077] L is a direct bond;

[0078] R³ is selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, and cyclohexyl;

[0079] R⁴ is selected from the group consisting of C₁₋₁₂alkanyl,C₄₋₈alkanyloxy, C₃₋₈cycloalkanyloxy, C₁₋₈alkanylamino,C₃₋₈cycloalkanylamino, C₃₋₁₄ cyclic heteroalkanyl, C₁₋₆fluorinatedalkanyl and —N(R⁵)(R⁶), wherein the alkanyls in any of the foregoingalkanyl-containing substituents of R⁴ is optionally substituted withthienyl or phenyl; or when n is 2 or 3, optionally two R⁴ substituentstaken together form a C₃₋₁₄ cyclic heteroalkyl or C₃₋₁₄ cyclic alkanyl;

[0080] R⁵ is hydrogen, C₁₋₁₆alkyl, alkanylcarbonyl or arylcarbonyl;

[0081] R₆ is C₄₋₁₆ alkyl, alkanylcarbonyl, C₁₋₃alkyl substituted with asubstituent selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl, and furyl, or arylcarbonyl; or optionally R⁶ andone of R⁴ taken together form a saturated or partially unsaturatedcyclic heteroalkyl or a heteroaryl; or R⁵ and R⁶ optionally takentogether form a bridged or non-bridged cyclic heteroalkanyl, whereinsaid heteroalkanyl is optionally substituted with C₁₋₆alkanylcarbonyl;

[0082] wherein the alkanyls in any of the foregoing alkanyl-containingsubstituents of R⁴, R⁵ or R⁶ are optionally and independentlysubstituted with pyrrolyl, pyridyl, furyl, thienyl, phenyl, furyl,C₁₋₄alkylpyrrolyl, C₁₋₄alkylpyridyl, C₁₋₄alkylthienyl, C₁₋₄alkylphenyl,or C₁₋₄alkylfuryl;

[0083] n is 1, 2 or 3;

[0084] Z is O or S; and

[0085] enantiomers, diastereomers, tautomers, solvates, andpharmaceutically acceptable salts thereof.

[0086] Finally, the present invention is directed to pharamceuticalcompositions containing compounds of Formula (I), as well as to methodsof treatment of diseases and conditions by administration of thesecompositions, and also to pharmaceutical kits containing them.

BRIEF DESCRIPTION OF THE DRAWINGS

[0087]FIG. 1. Effect of a compound of the invention on Colon WeightLoss. Data presented are mean % inhibition±s.e. of colon weight lossfrom 3 experiments following twice daily oral administration of thecompound at the doses indicated.

[0088]FIG. 2. Effect of a compound of the invention on Colon Length.Data presented are mean % inhibition±s.e. of colon shrinkage from 3experiments following twice daily oral administration of the compound atthe doses indicated

[0089]FIG. 3. Effect of a compound of the invention on Colon DamageScore. Data presented are mean % inhibition±s.e. of macroscopic colondamage scores from 3 experiments following twice daily oraladministration of the compound at the doses indicated.

[0090]FIG. 4. Effect of a compound of the invention on Stool Score. Datapresented are mean % inhibition±s.e. of stool scores from 3 experimentsfollowing twice daily oral administration of the compound at the dosesindicated.

[0091]FIG. 5. Effect of a compound of the invention on Total Score. Datapresented are mean % inhibition±s.e. of total scores from 3 experimentsfollowing twice daily oral administration of the compound at the dosesindicated.

[0092]FIG. 6. Effect of a compound of the invention on MPO. Datapresented are mean % inhibition±s.e. of MPO accumulation from 3experiments following twice daily oral administration of the compound atthe doses indicated.

[0093]FIG. 7. Effect of a compound of the invention on guinea pigbronchial ring constriction.

DETAILED DESCRIPTION OF THE INVENTION

[0094] As used herein, the following underlined terms are intended tohave the following meanings:

[0095] “C_(a-b)” (where a and b are integers) refers to a radicalcontaining from a to b carbon atoms inclusive. For example, C₁₋₃ denotesa radical containing 1, 2 or 3 carbon atoms.

[0096] “Fluorinated alkyl” refers to a saturated branched or straightchain hydrocarbon radical derived by removal of 1 hydrogen atom from theparent alkane; the parent alkane contains from 1 to 6 carbon atoms with1 or more hydrogen atoms substituted with fluorine atoms up to andincluding substitution of all hydrogen atoms with fluorine. Preferredfluorinated alkyls include trifluoromethyl substituted alkyls andperfluorinated alkyls; more preferred fluorinated alkyls includetrifluoromethyl, perfluoroethyl, 2,2,2-trifluoroethyl, perfluoropropyl,3,3,3-trifluoroprop-1-yl, 3,3,3-trifluoroprop-2-yl,1,1,1,3,3,3-hexafluoroprop-2-yl; a particularly preferred fluorinatedalkyl, is trifluoromethyl.

[0097] “Fluorinated alkanyloxy” refers to a radical derived from afluorinated alkyl, radical attached to an oxygen atom with the oxygenatom having one open valence for attachment to a parent structure.

[0098] “Alkyl:” refers to a saturated or unsaturated, branched,straight-chain or cyclic monovalent hydrocarbon radical derived by theremoval of one hydrogen atom from a single carbon atom of a parentalkane, alkene or alkyne. Typical alkyl groups include, but are notlimited to, methyl; ethyls such as ethanyl, ethenyl, ethynyl; propylssuch as propan-1-yl, propan-2-yl, cyclopropan-1-yl, prop-1-en-1-yl,prop-1-en-2-yl, prop-2-en-1-yl, cycloprop-1-en-1-yl;cycloprop-2-en-1-yl, prop-1-yn-1-yl, prop-2-yn-1-yl, etc.; butyls suchas butan-1-yl, butan-2-yl, 2-methyl-propan-1-yl, 2- methyl-propan-2-yl,cyclobutan-1-yl, but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl,but-2-en-1-yl, but-2-en-2-yl, buta-1,3dien-1-yl, buta-1,3-dien-2- yl,cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1,3-dien-1-yl,but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, etc.; and the like. Wherespecific levels of saturation are intended, the nomenclature “alkanyl”,“alkenyl” and/or “alkynyl” is used, as defined below. In preferredembodiments, the alkyl groups are (C₁₋₈) alkyl, with (C₁₋₃) beingparticularly preferred.]

[0099] “Alkanyl:” refers to a saturated branched, straight-chain orcyclic monovalent hydrocarbon radical derived by the removal of onehydrogen atom from a single carbon atom of a parent alkane. Typicalalkanyl groups include, but are not limited to, methanyl; ethanyl;propanyls such as propan-1-yl, propan-2-yl, cyclopropan-1-yl, etc.;butyanyls such as butan-1-yl, butan-2-yl, 2methyl-propan-1-yl,2-methyl-propan-2-yl, cyclobutan-1-yl, etc.; and the like. In preferredembodiments, the alkanyl groups are (C₁₋₈) alkanyl, with (C₁₋₃) beingparticularly preferred.

[0100] “Alkenyl:” refers to an unsaturated branched, straight-chain orcyclic monovalent hydrocarbon radical having at least one carbon-carbondouble bond derived by the removal of one hydrogen atom from a singlecarbon atom of a parent-alkene. The radical may be in either the cis ortrans conformation about the double bond(s). Typical alkenyl groupsinclude, but are not limited to, ethenyl; propenyls such asprop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl, prop-2-en-2-yl,cycloprop-1-en-1-yl; cycloprop-2-en-1-yl; butenyls such asbut-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl,but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl,cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1,3-dien-1-yl, etc.;and the like. In preferred embodiments, the alkenyl group is (C₂₋₈)alkenyl, with (C₂₋₃) being particularly preferred.

[0101] “Alkynyl:” refers to an unsaturated branched, straight-chain orcyclic monovalent hydrocarbon radical having at least one carbon-carbontriple bond derived by the removal of one hydrogen atom from a singlecarbon atom of a parent alkyne. Typical alkynyl groups include, but arenot limited to, ethynyl; propynyls such as prop-1-yn-1-yl,prop-2-yn-1-yl, etc.; butynyls such as but-1-yn-1-yl, but-1-yn-3-yl,but-3-yn-1-yl, etc.; and the like. In preferred embodiments, the alkynylgroup is (C₂₋₈) alkynyl, with (C₂₋₃) being particularly preferred.

[0102] “Alkyldiyl:” refers to a saturated or unsaturated, branched,straight-chain or cyclic divalent hydrocarbon radical derived by theremoval of one hydrogen atom from each of two different carbon atoms ofa parent alkane, alkene or alkyne, or by the removal of two hydrogenatoms from a single carbon atom of a parent alkane, alkene or alkyne.The two monovalent radical centers can form bonds with the same ordifferent atoms. Typical alkyldiyls include, but are not limited tomethandiyl; ethyldiyls such as ethan-1,1-diyl, ethan-1,2-diyl,ethen-1,1-diyl, ethen-1,2-diyl; propyldiyls such as propan-1,1-diyl,propan-1,2diyl, propan-2,2-diyl, propan-1,3-diyl, cyclopropan-1,1-diyl,cyclopropan-1,2diyl, prop-1-en-1,1-diyl, prop-1-en-1,2-diyl,prop-2-en-1,2-diyl, prop-1-en-1,3diyl, cycloprop-1-en-1,2-diyl,cycloprop-2-en-1,2-diyl, cycloprop-2-en-1,1-diyl, prop-1-yn-1,3-diyl,etc.; butyldiyls such as, butan-1,1-diyl, butan-1,2-diyl,butan-1,3-diyl, butan-1,4-diyl, butan-2,2-diyl,2-methyl-propan-1,1-diyl, 2-methyl-propan-1,2-diyl, cyclobutan-1,1-diyl;cyclobutan-1,2-diyl, cyclobutan-1,3-diyl, but-1-en-1,1-diyl;but-1-en-1,2-diyl, but-1-en-1,3-diyl, but-1-en-1,4-diyl,2-methyl-prop-1-en-1,1-diyl, 2-methylprop-2-en-1,1-diyl,buta-1,3-dien-1,1-diyl, buta-1,3-dien-1,2-diyl, buta-1,3-dien-1,3-diyl,buta-1,3-dien-1,4-diyl, cyclobut-1en-1 ,2-diyl, cyclobut-1-en-1,3-diyl,cyclobut-2-en-1,2-diyl, cyclobuta-1,3-dien-1,2-diyl,cyclobuta-1,3-dien-1,3-diyl, but-1-yn-1,3-diyl, but-1-yn-1,4-diyl,buta-1,3-diyn-1,4-diyl, etc.; and the like. Where specific levels ofsaturation are intended, the nomenclature alkandiyl, alkendiyl and/oralkyndiyl is used. In preferred embodiments, the alkyldiyl group is(C₁₋₈) alkyldiyl, with (C₁₋₈) being particularly preferred. Alsopreferred are saturated acyclic alkandiyl radicals in which the radicalcenters are at the terminal carbons, e.g., methandiyl; ethan-1,2-diyl;propan-1,3-diyl; butan-1,4-diyl; and the like (also referred to asalkylenos, as defined infra).

[0103] “Vic Alkyldiyl:” refers to a saturated or unsaturated, branched,straight-chain or cyclic hydrocarbon radical having two adjacentmonovalent radical centers derived by the removal of one hydrogen atomfrom each of two adjacent carbon atoms of a parent alkane, alkene oralkyne. The two monovalent radical centers can form bonds with the sameor different atom(s). Typical vic alkyldiyls include, but are notlimited to vic ethyldiyls such as ethan-1,2-diyl, ethen-1,2-diyl; vicpropyldiyls such as propan-1,2-diyl, cyclopropan-1,2-diyl,prop-1-en-1,2-diyl, prop-2-en-1,2-diyl, cycloprop-1-en-1,2-diyl, etc.;vic butyldiyls such as butan-1,2-diyl, 2-methyl-propan-1,2-diyl,cyclobutan-1,2-diyl, but-1-en-1,2-diyl, cyclobut-1-en-1,2-diyl,buta-1,3-dien-1,2-diyl, cyclobuta-1,3-dien-1,2-diyl, but-3-yn-1,2-diyl,etc.; and the like. Where specific levels of saturation are intended,the nomenclature vic alkandiyl, vic alkendiyl and/or vic alkyndiyl isused. In preferred embodiments, the vic alkyldiyl group is (C₂₋₈) vicalkyldiyl, with (C₂₋₃) being particularly preferred.

[0104] “Gem Alkyldiyl:” refers to a saturated or unsaturated, branched,straight-chain or cyclic hydrocarbon radical having one divalent radicalcenter derived by the removal of two hydrogen atoms from a single carbonatom of a parent alkane, alkene or alkyne. The divalent radical centerforms bonds with two different atoms. Typical gem alkyldiyls include,but are not limited to gem methanyldiyl; gem ethyldiyls such asethan-1,1-diyl,ethen-1,1-diyl; gem propyldiyls such as propan-1,1-diyl,propan-2,2-diyl, cyclopropan-1,1-diyl, prop-1-en-1,1-diyl,cycloprop-2-en-1,1-diyl, prop-2-yn-1,1-diyl, etc.; butyldiyls such asbutan-1,1-diyl, butan-2,2-diyl, 2-methyl-propan-1,2-diyl,cyclobutan-1,1-diyl, but-1-en-1,1-diyl, 2-methyl-prop-1-en-1,1-diyl,2-methyl-prop-2-en-1,1-diyl, cyclobut-2-en-1,1-diyl,buta-1,3-dien-1,1-diyl, etc.; and the like. Where specific levels ofsaturation are intended, the nomenclature gem alkandiyl, gem alkendiyland/or gem alkyndiyl is used. In preferred embodiments, the gemalkyldiyl group is (C₁₋₆) gem alkyldiyl, with (C₁₋₃) being particularlypreferred.

[0105] “Alkyleno:” refers to a saturated or unsaturated, straight-chainor branched acyclic bivalent hydrocarbon bridge radical derived by theremoval of one hydrogen atom from each of the two terminal carbon atomsof an acyclic parent alkane, alkene or alkyne. Typical alkyleno groupsinclude, but are not limited to, methano; ethylenos such as ethano,etheno, ethyno; propylenos such as propano, propeno, prop-1,2-dieno,propyno, etc.; butylenos such as butano, 2-methyl-propano, but-1-eno,but-2-eno, 2-methyl-prop-1-eno, 2-methanylidene-propano, but-1,3-dieno,but-1-yno, but-2-yno, but-1,3-diyno, etc.; and the like. Where specificlevels of saturation are intended, the nomenclature alkano, alkenoand/or alkyno is used. In preferred embodiments, the alkyleno group is(C₁₋₈) alkyleno, with (C₁₋₃) being particularly preferred. Alsopreferred are straight-chain saturated alkano radicals, e.g., methano,ethano, propano, butano, and the like.

[0106] “Alkylidene:” refers to a saturated or unsaturated, branched,straight-chain or cyclic divalent hydrocarbon radical derived by removalof two hydrogen atoms from the same carbon atom of a parent alkane,alkene or alkyne. The divalent radical center forms a double bond with asingle atom. Typical alkylidene radicals include, but are not limitedto, methanylidene, ethylidenes such as ethanylidene, ethenylidene;propylidenes such as propan-1-ylidene, propan-2-ylidene,cyclopropan-1-ylidene, prop-1-en-1-ylidene, prop-2-en-1-ylidene,cycloprop-2-en-1-ylidene, etc.; butylidenes such as butan-1-ylidene,butan-2-ylidene, 2-methyl-propan-1-ylidene, cyclobutan-1-ylidene,but-1-en-1-ylidene, but-2-en-1-ylidene, but-3-en-1-ylidene,buta-1,3-dien-1-ylidene; cyclobut-2-en-1-ylidene, etc.; and the like.Where specific levels of saturation are intended, the nomenclaturealkanylidene, alkenylidene and/or alkynylidene is used. In preferredembodiments, the alkylidene group is (C₁₋₈) alkylidene, with (C₁₋₃)being particularly preferred. Also preferred are acyclic saturatedalkanylidene radicals in which the divalent radical is at a terminalcarbon, e.g., methanylidene, ethan-1-ylidene, propan-1-ylidene,butan-1-ylidene, 2-methyl-propan-1-ylidene, and the like.

[0107] “Alkylidyne:” refers to a saturated or unsaturated, branched orstraight-chain trivalent hydrocarbon radical derived by removal of threehydrogen atoms from the same carbon atom of a parent alkane, alkene oralkyne. The trivalent radical center forms a triple bond with a singleatom. Typical alkylidyne radicals include, but are not limited to,methanylidyne; ethanylidyne; propylidynes such as propan-1-ylidyne,prop-2-en-1-ylidyne, prop-2-yn-1-ylidyne; butylidynes such asbutan-1-ylidyne, 2-methyl-propan-1-ylidyne, but-2-en-1-ylidyne,but-3-en-1-ylidyne, buta-2,3-dien-1-ylidyne, but-2-yn-1-ylidyne,but-3-yn-1-ylidyne, etc.; and the like. Where specific levels ofsaturation are intended, the nomenclature alkanylidyne, alkenylidyneand/or alkynylidyne is used. In preferred embodiments, the alkylidynegroup is (C₁₋₈) alkylidyne, with (C₁₋₃) being particularly preferred.Also preferred are saturated alkanylidyne radicals, e.g., methanylidyne,ethanylidyne, propan-1-ylidyne, butan-1-ylidyne,2-methyl-propan-1-ylidyne, and the like.

[0108] “Heteroalkyl, Heteroalkanyl, Heteroalkenyl, Heteroalkynyl,Heteroalkylidene, Heteroalkylidyne, Heteroalkyldiyl, Vic Heteralkyldiyl,Gem Heteroalkyldiyl, Heteroalkyleno and Heteroalkyldiylidene:” refer toalkyl, alkanyl, alkenyl, alkynyl, alkylidene, alkylidyne, alkyldiyl, vicalkyldiyl, gem alkyldiyl, alkyleno and alkyldiylidene radicals,respectively, in which one or more carbon atoms (and any necessaryassociated hydrogen atoms) are independently replaced with the same ordifferent heteroatoms (including any necessary hydrogen or other atoms).Typical heteroatoms to replace the carbon atom(s) include, but are notlimited to, N, P, O, S, Si, etc. Preferred heteroatoms are O, N and S.Thus, heteroalkyl, heteroalkanyl, heteroalkenyl, heteroalkynyl,heteroalkylidene, heteroalkylidyne, heteroalkyldiyl, vicheteroalkyldiyl, gem heteroalkyldiyl, heteroalkyleno andheteroalkyldiylidene radicals can contain one or more of the same ordifferent heteroatomic groups, including, by way of example and notlimitation, epoxy (—O—), epidioxy (—O—O—), thioether (—S—), epidithio(—SS—), epoxythio (—O—S—), epoxylmino (—O—NR′—), imino (—NR′—), biimmino(—NR′—NR′—), azino (═N—N═), azo (—N═N—), azoxy (—N—O—N—), azimino(—NR′—N═N—), phosphano (—PH—), λ⁴-sulfano (—SH₂—), sulfonyl (—S(O)₂—),and the like, where each R′ is independently hydrogen or (C₁-C₆) alkyl.

[0109] “Parent Aromatic Ring System:” refers to an unsaturated cyclic orpolycyclic ring system having a conjugated π electron system.Specifically included within the definition of “parent aromatic ringsystem” are fused ring systems in which one or more rings are aromaticand one or more rings are saturated or unsaturated, such as, forexample, indane, indene, phenalene, etc. Typical parent aromatic ringsystems include, but are not limited to, aceanthrylene, acenaphthylene,acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene,fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene,s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene,ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene,phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene,rubicene, triphenylene, trinaphthalene, and the like

[0110] “Aryl:” refers to a monovalent aromatic hydrocarbon radicalderived by the removal of one hydrogen atom from a single carbon atom ofa parent aromatic ring system. Typical aryl groups include, but are notlimited to, radicals derived from aceanthrylene, acenaphthylene,acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene,fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene,s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene,ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene,phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene,rubicene, triphenylene, trinaphthalene, and the like. In preferredembodiments, the aryl group is (C₅-₂₀) aryl, with (C₅₋₁₀) beingparticularly preferred. Particularly preferred aryl groups are phenyland naphthyl groups.

[0111] “Arylalkyl:” refers to an acyclic alkyl group in which one of thehydrogen atoms bonded to a carbon atom, typically a terminal carbonatom, is replaced with an aryl radical. Typical arylalkyl groupsinclude, but are not limited to, benzyl, 2-phenylethan-1-yl,2-phenylethen-1-yl, naphthylmethyl, 2naphthylethan-1-yl,2-naphthylethen-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl and thelike. Where specific alkyl moieties are intended, the nomenclaturearylalkanyl, arylakenyl and/or arylalkynyl is used. [In preferredembodiments, the arylalkyl group is (C₆-₂₆) arylalkyl, e.g., thealkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C₆₋₂₆) andthe aryl moiety is (C₅-₂₀). In particularly preferred embodiments thearylalkyl group is (C₆-₁₃), e.g., the alkanyl, alkenyl or alkynyl moietyof the arylalkyl group is (C₁₋₃) and the aryl moiety is (C₅₋₁₀). Evenmore preferred arylalkyl groups are phenylalkanyls.

[0112] “Alkanyloxy:” refers to a saturated branched, straight-chain orcyclic monovalent hydrocarbon alcohol radical derived by the removal ofthe hydrogen atom from the hydroxide oxygen of the alcohol. Typicalalkanyloxy groups include, but are not limited to, methanyl; ethanyloxy;propanyloxy groups such as propan-1-yloxy (CH₃CH₂CH₂O—), propan-2-yloxy((CH₃)₂CHO—), cyclopropan-1-yloxy, etc.; butyanyloxy groups such asbutan-1-yloxy, butan-2-yloxy, 2-methyl-propan-1-yloxy,2-methyl-propan-2-yloxy, cyclobutan-1-yloxy, etc.; and the like. Inpreferred embodiments, the alkanyloxy groups are (C₁₋₈) alkanyloxygroups, with (C₁₋₃) being particularly preferred.

[0113] “Parent Heteroaromatic Ring System:” refers to a parent aromaticring system in which one or more carbon atoms are each independentlyreplaced with a heteroatom. Typical heteratoms to replace the carbonatoms include, but are not limited to, N, P, O, S, Si etc. Specificallyincluded within the definition of “parent heteroaromatic ring systems”are fused ring systems in which one or more rings are aromatic and oneor more rings are saturated or unsaturated, such as, for example,arsindole, chromane, chromene, indole, indoline, xanthene, etc. Typicalparent heteroaromatic ring systems include, but are not limited to,arsindole, carbazole, β-carboline, chromane, chromene, cinnoline, furan,imidazole, indazole, indole, indoline, indolizine, isobenzofuran,isochromene, isoindole, isoindoline, isoquinoline, isothiazole,isoxazole, naphthyridine, oxadiazole, oxazole, perimidine,phenanthridine, phenanthroline, phenazine, phthalazine, pteridine,purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine,pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline,tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and thelike.

[0114] “Heteroaryl:” refers to a monovalent heteroaromatic radicalderived by the removal of one hydrogen atom from a single atom of aparent heteroaromatic ring system. Typical heteroaryl groups include,but are not limited to, radicals derived from acridine, arsindole,carbazole, β-carboline, chromane, chromene, cinnoline, furan, imidazole,indazole, indole, indoline, indolizine, isobenzofuran, isochromene,isoindole, isoindoline, isoquinoline, isothiazole, isoxazole,naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine,phenanthroline, phenazine, phthalazine, pteridine, purine, pyran,pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole,pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline,tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and thelike. In preferred embodiments, the heteroaryl group is a 5-20 memberedheteroaryl, with 5-10 membered heteroaryl being particularly preferred.Specific preferred heteroaryls for the present invention are quinoline,isoquinoline, pyridine, pyrimidine, furan, thiophene and imidazole.

[0115] “Substituted:” refers to a radical in which one or more hydrogenatoms are each independently replaced with the same or differentsubstituent(s). Typical substituents include, but are not limited to,—X, —R, —O⁻, ═O, —OR, —O—OR, —SR, —S⁻, ═S, —NRR, ═NR, —CX₃, —CN, —OCN,—SCN, —NCO, —NCS, —NO, —NO₂, ═N₂, —N₃, —NHOH, —S(O)₂O⁻, —S(O)₂OH,—S(O)₂R, —P(O)(O⁻)₂, —P(O)(OH)₂, —C(O)R, —C(O)X, —C(S)R, —C(S)X,—C(O)OR, —C(O)O⁻, —C(S)OR, —C(O)SR, —C(S)SR, —C(O)NRR, —C(S)NRR and—C(NR)NRR, where each X is independently a halogen (preferably —F, —Clor —Br) and each R is independently —H, alkyl, alkanyl, alkenyl,alkynyl, alkylidene, alkylidyne, aryl, arylalkyl, arylheteroalkyl,heteroaryl, heteroarylalkyl or heteroaryl-heteroalkyl, as definedherein. Preferred substituents include hydroxy, halogen, C₁₋₈alkyl,C₁₋₈alkanyloxy, fluorinated alkanyloxy, fluorinated alkyl,C₁₋₈alkylthio, C₃₋₈cycloalkyl, C₃₋₈cycloalkanyloxy, nitro, amino,C₁₋₈alkylamino, C₁₋₈dialkylamino, C₃₋₈cycloalkylamino, cyano, carboxy,C₁₋₇alkanyloxycarbonyl, C₁₋₇alkylcarbonyloxy, formyl, carbamoyl, phenyl,aroyl, carbamoyl, amidino, (C₁₋₈alkylamino)carbonyl, (arylamino)carbonyland aryl(C₁₋₈alkyl)carbonyl.

[0116] “Aroyl” refers to arylacyl substituents.

[0117] “Acyl” refers to alkylcarbonyl substituents.

[0118] With reference to substituents, the term “independently” meansthat when more than one of such substituent is possible, suchsubstituents may be the same or different from each other.

[0119] Throughout this disclosure, the terminal portion of thedesignated side chain is described first, followed by the adjacentfunctionality toward the point of attachment. Thus, for example, a“phenylC₁₋₆alkanylaminocarbonylC₁₋₆alkyl” substituent refers to a groupof the formula

[0120] The present invention is directed to a compound of Formula (I):

[0121] wherein:

[0122] R¹ is a substituent independently selected from the groupconsisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionallysubstituted with one or more substituents independently selected fromthe group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy;C₁₋₈alkanyloxy optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl;C₁₋₈alkanylthio optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy;nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino;C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl;C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl;C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;wherein the heteroatom contained in the quinoline ring of Formula (I) isoptionally substituted with an oxo substituent;

[0123] m is 0, 1 or 2;

[0124] R² is hydrogen or C₁₋₈alkanyl;

[0125] L is a direct bond or C₁₋₄alkyldiyl optionally substituted with asubstituent selected from the group consisting of C₁₋₈alkanyl,C₃₋₈cycloalkanyl and phenyl optionally substituted with one to threesubstituents independently selected from the group consisting ofC₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl,fluorinated alkanyloxy, amino, di(C₁₋₃)alkanylamino, andC₁₋₃alkanylamino;

[0126] R³ is selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl and cyclohexyl;

[0127] R⁴ is independently selected from the group consisting ofC₄₋₈alkanyloxy, C₃₋₈cycloalkanyloxy, C₁₋₈alkanylamino,C₃₋₈cycloalkanylamino, C₃₋₁₄ cyclic heteroalkanyl and —N(R⁵)(R⁶); orwhen n is 2 or 3, optionally two R⁴ substituents taken together form aC₃₋₁₄ cyclic heteroalkyl or C₃₋₁₄ cyclic alkanyl;

[0128] R⁵ is hydrogen, C₁₋₁₆alkyl, alkanylcarbonyl or arylcarbonyl;

[0129] R₆ is C₄₋₁₆ alkyl, alkanylcarbonyl, C₁₋₃alkyl substituted with asubstituent selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl, and furyl, or arylcarbonyl; or optionally R⁶ andone of R⁴ taken together form a saturated or partially unsaturatedcyclic heteroalkyl or a heteroaryl; or optionally R⁵ and R⁶ takentogether form a bridged or non-bridged cyclic heteroalkanyl, whereinsaid heteroalkanyl is optionally substituted with C₁₋₆alkanylcarbonyl;

[0130] wherein the alkanyls in any of the foregoing alkanyl-containingsubstituents of R⁴, R⁵ or R⁶ are optionally and independentlysubstituted with pyrrolyl, pyridyl, furyl, thienyl, phenyl, furyl,C₁₋₄alkylpyrrolyl, C₁₋₄alkylpyridyl, C₁₋₄alkylthienyl, C₁₋₄alkylphenyl,or C₁₋₄alkylfuryl;

[0131] n is 1, 2 or 3;

[0132] Z is O or S; and

[0133] enantiomers, diastereomers, tautomers, solvates, andpharmaceutically acceptable salts thereof.

[0134] In another embodiment, the present invention is directed to acompound of Formula (I) wherein:

[0135] R¹ is a substituent independently selected from the groupconsisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionallysubstituted with one or more substituents independently selected fromthe group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy;C₁₋₈alkanyloxy optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl;C₁₋₈alkanylthio optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy;nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino;C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl;C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl;C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;wherein the heteroatom contained in the quinoline ring of Formula (I) isoptionally substituted with an oxo substituent;

[0136] m is 0, 1 or 2;

[0137] R² is hydrogen or C₁₋₈alkanyl;

[0138] L is a C₁₋₄alkyldiyl optionally substituted with a substituentselected from the group consisting of C₁₋₈alkanyl, C₃₋₈cycloalkanyl andphenyl optionally substituted with one to three substituentsindependently selected from the group consisting of C₁₋₈alkanyl,halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl, fluorinatedalkanyloxy, amino, di(C₁₋₃)alkanylamino, and C₁₋₃alkanylamino;

[0139] R³ is selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl and cyclohexyl;

[0140] R⁴ is independently selected from the group consisting ofC₁₋₈alkanyl, C₄₋₈alkanyloxy, C₃₋₈cycloalkanyloxy, C₁₋₈alkanylamino,C₃₋₈cycloalkanylamino, C₃₋₁₄ cyclic heteroalkanyl and —N(R⁵)(R⁶); orwhen n is 2 or 3, optionally two R⁴ substituents taken together form aC₃₋₁₄ cyclic heteroalkyl or C₃₋₁₄ cyclic alkanyl;

[0141] R⁵ is hydrogen, C₁₋₁₆alkyl, alkanylcarbonyl or arylcarbonyl;

[0142] R₆ is C₄₋₁₆ alkyl, alkanylcarbonyl, C₁₋₃alkyl substituted with asubstituent selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl, and furyl, or arylcarbonyl; or optionally R⁶ andone of R⁴ taken together form a saturated or partially unsaturatedcyclic heteroalkyl or a heteroaryl; or R⁵ and R⁶ optionally takentogether form a bridged or non-bridged cyclic heteroalkanyl, whereinsaid heteroalkanyl is optionally substituted with C₁₋₆alkanylcarbonyl;

[0143] wherein the alkanyls in any of the foregoing alkanyl-containingsubstituents of R⁴, R⁵ or R⁶ are optionally and independentlysubstituted with pyrrolyl, pyridyl, furyl, thienyl, phenyl, furyl,C₁₋₄alkylpyrrolyl, C₁₋₄alkylpyridyl, C₁₋₄alkylthienyl, C₁₋₄alkylphenyl,or C₁₋₄alkylfuryl;

[0144] n is 1, 2 or 3;

[0145] Z is O or S; and

[0146] enantiomers, diastereomers, tautomers, solvates, andpharmaceutically acceptable salts thereof.

[0147] In another embodiment, the present invention is directed to acompound of Formula (I) wherein:

[0148] R¹ is a substituent independently selected from the groupconsisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionallysubstituted with one or more substituents independently selected fromthe group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy;C₁₋₈alkanyloxy optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl;C₁₋₈alkanylthio optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy;nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino;C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl;C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl;C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;wherein the heteroatom contained in the quinoline ring of Formula (I) isoptionally substituted with an oxo substituent;

[0149] m is 0, 1 or 2;

[0150] R² is hydrogen or C₁₋₈alkanyl;

[0151] L is a direct bond or C₁₋₄alkyldiyl optionally substituted with asubstituent selected from the group consisting of C₁₋₈alkanyl,C₃₋₈cycloalkanyl and phenyl optionally substituted with one to threesubstituents independently selected from the group consisting ofC₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl,fluorinated alkanyloxy, amino, di(C₁₋₃)alkanylamino, andC₁₋₃alkanylamino;

[0152] R³ is selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl and cyclohexyl;

[0153] R⁴ is independently selected from the group consisting ofC₁₋₈alkanyl, C₁₋₈alkanyloxy, C₃₋₈cycloalkanyloxy, C₁₋₈alkanylamino,C₃₋₈cycloalkanylamino, C₃₋₁₄ cyclic heteroalkanyl, C₁₋₆ fluorinatedalkyl, and —N(R⁵)(R⁶); or when n is 2 or 3, optionally two R⁴substituents taken together form a C₃₋₁₄ cyclic heteroalkyl or C₃₋₁₄cyclic alkanyl;

[0154] R⁵ is hydrogen, C₁₋₁₆alkyl, alkanylcarbonyl or arylcarbonyl;

[0155] R₆ is C₄₋₁₆ alkyl, alkanylcarbonyl, C₁₋₃alkyl substituted with asubstituent selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl, and furyl, or arylcarbonyl; or optionally R⁶ andone of R⁴ taken together form a saturated or partially unsaturatedcyclic heteroalkyl or a heteroaryl; or R⁵ and R⁶ optionally takentogether form a bridged or non-bridged cyclic heteroalkanyl, whereinsaid heteroalkanyl is optionally substituted with C₁₋₆alkanylcarbonyl;

[0156] wherein the alkanyls in any of the foregoing alkanyl-containingsubstituents of R⁴, R⁵ or R⁶ are optionally and independentlysubstituted with pyrrolyl, pyridyl, furyl, thienyl, phenyl, furyl,C₁₋₄alkylpyrrolyl, C₁₋₄alkylpyridyl, C₁₋₄alkylthienyl, C₁₋₄alkylphenyl,or C₁₋₄alkylfuryl;

[0157] n is 2 or 3;

[0158] Z is O or S; and

[0159] enantiomers, diastereomers, tautomers, solvates, andpharmaceutically acceptable salts thereof.

[0160] In another embodiment, the present invention is directed to acompound of Formula (I) wherein:

[0161] R¹ is a substituent independently selected from the groupconsisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionallysubstituted with one or more substituents independently selected fromthe group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy;C₁₋₈alkanyloxy optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl;C₁₋₈alkanylthio optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy;nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino;C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl;C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl;C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;wherein the heteroatom contained in the quinoline ring of Formula (I) isoptionally substituted with an oxo substituent;

[0162] m is 0, 1 or 2;

[0163] R² is hydrogen or C₁₋₈alkanyl;

[0164] L is ethen-1,2-diyl;

[0165] R³ is selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl and cyclohexyl;

[0166] R⁴ is independently selected from the group consisting ofC₁₋₁₂alkanyl, C₄₋₈alkanyloxy, C₃₋₈cycloalkanyloxy, C₁₋₈alkanylamino,C₃₋₈cycloalkanylamino, C₃₋₁₄ cyclic heteroalkanyl, C₁₋₆ fluorinatedalkyl, halogen, and —N(R⁵)(R⁶); or when n is 2 or 3, optionally two R⁴substituents taken together form a C₃₋₁₄ cyclic heteroalkyl or C₃₋₁₄cyclic alkanyl;

[0167] R⁵ is hydrogen, C₁₋₁₆alkyl, alkanylcarbonyl or arylcarbonyl;

[0168] R₆ is C₄₋₁₆ alkyl, alkanylcarbonyl, C₁₋₃alkyl substituted with asubstituent selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl, and furyl, or arylcarbonyl; or optionally R⁶ andone of R⁴ taken together form a saturated or partially unsaturatedcyclic heteroalkyl or a heteroaryl; or R⁵ and R⁶ optionally takentogether form a bridged or non-bridged cyclic heteroalkanyl, whereinsaid heteroalkanyl is optionally substituted with C₁₋₆alkanylcarbonyl;

[0169] wherein the alkanyls in any of the foregoing alkanyl-containingsubstituents of R⁴, R⁵ or R⁶ are optionally and independentlysubstituted with pyrrolyl, pyridyl, furyl, thienyl, phenyl, furyl,C₁₋₄alkylpyrrolyl, C₁₋₄alkylpyridyl, C₁₋₄alkylthienyl, C₁₋₄alkylphenyl,or C₁₋₄alkylfuryl;

[0170] n is 1, 2 or 3;

[0171] Z is O or S; and

[0172] enantiomers, diastereomers, tautomers, solvates, andpharmaceutically acceptable salts thereof.

[0173] In another embodiment, the present invention is directed to acompound of Formula (I) wherein:

[0174] R¹ is a substituent independently selected from the groupconsisting of hydroxy; halogen; C₁₋₈alkanyl optionally substituted withone or more substituents independently selected from the groupconsisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy;C₁₋₈alkanyloxy optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl;C₁₋₈alkanylthio optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy;nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino;C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl;C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl;C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;wherein the heteroatom contained in the quinoline ring of Formula (I) isoptionally substituted with an oxo substituent;

[0175] m is 1 or 2;

[0176] R² is hydrogen or C₁₋₈alkanyl;

[0177] L is a direct bond or C₁₋₄alkyldiyl optionally substituted with asubstituent selected from the group consisting of C₁₋₈alkanyl,C₃₋₈cycloalkanyl and phenyl optionally substituted with one to threesubstituents independently selected from the group consisting ofC₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl,fluorinated alkanyloxy, amino, di(C₁₋₃)alkanylamino, andC₁₋₃alkanylamino;

[0178] R³ is selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl and cyclohexyl;

[0179] R⁴ is independently selected from the group consisting ofC₁₋₈alkanyl, C₁₋₈alkanyloxy, C₃₋₈cycloalkanyloxy, C₁₋₈alkanylamino,C₃₋₈cycloalkanylamino, C₃₋₁₄ cyclic heteroalkanyl, C₁₋₆ fluorinatedalkyl, and —N(R⁵)(R⁶); or when n is 2 or 3, optionally two R⁴substituents taken together form a C₃₋₁₄ cyclic heteroalkyl or C₃₋₁₄cyclic alkanyl;

[0180] R⁵ is hydrogen, C₁₋₁₆alkyl, alkanylcarbonyl or arylcarbonyl;

[0181] R₆ is C₄₋₁₆ alkyl, alkanylcarbonyl, C₁₋₃alkyl substituted with asubstituent selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl, and furyl, or arylcarbonyl; or optionally R⁶ andone of R⁴ taken together form a saturated or partially unsaturatedcyclic heteroalkyl or a heteroaryl; or R⁵ and R⁶ optionally takentogether form a bridged or non-bridged cyclic heteroalkanyl, whereinsaid heteroalkanyl is optionally substituted with C₁₋₆alkanylcarbonyl;

[0182] wherein the alkanyls in any of the foregoing alkanyl-containingsubstituents of R⁴, R⁵ or R⁶ are optionally and independentlysubstituted with pyrrolyl, pyridyl, furyl, thienyl, phenyl, furyl,C₁₋₄alkylpyrrolyl, C₁₋₄alkylpyridyl, C₁₋₄alkylthienyl, C₁₋₄alkylphenyl,or C₁₋₄alkylfuryl;

[0183] n is 1, 2 or 3;

[0184] Z is O or S; and

[0185] enantiomers, diastereomers, tautomers, solvates, andpharmaceutically acceptable salts thereof.

[0186] The present invention is directed to a compound of Formula (I)wherein:

[0187] R¹ is a substituent independently selected from the groupconsisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionallysubstituted with one or more substituents independently selected fromthe group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy;C₁₋₈alkanyloxy optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl;C₁₋₈alkanylthio optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy;nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino;C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl;C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl;C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;wherein the heteroatom contained in the quinoline ring of Formula (I) isoptionally substituted with an oxo substituent;

[0188] m is 0, 1 or 2;

[0189] R² is hydrogen or C₁₋₈alkanyl;

[0190] L is a direct bond;

[0191] R³ is selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, and cyclohexyl;

[0192] R⁴ is selected from the group consisting of C₁₋₈alkanyl,C₄₋₈alkanyloxy, C₃₋₈cycloalkanyloxy, C₁₋₈alkanylamino,C₃₋₈cycloalkanylamino, C₃₋₁₄ cyclic heteroalkanyl, C₁₋₆ fluorinatedalkyl, and —N(R⁵)(R⁶), wherein the alkanyls in any of the foregoingalkanyl-containing substituents of R⁴ is optionally substituted withthienyl or phenyl; or when n is 2 or 3, optionally two R⁴ substituentstaken together form a C₃₋₁₄ cyclic heteroalkyl or C₃₋₁₄ cyclic alkanyl;

[0193] R⁵ is hydrogen, C₁₋₁₆alkyl, alkanylcarbonyl or arylcarbonyl;

[0194] R₆ is C₄₋₁₆ alkyl, alkanylcarbonyl, C₁₋₃alkyl substituted with asubstituent selected from the group consisting of pyrrolyl, pyridyl,furyl, thienyl, phenyl, and furyl, or arylcarbonyl; or optionally R⁶ andone of R⁴ taken together form a saturated or partially unsaturatedcyclic heteroalkyl or a heteroaryl; or R⁵ and R⁶ optionally takentogether form a bridged or non-bridged cyclic heteroalkanyl, whereinsaid heteroalkanyl is optionally substituted with C₁₋₆alkanylcarbonyl;

[0195] wherein the alkanyls in any of the foregoing alkanyl-containingsubstituents of R⁴, R⁵ or R⁶ are optionally and independentlysubstituted with pyrrolyl, pyridyl, furyl, thienyl, phenyl, furyl,C₁₋₄alkylpyrrolyl, C₁₋₄alkylpyridyl, C₁₋₄alkylthienyl, C₁₋₄alkylphenyl,or C₁₋₄alkylfuryl;

[0196] n is 1, 2 or 3;

[0197] Z is O or S; and

[0198] enantiomers, diastereomers, tautomers, solvates, andpharmaceutically acceptable salts thereof.

[0199] Embodiments of the present invention also include those whereinfor compounds of Formula (I):

[0200] a) L is a direct bond;

[0201] b) L is C₁₋₄alkyldiyl;

[0202] c) L is ethen-1,2-diyl;

[0203] d) L is ethen-1,2-diyl, and one R⁴ is C₁₋₆ fluorinated alkanyl;

[0204] e) L is ethen-1,2-diyl, and one R⁴ is halogen;

[0205] f) L is ethen-1,2-diyl, n is 2, one R⁴ is halogen and the otherR⁴ is C₁₋₆ fluorinated alkanyl;

[0206] g) R³ is phenyl;

[0207] h) R³ is pyridyl;

[0208] i) R³ is thienyl;

[0209] j) R³ is furyl;

[0210] k) R³ is cyclohexyl;

[0211] l) n is 1;

[0212] m) n is 2 or 3 and R⁴ is C₁₋₁₂alkanyl;

[0213] n) R⁴ is —N(R⁵)(R⁶);

[0214] o) L is C₁₋₄alkyldiyl, R³ is phenyl, n is 1 and R⁴ isC₁₋₁₂alkanyl;

[0215] p) R³ is phenyl, n is 1 and R⁴ is —N(R⁵)(R⁶);

[0216] q) R³ is phenyl, n is 2 or 3, and two R⁴ substituents takentogether form a C₃₋₁₄ cyclic heteroalkyl or C₃₋₁₄ cyclic alkyl;

[0217] r) Z is O;

[0218] s) m is 0;

[0219] t) R² is hydrogen; and

[0220] u) combinations of a) through t) above.

[0221] The present invention is also directed to a compound selectedfrom the group consisting of

[0222] 1-Acetyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide;

[0223] 1-Benzoyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide;

[0224] 1-Butyryl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide;

[0225] 1-Cyclohexanecarbonyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide;

[0226] 1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide;

[0227] 1-Isopropyl-2-trifluoromethyl-1H-benzoimidazole-5-carboxylic acidquinolin-3-ylamide;

[0228] 1-Methyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acidquinolin-3-ylamide;

[0229] 1-Methyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide;

[0230] 1-Pentyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acidquinolin-3-ylamide;

[0231] 1-Pentyl-1H-indole-5-carboxylic acid quinolin-3-ylamide;

[0232] 1-Pentyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide;

[0233] 1-Propyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide;

[0234] 2-(4-Dipentylamino-phenyl)-N-quinolin-3-yl-acetamide;

[0235] 2-(4-Pentyl-phenyl)-N-quinolin-3-yl-acetamide;

[0236] 2-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-acetamide;

[0237] 2-(Heptyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0238] 2-(Methyl-pentyl-amino)-N-quinolin-3-yl-benzamide;

[0239] 2,3-Dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;

[0240] 2-{4-(Methyl-pentyl-amino)-phenyl}-N-quinolin-3-yl-acetamide;

[0241] 2-Chloro-4-(cyclohexylmethyl-amino)-N-quinolin-3-yl-benzamide;

[0242] 2-Chloro-4-pentylamino-N-quinolin-3-yl-benzamide;

[0243] 2-Heptylamino-N-quinolin-3-yl-benzamide;

[0244] 2-Pentylamino-N-quinolin-3-yl-benzamide;

[0245]3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-propionamide;

[0246]3-(1-Cyclohexylmethyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-propionamide;

[0247] 3-(1-Propyl-1H-indol-5-yl)-N-quinolin-3-yl-propionamide;

[0248]3-(1-Propyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-propionamide;

[0249] 3-(2,2-Dimethyl-chroman-6-yl)-N-quinolin-3-yl-acrylamide;

[0250] 3-(2,2-Dimethyl-chroman-6-yl)-N-quinolin-3-yl-propionamide;

[0251] 3-(4-Azepan-1-yl-phenyl)-N-quinolin-3-yl-acrylamide;

[0252] 3-(4-Azepan-1-yl-phenyl)-N-quinolin-3-yl-propionamide;

[0253] 3-(4-Cyclohexylmethyl-phenyl)-N-quinolin-3-yl-propionamide;

[0254] 3-(4-Dipentylamino-phenyl)-N-quinolin-3-yl-propionamide;

[0255] 3-(4-Pentyl-phenyl)-N-quinolin-3-yl-acrylamide;

[0256] 3-(4-Pentyl-phenyl)-N-quinolin-3-yl-propionamide;

[0257] 3-(4-sec-Butyl-phenyl)-N-quinolin-3-yl-propionamide;

[0258] 3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-acrylamide;

[0259] 3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-propionamide;

[0260] 3-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0261] 3-(Heptyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0262] 3-(Methyl-pentyl-amino)-N-quinolin-3-yl-benzamide;

[0263] 3,4,5,6-Tetrahydro-2H-[1,2′]bipyridinyl-5′-carboxylic acidquinolin-3-ylamide;

[0264] 3,4,5,6-Tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylic acidquinolin-3-ylamide;

[0265]3-[4-(Methyl-phenethyl-amino)-phenyl]-N-quinolin-3-yl-propionamide;

[0266]3-{4-(1,1-Dimethyl-3-phenyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;

[0267]3-{4-(1,1-Dimethyl-pentyl)-2,6-dimethoxy-phenyl}-N-quinolin-3-yl-propionamide;

[0268] 3-{4-(1,1-Dimethyl-pentyl)-phenyl}-N-quinolin-3-yl;

[0269]3-{4-(1,1-Dimethyl-propyl)-2,6-dimethoxy-phenyl}-N-quinolin-3-yl-propionamide;

[0270] 3-{4-(1,1-Dimethyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;

[0271]3-{4-(1-Cyclohexyl-1-methyl-ethyl)-phenyl}-N-quinolin-3-yl-propionamide;

[0272] 3-{4-(1-Methyl-pentyl)-phenyl}-N-quinolin-3-yl-propionamide;

[0273] 3-{4-(1-Methyl-pentyl)-phenyl}-N-quinolin-3-yl-propionamide;

[0274] 3-{4-(Benzyl-methyl-amino)-phenyl}-N-quinolin-3-yl-propionamide;

[0275]3-{4-(Cyclohexyl-methyl-amino)-phenyl}-N-quinolin-3-yl-acrylamide;

[0276]3-{4-(Cyclohexyl-methyl-amino)-phenyl})-N-quinolin-3-yl-propionamide;

[0277]3-{4-(Cyclohexylmethyl-methyl-amino)-phenyl}-N-quinolin-3-yl-propionamide;

[0278] 3-{4-(Methyl-pentyl-amino)-phenyl}-N-quinolin-3-yl-acrylamide;

[0279] 3-{4-(Methyl-pentyl-amino)-phenyl}-N-quinolin-3-yl-propionamide;

[0280] 3-{4-(Methyl-propyl-amino)-phenyl}-N-quinolin-3-yl-propionamide;

[0281]3-{5-(1,1-Dimethyl-propyl)-thiophen-2-yl}-N-quinolin-3-yl-propionamide;

[0282] 3-Cyclohexylamino-N-quinolin-3-yl-benzamide;

[0283] 3-Dipentylamino-N-quinolin-3-yl-benzamide;

[0284] 3-Heptylamino-N-quinolin-3-yl-benzamide;

[0285] 3-indan-5-yl-N-quinolin-3-yl-propionamide;

[0286] 3-Methyl-4-(methyl-pentyl-amino)-N-quinolin-3-yl-benzamide;

[0287] 3-Methyl-4-pentylamino-N-quinolin-3-yl-benzamide;

[0288] 3-Pentylamino-N-quinolin-3-yl-benzamide;

[0289] 4-(1,3-Dihydro-isoindol-2-yl)-N-quinolin-3-yl-benzamide;

[0290] 4-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-N-quinolin-3-yl-benzamide;

[0291] 4-(2,6-Dimethyl-morpholin-4-yl)-N-quinolin-3-yl-benzamide;

[0292] 4-(3,5-Dimethyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;

[0293] 4-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-benzamide;

[0294] 4-(3-Methyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;

[0295] 4-(4-Benzoyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;

[0296] 4-(4-Benzyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;

[0297] 4-(4-Phenylacetyl-piperazin-1-yl)-N-quinolin-3-yl-benzamide;

[0298] 4-(4-Phenyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;

[0299] 4-(4-Propyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;

[0300] 4-(Acetyl-cyclohexyl-amino)-N-quinolin-3-yl-benzamide;

[0301] 4-(Benzyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0302] 4-(Benzyl-pentyl-amino)-N-quinolin-3-yl-benzamide;

[0303] 4-(Cycloheptyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0304] 4-(Cyclohexanecarbonyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0305] 4-(Cyclohexyl-ethyl-amino)-N-quinolin-3-yl-benzamide;

[0306] 4-(Cyclohexylmethyl-amino)-3-methyl-N-quinolin-3-yl-benzamide;

[0307] 4-(Cyclohexyl-methyl-amino)-3-methyl-N-quinolin-3-yl-benzamide;

[0308] 4-(Cyclohexyl-methyl-amino)-N-methyl-N-quinolin-3-yl-benzamide;

[0309] 4-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0310]4-(Cyclohexylmethyl-methyl-amino)-3-methyl-N-quinolin-3-yl-benzamide;

[0311] 4-(Cyclohexylmethyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0312] 4-(Cyclohexylmethyl-phenethyl-amino)-N-quinolin-3-yl-benzamide;

[0313] 4-(Cyclohexyl-propyl-amino)-N-quinolin-3-yl-benzamide;

[0314] 4-(Cyclopentyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0315] 4-(Dec-4-enyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0316] 4-(Hept-4-enyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0317] 4-(Heptyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0318] 4-(Methyl-butyl-amino)-N-quinolin-3-yl-benzamide;

[0319] 4-(Methyl-hexyl-amino)-N-quinolin-3-yl-benzamide;

[0320] 4-(Methyl-non-6-enyl-amino)-N-quinolin-3-yl-benzamide;

[0321] 4-(Methyl-nonyl-amino)-N-quinolin-3-yl-benzamide;

[0322] 4-(Methyl-pentyl-amino)-N-quinolin-3-yl-benzamide;

[0323] 4-(Methyl-phenethyl-amino)-N-quinolin-3-yl-benzamide;

[0324] 4-(Methyl-propyl-amino)-N-quinolin-3-yl-benzamide;

[0325] 4-(Methyl-tetradecyl-amino)-N-quinolin-3-yl-benzamide;

[0326] 4-(Octyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0327] 4-(Phenethyl-propyl-amino)-N-quinolin-3-yl-benzamide;

[0328] 4-[1,4′]Bipiperidinyl-1′-yl-N-quinolin-3-yl-benzamide;

[0329] 4-{(3,3-Dimethyl-butyl)-methyl-amino}-N-quinolin-3-yl-benzamide;

[0330] 4-{4-(1,1-Dimethyl-pentyl)-phenyl}-but-3-enoic acidquinolin-3-ylamide;

[0331] 4-{4-(1,1-Dimethyl-pentyl)-phenyl}-N-quinolin-3-yl-butyramide;

[0332] 4-{4-(1,1-Dimethyl-propyl)-phenyl}-but-3-enoic acidquinolin-3-ylamide;

[0333] 4-{4-(1,1-Dimethyl-propyl)-phenyl}-N-quinolin-3-yl-butyramide;

[0334] 4-{Methyl-(3-methyl-butyl)-amino}-N-quinolin-3-yl-benzamide;

[0335] 4-{Methyl-(3-phenyl-allyl)-amino}-N-quinolin-3-yl-benzamide;

[0336] 4-{Methyl-(3-phenyl-propyl)-amino}-N-quinolin-3-yl-benzamide;

[0337]4-{Methyl-(tetrahydro-pyran-4-yl)-amino}-N-quinolin-3-yl-benzamide;

[0338]4-{Methyl-{3-(5-methyl-furan-2-yl)-butyl}-amino}-N-quinolin-3-yl-benzamide;

[0339] 4-Azepan-1-yl-N-quinolin-3-yl-benzamide;

[0340] 4-Azepan-1-yl-N-quinolin-3-yl-benzamide;

[0341] 4-Azocan-1-yl-N-quinolin-3-yl-benzamide;

[0342] 4-Azonan-1-yl-N-quinolin-3-yl-benzamide;

[0343] 4-Benzyl-3,4,5,6-tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylicacid quinolin-3-ylamide;

[0344] 4-Butoxy-N-quinolin-3-yl-benzamide;

[0345] 4-Butyl-cyclohexanecarboxylic acid quinolin-3-ylamide;

[0346] 4-Butyl-cyclohexanecarboxylic acid quinolin-3-ylamide;

[0347] 4-Cycloheptylamino-N-quinolin-3-yl-benzamide;

[0348] 4-Cyclohexylamino-N-methyl-N-quinolin-3-yl-benzamide;

[0349] 4-Cyclohexylamino-N-quinolin-3-yl-benzamide;

[0350] 4-Cyclopentylamino-N-quinolin-3-yl-benzamide;

[0351] 4-Dibenzylamino-N-quinolin-3-yl-benzamide;

[0352] 4-Dibutylamino-N-quinolin-3-yl-benzamide;

[0353] 4-Dihexylamino-N-quinolin-3-yl-benzamide;

[0354] 4-Dipentylamino-N-quinolin-3-yl-benzamide;

[0355] 4-Dipropylamino-N-quinolin-3-yl-benzamide;

[0356] 4-Morpholin-4-yl-N-quinolin-3-yl-benzamide;

[0357] 4-Pentylamino-N-quinolin-3-yl-benzamide;

[0358] 4-Phenethylamino-N-quinolin-3-yl-benzamide;

[0359] 4-Piperazin-1-yl-N-quinolin-3-yl-benzamide;

[0360] 4-Piperidin-1-yl-N-quinolin-3-yl-benzamide;

[0361] 4-Propyl-3,4,5,6-tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylicacid quinolin-3-ylamide;

[0362] 4-Pyrrolidin-1-yl-N-quinolin-3-yl-benzamide;

[0363] 4-tert-Butyl-cyclohexanecarboxylic acid quinolin-3-ylamide;

[0364] 4-tert-Butyl-cyclohexanecarboxylic acid quinolin-3-ylamide;

[0365] 5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carboxylicacid quinolin-3-ylamide;

[0366] 5,6,7,8-Tetrahydro-naphthalene-2-carboxylic acidquinolin-3-ylamide;

[0367] 5-Chloro-1H-indole-2-carboxylic acid quinolin-3-ylamide;

[0368] 5-Pentyl-thiophene-2-carboxylic acid quinolin-3-ylamide;

[0369] 6-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-nicotinamide;

[0370] 6-(Benzyl-methyl-amino)-N-quinolin-3-yl-nicotinamide;

[0371] 6-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-nicotinamide;

[0372] 6-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-nicotinamide;

[0373] 6-(Heptyl-methyl-amino)-N-quinolin-3-yl-nicotinamide;

[0374] 6-(Methyl-pentyl-amino)-N-quinolin-3-yl-nicotinamide;

[0375] 6-(Methyl-phenethyl-amino)-N-quinolin-3-yl-nicotinamide;

[0376] 6-Azepan-1-yl-N-quinolin-3-yl-nicotinamide;

[0377] 6-Azocan-1-yl-N-quinolin-3-yl-nicotinamide;

[0378] 6-Cyclohexylamino-N-quinolin-3-yl-nicotinamide;

[0379] 6-Pentylamino-N-quinolin-3-yl-nicotinamide;

[0380] cis-4-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-benzamide;

[0381] cis-6-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-nicotinamide;

[0382] N-Quinolin-3-yl-3-(3-trifluoromethyl-phenyl)-acrylamide;

[0383]N-Quinolin-3-yl-3-(4-tricyclo{5.3.1.13,9}dodec-1-yl-phenyl)-propionamide;

[0384] N-Quinolin-3-yl-3-(4-trifluoromethyl-phenyl)-acrylamide;

[0385]N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propionamide;

[0386]N-Quinolin-3-yl-3-(5,6,7,8-tetrahydro-naphthalen-2-yl)-propionamide;

[0387] N-Quinolin-3-yl-4-(tetrahydro-pyran-4-ylamino)-benzamide;

[0388] N-Quinolin-3-yl-4-thiomorpholin-4-yl-benzamide;

[0389]R-4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;

[0390]S-4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;

[0391] trans-4-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-benzamide;

[0392]trans-6-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-nicotinamide;

[0393] 4-tert-Butyl-N-(4-hydroxy-quinolin-3-yl)-benzamide;

[0394] 3-(4-tert-Butyl-phenyl)-N-(4-hydroxy-quinolin-3-yl)-acrylamide;

[0395]N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-acrylamide;

[0396]N-(4-Chloro-quinolin-3-yl)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-acrylamide;

[0397] N-(4-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;

[0398] N-(2-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;

[0399] 4-tert-Butyl-N-(2-methoxy-quinolin-3-yl)-benzamide;

[0400] 4-Azepan-1-yl-N-(4-chloro-quinolin-3-yl)-benzamide;

[0401]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(2-chloro-quinolin-3-yl)-benzamide;

[0402] 4-Azepan-1-yl-N-(2-chloro-quinolin-3-yl)-benzamide;

[0403]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(4-chloro-quinolin-3-yl)-benzamide;

[0404]3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;

[0405] 1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid(2-chloro-quinolin-3-yl)-amide;

[0406]N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-2,3-dihydro-1H-indol-5-yl)-acrylamide;

[0407] 3-(1-Cyclohexyl-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;

[0408]N-(4-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;

[0409] 1-Cyclohexyl-1H-indole-5-carboxylic acid(4-chloro-quinolin-3-yl)-amide;

[0410] 1-Cyclohexyl-1H-indole-5-carboxylic acid quinolin-3-ylamide;

[0411] 1-Cyclohexyl-1H-indole-5-carboxylic acid(2-chloro-quinolin-3-yl)-amide;

[0412]N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;

[0413] 4-(Cyclohexyl-methyl-amino)-N-(8-fluoro-quinolin-3-yl)-benzamide;

[0414] 4-Azocan-1-yl-N-(8-fluoro-quinolin-3-yl)-benzamide;

[0415]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-fluoro-quinolin-3-yl)-benzamide;

[0416]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;

[0417]4-(Cyclohexyl-methyl-amino)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;

[0418] 4-(Cyclohexyl-methyl-amino)-N-(6-fluoro-quinolin-3-yl)-benzamide;

[0419] 4-Azocan-1-yl-N-(6-fluoro-quinolin-3-yl)-benzamide;

[0420]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(6-fluoro-quinolin-3-yl)-benzamide;

[0421]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;

[0422] 4-Azocan-1-yl-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;

[0423]4-(Cyclohexyl-methyl-amino)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;

[0424] 4-Azocan-1-yl-N-(5-fluoro-quinolin-3-yl)-benzamide;

[0425]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(5-fluoro-quinolin-3-yl)-benzamide;

[0426] 3-Phenyl-propynoic acid quinolin-3-ylamide;

[0427] trans-2-Phenyl-cyclopropanecarboxylic acid quinolin-3-ylamide;

[0428] 3-(4-tert-Butyl-phenyl)-propynoic acid quinolin-3-ylamide; and

[0429] 2-(4-tert-Butyl-phenyl)-cyclopropanecarboxylic acidquinolin-3-ylamide.

[0430] The present invention is also directed to a compound selectedfrom the group consisting of

[0431] 1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide;

[0432] 1-Pentyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acidquinolin-3-ylamide;

[0433] 1-Pentyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide;

[0434] 1-Propyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide;

[0435] 3-(4-sec-Butyl-phenyl)-N-quinolin-3-yl-propionamide;

[0436] 3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-acrylamide;

[0437] 3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-propionamide;

[0438] 3,4,5,6-Tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylic acidquinolin-3-ylamide;

[0439]3-{4-(1,1-Dimethyl-3-phenyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;

[0440]3-{4-(1,1-Dimethyl-pentyl)-2,6-dimethoxy-phenyl}-N-quinolin-3-yl-propionamide;

[0441] 3-{4-(1,1-Dimethyl-pentyl)-phenyl}-N-quinolin-3-yl;

[0442]3-{4-(1,1-Dimethyl-propyl)-2,6-dimethoxy-phenyl}-N-quinolin-3-yl-propionamide;

[0443] 3-{4-(1,1-Dimethyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;

[0444]3-{4-(1-Cyclohexyl-1-methyl-ethyl)-phenyl}-N-quinolin-3-yl-propionamide;

[0445] 3-{4-(1-Methyl-pentyl)-phenyl}-N-quinolin-3-yl-propionamide;

[0446]3-{5-(1,1-Dimethyl-propyl)-thiophen-2-yl}-N-quinolin-3-yl-propionamide;

[0447] 4-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-benzamide;

[0448] 4-(4-Benzyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;

[0449] 4-(Cycloheptyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0450] 4-(Cyclohexyl-ethyl-amino)-N-quinolin-3-yl-benzamide;

[0451] 4-(Cyclohexyl-methyl-amino)-3-methyl-N-quinolin-3-yl-benzamide;

[0452] 4-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0453] 4-(Cyclohexylmethyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0454] 4-(Cyclopentyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0455] 4-(Dec-4-enyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0456] 4-(Hept-4-enyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0457] 4-(Heptyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0458] 4-(Methyl-non-6-enyl-amino)-N-quinolin-3-yl-benzamide;

[0459] 4-(Methyl-nonyl-amino)-N-quinolin-3-yl-benzamide;

[0460] 4-(Methyl-phenethyl-amino)-N-quinolin-3-yl-benzamide;

[0461] 4-(Octyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0462] 4-{(3,3-Dimethyl-butyl)-methyl-amino}-N-quinolin-3-yl-benzamide;

[0463]4-{Methyl-{3-(5-methyl-furan-2-yl)-butyl}-amino}-N-quinolin-3-yl-benzamide;

[0464] 4-Azepan-1-yl-N-quinolin-3-yl-benzamide;

[0465] 4-Azepan-1-yl-N-quinolin-3-yl-benzamide;

[0466] 4-Azocan-1-yl-N-quinolin-3-yl-benzamide;

[0467] 4-Azonan-1-yl-N-quinolin-3-yl-benzamide;

[0468] 4-Benzyl-3,4,5,6-tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylicacid quinolin-3-ylamide;

[0469] 5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carboxylicacid quinolin-3-ylamide;

[0470] 6-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-nicotinamide;

[0471] 6-Azocan-1-yl-N-quinolin-3-yl-nicotinamide;

[0472] cis-4-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-benzamide;

[0473] cis-6-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-nicotinamide;

[0474]N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propionamide;

[0475]R-4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;

[0476]S-4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;

[0477] trans-4-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-benzamide;

[0478]trans-6-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-nicotinamide;

[0479] 4-tert-Butyl-N-(4-hydroxy-quinolin-3-yl)-benzamide;

[0480] 3-(4-tert-Butyl-phenyl)-N-(4-hydroxy-quinolin-3-yl)-acrylamide;

[0481]N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-acrylamide;

[0482]N-(4-Chloro-quinolin-3-yl)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-acrylamide;

[0483] N-(4-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;

[0484] N-(2-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;1 5 4-tert-Butyl-N-(2-methoxy-quinolin-3-yl)-benzamide;

[0485] 4-Azepan-1-yl-N-(4-chloro-quinolin-3-yl)-benzamide;

[0486]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(2-chloro-quinolin-3-yl)-benzamide;

[0487] 4-Azepan-1-yl-N-(2-chloro-quinolin-3-yl)-benzamide;

[0488]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(4-chloro-quinolin-3-yl)-benzamide;

[0489]3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;

[0490] 1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid(2-chloro-quinolin-3-yl)-amide;

[0491]N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-2,3-dihydro-1H-indol-5-yl)-acrylamide;

[0492] 3-(1-Cyclohexyl-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;

[0493]N-(4-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;

[0494] 1-Cyclohexyl-1H-indole-5-carboxylic acid(4-chloro-quinolin-3-yl)-amide;

[0495] 1-Cyclohexyl-1H-indole-5-carboxylic acid quinolin-3-ylamide;

[0496] 1-Cyclohexyl-1H-indole-5-carboxylic acid(2-chloro-quinolin-3-yl)-amide;

[0497]N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;

[0498] 4-(Cyclohexyl-methyl-amino)-N-(8-fluoro-quinolin-3-yl)-benzamide;

[0499] 4-Azocan-1-yl-N-(8-fluoro-quinolin-3-yl)-benzamide;

[0500]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-fluoro-quinolin-3-yl)-benzamide;

[0501]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;

[0502]4-(Cyclohexyl-methyl-amino)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;

[0503] 4-(Cyclohexyl-methyl-amino)-N-(6-fluoro-quinolin-3-yl)-benzamide;

[0504] 4-Azocan-1-yl-N-(6-fluoro-quinolin-3-yl)-benzamide;

[0505]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(6-fluoro-quinolin-3-yl)-benzamide;

[0506]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;

[0507] 4-Azocan-1-yl-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;

[0508]4-(Cyclohexyl-methyl-amino)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;

[0509] 4-Azocan-1-yl-N-(5-fluoro-quinolin-3-yl)-benzamide;

[0510]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(5-fluoro-quinolin-3-yl)-benzamide;

[0511] 3-Phenyl-propynoic acid quinolin-3-ylamide;

[0512] trans-2-Phenyl-cyclopropanecarboxylic acid quinolin-3-ylamide;

[0513] 3-(4-tert-Butyl-phenyl)-propynoic acid quinolin-3-ylamide; and

[0514] 2-(4-tert-Butyl-phenyl)-cyclopropanecarboxylic acidquinolin-3-ylamide.

[0515] The present invention is also directed to a compound selectedfrom the group consisting of

[0516] 1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide;

[0517] 1-Pentyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide;

[0518] 1-Propyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide;

[0519] 3-(4-sec-Butyl-phenyl)-N-quinolin-3-yl-propionamide;

[0520] 3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-acrylamide;

[0521] 3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-propionamide;

[0522] 3,4,5,6-Tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylic acidquinolin-3-ylamide;

[0523]3-{4-(1,1-Dimethyl-3-phenyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;

[0524]3-{4-(1,1-Dimethyl-pentyl)-2,6-dimethoxy-phenyl}-N-quinolin-3-yl-propionamide;

[0525] 3-{4-(1,1-Dimethyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;

[0526] 3-{4-(1-Methyl-pentyl)-phenyl}-N-quinolin-3-yl-propionamide;

[0527]3-{5-(1,1-Dimethyl-propyl)-thiophen-2-yl}-N-quinolin-3-yl-propionamide;

[0528] 4-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-benzamide;

[0529] 4-(4-Benzyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;

[0530] 4-(Cycloheptyl-methyl-amino)-N-quinolin-3-yl-benzamide;;

[0531] 4-(Cyclohexyl-ethyl-amino)-N-quinolin-3-yl-benzamide;

[0532] 4-(Cyclohexyl-methyl-amino)-3-methyl-N-quinolin-3-yl-benzamide;

[0533] 4-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0534] 4-(Cyclohexylmethyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0535] 4-(Cyclopentyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0536] 4-(Dec-4-enyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0537] 4-(Heptyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0538] 4-(Methyl-nonyl-amino)-N-quinolin-3-yl-benzamide;

[0539] 4-(Methyl-phenethyl-amino)-N-quinolin-3-yl-benzamide;

[0540] 4-(Octyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0541] 4-{(3,3-Dimethyl-butyl)-methyl-amino}-N-quinolin-3-yl-benzamide;

[0542] 4-Azepan-1-yl-N-quinolin-3-yl-benzamide;

[0543] 4-Azepan-1-yl-N-quinolin-3-yl-benzamide;

[0544] 4-Azocan-1-yl-N-quinolin-3-yl-benzamide;

[0545] 4-Azonan-1-yl-N-quinolin-3-yl-benzamide;

[0546] 4-Benzyl-3,4,5,6-tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylicacid quinolin-3-ylamide;

[0547] 6-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-nicotinamide;

[0548]N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propionamide;

[0549]R-4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;S-4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;

[0550] 4-tert-Butyl-N-(4-hydroxy-quinolin-3-yl)-benzamide;

[0551] 3-(4-tert-Butyl-phenyl)-N-(4-hydroxy-quinolin-3-yl)-acrylamide;

[0552]N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-acrylamide;

[0553]N-(4-Chloro-quinolin-3-yl)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-acrylamide;

[0554] N-(4-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;

[0555] N-(2-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;

[0556] 4-tert-Butyl-N-(2-methoxy-quinolin-3-yl)-benzamide;

[0557] 4-Azepan-1-yl-N-(4-chloro-quinolin-3-yl)-benzamide;

[0558]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(2-chloro-quinolin-3-yl)-benzamide;

[0559] 4-Azepan-1-yl-N-(2-chloro-quinolin-3-yl)-benzamide;

[0560]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(4-chloro-quinolin-3-yl)-benzamide;

[0561]3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;

[0562] 1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid(2-chloro-quinolin-3-yl)-amide;

[0563]N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-2,3-dihydro-1H-indol-5-yl)-acrylamide;

[0564] 3-(1-Cyclohexyl-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;

[0565]N-(4-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;

[0566] 1-Cyclohexyl-1H-indole-5-carboxylic acid(4-chloro-quinolin-3-yl)-amide;

[0567] 1-Cyclohexyl-1H-indole-5-carboxylic acid quinolin-3-ylamide;

[0568] 1-Cyclohexyl-1H-indole-5-carboxylic acid(2-chloro-quinolin-3-yl)-amide;

[0569]N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;

[0570] 4-(Cyclohexyl-methyl-amino)-N-(8-fluoro-quinolin-3-yl)-benzamide;

[0571] 4-Azocan-1-yl-N-(8-fluoro-quinolin-3-yl)-benzamide;

[0572]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-fluoro-quinolin-3-yl)-benzamide;

[0573]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;

[0574]4-(Cyclohexyl-methyl-amino)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;

[0575] 4-(Cyclohexyl-methyl-amino)-N-(6-fluoro-quinolin-3-yl)-benzamide;

[0576] 4-Azocan-1-yl-N-(6-fluoro-quinolin-3-yl)-benzamide;

[0577]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(6-fluoro-quinolin-3-yl)-benzamide;

[0578]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;

[0579] 4-Azocan-1-yl-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;

[0580]4-(Cyclohexyl-methyl-amino)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;

[0581] 4-Azocan-1-yl-N-(5-fluoro-quinolin-3-yl)-benzamide;

[0582]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(5-fluoro-quinolin-3-yl)-benzamide;

[0583] 3-Phenyl-propynoic acid quinolin-3-ylamide;

[0584] trans-2-Phenyl-cyclopropanecarboxylic acid quinolin-3-ylamide;

[0585] 3-(4-tert-Butyl-phenyl)-propynoic acid quinolin-3-ylamide; and

[0586] 2-(4-tert-Butyl-phenyl)-cyclopropanecarboxylic acidquinolin-3-ylamide.

[0587] The present invention is also directed to a compound selectedfrom the group consisting of

[0588] 1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide;

[0589] 1-Propyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide;

[0590] 3-(4-sec-Butyl-phenyl)-N-quinolin-3-yl-propionamide;

[0591] 3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-acrylamide;

[0592] 3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-propionamide;

[0593]3-{4-(1,1-Dimethyl-3-phenyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;

[0594]3-{4-(1,1-Dimethyl-pentyl)-2,6-dimethoxy-phenyl}-N-quinolin-3-yl-propionamide;

[0595] 3-{4-(1,1-Dimethyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;

[0596] 3-{4-(1-Methyl-pentyl)-phenyl}-N-quinolin-3-yl-propionamide;

[0597]3-{5-(1,1-Dimethyl-propyl)-thiophen-2-yl}-N-quinolin-3-yl-propionamide;

[0598] 4-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-benzamide;

[0599] 4-(4-Benzyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;

[0600] 4-(Cycloheptyl-methyl-amino)-N-quinolin-3-yl-benzamide;;

[0601] 4-(Cyclohexyl-ethyl-amino)-N-quinolin-3-yl-benzamide;

[0602] 4-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0603] 4-(Cyclohexylmethyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0604] 4-(Octyl-methyl-amino)-N-quinolin-3-yl-benzamide;

[0605] 4-Azepan-1-yl-N-quinolin-3-yl-benzamide;

[0606] 4-Azepan-1-yl-N-quinolin-3-yl-benzamide;

[0607] 4-Azocan-1-yl-N-quinolin-3-yl-benzamide;

[0608] 4-Azonan-1-yl-N-quinolin-3-yl-benzamide;

[0609] 6-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-nicotinamide;

[0610]N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propionamide;

[0611]R-4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;S-4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;

[0612] 4-tert-Butyl-N-(4-hydroxy-quinolin-3-yl)-benzamide;

[0613] 3-(4-tert-Butyl-phenyl)-N-(4-hydroxy-quinolin-3-yl)-acrylamide;

[0614]N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-acrylamide;

[0615]N-(4-Chloro-quinolin-3-yl)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-acrylamide;

[0616] N-(4-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;

[0617] N-(2-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;

[0618] 4-tert-Butyl-N-(2-methoxy-quinolin-3-yl)-benzamide;

[0619] 4-Azepan-1-yl-N-(4-chloro-quinolin-3-yl)-benzamide;

[0620]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(2-chloro-quinolin-3-yl)-benzamide;

[0621] 4-Azepan-1-yl-N-(2-chloro-quinolin-3-yl)-benzamide;

[0622]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(4-chloro-quinolin-3-yl)-benzamide;

[0623]3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;

[0624] 1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid(2-chloro-quinolin-3-yl)-amide;

[0625]N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-2,3-dihydro-1H-indol-5-yl)-acrylamide;

[0626] 3-(1-Cyclohexyl-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;

[0627]N-(4-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;

[0628] 1-Cyclohexyl-1H-indole-5-carboxylic acid(4-chloro-quinolin-3-yl)-amide;

[0629] 1-Cyclohexyl-1H-indole-5-carboxylic acid quinolin-3-ylamide;

[0630] 1-Cyclohexyl-1H-indole-5-carboxylic acid(2-chloro-quinolin-3-yl)-amide;

[0631]N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;

[0632] 4-(Cyclohexyl-methyl-amino)-N-(8-fluoro-quinolin-3-yl)-benzamide;

[0633] 4-Azocan-1-yl-N-(8-fluoro-quinolin-3-yl)-benzamide;

[0634]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-fluoro-quinolin-3-yl)-benzamide;

[0635]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;

[0636]4-(Cyclohexyl-methyl-amino)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;

[0637] 4-(Cyclohexyl-methyl-amino)-N-(6-fluoro-quinolin-3-yl)-benzamide;

[0638] 4-Azocan-1-yl-N-(6-fluoro-quinolin-3-yl)-benzamide;

[0639]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(6-fluoro-quinolin-3-yl)-benzamide;

[0640]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;

[0641] 4-Azocan-1-yl-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;

[0642]4-(Cyclohexyl-methyl-amino)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;

[0643] 4-Azocan-1-yl-N-(5-fluoro-quinolin-3-yl)-benzamide;

[0644]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(5-fluoro-quinolin-3-yl)-benzamide;

[0645] 3-Phenyl-propynoic acid quinolin-3-ylamide;

[0646] trans-2-Phenyl-cyclopropanecarboxylic acid quinolin-3-ylamide;

[0647] 3-(4-tert-Butyl-phenyl)-propynoic acid quinolin-3-ylamide; and

[0648] 2-(4-tert-Butyl-phenyl)-cyclopropanecarboxylic acidquinolin-3-ylamide.

[0649] The present invention is also directed to a compound selectedfrom the group consisting of

[0650] 1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide;

[0651] 3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-acrylamide;

[0652] 3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-propionamide;

[0653] 3-{4-(1,1-Dimethyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;

[0654] 4-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-benzamide;

[0655] 4-Azepan-1-yl-N-quinolin-3-yl-benzamide;

[0656] 6-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-nicotinamide;

[0657] 4-tert-Butyl-N-(4-hydroxy-quinolin-3-yl)-benzamide;

[0658] 3-(4-tert-Butyl-phenyl)-N-(4-hydroxy-quinolin-3-yl)-acrylamide;

[0659]N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-acrylamide;

[0660]N-(4-Chloro-quinolin-3-yl)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-acrylamide;

[0661] N-(4-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;

[0662] N-(2-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;

[0663] 4-tert-Butyl-N-(2-methoxy-quinolin-3-yl)-benzamide;

[0664] 4-Azepan-1-yl-N-(4-chloro-quinolin-3-yl)-benzamide;

[0665]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(2-chloro-quinolin-3-yl)-benzamide;

[0666] 4-Azepan-1-yl-N-(2-chloro-quinolin-3-yl)-benzamide;

[0667]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(4-chloro-quinolin-3-yl)-benzamide;

[0668]3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;

[0669] 1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid(2-chloro-quinolin-3-yl)-amide;

[0670]N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-2,3-dihydro-1H-indol-5-yl)-acrylamide;

[0671] 3-(1-Cyclohexyl-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;

[0672]N-(4-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;

[0673] 1-Cyclohexyl-1H-indole-5-carboxylic acid(4-chloro-quinolin-3-yl)-amide;

[0674] 1-Cyclohexyl-1H-indole-5-carboxylic acid quinolin-3-ylamide;

[0675] 1-Cyclohexyl-1H-indole-5-carboxylic acid(2-chloro-quinolin-3-yl)-amide;

[0676]N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;

[0677] 4-(Cyclohexyl-methyl-amino)-N-(8-fluoro-quinolin-3-yl)-benzamide;

[0678] 4-Azocan-1-yl-N-(8-fluoro-quinolin-3-yl)-benzamide;

[0679]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-fluoro-quinolin-3-yl)-benzamide;

[0680]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;

[0681]4-(Cyclohexyl-methyl-amino)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;

[0682] 4-(Cyclohexyl-methyl-amino)-N-(6-fluoro-quinolin-3-yl)-benzamide;

[0683] 4-Azocan-1-yl-N-(6-fluoro-quinolin-3-yl)-benzamide;

[0684]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(6-fluoro-quinolin-3-yl)-benzamide;

[0685]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;

[0686] 4-Azocan-1-yl-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;

[0687]4-(Cyclohexyl-methyl-amino)-N-(7-trifluoromethyl-quinolin-3-yl-)benzamide;

[0688] 4-Azocan-1-yl-N-(5-fluoro-quinolin-3-yl)-benzamide;

[0689]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(5-fluoro-quinolin-3-yl)-benzamide;

[0690] 3-Phenyl-propynoic acid quinolin-3-ylamide;

[0691] trans-2-Phenyl-cyclopropanecarboxylic acid quinolin-3-ylamide;

[0692] 3-(4-tert-Butyl-phenyl)-propynoic acid quinolin-3-ylamide; and

[0693] 2-(4-tert-Butyl-phenyl)-cyclopropanecarboxylic acidquinolin-3-ylamide.

[0694] The compounds of the present invention may also be present in theform of pharmaceutically acceptable salts. For use in medicine, thesalts of the compounds of this invention refer to non-toxic“pharmaceutically acceptable salts” (Ref. International J. Pharm., 1986,33, 201-217; J. Pharm.Sci., 1997 (Jan), 66, 1, 1). Other salts wellknown to those in the art may, however, be useful in the preparation ofcompounds according to this invention or of their pharmaceuticallyacceptable salts. Representative organic or inorganic acids include, butare not limited to, hydrochloric, hydrobromic, hydriodic, perchloric,sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic,succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic,methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic,2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic,salicylic, saccharinic or trifluoroacetic acid. Representative organicor inorganic bases include, but are not limited to, basic or cationicsalts such as benzathine, chloroprocaine, choline, diethanolamine,ethylenediamine, meglumine, procaine, aluminum, calcium, lithium,magnesium, potassium, sodium and zinc.

[0695] The present invention includes within its scope prodrugs of thecompounds of this invention. In general, such prodrugs will befunctional derivatives of the compounds that are readily convertible invivo into the required compound. Thus, in the methods of treatment ofthe present invention, the term “administering” shall encompass thetreatment of the various disorders described with the compoundspecifically disclosed or with a compound which may not be specificallydisclosed, but which converts to the specified compound in vivo afteradministration to the patient. Conventional procedures for the selectionand preparation of suitable prodrug derivatives are described, forexample, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.

[0696] Where the compounds according to this invention have at least onechiral center, they may accordingly exist as enantiomers. Where thecompounds possess two or more chiral centers, they may additionallyexist as diastereomers. It is to be understood that all such isomers andmixtures thereof are encompassed within the scope of the presentinvention. Furthermore, some of the crystalline forms for the compoundsmay exist as polymorphs and as such are intended to be included in thepresent invention. In addition, some of the compounds may form solvateswith water (i.e., hydrates) or common organic solvents, and suchsolvates are also intended to be encompassed within the scope of thisinvention.

[0697] Where the processes for the preparation of the compoundsaccording to the invention give rise to mixture of stereoisomers, theseisomers may be separated by conventional techniques such as preparativechromatography. The compounds may be prepared in racemic form, orindividual enantiomers may be prepared either by enantiospecificsynthesis or by resolution. The compounds may, for example, be resolvedinto their component enantiomers by standard techniques, such as theformation of diastereomeric pairs by salt formation with an opticallyactive acid, such as (−)-di-p-toluoyl-d-tartaric acid and/or(+)-di-p-toluoyl-1-tartaric acid followed by fractional crystallizationand regeneration of the free base. The compounds may also be resolved byformation of diastereomeric esters or amides, followed bychromatographic separation and removal of the chiral auxiliary.Alternatively, the compounds may be resolved using a chiral HPLC column.

[0698] During any of the processes for preparation of the compounds ofthe present invention, it may be necessary and/or desirable to protectsensitive or reactive groups on any of the molecules concerned. This maybe achieved by means of conventional protecting groups, such as thosedescribed in Protective Groups in Organic Chemistry, ed. J. F. W.McOmie, Plenum Press, 1973; and T. W. Greene & P. G. M. Wuts, ProtectiveGroups in Organic Synthesis, 3^(rd) Edition, John Wiley & Sons, 1999.The protecting groups may be removed at a convenient subsequent stageusing methods known from the art.

[0699] Even though the compounds of the present invention (includingtheir pharmaceutically, acceptable salts and pharmaceutically acceptablesolvates) can be administered alone, they will generally be administeredin admixture with a pharmaceutical carrier, excipient or diluentselected with regard to the intended route of administration andstandard pharmaceutical or veterinary practice. Thus, the presentinvention is directed to pharmaceutical and veterinary compositionscomprising compounds of Formula (I) and one or more pharmaceuticallyacceptable carriers, excipients or diluents.

[0700] By way of example, in the pharmaceutical and veterinarycompositions of the present invention, the compounds of the presentinvention may be admixed with any suitable binder(s), lubricant(s),suspending agent(s), coating agent(s), and/or solubilising agent(s).

[0701] Tablets or capsules of the compounds may be administered singlyor two or more at a time, as appropriate. It is also possible toadminister the compounds in sustained release formulations.

[0702] Alternatively, the compounds of the general Formula (I) can beadministered by inhalation or in the form of a suppository or pessary,or they may be applied topically in the form of a lotion, solution,cream, ointment or dusting powder. An alternative means of transdermaladministration is by use of a skin patch. For example, they can beincorporated into a cream consisting of an aqueous emulsion ofpolyethylene glycols or liquid paraffin. They can also be incorporated,at a concentration of between 1 and 10% by weight, into an ointmentconsisting of a white wax or white soft paraffin base together with suchstabilisers and preservatives as may be required.

[0703] For some applications, preferably the compositions areadministered orally in the form of tablets containing excipients such asstarch or lactose, or in capsules or ovules either alone or in admixturewith excipients, or in the form of elixirs, solutions or suspensionscontaining flavouring or coloring agents.

[0704] The compositions (as well as the compounds alone) can also beinjected parenterally, for example intracavernosally, intravenously,intramuscularly or subcutaneously. In this case, the compositions willcomprise a suitable carrier or diluent.

[0705] For parenteral administration, the compositions are best used inthe form of a sterile aqueous solution which may contain othersubstances, for example enough salts or monosaccharides to make thesolution isotonic with blood.

[0706] For buccal or sublingual administration the compositions may beadministered in the form of tablets or lozenges which can be formulatedin a conventional manner.

[0707] By way of further example, pharmaceutical and veterinarycompositions containing one or more of the compounds of the inventiondescribed herein as the active ingredient can be prepared by intimatelymixing the compound or compounds with a pharmaceutical carrier accordingto conventional pharmaceutical compounding techniques. The carrier maytake a wide variety of forms depending upon the desired route ofadministration (e.g., oral, parenteral). Thus for liquid oralpreparations such as suspensions, elixirs and solutions, suitablecarriers and additives include water, glycols, oils, alcohols, flavoringagents, preservatives, stabilizers, coloring agents and the like; forsolid oral preparations, such as powders, capsules and tablets, suitablecarriers and additives include starches, sugars, diluents, granulatingagents, lubricants, binders, disintegrating agents and the like. Solidoral preparations may also be coated with substances such as sugars orbe enteric-coated so as to modulate the major site of absorption. Forparenteral administration, the carrier will usually consist of sterilewater and other ingredients may be added to increase solubility orpreservation. Injectable suspensions or solutions may also be preparedutilizing aqueous carriers along with appropriate additives.

[0708] Advantageously, compounds of the present invention may beadministered in a single daily dose, or the total daily dosage may beadministered in divided doses of two, three or four times daily.Furthermore, compounds for the present invention can be administered inintranasal form via topical use of suitable intranasal vehicles, or viatransdermal skin patches well known to those skilled in that art. To beadministered in the form of a transdermal delivery system, the dosageadministration will, of course, be continuous rather than intermittentthroughout the dosage regimen.

[0709] A therapeutically effective amount for use of the instantcompounds or a pharmaceutical composition thereof comprises a dose rangeof from about 0.001 mg to about 1,000 mg, in particular from about 0.1mg to about 500 mg or, more particularly from about 1 mg to about 250 mgof active ingredient per day for an average (70 kg) human.

[0710] For oral administration, a pharmaceutical composition ispreferably provided in the form of tablets containing, 0.01, 0.05, 0.1,0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 and 500milligrams of the active ingredient for the symptomatic adjustment ofthe dosage to the subject to be treated.

[0711] It is also apparent to one skilled in the art that thetherapeutically effective dose for active compounds of the invention ora pharmaceutical composition thereof will vary according to the desiredeffect. Therefore, optimal dosages to be administered may be readilydetermined and will vary with the particular compound used, the mode ofadministration, the strength of the preparation, and the advancement ofthe disease condition. In addition, factors associated with theparticular subject being treated, including subject age, weight, dietand time of administration, will result in the need to adjust the doseto an appropriate therapeutic level. The above dosages are thusexemplary of the average case. There can, of course, be individualinstances where higher or lower dosage ranges are merited, and such arewithin the scope of this invention.

[0712] Compounds of this invention may be administered in any of theforegoing compositions and dosage regimens or by means of thosecompositions and dosage regimens established in the art whenever use ofthe compounds of the invention as vanilloid receptor modulators isrequired for a subject in need thereof.

[0713] The invention also provides a pharmaceutical or veterinary packor kit comprising one or more containers filled with one or more of theingredients of the pharmaceutical and veterinary compositions of theinvention. Optionally associated with such container(s) can be a noticein the form prescribed by a governmental agency regulating themanufacture, use or sale of pharmaceuticals or biological products,which notice reflects approval by the agency of manufacture, use or salefor human administration.

[0714] As modulators of the vanilloid VR1 ion channel, the compounds ofFormula (I), are useful in methods for treating or preventing a diseaseor condition in a mammal which disease or condition is affected by themodulation of one or more vanilloid receptors. Such methods comprisesadministering to a mammal in need of such treatment or prevention atherapeutically effective amount of a compound, salt or solvate ofFormula (I). In particular, the compounds of Formula (I) are useful inmethods for preventing or treating a chronic- or acute-pain causingdiseases or conditions and pulmonary dysfunction, and more particulalry,in treating diseases or conditions that cause inflammatory pain, burningpain, itch or urinary incontinence, and chronic obstructive pulmonarydisease.

[0715] By way of example only, the compounds of Formula (I), are usefulfor treating diseases and conditions selected from the group consistingof osteoarthritis, rheumatoid arthritis, fibromyalgia, migraine,headache, toothache, burn, sunburn, snake bite (in particular, venomoussnake bite), spider bite, insect sting, neurogenic bladder, benignprostatic hypertrophy, interstitial cystitis, urinary tract infection,cough asthma, pharyngitis, mucositis, pancreatitis, enteritis,cellulites, peripheral neuropathy, bilateral peripheral neuropathy,diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia,causalgia, sciatic neuritis, mandibular joint neuralgia, peripheralneuritis, polyneuritis, stump pain, phantom limb pain, bony fractures,post-operative ileus, Irritable Bowel Syndrome, Inflammatory BowelDiseases such as Crohn's Disease and ulcerative colitis, cholecystitis,pancreatitis, postmastectomy pain syndrome, oral neuropathic pain,Charcot's pain, reflex sympathetic dystrophy, Guillain-Barre syndrome,meralgia paresthetica, burning-mouth syndrome, optic neuritis,postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault'sneuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia,geniculate neuralgia, glossopharyngial neuralgia, migrainous neuralgia,idiopathic neuralgia, intercostals neuralgia, mammary neuralgia,Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, redneuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbitalneuralgia, vidian neuralgia, sinus headache, tension headache, labor,childbirth, intestinal gas, menstruation, cancer, and trauma.

[0716] Thus, one embodiment of the present invention is a method oftreating or preventing ulcerative colitis comprising administering to amammal in need of such treatment or prevention a therapeuticallyeffective amount of a compound, salt or solvate of formulae (I), (II),(III), or (IV).

[0717] While the present invention comprises compositions comprising oneor more of the compounds of Formula (I), the present invention alsocomprises compositions comprising intermediates used in the manufactureof compounds of Formula (I).

General Synthetic Methods

[0718] Representative compounds of the present invention can besynthesized in accordance with the general synthetic methods describedbelow and are illustrated in the schemes that follows. Since the schemesare an illustration, the invention should not be construed as beinglimited by the chemical reactions and conditions expressed. Thepreparation of the various starting materials used in the schemes iswell within the skill of persons versed in the art.

[0719] It is generally preferred that the respective product of eachprocess step be separated from other components of the reaction mixtureand subjected to purification before its use as a starting material in asubsequent step. Separation techniques typically include evaporation,extraction, precipitation and filtration. Purification techniquestypically include column chromatography (Still, W. C. et. al., J. Org.Chem. 1978, 43, 2921), thin-layer chromatography, crystallization anddistillation. The structures of the final products, intermediates andstarting materials are confirmed by spectroscopic, spectrometric andanalytical methods including nuclear magnetic resonance (NMR), massspectrometry (MS) and liquid chromatography (HPLC). In the descriptionsfor the preparation of compounds of this invention, ethyl ether,tetrahydrofuran and dioxane are common examples of an ethereal solvent;benzene, toluene, hexanes and cyclohexane are typical hydrocarbonsolvents and dichloromethane and dichloroethane are representativehalogenhydrocarbon solvents. In those cases wherein the product isisolated as the acid addition salt the free base may be obtained bytechniques known to those skilled in the art. In those cases in whichthe product is isolated as an acid addition salt, the salt may containone or more equivalents of the acid.

[0720] Protecting group manipulations well know to those skilled in theart may be needed at various stages of the syntheses depending uponsubstituents and functional groups that are present on the reactants.

[0721] HBTU=O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluroniumhexafluorophosphate

[0722] CDI=1,1′-carbonyldiimidazole

[0723] TEA=triethylamine

[0724] DIEA=N,N-diisopropylethylamine

[0725] DMF=N,N-dimethylformamide

[0726] TFA=trifluoroacetic acid

[0727] DMSO=dimethyl sulfoxide

[0728] mCPBA=3-chloroperoxybenzoic acid

Scheme A

[0729] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme A below.

[0730] More specifically, a suitably substituted benzene (IA) wasreacted with hexamethylenetetramine and an acid such as trifluoroaceticacid at an elevated temperature preferably at a temperature in the rangeof 80-100° C., to yield the corresponding compound of formula (IIA).

[0731] The compound of formula (IIA) was reacted with an oxidizing agentsuch as manganese dioxide, Jones reagent and the like in a suitablesolvent such as acetone, dichloromethane and the like to yield thecorresponding compound of formula (IIIA).

[0732] The compound of formula (IIIA) was then reacted with a suitablysubstituted 3-aminoquinoline using peptide coupling methods known tothose skilled in the art to provide a compound of formula (IVA).

Scheme B

[0733] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme B below.

[0734] More specifically, a compound of formula (IIA), prepared asdescribed above was reacted with a Wittig reagent such asethyl(triphenylphosphoranylidene)acetate (purchased from AldrichChemicals) in a suitable solvent such as benzene or toluene at anelevated temperature, preferably at a temperature in a range of 80-100°C. to yield the compound of formula (IB).

[0735] The compound of formula (IB) was reduced by treating withhydrogen gas at an elevated pressure in the range of about 40-50 psi ina suitable solvent such as ethanol or methanol and the like, in thepresence of a catalyst such as 10% palladium on carbon at ambienttemperature to yield the corresponding compound of formula (IIB).

[0736] The compound of formula (IIB) was saponified by reaction withsuitable base such as sodium hydroxide, potassium hydroxide, lithiumhydroxide, sodium carbonate, potassium carbonate and the like in asolvent such as ethanol, methanol, aqueous tetrahydrofuran and the like,at a temperature from ambient temperature to a temperature of about70-100° C. to yield the corresponding compound of formula (IIIB).

[0737] The compound of formula (IIIB) was then reacted with a suitablysubstituted 3-aminoquinoline using peptide coupling methods known tothose skilled in the art to provide a compound of formula (IVB).

Scheme C

[0738] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme C below.

[0739] More specifically, a compound of formula (IIA), prepared asdescribed above, was reacted with a Wittig reagent such as(2-carboxyethyl)triphenylphosphonium chloride (prepared as described inthe literature, Journal of Organic Chemistry 1962, 3407) in the presenceof a strong base such as potassium t-butoxide in a suitable solvent sucha tetrahydrofuran or diethylether and the like at a temperature rangingfrom 0° C. to ambient temperature to yield the compound of formula (IC).

[0740] The compound of formula (IC) was reduced by treating withhydrogen gas at an elevated pressure in the range of about 40-50 psi ina suitable solvent such as ethanol or methanol and the like, in thepresence of a catalyst such as 10% palladium on carbon at ambienttemperature to yield the corresponding compound of formula (IIIC).

[0741] The compound of formula ((IIIC) was reacted with a suitablysubstituted 3-aminoquinoline using peptide coupling methods known tothose skilled in the art to provide a compound of formula (IVC).

[0742] In addition, a compound of formula (IC) was reacted with asuitably substituted 3-aminoquinoline using peptide coupling methodsknown to those skilled in the art to provide a compound of formula(IIC).

Scheme D

[0743] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme D below.

[0744] More specifically, a suitably substituted aldehyde of formula(ID) was reacted with a Grignard reagent such as ethylmagnesium bromidein a suitable solvent such as tetrahydrofuran or diethylether to yieldthe corresponding compound of formula (IID).

[0745] The compound of formula (IID) was reacted with an oxidizing agentsuch as manganese dioxide or Jones reagent in a suitable solvent such asacetone, dichloromethane and the like at a temperature of 0° C. to roomtemperature to yield the corresponding compound of formula (IIID).

[0746] The compound of formula (IIID) was reacted with titaniumtetrachloride and dimethylzinc in a suitable solvent such asdichloromethane at a temperature in the range of −50° C. to ambienttemperature to yield the corresponding compound of formula (IVD).

[0747] The compound of formula (IVD) was reacted with n-butyllithium andDMF in a suitable solvent such as diethylether ot tetrahydrofuran andthe like at about 0° C. to yield the corresponding aldehyde of formula(VD).

[0748] The compound of formula (VD) was reacted with a Wittig reagentsuch as ethyl(triphenylphosphoranyl idene)acetate (purchased fromAldrich Chemicals) in a suitable solvent such a benzene or toluene at anelevated temperature, preferably at a temperature in a range of 80-100°C. to yield the compound of formula (VID).

[0749] The compound of formula (VID) was reduced by treating withhydrogen gas at an elevated pressure in the range of about 40-50 psi ina suitable solvent such as ethanol or methanol and the like, in thepresence of a catalyst such as 10% palladium on carbon at ambienttemperature to yield the corresponding compound of formula (VIID).

[0750] The compound of formula (VIID) was saponified by reaction withsuitable base such as sodium hydroxide, potassium hydroxide, lithiumhydroxide, sodium carbonate, potassium carbonate and the like in asolvent such as ethanol, methanol, aqueous tetrahydrofuran and the like,at a temperature from ambient temperature to a temperature of about70-100° C. to yield the corresponding compound of formula (VIIID).

[0751] The compound of formula (VIIID) was then reacted with a suitablysubstituted 3-aminoquinoline using peptide coupling methods known tothose skilled in the art to provide a compound of formula (IXD).

Scheme E

[0752] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme E below.

[0753] More specifically, 2-bromothiophene was converted to1-(5-bromothiophe-2-yl)-propan-1-one (IE) as described in the literature(JACS 1950, 3695). The compound of formula (IE) was reacted withtitanium tetrachloride and dimethylzinc in a suitable solvent such asdichloromethane at a temperature in the range of −50° C. to ambienttemperature to yield the corresponding compound of formula (IIE). Thecompound of formula (IIE) was reacted with n-butyllithium and DMF in asuitable solvent such as diethylether ot tetrahydrofuran and the like atabout 0° C. to yield the corresponding aldehyde of formula (IIIE).

[0754] The compound of formula (IIIE) was reacted with a Wittig reagentsuch as ethyl(triphenylphosphoranylidene)acetate (purchased from AldrichChemicals) in a suitable solvent such a benzene or toluene at anelevated temperature, preferably at a temperature in a range of 80-100°C. to yield the compound of formula (IVE).

[0755] The compound of formula (IVE) was reduced by treating withhydrogen gas at an elevated pressure in the range of about 40-50 psi ina suitable solvent such as ethanol or methanol and the like, in thepresence of a catalyst such as 10% palladium on carbon at ambienttemperature to yield the corresponding compound of formula (VE).

[0756] The compound of formula (VE) was saponified by reaction withsuitable base such as sodium hydroxide, potassium hydroxide, lithiumhydroxide, sodium carbonate, potassium carbonate and the like in asolvent such as ethanol, methanol, aqueous tetrahydrofuran and the like,at a temperature from ambient temperature to a temperature of about70-100° C. to yield the corresponding compound of formula (VIE).

[0757] The compound of formula (VIE) was then reacted with a suitablysubstituted 3-aminoquinoline using peptide coupling methods known tothose skilled in the art to provide a compound of formula (VIIE).

Scheme F

[0758] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme F below.

[0759] More specifically, a suitably substituted cyano-bromobenzene wasreacted with a Grignard reagent such as phenethyl magnesium chloride ina suitable solvent such as diethylether, tetrahydrofuran and the like toyield the corresponding ketone of formula (IF).

[0760] The compound of formula (IF) was reacted with titaniumtetrachloride and dimethylzinc in a suitable solvent such asdichloromethane at a temperature in the range of −50° C. to ambienttemperature to yield the corresponding compound of formula (IIF).

[0761] The compound of formula (IIF) underwent a Heck reaction with anunsaturated substrate such as methyl acrylate in the presence of apalladium catalyst such as palladium acetate and a ligand such astri-o-tolylphosphine or triphenylphosphine in a solvent such as THF,ether and the like at an elevated temperature, preferably at atemperature in a range of 80-100° C. to yield the corresponding compoundof formula (IIIF).

[0762] The compound of formula (IIIF) was reduced by treating withhydrogen gas at an elevated pressure in the range of about 40-50 psi ina suitable solvent such as ethanol or methanol and the like, in thepresence of a catalyst such as 10% palladium on carbon at ambienttemperature to yield the corresponding compound of formula (IVF).

[0763] The compound of formula (IVF) was saponified by reaction withsuitable base such as sodium hydroxide, potassium hydroxide, lithiumhydroxide, sodium carbonate, potassium carbonate and the like in asolvent such as ethanol, methanol, aqueous tetrahydrofuran and the like,at a temperature from ambient temperature to a temperature of about70-100° C. to yield the corresponding compound of formula (VF).

[0764] The compound of formula (VF) was then reacted with a suitablysubstituted 3-aminoquinoline using peptide coupling methods known tothose skilled in the art to provide a compound of formula (VIF).

Scheme G

[0765] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme G below.

[0766] More specifically, a suitably substituted quinoline ester isreacted with an alkyl triflate such as methyl, n-butyl or n-pentyltriflate to yield the corresponding compound of formula (IG).

[0767] The compound of formula (IG) was reduced by treating withhydrogen gas at an elevated pressure in the range of about 40-50 psi ina suitable solvent such as ethanol or methanol and the like, in thepresence of a catalyst such as 10% palladium on carbon at ambienttemperature to yield the corresponding compound of formula (IIG).

[0768] The compound of formula (IIG) was saponified by reaction withsuitable base such as sodium hydroxide, potassium hydroxide, lithiumhydroxide, sodium carbonate, potassium carbonate and the like in asolvent such as ethanol, methanol, aqueous tetrahydrofuran and the like,at a temperature from ambient temperature to a temperature of about70-100° C. to yield the corresponding compound of formula (IIIG).

[0769] The compound of formula (IIIG) was reacted with a chlorinatingagent such as oxalyl chloride or thionyl chloride in the presence of anacylation catalyst such as DMF in a suitable solvent such as methylenechloride, chloroform or dichloroethane and the like at a temperature ofabout 0° C. to yield the corresponding compound of formula (IVG).

[0770] The compound of formula (IVG) was reacted with a suitablysubstituted 3-aminoquinoline in the presence of an organic base such asdiisopropylethylamine or triethylamine and the like, in a suitablesolvent such as methylene chloride, dichloroethane, DMF and the like, toyield the corresponding compound of formula (VG).

Scheme H

[0771] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme H below.

[0772] More specifically, a suitably substituted nitro-cinnamate wasreduced by treating with hydrogen gas at an elevated pressure in therange of about 40-50 psi in a suitable solvent such as ethanol ormethanol and the like, in the presence of a catalyst such as 10%palladium on carbon at ambient temperature to yield the correspondingcompound of formula (IH).

[0773] The compound of formula (IH) was reacted with an appropriatelysubstituted aldehyde or ketone in the presence of a reducing agent suchas tetramethylammonium triacetoxyborohydride, sodiumtriacetoxyborohydride, sodium cyanoborohydride and the like in asuitable solvent such as dichloroethane, dichloromethane, chloroform,methanol, tetrahydrofuran and the like at a temperature in the range ofambient temperature to a temperature of about 70-100 ° C. to yield thecorresponding amine of formula (IIH).

[0774] The compound of formula (IIH) could be reacted with a suitablysubstituted aldehyde and a reducing agent such as tetramethylammoniumtriacetoxyborohydride, sodium triacetoxyborohydride, sodiumcyanoborohydride and the like in a suitable solvent such asdichloroethane, dichloromethane, chloroform, methanol, tetrahydrofuranand the like at a temperature in the range of ambient temperature to atemperature of about 70-100° C. to yield the corresponding amine offormula (IIIH).

[0775] The compound of formula (IIIH) was saponified by reaction withsuitable base such as sodium hydroxide, potassium hydroxide, lithiumhydroxide, sodium carbonate, potassium carbonate and the like in asolvent such as ethanol, methanol, aqueous tetrahydrofuran and the like,at a temperature from ambient temperature to a temperature of about70-100° C. to yield the corresponding compound of formula (IVH).

[0776] The compound of formula (IVH) was then reacted with a suitablysubstituted 3-aminoquinoline using peptide coupling methods known tothose skilled in the art to provide a compound of formula (VH).

Scheme I

[0777] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme I below.

[0778] More specifically, a suitably substituted amino-cinnamate wasreacted initially with a suitably substituted aldehyde or ketone and areducing agent such as tetramethylammonium triacetoxyborohydride, sodiumtriacetoxyborohydride, sodium cyanoborohydride and the like in asuitable solvent such as dichloroethane, dichloromethane, chloroform,methanol, tetrahydrofuran and the like at a temperature in the range ofambient temperature to a temperature of about 70-100° C. This reactioncould be followed, in the same reaction vessel, by reaction with asuitably substituted aldehyde and a reducing agent such astetramethylammonium triacetoxyborohydride, sodium triacetoxyborohydride,sodium cyanoborohydride and the like in a suitable solvent such asdichloroethane, dichloromethane, chloroform, methanol, tetrahydrofuranand the like at a temperature in the range of ambient temperature to atemperature of about 70-100° C. to yield the corresponding amine offormula (II).

[0779] The compound of formula (II) was saponified by reaction withsuitable base such as sodium hydroxide, potassium hydroxide, lithiumhydroxide, sodium carbonate, potassium carbonate and the like in asolvent such as ethanol, methanol, aqueous tetrahydrofuran and the like,at a temperature from ambient temperature to a temperature of about70-100° C. to yield the corresponding compound of formula (III).

[0780] The compound of formula (III) was then reacted with a suitablysubstituted 3-aminoquinoline using peptide coupling methods known tothose skilled in the art to provide a compound of formula (III).

Scheme J

[0781] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme J below.

[0782] More specifically, a compound of formula (IH), obtained asdescribed above, was reacted with a suitably substituted aldehyde and areducing agent such as tetramethylammonium triacetoxyborohydride, sodiumtriacetoxyborohydride, sodium cyanoborohydride and the like in asuitable solvent such as dichloroethane, dichloromethane, chloroform,methanol, tetrahydrofuran and the like at a temperature in the range ofambient temperature to a temperature of about 70-100° C. to yield thecorresponding tertiary amine of formula (IJ).

[0783] The compound of formula (IJ) was saponified by reaction withsuitable base such as sodium hydroxide, potassium hydroxide, lithiumhydroxide, sodium carbonate, potassium carbonate and the like in asolvent such as ethanol, methanol, aqueous tetrahydrofuran and the like,at a temperature from ambient temperature to a temperature of about70-100° C. to yield the corresponding compound of formula (IIJ).

[0784] The compound of formula (IIJ) was then reacted with a suitablysubstituted 3-aminoquinoline using peptide coupling methods known tothose skilled in the art to provide a compound of formula (IIIJ).

Scheme K

[0785] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme K below.

[0786] More specifically, a compound of formula (IIA), prepared asdescribed above, was saponified by reaction with suitable base such assodium hydroxide, potassium hydroxide, lithium hydroxide, sodiumcarbonate, potassium carbonate and the like in a solvent such asethanol, methanol, aqueous tetrahydrofuran and the like, at atemperature from ambient temperature to a temperature of about 70-100°C. to yield the corresponding compound of formula (IK).

[0787] The compound of formula (IK) was then reacted with a suitablysubstituted 3-aminoquinoline using peptide coupling methods known tothose skilled in the art to provide a compound of formula (IIK).

Scheme L

[0788] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme L below.

[0789] More specifically, a suitable substituted aldehyde of formula(IIA) was reacted with the reagent tosylmethylisocyanide (TosMIC) in thepresence of a strong base such as potassium t-butoxide or sodiumt-butoxide in a solvent such as dimethoxyethane or tetrahydrofuran andthe like at a temperature in the range of −50° C. to 100° C. to yieldthe corresponding compound of formula (IL).

[0790] The compound of formula (IL) was hydrolyzed by reaction withsuitable base such as sodium hydroxide, potassium hydroxide and the likein a solvent such as ethanol, methanol, aqueous tetrahydrofuran and thelike, at an elevated temperature, preferably a temperature in the rangeof about 70-100° C. to yield the corresponding compound of formula(IIL).

[0791] The compound of formula (IIL) was reacted with a suitablysubstituted 3-aminoquinoline with a suitable coupling agent such asHATU, HBTU, 1,1′-carbonyl diimidazole and the like in the presence of anorganic base such as diisopropylethylamine or triethylamine and thelike, in a suitable solvent such as methylene chloride, dichloroethane,DMF and the like, to yield the corresponding compound of formula (IIIL).

Scheme M

[0792] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme M below.

[0793] More specifically, a suitably substituted benzaldehyde ester andthe aldehyde portion was reductively aminated with an appropriatelysubstituted amine in the presence of a reducing agent such astetramethylammonium triacetoxyborohydride, sodium triacetoxyborohydride,sodium cyanoborohydride and the like in a suitable solvent such asdichloroethane, dichloromethane, chloroform, methanol, tetrahydrofuranand the like at a temperature in the range of ambient temperature to atemperature of about 70-100° C. to yield the corresponding amine offormula (IM).

[0794] The compound of formula (IM) was then saponified by reaction withsuitable base such as sodium hydroxide, potassium hydroxide, lithiumhydroxide, sodium carbonate, potassium carbonate and the like in asolvent such as ethanol, methanol, aqueous tetrahydrofuran and the like,at a temperature from ambient temperature to a temperature of about70-100° C. to yield the corresponding compound of formula (IIM).

[0795] The compound of formula (IIM) was reacted with a chlorinatingagent such as oxalyl chloride or thionyl chloride in the presence of anacylation catalyst such as DMF in a suitable solvent such as methylenechloride, chloroform, dichloroethane and the like at a temperature ofabout 0° C. to yield the corresponding compound of formula (IIIM).

[0796] The compound of formula (IIIM) was reacted with a suitablysubstituted 3-aminoquinoline in the presence of an organic base such asdiisopropylethylamine or triethylamine and the like, in a suitablesolvent such as methylene chloride, dichloroethane, DMF and the like, toyield the corresponding compound of formula (IVM).

Scheme N

[0797] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme N below.

[0798] More specifically, a compound of formula (IN) was reacted with asuitably substituted 3-aminoquinoline with a suitable coupling agentsuch as HATU, HBTU, 1,1′-carbonyl diimidazole and the like in thepresence of an organic base such as diisopropylethylamine ortriethylamine and the like, in a suitable solvent such as methylenechloride, dichloroethane, DMF and the like, to yield the correspondingcompound of formula (IIIN).

[0799] Alternatively a compound of formula (IIN) was reacted with asuitably substituted 3-aminoquinoline in the presence of an organic basesuch as diisopropylethylamine or triethylamine and the like, in asuitable solvent such as methylene chloride, dichloroethane, DMF and thelike, to yield the corresponding compound of formula (IIIN).

Scheme O

[0800] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme O below.

[0801] More specifically, a compound of formula (IIIN) was reacted witha sulfurizing agent such as Lawesson's reagent or phosphorouspentasulfide in a suitable solvent such as benzene, toluene and the likeat an elevated temperature, preferably a temperature in the range ofabout 70-100° C. to yield the corresponding compound of formula (IO).

Scheme P

[0802] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme P below.

[0803] More specifically, a compound of formula (IJ), obtained asdescribed above, was reacted with glutaraldehyde in the presence of areducing agent such as sodium borohydride, tetramethylammoniumtriacetoxyborohydride, sodium triacetoxyborohydride, sodiumcyanoborohydride and the like in a suitable solvent such asdichloroethane, dichloromethane, chloroform, methanol, tetrahydrofuranand the like at a temperature in the range of ambient temperature to atemperature of about 70-100° C. to yield the corresponding tertiaryamine of formula (IO).

[0804] The compound of formula (IO) was saponified by reaction withsuitable base such as lithium hydroxide, sodium hydroxide, potassiumhydroxide, sodium carbonate, potassium carbonate and the like in asolvent such as ethanol, methanol, aqueous tetrahydrofuran and the like,at a temperature from ambient temperature to a temperature of about70-100° C. to yield the corresponding carboxylic acid of formula (IIO).

[0805] The compound of formula (IIO) was reacted with a chlorinatingagent such as oxalyl chloride or thionyl chloride in the presence of anacylation catalyst such as DMF in a suitable solvent such as methylenechloride, chloroform, dichloroethane and the like at a temperature ofabout 0° C. to yield the corresponding compound of formula (IIIO).

[0806] The compound of formula (IIIO) was reacted with a suitablysubstituted 3-aminoquinoline in the presence of an organic base such asdiisopropylethylamine or triethylamine and the like, in a suitablesolvent such as methylene chloride, dichloroethane, DMF and the like, toyield the corresponding compound of formula (IVO).

Scheme AA

[0807] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme AA below.

[0808] More specifically, a suitably substituted 3-aminoquinoline (IAA)and a suitably substituted ester was treated with trimethylaluminum inan aprotic solvent, such as 1,2-dichloroethane or toluene, at atemperature in the range of 0-100° C., to yield the correspondingcompound of the formula IVAA or VAA.

Scheme BB

[0809] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme BB below.

Scheme BB

[0810] More specifically, an acid of the formula (IIBB) was activatedwith a suitable activating reagent, such as HBTU or CDI or HATU, and asuitable base, such as TEA or DIEA, in a suitable solvent, such asacetonitrile or DMF or dichloromethane, at a temperature range 0-200°C., and subsequently treated with a suitably substituted3-aminoquinoline (IBB), at a temperature range of 0-200° C. to yield thecorresponding compound of the formula (IIIBB).

[0811] The compound of the formula (IIIBB) was treated with an acid,such as TFA or hydrochloric acid, in a suitable solvent, such asdichloromethane or methanol, at a temperature range of 0-100° C., toyield the corresponding compound of the formula (IVBB).

[0812] The compound of the formula (IVBB) and a suitably substitutedketone or aldehyde was treated with a suitable reducing agent, such astetramethylammonium triacetoxyborohydride or sodium cyanoborohydride, ina suitable solvent, such as 1,2-dichloroethane or methanol, at atemperature range of 0-100° C., to yield the corresponding compound ofthe formula (VBB).

[0813] The compound of the formula (VBB) and a suitably substitutedaldehyde or paraformaldehyde was treated with a suitable reducing agent,such as tetramethylammonium triacetoxyborohydride or sodiumcyanoborohydride, in a suitable solvent, such as 1,2-dichloroethane ormethanol, at a temperature range of 0-100° C., to yield thecorresponding compound of the formula (VIBB).

Scheme CC

[0814] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme CC below.

[0815] More specifically, a suitably substituted aminobenzoic acid (ICC)was treated with di-tert-butyl dicarbonate and a suitable base, such assodium hydroxide or sodium carbonate, in a suitable solvent, such aswater or dioxane, at a temperature range of 0-100° C., to yield thecorresponding compound of the formula (IICC).

[0816] An acid of the formula (IICC) was activated with and a suitableactivating reagent, such as HBTU or CDI or HATU, and a suitable base,such as TEA or DIEA, in a suitable solvent, such as acetonitrile or DMFor dichloromethane, at a temperature range 0-200° C., and subsequentlytreated with a suitably substituted 3-aminoquinoline, at a temperaturerange of 0-200° C. to yield the corresponding compound of the formula(IIICC).

[0817] The compound of the formula (IIICC) was treated with an acid,such as TFA or hydrochloric acid, in a suitable solvent, such asdichloromethane or methanol, at a temperature range of 0-100° C., toyield the corresponding compound of the formula (IVCC).

[0818] The compound of the formula (IVCC) and a suitably substitutedaldehyde was treated with a suitable reducing agent, such astetramethylammonium triacetoxyborohydride or sodium cyanoborohydride, ina suitable solvent, such as 1,2-dichloroethane or methanol, at atemperature range of 0-100° C., to yield the corresponding compound ofthe formula (VCC).

Scheme DD

[0819] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme DD below.

[0820] More specifically, 4-fluorobenzoic acid was activated with asuitable activating reagent, such as HBTU or CDI or HATU, and a suitablebase, such as TEA or DIEA, in a suitable solvent, such as acetonitrileor DMF or dichloromethane, at a temperature range 0-200° C., andsubsequently treated with a suitably substituted 3-aminoquinoline (IDD),at a temperature range of 0-200° C., to yield the corresponding compoundof the formula (IIDD).

[0821] The compound of the formula (IIDD) was treated with an amine(NHR⁵R⁶) in a suitable solvent, such as DMSO or DMF or methanol ortoluene, at a temperature of 50-200° C., to yield the correspondingcompound of the formula (IIIDD).

Scheme EE

[0822] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme EE below.

[0823] More specifically, 6-chloronicotinic acid was activated with asuitable activating reagent, such as HBTU or CDI or HATU, and a suitablebase, such as TEA or DIEA, in a suitable solvent, such as acetonitrileor DMF or dichloromethane, at a temperature range 0-200° C., andsubsequently treated with a suitably substituted 3-aminoquinoline (IEE),at a temperature range of 0-200° C., to yield the corresponding compoundof the formula (IIEE).

[0824] The compound of the formula (IIEE) was treated with an amine(NHR⁵R⁶) in a suitable solvent, such as DMSO or DMF or methanol ortoluene, at a temperature of 50-200° C., to yield the correspondingcompound of the formula (IIIEE).

Scheme FF

[0825] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme FF below.

[0826] More specifically, 5-bromoindoline (IFF) was treated with asuitable ketone or aldehyde and a suitable reducing agent, such astetramethylammonium triacetoxyborohydride or sodium cyanoborohydride, ina suitable solvent, such as 1,2-dichloroethane or methanol, at atemperature range of 0-100° C., to yield the corresponding compound ofthe formula (IIFF).

[0827] The compound of the formula (IIFF), methyl acrylate, a suitablecatalyst, such as palladium(II)acetate, a suitable phosphine ligand,such as tri-(otolyl)phosphine, a suitable base, such as TEA or DIEA, washeated to a temperature of 50-200° C., to yield the correspondingcompound of the formula (IIIFF).

[0828] A compound of the formula (IIIFF) and suitably substituted3-aminoquinoline was treated with trimethylaluminum in an aproticsolvent, such as 1,2-dichloroethane or toluene, at a temperature in therange of 0-200° C., to yield the corresponding compound of the formula(IVFF).

[0829] The compound of the formula (IIFF), a suitable catalyst, such asbis(triphenylphosphine)palladium(II)chloride, a suitable phosphineligand, such as triphosphine, a suitable base, such as TEA or DIEA, inthe presence of carbon monoxide (20-200 psi) was heated to a temperatureof 50-200° C., to yield the corresponding compound of the formula (VFF).

[0830] A compound of the formula (VFF) and suitably substituted3-aminoquinoline was treated with trimethylaluminum in an aproticsolvent, such as 1,2-dichloroethane or toluene, at a temperature in therange of 0-200° C., to yield the corresponding compound of the formula(VIFF).

Scheme GG

[0831] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme GG below.

[0832] More specifically, a compound of the formula (IGG) was treatedwith a suitable base, such as sodium hydride, and an alkyl halide, in asuitable solvent, such as DMF or THF or DMSO, at a temperature range of0-200° C., to yield the corresponding compound of the formula (IIGG,R^(A)=Me).

[0833] A compound of the formula (IIGG, R^(A)=Me) was saponified with asuitable source of hydroxide, such as sodium hydroxide or potassiumhydroxide, in a suitable solvent, such as methanol or water or THF, at atemperature range of of 0-200° C., to yield the corresponding compoundof the formula (IIIGG, R^(A)=H).

[0834] An acid of the formula (IIIGG, R^(A)=H) was activated with asuitable activating reagent, such as HBTU or CDI or HATU, and a suitablebase, such as TEA or DIEA, in a suitable solvent, such as acetonitrileor DMF or dichloromethane, at a temperature range 0-200° C., andsubsequently treated with a suitably substituted 3-aminoquinoline, at atemperature range of 0-200° C., to yield the corresponding compound ofthe formula (IVGG).

Scheme HH

[0835] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme HH below.

[0836] More specifically, 4-fluorobenzaldehyde was treated with an amine(NHR⁵R⁶) in a suitable solvent, such as acetonitrile or DMSO or toluene,at a temperature range of 50-200° C., to yield a compound of the formula(IIHH).

[0837] A compound of the formula (IIHH)was treated with a suitableWittig reagent, such as triethyl phosphonoacetate, a suitable base, suchas DBU, and lithium chloride, in a suitable solvent, such asacetonitrile or dichloromethane, at a temperature of 50-200° C., toyield a compound of the formula (IIIHH).

[0838] A compound of the formula (IIIHH) and a suitably substituted3-aminoquinoline was treated with trimethyl aluminum in a suitablesolvent, such as 1,2-dichloroethane or toluene, at a temperature rangeof 0-200° C., to yield a compound of the formula (IVHH).

[0839] A compound of the formula (IIIHH) was hydrogenated at 20-80 psi,with a suitable catalyst, such as palladium, in a suitable solvent, suchas methanol, at a temperature range of 0-200° C., to yield a compound ofthe formula (VHH).

[0840] A compound of the formula (VHH) and a suitably substituted3-aminoquinoline was treated with trimethylaluminum in a suitablesolvent, such as 1,2-dichloroethane or toluene, at a temperature rangeof 0-200° C., to yield a compound of the formula (VIHH).

Scheme JJ

[0841] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme JJ below.

[0842] More specifically, a compound of the formula (IJJ) was treatedwith a suitable oxidizing agent, such as mCPBA, in a suitable solvent,such as dichloromethane, at a temperature range of −40-100° C., to yielda compound of the formula (IIJJ).

Scheme KK

[0843] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme KK below.

[0844] More specifically, a compound of formula (IKK) was treated withpiperazine in a suitable solvent, such as dimethylsulfoxide, at atemperature in the range of 50-250° C., to yield the correspondingcompound of the formula (IIKK).

[0845] The compound of the formula (IIKK) was coupled to a suitableorganic carboxylic acid, using coupling methods known to those skilledin the art to provide the compound of the formula (IIIKK).

Scheme LL

[0846] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme LL below.

[0847] More specifically, 5-bromoindoline (ILL) was treated withdi-tert-butyldicarbonate in a suitable solvent, such as dichloromethane,at a temperature in the range of 0-100° C., to yield the correspondingBOC-protected 5-bromoindoline (IILL).

[0848] The compound of the formula (IILL) was treated with anappropriate catalyst, such as bistriphenylphosphinopalladium(II)chloride, an appropriate organic base, such as tributylamine, in thepresence of carbon monoxide gas at 10 to 1000 psi, in methanol, at atemperature in the range of 20-200° C., to yield a the ester of theformula (IIILL).

[0849] The ester of the formula (IIILL) was converted to thecorresponding acid of the formula (IVLL) using saponification methodsknown to those skilled in the art.

[0850] The acid of the formula (IVLL) was coupled to an appropriatelysubstituted 3-aminoquinoline, using methods known to those skilled inthe art, to yield a compound of the formula (VLL).

[0851] A BOC-protected compound of the formula (VLL) was deprotectedusing an appropriate organic or inorganic acid, such as trifluoroaceticacid or hydrochloric acid, in a suitable solvent, such asdichloromethane or dioxane, at a temperature in the range of 0-100° C.,to yield the compound of the formula (VILL).

[0852] A compound of the formula (VILL) was treated with an appropriateacid chloride and a suitable organic base, such asN,N-diisopropylethylamine, in a suitable solvent, such as1,2-dichloroethane or tetrahydrofuran, at a temperature in the range of0-100° C., to yield the compound of the formula (VIILL) wherein R⁵ is analkanylcarbonyl or arylcarbonyl as defined herein.

Scheme MM

[0853] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme MM below.

[0854] More specifically, a compound of formula (IM) was treated withthe appropriate acid chloride and a suitable organic base, such astriethyamine or N,N-diisopropylethylamine, in a suitable solvent, suchas 1,2-dichloroethane, at a temperature in the range of 0-100° C., toyield the corresponding compound of the formula (IIMM) wherein R⁵ is analkanylcarbonyl or arylcarbonyl as defined herein.

Scheme NN

[0855] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme NN below.

[0856] More specifically, a suitably substituted compound of formula(INN) was treated with diethyl ethoxymethylenemalonate and heated to atemperature in the range of 0-300° C., to yield the correspondingcompound of the formula (IINN). A compound of formula (IINN) was addedto a high boiling solvent such as diphenylether at a temperature in therange of 200-400° C. to yield the corresponding compound of the formula(IIINN).

[0857] A compound of formula (IIINN) was treated with thionyl chlorideor phosphorous oxychloride at a temperature in the range of 25-200° C.,to yield the corresponding compound of the formula (IVNN).

[0858] A compound of formula (IVNN) was treated in with hydrogen gasover an appropriate catalyst, such as palladium, in an appropriatesolvent, such as ethanol or ethyl acetate or tetrahydrofuran at atemperature in the range of 25-200° C., to yield the correspondingcompound of the formula (VNN).

[0859] A compound of the formula (VNN) was treated with a source ofhydroxide ion, such as sodium hydroxide, in an appropriate solvent, suchas methanol or water, or mixture of solvents, such as methanol andwater, at a temperature in the range of 0-200° C., to yield thecorresponding compound of the formula (VINN). A compound of the formula(VINN) was treated with diphenylphosphoryl azide in the presence of abase, such as TEA or diisopropylethylamine, in t-butanol at atemperature in the range of 25-300° C. to yield the correspondingcompound of the formula (VIINN).

[0860] A compound of the formula (VIINN) was treated with an acid, suchas trifluoroacetic acid or hydrochloric acid or trifluoroacetic acidwith water, with or without a solvent, such as DCE or DCM or THF ormethanol, at a temperature in the range of 0-200° C., to yield thecorresponding compound of the formula (VIIINN).

[0861] A compound of the formula (VIIINN) was treated with theappropriate ester and trimethylaluminum in an appropriate aproticsolvent or mixture of solvents, such as DCE or DCM or toluene at atemperature in the range of 25-300° C., to yield the correspondingcompound of the formula (IXNN).

Scheme OO

[0862] Certain target compounds of the present invention may be preparedaccording to the process outlined in Scheme OO below.

[0863] More specifically, an ester of the formula (IOO) and anaminoquinoline of the formula (IIOO) was treated with thetrimethylaluminum in an appropriate aprotic solvent or mixture ofsolvents, such as DCE or DCM or toluene, at a temperature in the rangeof 25-300° C., to yield the corresponding compound of the formula(IIIOO).

SPECIFIC SYNTHETIC EXAMPLES

[0864] Specific compounds which are representative of the invention maybe prepared as per the following examples offered by way of illustrationand not by way of limitation. No attempt has been made to optimize theyields obtained in any of the reactions. One skilled in the art wouldknow how to increase such yields through routine variations in reactiontimes, temperatures, solvents and/or reagents.

[0865] Unless otherwise indicated, ¹H NMR's were run on a Bruker AC-300instrument. Mass spectral analyses were performed on a Fisons instrument(Hewlett-Packard HPLC driven electrospray MS instrument).

Preparation of Hydrocarbon Starting Materials

[0866]

[0867] A. To 25 mL anhydrous THF in a round bottom flask equipped with astir bar under a nitrogen atmosphere was added butylmagnesium chloride(2M in Et₂O, 20 mL, 40 mmol). Acetophenone (4.2 mL, 36.0 mmol) wasdissolved in 25 mL anhydrous THF and added dropwise via addition funnelto the reaction over a period of 17 minutes. The reaction was thenstirred overnight and quenched by addition of saturated ammoniumchloride solution (50 mL) and extracted once with 100 mL diethylether.The organics were washed once with additional saturated ammoniumchloride (50 mL), once with water (50 mL) and once with brine (50 mL).The organics were then dried over Na₂SO₄, filtered and concentrated invacuo to yield the product as a nearly colorless oil (6.33 g, 35.5mmol). This product was carried on to the next step without furtherpurification.

[0868] B. The tertiary alcohol from step A, 2-phenyl-hexan-2-ol (35.5mmol), was dissolved in 50 mL ethanol along with Pd(OH)₂ (0.695 g). Themixture was hydrogenated at ˜50 psi overnight, filtered over a pad ofcelite and the reaction was found to be incomplete. Fresh Pd(OH)₂ (0.741g) was added and the hydrogenation was continued overnight. The reactionmixture was filtered over a pad of celite and evaporated in vacuo toyield the title product as a tan liquid (3.874 g, 23.9 mmol). ¹H NMR(CDCl₃): δ 7.28 (m, 2H), 7.18 (m, 3H), 2.68 (h, 1H), 1.57 (m, 2H),1.34-1.03 (m, 7H), 0.87 (t, 3H).

[0869] Cyclohexylmethyl-benzene

[0870] A. To a nitrogen flushed 3-neck round bottom flask equipped witha stir bar and addition funnel was added 25 mL anhydrous THF andphenylmagnesium bromide (3M in Et₂O, 10.0 mL, 30.0 mmol). A solution ofcyclohexanecarboxaldehyde (3.3 mL, 27.2 mmol) in 15 mL anhydrous THF wasadded to the reaction mixture via addition funnel over a period of 6minutes. The reaction was allowed to stir for 48 hours at which time itwas quenched with saturated ammonium chloride (25 mL) and then extractedwith 100 mL diethylether. The organics were washed once with additionalsaturated ammonium chloride (50 mL), once with water (50 mL) and oncewith brine (50 mL). The organics were then dried over Na₂SO₄, filteredand concentrated in vacuo to yield the crude product, which was carriedon without further purification

[0871] B. The secondary alcohol from step A, was dissolved in 50 mLethanol along with Pd(OH)₂ (0.546 g). The mixture was hydrogenated at˜50 psi overnight at which time an additional amount of Pd(OH)₂ (1.08 g)was added and the hydrogenation was continued overnight. The reactionmixture was filtered over a pad of celite and evaporated in vacuo toyield the title product as a nearly colorless oil (4.560 g, 26.2 mmol).¹H NMR (CDCl₃): δ 7.28 (m, 2H), 7.17 (m, 3H), 2.49 (d, 2H), 1.81-1.35(m, 6H), 1.30-1.03 (m, 3H), 1.02-0.79 (m, 2H).

[0872] (1-Cyclohexyl-1-methyl-ethyl)-benzene

[0873] To a nitrogen flushed 3-neck round bottom flask equipped with astir bar and addition funnel was added cyclohexylmagnesium chloride (2Min Et₂O, 7.5 mL, 15 mmol). The solution was evaporated under a stream ofnitrogen then slightly warmed under vacuum to remove any residual ether.The dried Grignard reagent was then dissolved in 25 mL methylenechloride and cooled in an ice bath. A solution ofα,α-dimethylbenzylchloride in 25 mL methylene chloride was added to thereaction mixture via addition funnel over a period of 6 minutes. The icebath was then allowed to melt and the reaction was allowed to warm upovernight. The reaction mixture was diluted with 100 mL diethylether andwashed once with saturated ammonium chloride (50 mL), once with 1N HCl(50 mL), once with 1N NaOH (50 mL) and once with brine (50 mL). Theorganics were then dried over Na₂SO₄, filtered and concentrated in vacuoto yield the crude product, which was used without further purification.

[0874] (1,1-Dimethyl-pentyl)-benzene

[0875] To a nitrogen flushed round bottom flask equipped with a stir barand addition funnel was added 80 mL dichloromethane. TiCl₄ (4.6 mL, 41.9mmol) was added and the mixture was cooled in a dry ice-acetonitrilebath to ˜−50° C. To this was added Me₂Zn (2M in toluene, 21 mL, 42mmol). The resulting thick slurry was allowed to stir for ˜10 minutes. Asolution of valerophenone (3.3 mL, 20.1 mmol) in 20 mL methylenechloride was added to the reaction mixture via addition funnel over aperiod of 16 minutes. The ice bath was then allowed to melt and thereaction was allowed to warm up overnight at which time the reaction wascarefully poured into 500 mL ice/water and then extracted twice with 100mL methylene chloride. The combined organics were washed twice with 1NHCl (100 mL) and once with brine (100 mL). The organics were then driedover Na₂SO₄, filtered and concentrated in vacuo to yield the crudeproduct, which was used without further purification. ¹H NMR (CDCl₃): δ7.37-7.08 (m, 5H), 1.62 (m, 2H), 7.31 (s, 6H), 1.22 (t, 2H), 1.05 (m,2H), 0.82 (t, 3H).

Example (1) 3-[4-(1-Methyl-pentyl)-phenyl]-N-quinolin-3-yl-benzamide

[0876]

[0877] A. 4-(1-Methyl-pentyl)-benzaldehyde. (1-Methyl-pentyl)-benzene(3.771 g, 21.15 mmol) was stirred under nitrogen with trifluoroaceticacid (25 mL) in a round bottom flask equipped with a reflux condenser.To this was added hexamethylenetetramine (3.29 g, 23.5 mmol) and thenthe mixture was heated at reflux for 9 hours. Concentration of thereaction mixture under vacuum gave a residue that was carefullypartitioned between 250 mL diethylether and 50 mL saturated NaHCO₃. Theaqueous was removed and the organics were washed twice more with 50 mLsaturated NaHCO₃ solution. The organics were then dried over Na₂SO₄,filtered and concentrated in vacuo to yield the crude product as a brownoil (4.245 g, 20.8 mmol) which was carried on without furtherpurification. ¹H NMR (CDCl₃): 9.99 (s, 1H), 7.82 (d, 2H), 7.34 (d, 2H),2.78 (h, 1H), 1.60 (q, 2H), 1.38-1.03 (m, 7H), 0.87 (t, 3H).

[0878] B. 4-(1-Methyl-pentyl)-benzoic acid.4-(1-Methyl-pentyl)-benzaldehyde obtained in step A (0.615 g, 3.01 mmol)was stirred with 10 mL acetone in a round bottom flask. Jones reagent(0.7 M, 10 mL, 7 mmol) was added and the reaction was stirred for 48hours. The reaction was quenched by addition of 2 mL iPrOH and thendiluted with 50 mL water. The mixture was then extracted three timeswith diethylether (25 mL) and the combined organics washed once with 25mL water, dried over Na₂SO₄, treated with charcoal, filtered and thenevaporated in vacuo. The residue was then dissolved in 25 mL 1N NaOHsolution and washed twice with 25 mL diethylether. The aqueous solutionwas partially evaporated to remove the residual diethylether thenacidified with 25 mL 2N HCl. The mixture was extracted once with 20 mLdiethylether. The organics were dried over Na₂SO₄, filtered, andconcentrated in vacuo to yield the product as a light tan thick oil(0.353 g, 1.71 mmol). ¹H NMR (DMSO-d₆): 12.74 (s, 1H), 7.88 (d, 2H),7.34 (d, 2H), 2.76 (h, 1H), 1.55 (q, 2H), 1.32-0.96 (m, 7H), 0.82 (t,3H); MS: m/z 205 (M-H)⁻.

[0879] C. 3-[4-(1-Methyl-pentyl)-phenyl]-N-quinolin-3-yl-propionamide.4(1-Methyl-pentyl)-benzoic acid from step B (0.114 g, 0.55 mmol) wasdissolved in 5 mL DMF with stirring. To this was added Et₃N (0.10 mL,0.72 mmol), 3-aminoquinoline (0.082 g, 0.57 mmol) and lastly HBTU (0.224g, 0.59 mmol). The reaction was allowed to stir overnight then pouredinto 25 mL EtOAc and washed with saturated NaHCO₃ solution (25 mL) thenbrine (25 mL). The organics were dried over Na₂SO₄, filtered, evaporatedin vacuo and the residue chromatographed over silica gel eluting with 0%to 40% EtOAc in hexanes. Evaporation of the proper fractions yielded thetitle product (0.120 g, 0.36 mmol). ¹H NMR (DMSO-d₆): 8.93 (d, 1H), 8.86(d, 1H), 8.09 (m, 2H), 7.88 (m, 3H), 7.67 (dt, 1H), 7.57 (t, 1H), 7.35(d, 2H), 2.79 (h, 1H), 1.61 (q, 2H), 1.37-1.04 (m, 7H), 0.87 (t, 3H);MS: m/z 333.4 (MH⁺).

[0880] Following the procedure described above for Example 1 and theappropriate reagents, starting materials and purification methods knownto those skilled in the art, the following compounds were prepared:Example MS MS # Compound name (calc) (obs)  (2)4-(1,1-Dimethyl-propyl)-N-quinolin-3-yl- 318.4 319.2 benzamide  (3)4-Cyclohexylmethyl-N-quinolin-3-yl- 344.6 345.6 benzamide  (4)N-Quinolin-3-yl-4- 382.5 383.7 tricyclo[5.3.1.13,9]dodec-1-yl-benzamide (5) 4-sec-Butyl-N-quinolin-3-yl-benzamide 304.4 305.2  (6)4-(1,1-Dimethyl-pentyl)-N-quinolin-3-yl- 346.5 347.1 benzamide  (7)Indan-5-carboxylic acid quinolin-3-ylamide 288.4 289.1  (8)5,6,7,8-Tetrahydro-naphthalene-2- 302.4 303.1 carboxylic acidquinolin-3-ylamide  (9) 4-(1-Cyclohexyl-1-methyl-ethyl)-N- 372.5 373.2quinolin-3-yl-benzamide (10) 5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-358.5 359.1 naphthalene-2-carboxylic acid quinolin-3- ylamide (11)4-tert-Butyl-cyclohexanecarboxylic acid 310.4 311.1 quinolin-3-ylamide(12) 1-Isopropyl-2-trifluoromethyl-1H- 398.3 399.3benzoimidazole-5-carboxylic acid quinolin- 3-ylamide (13)4-Butyl-cyclohexanecarboxylic acid 310.4 311.1 quinolin-3-ylamide

Example (14)3-[4-(1,1-Dimethyl-propyl)-phenyl]-N-quinolin-3-yl-propionamide

[0881]

[0882] A. 3-[4-(1,1-Dimethyl-propyl)-phenyl]-acrylic acid ethyl ester.To a nitrogen flushed round bottom flask equipped with a stir bar andreflux condenser was added 4-(1,1-dimethyl-propyl)-benzaldehyde (1.767g, 10.02 mmol) and 25 mL benzene.(Carbethoxymethylene)triphenylphosphorane (3.497 g, 10.03 mmol) wasadded and the solution was heated at reflux for 4 hours. The reactionwas evaporated in vacuo and the residue triturated with 50 mL Et₂O andthen filtered. The filtrate was evaporated in vacuo and chromatographedover silica gel eluting with 0% to 5% EtOAc in hexanes. Evaporation ofthe appropriate fractions yielded the product as a yellow oil (2.138 g,8.68 mmol). ¹H NMR (CDCl₃): δ 7.70 (d, 1H), 7.49 (d, 2H), 7.37 (d, 2H),6.42 (d, 1H), 4.28 (q, 2H), 1.67 (q, 2H), 1.36 (t, 3H), 1.28 (s, 6H),0.69 (t, 3H)

[0883] B. 3-[4-(1,1-dimethyl-propyl)-phenyl]-propionic acid ethyl ester.3-[4-(1,1-Dimethyl-propyl)-phenyl]-acrylic acid ethyl ester obtained instep A (2.138 g, 8.68 mmol) was dissolved in 50 mL ethanol along with10% Pd/C (0.216 g) and hydrogenated at ˜50 psi for 4.5 hours. Filtrationof the reaction mixture over a pad of celite and evaporation of thefiltrate yielded the product as a pale yellow oil (2.060 g, 8.29 mmol).¹H NMR (CDCl₃): δ 7.27 (d, 2H), 7.13 (d, 2H), 4.14 (q, 2H), 2.93 (t,2H), 2.62 (t, 2H), 1.64 (q, 2H), 1.28 (s, 6H), 1.24 (t, 3H), 0.68 (t,3H).

[0884] C. 3-[4-(1,1-dimethyl-propyl)-phenyl]-propionic acid. To a roundbottom flask equipped with a stir bar was added the ester obtained instep B, 3-[4-(1,1-dimethyl-propyl)-phenyl]-propionic acid ethyl ester(2.050 g, 8.25 mmol), 50 mL THF, 10 mL water and LiOH·H₂O (0.692 g, 16.5mmol). The reaction was stirred for 48 hours then evaporated in vacuo toan aqueous residue which was diluted with 50 mL water and acidified with25 mL 1N HCl. The precipitate solid was collected by filtration, rinsedwith water and dried under vacuum at 50° C. The product was obtained asa waxy white solid (1.697 g, 7.70 mmol). ¹H NMR (DMSO-d₆): δ 12.07 (brs, 1H), 7.22 (d, 2H), 7.13 (d, 2H), 2.80 (t, 2H), 2.52 (t, 2H), 1.60 (q,2H), 1.22 (s, 6H), 0.61 (t, 3H); MS: m/z 279.3 (M-H)⁻.

[0885] D.3-[4-(1,1-Dimethyl-propyl)-phenyl]-N-quinolin-3-yl-propionamide.3-Aminoquinoline (0.144 g, 1.00 mmol), Et₃N (0.16 mL, 1.15 mmol) and3-[4-(1,1-dimethyl-propyl)-phenyl]-propionic acid from step C (0.220 g,1.00 mmol) were dissolved in 5 mL DMF with stirring. HBTU (0.384 g, 1.01mmol) was added and the reaction was stirred for 48 hours. The reactionmixture was then partitioned between 100 mL 50% saturated NaHCO₃ and 100mL Et₂O. The organics were then washed twice with 100 mL water, oncewith 100 mL brine, dried over Na₂SO₄, filtered and evaporated in vacuo.The residue was chromatographed over silica gel eluting with 0% to 40%EtOAc in hexanes. Evaporation of the proper fractions yielded theproduct (0.286 g, 0.83 mmol). ¹H NMR (CDCl₃): δ 8.73 (s, 1H), 8.59 (s,1H), 8.04 (d, 1H), 7.81 (d, 1H), 7.65 (t, 1H), 7.55 (t, 1H), 7.29 (d,2H), 7.22 (d, 2H), 3.09 (t, 2H), 2.79 (t, 2H), 1.66 (q, 2H), 1.28 (s,6H), 0.68 (t, 3H); MS: m/z 347.7 (MH⁺).

[0886] Following the procedure described above for Example 13 and theappropriate reagents, starting materials and purification methods knownto those skilled in the art, the following compounds of the presentinvention were prepared: Example MS MS # Compound name (calc) (obs) (15)N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl- 386.5 387.25,6₎7,8-tetrahydro-naphthalen-2-yl)- propionamide (16)3-(4-sec-Butyl-phenyl)-N-quinolin-3-yl- 332.4 333.4 propionamide (17)3-[4-(1-Methyl-pentyl)-phenyl]-N- 360.5 361.5 quinolin-3-yl-propionamide(18) 3-[4-(1-Cyclohexyl-1-methyl-ethyl)- 400.6 401.2phenyl]-N-quinolin-3-yl-propionamide (19)3-[4-(1,1-Dimethyl-pentyl)-phenyl]-N- 374.5 375.2quinolin-3-yl-propionamide (20) 3-(4-Cyclohexylmethyl-phenyl)-N- 372.5373.6 quinolin-3-yl-propionamide (21) 3-Indan-5-yl-N-quinolin-3-yl-316.4 317.1 propionamide (22) N-Quinolin-3-yl-3-(4- 410.6 411.8tricyclo[5.3.1.13,9]dodec-1-yl-phenyl)- propionamide (23)3-(4-Pentyl-phenyl)-N-quinolin-3-yl- 346.5 347.0 propionamide (24)N-Quinolin-3-yl-3-(5,6,7,8-tetrahydro- 330.4 331.1naphthalen-2-yl)-propionamide

Example (25) 4-[4-(1,1-Dimethyl-pentyl)-phenyl]-but-3-enoic acidquinolin-3-ylamide

[0887]

[0888] A. 4-[4-(1,1-Dimethyl-pentyl)-phenyl]-but-3-enoic acid. To anitrogen flushed round bottom flask equipped with a stir bar andaddition funnel was added 4-(1,1-dimethyl-pentyl)-benzaldehyde (3.399 g,16.64 mmol), 50 mL THF and (2-carboxyethyl)-triphenylphosphoniumchloride (Journal of Organic Chemistry 1962, 3407). The reaction mixturewas cooled on an ice bath and a solution of potassium t-butoxide (1M inTHF, 35 mL, 35 mmol) was added dropwise via addition funnel over aperiod of 16 minutes. The ice was allowed to melt and the reaction wasallowed to warm up overnight. The thick slurry was then poured into 500mL water and washed once with 200 mL diethyl ether. The aqueous layerwas then acidified with 2.5 mL concentrated HCl and extracted twice with100 mL diethylether. The combined organics were dried over Na₂SO₄,filtered and then evaporated in vacuo. The residue was chromatographedby reverse-phase HPLC (C₁₋₈ eleuted with acetonitrile/water+0.1% TFA).The proper fractions were collected and lyophilized to yield the productas a cream colored powder (1.303 g, 5.00 mmol). ¹H NMR (DMSO-d₆): δ12.33 (s, 1H), 7.31 (q, 4H), 6.48 (d, 1H), 6.27 (dt, 1H), 3.20 (d, 2H),1.58 (m, 2H), 1.25 (s, 6H), 1.18 (m, 2H), 0.98 (m, 2H), 0.78 (t, 3H);MS: m/z 258.9 (M-H)⁻.

[0889] B. 4-[4-(1,1-Dimethyl-pentyl)-phenyl]-but-3-enoic acidquinolin-3-ylamide. The 4-[4-(1,1-dimethyl-pentyl)-phenyl]-but-3-enoicacid from step A (0.130 g, 0.50 mmol) was dissolved in 5 mL DMF withstirring. To this was added Et₃N (0.08 mL, 0.57 mmol), 3-aminoquinoline(0.077 g, 0.53 mmol) and lastly HBTU (0.204 g, 0.54 mmol). The reactionwas allowed to stir for 48 hours then poured into 25 mL EtOAc and washedwith saturated NaHCO₃ solution (25 mL) and then brine (25 mL). Theorganics were dried over Na₂SO₄, filtered and then evaporated in vacuoand the residue chromatographed over silica gel eluting with 0% to 60%EtOAc in hexanes. Evaporation of the proper fractions yielded the titlecompound (0.156 g, 0.40 mmol). ¹H NMR (CDCl₃): δ 8.74 (m, 2H), 8.04 (d,1H), 7.81 (d, 1H), 7.64 (m, 2H), 7.55 (t, 1H), 7.40 (d, 2H), 7.33 (d,2H), 6.70 (d, 1H), 6.40 (d of t, 1H), 3.43 (d, 2H), 1.61 (m, 2H), 1.32(s, 6H), 1.24 (m, 2H), 1.07 (m, 2H), 0.83 (t, 3H); MS: m/z 387.4 (MH⁺).

[0890] Following the procedure described above for Example 25 and theappropriate reagents, starting materials and purification methods knownto those skilled in the art, the following compounds of the presentinvention were prepared: Example # Compound name MS (calc) MS (obs) (26)4-[4-(1,1-Dimethyl-propyl)-phenyl]- 358.5 359.5 but-3-enoic acidquinolin-3-ylamide

Example (27)4-[4-(1,1-Dimethyl-pentyl)-phenyl]-N-quinolin-3-yl-butyramide

[0891]

[0892] A. 4-[4-(1,1-Dimethyl-pentyl)-phenyl]-butyric acid.4-[4-(1,1Dimethyl-pentyl)-phenyl]-but-3-enoic acid (1.03 g, 4.0 mmol),prepared as described above, was dissolved in 50 mL ethanol along with10% Pd/C (0.103 g) and hydrogenated at ˜50 psi overnight. Filtration ofthe reaction mixture over a pad of celite and evaporation of thefiltrate yielded the product as a light yellow oil (1.014 g, 3.86 mmol).¹H NMR (CDCl₃): δ 7.25 (d, 2H), 7.12 (d, 2H), 2.66 (t, 2H), 2.39 (t,2H), 1.98 (p, 2H), 1.58 (m, 2H), 1.28 (s, 6H), 1.22 (m, 2H), 1.04 (m,2H), 0.82 (t, 3H); MS: m/z 261.0 (M-H)⁻.

[0893] B. 4-[4-(1,1-Dimethyl-pentyl)-phenyl]-N-quinolin-3-yl-butyramide.4-[4-(1,1-Dimethyl-pentyl)-phenyl]-butyric acid from the previousreaction (0.264 g, 1.01 mmol) was dissolved in 5 mL DMF with stirring.To this was added Et₃N (0.16 mL, 1.15 mmol), 3-aminoquinoline (0.147 g,1.02 mmol) and lastly HBTU (0.403 g, 1.06 mmol). The reaction wasallowed to stir overnight then poured into 25 mL EtOAc and washed withsaturated NaHCO₃ solution (25 mL) then brine (25 mL). The organics weredried over Na₂SO₄, filtered and then evaporated in vacuo. The residuewas chromatographed over silica gel eluting with 0% to 55% EtOAc inhexanes. Evaporation of the proper fractions yielded the title product(0.186 g, 0.48 mmol). ¹H NMR (CDCl₃): δ 8.82 (s, 1H), 8.69 (d, 1H), 8.05(d, 1H), 7.82 (d, 1H), 7.64 (t, 1H), 7.56 (t, 1H), 7.33 (br s, 1H), 7.28(d, 2H), 7.17 (d, 2H), 2.72 (t, 2H), 2.48 (t, 2H), 2.14 (p, 2H), 1.59(m, 2H), 1.28 (s, 6H), 1.23 (m, 2H), 1.05 (m, 2H), 0.84 (t, 3H); MS: m/z389.5 (MH⁺).

[0894] Following the procedure described above for Example 27 and theappropriate reagents, starting materials and purification methods knownto those skilled in the art, the following compounds were prepared:Example # Compound name MS (calc) MS (obs) (28)4-[4-(1,1-Dimethyl-propyl)- 360.5 361.5 phenyl]-N-quinolin-3-yl-butyramide

Example (29)3-[4-(1,1-Dimethyl-propyl)-2,6-dimethoxy-phenyl]-N-quinolin-3-yl-propionamide

[0895]

[0896] A. 1-(3,5-Dimethoxy-phenyl)-propan-1-ol. To a nitrogen flushed3-neck round bottom flask equipped with a stir bar and addition funnelwas added 25 mL THF and EtMgBr (3M in Et₂O, 11.0 mL, 33.0 mmol). Asolution of 3,5-dimethoxybenzaldehyde (4.99 g, 30.0 mmol) in 25 mLanhydrous THF was added dropwise via addition funnel to the reactionmixture which was then allowed to stir overnight. The reaction wasdiluted with 100 mL Et₂O, washed twice with 50 mL saturated NH₄Clsolution, once with 50 mL water and once with 50 mL brine. The organicswere dried over Na₂SO₄, filtered and evaporated in vacuo to yield theproduct as a yellow oil (5.657 g, 28.83 mmol). ¹H NMR (CDCl₃): δ 6.52(m, 2H), 6.38 (m, 1H), 4.54 (m, 1H), 3.81 (s, 6H), 1.84 (d, 1H), 1.78(m, 2H), 0.95 (t, 3H).

[0897] B. 1-(3,5-Dimethoxy-phenyl)-propan-1-one. To a round bottom flaskequipped with a stir bar was added the product from step A,1-(3,5-dimethoxyphenyl)-propan-1-ol (5.657 g, 28.8 mmol), 100 mLdichloromethane and activated MnO₂ (12.51 g, 143.9 mmol). The reactionwas stirred at room temperature overnight then a reflux condenser wasinstalled and the reaction was heated at reflux for 2 days. The reactionmixture was filtered over a pad of celite and evaporated in vacuo togive a residue that was chromatographed over silica gel eluting with 0%to 7.5% EtOAc in hexanes. Evaporation of the proper fractions yieldedthe product as a colorless solid (2.050 g, 10.6 mmol). ¹H NMR (CDCl₃): δ7.10 (m, 2H), 6.64 (m, 1H), 3.85 (s, 6H), 2.98 (q, 2H), 1.22 (t, 3H).

[0898] C. 1-(1,1-Dimethyl-propyl)-3,5-dimethoxy-benzene. To a nitrogenflushed round bottom flask equipped with a stir bar and addition funnelwas added 80 mL methylene chloride. TiCl₄ (2.3 mL, 21.0 mmol) was addedand the reaction mixture was cooled in a dry ice-acetonitrile bath to−50° C. To this was added Me₂Zn (2M in toluene, 10.5 mL, 21 mmol) andthe resulting thick slurry was allowed to stir for ˜10 minutes. Asolution of 1-(3,5-dimethoxyphenyl)-propan-1-one, the product from stepB, (1.951 g, 10.0 mmol) in 20 mL methylene chloride was added to thereaction mixture via addition funnel over a period of 25 minutes. After3 hours the ice bath was removed and the reaction was allowed to warm upto room temperature overnight. The reaction was then carefully pouredinto 300 mL ice/water and extracted twice with 100 mL methylenechloride. The combined organics were washed twice with 1N HCl (100 mL)and once with brine (100 mL). The organics were then dried over Na₂SO₄,filtered and concentrated to a residue that was chromatographed oversilica gel eluting with 0% to 2.5% EtOAc in hexanes. Evaporation of theproper fractions yielded the product as a colorless liquid (1.077 g,5.17 mmol). ¹H NMR (CDCl₃): δ 6.49 (m, 2H), 6.29 (m, 1H), 3.81 (s, 6H),1.62 (q, 2H), 1.27 (s, 6H), 0.71 (t, 3H).

[0899] D. 4-(1,1-Dimethyl-propyl)-2,6-dimethoxy-benzaldehyde. To anitrogen flushed round bottom flask equipped with a stir bar was added1-(1,1-dimethyl-propyl)-3,5-dimethoxy-benzene, obtained in step C,(1.071 g, 5.14 mmol) and 10 mL Et₂O. The reaction was cooled in an icebath and n-butyllithium (2.5 M in hexanes, 2.7 mL 6.75 mmol) was addeddropwise to the reaction. The reaction mixture was then stirred at 0° C.for one hour, the ice bath was removed and the reaction was allowed towarm up to room temperature overnight. The tan slurry was then re-cooledin an ice bath and DMF (0.68 mL, 8.78 mmol) was added drop wise. Thereaction was stirred on the ice bath for 2 hours then for an additional3 hours at room temp. The reaction mixture was quenched with 50 mL 3%H₂SO₄ and extracted twice with 25 mL Et₂O. The combined organics weredried over Na₂SO₄, filtered and evaporated in vacuo to yield the productaldehyde as a yellow oil (1.2 g, 5.1 mmol). ¹H NMR (CDCl₃): δ 10.46 (s,1H), 6.53 (s, 2H), 3.92 (s, 6H), 1.67 (q, 2H), 1.29 (s, 6H), 0.73 (t,3H).

[0900] E. 3-[4-(1,1-Dimethyl-propyl)-2,6-dimethoxy-phenyl]-acrylic acidethyl ester. To a nitrogen flushed round bottom flask was added 15 mLacetonitrile and the aldehyde obtained in step D,4-(1,1-dimethyl-propyl)-2,6-dimethoxy-benzaldehyde (0.711 g, 3.01 mmol).LiCl (0.199 g, 4.69 mmol), triethyl phosphonoacetate (0.72 mL, 3.63mmol) and lastly DBU (0.51 mL, 3.41 mmol) were added and the reactionwas stirred overnight. The reaction mixture was then partitioned between10 mL water and 25 mL Et₂O. The organics were twashed twice with 10 mL1N HCl, once with 10 mL water, dried over Na₂SO₄, filtered andevaporated to a residue that was chromatographed over silica gel elutingwith 0% to 7.5% EtOAc in hexanes. Evaporation of the proper fractionsyielded the product as a white solid (0.626 g, 2.04 mmol). ¹H NMR(CDCl₃): δ 8.13 (d, 1H), 6.86 (d, 1H), 6.53 (s, 2H), 4.27 (q, 2H), 3.88(s, 6H), 1.66 (q, 2H), 1.35 (t, 3H), 1.30 (s, 6H), 0.72 (s, 3H); MS: m/z307.2 (MH⁺).

[0901] F. 3-[4-(1,1-Dimethyl-propyl)-2,6-dimethoxy-phenyl]-propionicacid ethyl ester.3-[4-(1,1-Dimethyl-propyl)-2,6-dimethoxy-phenyl]-acrylic acid ethylester (0.621 g, 2.03 mmol), obtained in step E, was dissolved in 25 mLethanol along with 10% Pd/C (0.068 g) and hydrogenated at ˜50 psi for 48hours for 48 hours. Filtration of the reaction mixture over a pad ofcelite and evaporation of the filtrate yielded the product as a pale tanoil (0.623 g, 2.02 mmol). ¹H NMR (CDCl₃): δ 6.49 (s, 2H), 4.13 (q, 2H),3.79 (s, 6H), 2.94 (dd, 2H), 2.48 (dd, 2H), 1.64 (q, 2H), 1.27 (m, 9H),0.72 (t, 3H); MS: m/z 309.1(MH⁺).

[0902] G. 3-[4-(1,1-Dimethyl-propyl)-2,6-dimethoxy-phenyl]-propionicacid.

[0903] To a round bottom flask equipped with a stir bar was added3-[4-(1,1-dimethyl-propyl)-2,6-dimethoxy-phenyl]-propionic acid ethylester (0.605 g, 1.96 mmol), obtained in step F, 25 mL THF, 5 mL waterand LiOH·H₂O (0.164 g, 3.91 mmol). The reaction was stirred untilcomplete by reverse phase HPLC then evaporated in vacuo to an aqueousresidue which was diluted with 25 mL water and then acidified with 5 mL2N HCl. The precipitated solid was collected by filtration, rinsed withwater and dried under vacuum at 50° C. to yield the product as a whitepowder (0.495 g, 1.77 mmol). ¹H NMR (DMSO-d₆): δ 12.04 (s, 1H), 6.53 (s,2H), 3.78 (s, 6H), 2.76 (dd, 2H), 2.26 (dd, 2H), 1.62 (q, 2H), 1.24 (s,6H), 0.67 (t, 3H).

[0904] H.3-[4-(1,1-Dimethyl-propyl)-2,6-dimethoxy-phenyl]-N-quinolin-3-yl-propionamide.Into a round bottom flask equipped with a stir bar was added 10 mLacetonitrile, the product obtained in step G3-[4-(1,1-dimethyl-propyl)-2,6-dimethoxy-phenyl]-propionic acid (0.422g, 1.51 mmol), iPr₂NEt (0.29 mL, 1.66 mmol), 3-aminoquinoline (0.218 g,1.51 mmol) and lastly PyBroP (0.713 g, 1.53 mmol). The reaction wasstirred overnight at room temperature, an additional amount of PyBroPwas added (0.145 g, 0.31 mmol) and the reaction was stirred for anadditional 2 hours at room temperature. The reaction mixture was thendiluted with 100 mL Et₂O and washed once with 25 mL saturated NaHCO₃ andtwice with 25 mL water. The organics were dried over Na₂SO₄, filteredand evaporated to a residue that was chromatographed over silica geleluting with 0% to 50% EtOAc in hexanes. Evaporation of the properfractions yielded, after trituration with hexanes, the title compoundwhich was dried under vacuum at 50° C. (0.301 g, 0.74 mmol). ¹H NMR(CDCl₃): δ 8.81 (s, 1H), 8.58 (d, 1H), 8.03 (m, 2H), 7.80 (d, 1H), 7.62(t, 1H), 7.53 (t, 1H), 6.57 (s, 2H), 3.88 (s, 6H), 3.10 (t, 2H), 2.80(t, 2H), 1.64 (q, 2H), 1.29 (s, 6H), 0.72 (t, 3H); MS: m/z 407.6 (MH⁺).

[0905] Following the procedure described above for Example 29 and theappropriate reagents, starting materials and purification methods knownto those skilled in the art, the following compounds of the presentinvention were prepared: Example # Compound name MS (calc) MS (obs) (30)3-[4-(1,1-Dimethyl-pentyl)-2,6- 406.5 407.6dimethoxy-phenyl]-N-quinolin-3-yl- propionamide

Example (31)3-[5-(1,1-Dimethyl-propyl)-thiophen-2-yl]-N-quinolin-3-yl-propionamide

[0906]

[0907] A. 2-Bromo-5-(1,1-dimethyl-propyl)-thiophene. To a nitrogenflushed round bottom flask equipped with a stir bar and addition funnelwas added 80 mL methylene chloride. TiCl₄ (2.3 mL, 21.0 mmol) was addedand the mixture cooled with a dry ice-acetonitrile bath to about −50° C.To this was added Me₂Zn (2M in toluene, 10.5 mL, 21 mmol). The resultingthick slurry was allowed to stir for at least 10 minutes. A solution of1-(5-bromo-thiophen-2-yl)-propan-1-one [prepared as described in JACS1950, 3695] (2.191 g, 10.1 mmol) in 20 mL methylene chloride was addedto the reaction mixture via addition over a period of 35 minutes. Theice bath was allowed to melt and the reaction was allowed to warm upovernight. The reaction was then carefully poured into 500 mL ice/waterand then extracted three times with 100 mL methylene chloride. Thecombined organics were washed twice with 1N HCl (100 mL) and once withbrine (100 mL). The organics were then dried over Na₂SO₄, treated withcharcoal, filtered and concentrated to a residue that waschromatographed over silica gel eluting with 100% hexanes. Evaporationof the proper fractions yielded the product as a colorless liquid (1.256g, 5.39 mmol). ¹H NMR (CDCl₃): δ 6.85 (d, 1H), 6.53 (d, 1H), 1.62 (q,2H), 1.31 (s, 6H), 0.81 (t, 3H).

[0908] B. 5-(1,1-Dimethyl-propyl)-thiophene-2-carboxaldehyde. To anitrogen flushed round bottom flask equipped with a stir bar was added50 mL anhydrous THF and 2-bromo-5-(1,1-dimethyl-propyl)-thiophene (1.25g, 5.36 mmol) prepared in step A. The reaction was cooled in a dryice-acetone bath and n-butyllithium solution (2.5 M in hexanes, 2.4 mL,6.0 mmol) was added drop wise. The ice bath was allowed to melt and thereaction was allowed to warm up overnight. The reaction was then cooledin a dry ice-acetone bath and a solution of 1 mL DMF in 4 mL anhydrousTHF was added dropwise. After the ice bath had melted over 6.5 hours thereaction was diluted with 200 mL Et₂O and washed twice with 50 mLsaturated NH₄Cl, 50 mL water and 50 mL brine. The organics were driedover Na₂SO₄, filtered and evaporated to a residue that waschromatographed over silica gel eluting with 5% to 10% EtOAc in hexanes.Evaporation of the proper fractions yielded the product aldehyde as ayellow liquid (0.249 g, 1.37 mmol). ¹H NMR (CDCl₃): δ 9.82 (s, 1H), 7.62(d, 1H), 6.93 (d, 1H), 1.70 (q, 2H), 1.38 (s, 6H), 0.81 (t, 3H).

[0909] C. 3-[5-(1,1-Dimethyl-propyl)-thiophen-2-yl]-acrylic acid ethylester. To a nitrogen flushed round bottom flask equipped with a stir barwas added 10 mL acetonitrile,5-(1,1-dimethyl-propyl)-thiophene-2-carboxaldehyde (0.236 g, 1.29 mmol)obtained in step B, LiCl (0.086 g, 2.03 mmol), DBU (0.23 mL, 1.54 mmol)and lastly triethyl phosphonoacetate (0.31 mL, 1.56 mmol). The reactionwas stirred overnight and then evaporated in vacuo. The residue waspartitioned between 10 mL water and 25 mL Et₂O. The organics were thenwashed twice with 10 mL 1N HCl, once with 10 mL brine and evaporated toa residue that was chromatographed over silica gel eluting with 0% to10% EtOAc in hexanes. Evaporation of the proper fractions yielded theproduct as a yellow oil (0.296 g, 1.17 mmol). ¹H NMR (CDCl₃): δ 7.72 (d,1H), 7.08 (d, 1H), 6.77 (d, 1H), 6.13 (d, 1H), 4.26 (q, 2H), 1.68 (q,2H), 1.32 (m, 9H), 0.80 (t, 3H).

[0910] D. 3-[5-(1,1-Dimethyl-propyl)-thiophen-2-yl]-propionic acid ethylester. 3-[5-(1,1-Dimethyl-propyl)-thiophen-2-yl]-acrylic acid ethylester (0.292 g, 1.16 mmol), obtained in the previous step, was dissolvedin 25 mL ethanol along with 10% Pd/C (0.053 g) and hydrogenated at ˜50psi for 48 hours. Filtration of the reaction mixture over a pad ofcelite and evaporation of the filtrate showed the reaction to beincomplete. The hydrogenation was then restarted with fresh 25 mL EtOHand 10% Pd/C (0.256 g) for 3 more days. Filtration of the reactionmixture over a pad of celite and evaporation of the filtrate yielded theproduct as a yellow oil (quant). ¹H NMR (CDCl₃): δ 6.59 (m, 2H), 4.16(q, 2H), 3.11 (t, 2H), 2.67 (t, 2H), 1.63 (q, 2H), 1.28 (m, 9H), 0.80(t, 3H).

[0911] E. 3-[5-(1,1-Dimethyl-propyl)-thiophen-2-yl]-propionic acid. To around bottom flask equipped with a stir bar was added3-[5-(1,1-dimethyl-propyl)-thiophen-2-yl]-propionic acid ethyl ester(1.16 mmol), obtained in step D, 25 mL THF, 5 mL water and LiOH·H₂O(0.107 g, 2.55 mmol). The reaction was stirred for 48 hours thenevaporated in vacuo to an aqueous residue which was diluted with 25 mLwater, acidified with 10 mL 1N HCl and extracted twice with 25 mL Et₂O.The combined organics were dried over Na₂SO₄, filtered and evaporated toyield the product as a thick yellow-orange oil (0.229 g, 1.01 mmol). ¹HNMR (CDCl₃): δ 6.64 (d, 1H), 6.58 (d, 1H), 3.12 (t, 2H), 2.73 (t, 2H),1.62 (q, 2H), 1.30 (s, 6H), 0.78 (t, 3H); MS: m/z 224.9 (MH)⁻.

[0912] F.3-[5-(1,1-Dimethyl-propyl)-thiophen-2-yl]-N-quinolin-3-yl-propionamide.To a round bottom flask equipped with a stir bar add 10 mLdichloromethane 3-[5-(1,1-dimethyl-propyl)-thiophen-2-yl]-propionic acid(0.228 g, 1.01 mmol) from step E, iPr₂NEt (0.39 mL, 2.2 mmol),3-aminoquinoline (0.146 g, 1.01 mmol) and lastly2-chloro-1,3-dimethylimidazolinium chloride (0.199 g, 1.18 mmol). Thereaction was stirred overnight, diluted with 15 mL dichloromethane andwashed twice with 25 mL 1N HCl and twice with 25 mL saturated NaHCO₃.Evaporation of the organics gave a residue that was chromatographed oversilica gel eluting with 0% to 45% EtOAc in hexanes. Evaporation of theproper fractions yielded the title compound as a yellow-tan solid (0.190g, 0.54 mmol). ¹H NMR (CDCl₃): δ 8.76 (s, 1H), 8.58 (d, 1H), 8.03 (d,1H), 7.81 (d, 1H), 7.64 (t, 1H), 7.54 (t, 1H), 7.39 (br s, 1H), 6.68 (d,1H), 6.61 (d, 1H), 3.26 (t, 2H), 2.81 (t, 2H), 1.63 (q, 2H), 1.29 (s,6H), 0.77 (t, 3H);

[0913] MS: m/z 353.5 (MH⁺).

Example (32)3-[4-(1,1-Dimethyl-3-phenyl-propyl)-phenyl]-N-quinolin-3-yl-propionamide

[0914]

[0915] A. 1-(4-Bromo-phenyl)-3-phenyl-propan-1-one. Into a nitrogenflushed 3-neck round bottom flask equipped with a stir bar, additionfunnel and reflux condenser was added 25 mL anhydrous THF,phenethylmagnesium chloride (1M in THF, 30 mL, 30 mmol) and CuBrcatalyst (0.083 g). Into the addition funnel was added a solution of4-bromobenzonitrile (4.97 g, 27.3 mmol) in 50 mL anhydrous THF. This wasadded dropwise to the Grignard solution over 7.5 minutes. When theaddition was complete the reaction was heated at reflux overnight. Aftercooling, the reaction was quenched with 100 15 mL 15% H₂SO₄ andextracted twice with 100 mL Et₂O. The combined organics were washed oncewith 100 mL saturated NH₄Cl, once with 100 mL brine, dried over Na₂SO₄,treated with charcoal, filtered, evaporated to a solid. This crude solidwas triturated with 20 mL EtOH, filtered off and rinsed with anadditional 10 mL EtOH. Drying the solid under vacuum yielded the productas an off-white crystalline powder (3.529 g, 12.2 mmol). ¹H NMR (CDCl₃):δ 7.84 (d, 2H), 7.62 (d, 2H), 7.29 (m, 5H), 3.30 (t, 2H), 3.09 (t, 2H).

[0916] B. 4-(1,1-Dimethyl-3-phenyl-propyl)-bromobenzene. To a nitrogenflushed round bottom flask equipped with a stir bar and addition funnelwas added 80 mL methylene chloride. TiCl₄ (2.7 mL, 24.6 mmol) was addedand the mixture cooled with a dry ice-acetonitrile bath to about −50° C.To this was added Me₂Zn (2M in toluene, 12.5 mL, 25.0 mmol). Theresulting thick slurry was allowed to stir for at least 10 minutes. Asolution of 1-(4-bromo-phenyl)-3phenyl-propan-1-one (3.385 g, 11.7 mmol)obtained in step A in 20 mL methylene chloride was put into the additionfunnel and this was added dropwise to the reaction over 24 minutes. Theice bath was allowed to melt and the reaction mixture was allowed towarm up overnight. The reaction was then carefully poured into 500 mLice/water and extracted twice with 100 mL methylene chloride. Thecombined organics were then washed twice with 1N HCl (100 mL) and oncewith brine (100 mL). The organics were dried over Na₂SO₄, treated withcharcoal, filtered and concentrated to a residue that waschromatographed over silica gel eluting with 100% hexanes. Evaporationof the proper fractions yielded the product as a colorless oil (0.858 g,2.83 mmol). ¹H NMR (CDCl₃): δ 7.48 (d, 2H), 7.27 (m, 5H), 7.09 (d, 2H),2.34 (m, 2H), 1.92 (m, 2H), 1.37 (s, 6H).

[0917] C. 3-[4-(1,1-Dimethyl-3-phenyl-propyl)-phenyl]-acrylic acidmethyl ester. Into a small pressure tube was added 1.5 mL Et₃N and astir bar. To this was added4-(1,1-dimethyl-3-phenyl-propyl)-bromobenzene obtained in step A (0.858g, 2.83 mmol), methyl acrylate (0.32 mL, 3.55 mmol), Pd(OAc)₂ (0.008 g,0.036 mmol) and tri-o-tolylphosphine (0.034 g, 0.11 mmol). The reactionmixture was deoxygenated by bubbling argon through the solution. Thevessel was then capped and heated at 100° C. for 3.5 hours. Aftercooling, the reaction was partitioned between 25 mL Et₂O and 25 mL 1NHCl. The organics were then washed once with 25 mL 1N HCl, dried overNa₂SO₄, filtered and evaporated in vacuo to yield the product as ayellow oil (0.873 g, 2.83 mmol). This oil was then chromatographed oversilica gel with 5% EtOAc in hexanes. Evaporation of the proper fractionsgave the title compound as an oil. ¹H NMR (CDCl₃): δ 7.72 (d, 1H), 7.52(d, 2H), 7.43 (d, 2H), 7.23 (d, 2H), 7.17 (d, 1H), 7.08 (d, 2H), 3.82(s, 3H), 2.37 (m, 2H), 1.94 (m, 2H), 1.38 (s, 6H).

[0918] D. 3-[4-(1,1-Dimethyl-3-phenyl-propyl)-phenyl]-propionic acidmethyl ester. The cinnamate ester obtained in step C,3-[4-(1,1-dimethyl-3phenyl-propyl)-phenyl]-acrylic acid methyl ester(0.867 g, 2.81 mmol) was dissolved in 25 mL methanol along with 10% Pd/C(0.161 g) and hydrogenated at ˜50 psi for 48 hours. Filtration of thereaction mixture over a pad of celite and evaporation of the filtrateyielded the product as colorless oil (0.647 g, 2.08 mmol). ¹H NMR(CDCl₃): δ 7.32 (d, 2H), 7.26 (d, 2H), 7.19 (m, 3H), 7.12 (m, 2H), 3.68(s, 3H), 2.96 (t, 2H), 2.67 (t, 2H), 2.37 (m, 2H), 1.92 (m, 2H), 1.34(s, 6H).

[0919] E. 3-[4-(1,1-Dimethyl-3-phenyl-propyl)-phenyl]-propionic acid. Toa round bottom flask equipped with a stir bar was added3-[4-(1,1-dimethyl-3phenyl-propyl)-phenyl]-propionic acid methyl esterobtained in step D (0.640 g 2.06 mmol), 25 mL THF, 5 mL water andLiOH·H2O (0.174 g, 4.15 mmol). The reaction was stirred for 3 days thenevaporated in vacuo to an aqueous residue which was diluted with 50 mLwater, acidified with 10 mL 1N HCl. The precipitated solid was collectedby filtration, rinsed with water and dried under vacuum to yield theproduct as a white powder (0.536 g, 1.81 mmol). ¹H NMR (DMSO-d₆): δ 7.33(d, 2H), 7.21 (m, 5H), 7.11 (d, 2H), 2.82 (t, 2H), 2.56 (t, 2H), 2.28(m, 2H), 1.86 (m, 2H), 1.31 (s, 6H); MS: m/z 294.9 (MH)⁻.

[0920] F.3-[4-(1,1-Dimethyl-3-phenyl-propyl)-phenyl]-N-quinolin-3-yl-propionamide.The carboxylic acid obtained in step E,3-[4-(1,1-dimethyl-3phenyl-propyl)-phenyl]-propionic acid, (0.150 g,0.51 mmol) was dissolved in 5 mL DMF with stirring. To this was addedEt₃N (0.08 mL, 0.57 mmol), 3-aminoquinoline (0.075 g, 0.52 mmol) andlastly HBTU (0.207 g, 0.55 mmol). The reaction was allowed to stirovernight then poured into 25 mL EtOAc and washed with saturated NaHCO₃solution (25 mL) then brine (25 mL). The organics were evaporated invacuo and the residue chromatographed over silica gel eluting with 0% to55% EtOAc in hexanes. Evaporation of the proper fractions yielded thetitle product (0.126 g, 0.298 mmol). ¹H NMR (CDCl₃): δ 8.73 (s, 1H),8.61 (d, 1H), 8.03 (d, 1H), 7.80 (d, 1H), 7.64 (t, 1H), 7.55 (t, 1H),7.37 (d, 2H), 7.28-7.10 (m, 6H), 7.07 (d, 2H), 3.10 (t, 2H), 2.78 (t,2H), 2.36 (m, 2H), 1.92 (m, 2H), 1.37 (s, 6H); MS: m/z 423.5 (MH⁺).

Example (33) 1-Pentyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acidquinolin-3-ylamide

[0921]

[0922] n-Pentyltriflate. To a nitrogen flushed round bottom flaskequipped with a stir bar was added pyridine (0.81 mL, 10.0 mmol) andn-pentanol (1.09 mL, 10.0 mmol). The reaction was cooled in an ice bathand triflic anhydride (1.69 mL, 10.0 mmol) was added dropwise. The icebath was allowed to melt over two hours at which time the entirereaction mixture was filtered over a column of silica gel eluting withdichloromethane. The filtrate was carefully evaporated in vacuo thencarried on without further purification(1.11 g, 5.04 mmol).

[0923] A. Triflate salt of 1-pentyl-quinoline-6-carboxylic acid methylester. To a nitrogen flushed round bottom flask equipped with a stir barwas added 10 mL EtOAc and quinoline-6-carboxylic acid methyl ester(0.729 g, 3.89 mmol). A solution of the pentyltriflate prepared asdescribed above (5.04 mmol) in 10 mL EtOAc was then added and thereaction mixture was stirred overnight. The reaction mixture wasevaporated in vacuo and carried on without further purification.

[0924] B. 1-Pentyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acid methylester. The triflate salt of 1-pentyl-quinoline-6-carboxylic acid methylester (3.89 mmol) obtained in step A was dissolved in 50 mL ethanolalong with 10% Pd/C (0.162 g) and hydrogenated at ˜50 psi overnight.Filtration of the reaction mixture over a pad of celite and evaporationof the filtrate gave a residue which was dissolved in 50 mLdichloromethane, washed twice with 25 mL saturated NaHCO₃, once with 25mL brine, dried over Na₂SO₄ and evaporated. The residue waschromatographed over silica gel eluting with 0% to 7.5% EtOAc inhexanes. Evaporation of the proper fractions yielded the product (0.756g, 2.89 mmol) as a yellow oil. ¹H NMR (CDCl₃): δ 7.73 (dd, 1H), 7.62 (d,1H), 6.52 (d, 1H), 3.88 (s, 3H), 3.36 (t, 2H), 3.30 (t, 2H), 2.79 (t,2H), 1.96 (m, 2H), 1.62 (m, 2H), 1.37 (m, 4 H), 0.94 (t, 3H); MS: m/z262.5 (MH⁺ ).

[0925] C. 1-Pentyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acid. Intoa round bottom flask equipped with a stir bar and reflux condenser wasadded a solution of 1-pentyl-1,2,3,4-tetrahydro-quinoline-6-carboxylicacid methyl ester obtained in step B (0.748 g, 2.86 mmol) in 25 mL EtOH.NaOH solution (1N, 10.0 mL, 10.0 mmol) was added and the reactionmixture was heated at reflux overnight then evaporated in vacuo to anaqueous residue which was diluted with 25 mL water and acidified with 10mL 1N HCl. The precipitated solid was collected by filtration, rinsedwith water and dried to yield the product as a pale tan powder (quant).¹H NMR (DMSO-d₆): δ 11.89 (br s, 1H), 7.58 (dd, 1H), 7.47 (d, 1H), 6.57(d, 1H), 3.32 (m, 4H), 2.69 (t, 2H), 1.84 (m, 2H), 1.53 (m, 2H), 1.31(m, 4H), 0.88 (t, 3H); MS: m/z 248.4 (MH⁺ ).

[0926] D. 1-Pentyl-1,2,3,4-tetrahydro-quinoline-6-carbonyl chloride.Into a nitrogen flushed round bottom flask equipped with a stir bar wassuspended the acid obtained in step C,1-pentyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acid (0.554 g, 2.20mmol), in 25 mL dichloromethane. To the suspension was added two dropsof DMF followed by oxalyl chloride (0.58 mL, 6.65 mmol). The reactionwas stirred for 1.5 hours then evaporated in vacuo to give the acidchloride that was carried on without further purification.

[0927] E. 1-Pentyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acidquinolin-3-ylamide. The acid chloride obtained in step D,1-pentyl-1,2,3,4-tetrahydro-quinoline-6-carbonyl chloride (1.10 mmol),was dissolved in 5 mL acetonitrile with stirring. To the solution wasadded Et₃N (0.35 mL, 2.51 mmol) and 3-aminoquinoline (0.144 g, 1.00mmol). The reaction was stirred overnight, diluted with 50 mL Et₂O,extracted twice with 50 mL 1N NaOH and once with 100 mL brine. Theorganics were dried over Na₂SO₄, filtered, evaporated and thenchromatographed over silica gel eluting with 0% to 7.5% EtOAc inhexanes. Evaporation of the proper fractions yielded the product as afreebase which was converted to its hydrochloride salt by treatment withethereal HCl. Evaporation of the ether in vacuo and drying under vacuumat 50° C. yielded the product as an orange powder (0.078 g, 0.17 mmol).¹H NMR (CDCl₃): δ 10.80 (s, 1H), 10.39 (s, 1H), 9.98 (s, 1H), 8.61 (d,1H), 8.17 (dd, 1H), 8.04 (m, 2H), 7.87 (t, 1H), 7.78 (t, 1H), 6.64 (d,1H), 3.38 (t, 2H), 3.31 (t, 2H), 2.87 (t, 2H), 1.98 (m, 2H), 1.63 (m,2H), 1.36 (m, 4H), 0.93 (t, 3H); MS: m/z 374.7 (MH⁺ ).

[0928] Following the procedure described above for Example 33 and theappropriate reagents, starting materials and purification methods knownto those skilled in the art, the following compound was prepared:Example # Compound name MS (calc) MS (obs) (34)1-Methyl-1,2,3,4-tetrahydro- 317.4 318.5 quinoline-6-carboxylic acidquinolin- 3-ylamide

Example (35)3-[4-(Cyclohexylmethyl-methyl-amino)-phenyl]-N-quinolin-3-yl-propionamide

[0929]

[0930] A. 3-(4-Amino-phenyl)-propionic acid ethyl ester. Ethyl4-nitrocinnamate (6.66 g, 30.1 mmol) was dissolved in 60 mL EtOH alongwith 5% Pd/C (0.667 g) and hydrogenated at ˜50 psi for 1.5 hours.Filtration of the reaction mixture over a pad of celite and evaporationof the filtrate gave the product as a pale peach colored liquid (5.776g, 29.9 mmol). ¹H NMR (CDCl₃): δ 6.99 (d, 2H), 6.62 (d, 2H), 4.12 (q,2H), 3.64 (br s, 2H), 2.85 (t, 2H), 2.58 (t, 2H), 1.23 (t, 3H).

[0931] B. 3-[4-(Cyclohexyl methyl-amino)-phenyl]-propionic acid ethylester. Into a nitrogen flushed round bottom flask equipped with a stirbar was added 30 mL dichloroethane, the aniline obtained in step A,3-(4-aminophenyl)-propionic acid ethyl ester (1.451 g, 7.51 mmol),cyclohexanecarboxaldehyde (0.91 mL, 7.51 mmol), and tetramethylammoniumtriacetoxyborohydride (3.982 g, 15.13 mmol). The reaction was stirredovernight then diluted with 25 mL dichloromethane, extracted twice with50 mL water, once with 50 mL saturated NaHCO₃ and once with 50 mL brine.The organics were dried over Na₂SO₄, filtered and evaporated in vacuo toyield the crude product which was carried on without furtherpurification (2.161 g, 7.47 mmol). MS: m/z 290.1 (MH⁺).

[0932] C. 3-[4-(Cyclohexylmethyl-methyl-amino)-phenyl]-propionic acidethyl ester. To a round bottom flask equipped with a stir bar and refluxcondenser was added 50 mL dichloromethane, the product from step B,3-[4(cyclohexylmethyl-amino)-phenyl]-propionic acid ethyl ester (2.161g, 7.47 mmol), paraformaldehyde (1.130 g, 37.6 mmol) andtetramethylammonium triacetoxyborohydride (3.950 g, 15.0 mmol). Thereaction was heated at reflux overnight, cooled and diluted with 50 mLdichloromethane. The mixture was then extracted twice with 50 mL water,once with 50 mL saturated NaHCO₃ and once with 50 mL brine. The organicswere dried over Na₂SO₄, filtered, evaporated and chromatographed oversilica gel eluting with 0% to 5% EtOAc in hexanes. Evaporation of theproper fractions yielded the product as a colorless oil (1.611 g, 5.31mmol). ¹H NMR (CDCl₃): δ 7.06 (d, 2H), 6.62 (d, 2H), 4.13 (q, 2H), 3.08(d, 2H), 2.93 (s, 3H), 2.86 (t, 2H), 2.58 (t, 2H), 1.72 (m, 6H), 1.22(m, 6H), 0.93 (m, 2H); MS: m/z 304.1 (MH⁺).

[0933] D. 3-[4-(Cyclohexylmethyl-m⁻thyl-amino)-ph⁻nyl]-propionic acid.To a round bottom flask equipped with a stir bar was added thepropionate ester obtained in step C,3-[4-(cyclohexylmethyl-methyl-amino)-phenyl]-propionic acid ethyl ester(1.611 g, 5.31 mmol), 50 mL THF, 10 mL water and LiOH·H2 O (0.252 g,6.01 mmol). The reaction was stirred for 2 days, evaporated in vacuo toan aqueous residue which was then diluted with 50 mL water and acidifiedwith 6.0 mL 1N HCl. The precipitated solid was collected by filtration,rinsed with water and dried under vacuum at 50° C. The product wasobtained as an off-white powder (1.299 g, 4.72 mmol). ¹H NMR (DMSO-d₆):δ 12.02 (s, 1H), 6.99 (d, 2H), 6.55 (d, 2H), 3.08 (d, 2H), 2.86 (s, 3H),2.70 (t, 2H), 2.46 (t, 2H), 1.66 (m, 6H), 1.17 (m, 3H), 0.92 (m, 2H);MS: m/z 276.1 (MH⁺).

[0934] E.3-[4-(Cyclohexylmethyl-methyl-amino)-phenyl]-N-quinolin-3-yl-propionamide.The propionic acid obtained in step D,3-[4-(cyclohexylmethylmethyl-amino)-phenyl]-propionic acid (0.282 g,1.02 mmol) was dissolved in 5 mL DMF with stirring. To this was addedEt₃N (0.16 mL, 1.15 mmol), 3-aminoquinoline (0.147 g, 1.02 mmol) andlastly HBTU (0.396 g, 1.04 mmol). The reaction was allowed to stir for48 hours then poured into 25 mL Et₂O and washed three times with 10 mLwater. The organic layers were dried over Na₂SO₄, filtered and thesolution was allowed to stand and partially evaporate which caused asolid to form. This solid was collected, rinsed with a small amount ofEt₂O, and dried under vacuum to give the product as a cream coloredpowder (0.267 g, 0.66 mmol). ¹H NMR (CDCl₃): δ 8.77 (s, 1H), 8.55 (s,1H), 8.04 (d, 1H), 7.83 (d, 1H), 7.66 (t, 1H), 7.55 (t, 1H), 7.27 (s,1H), 7.14 (d, 2H), 6.64 (d, 2H), 3.12 (d, 2H), 3.02 (t, 2H), 2.95 (s,3H), 2.73 (t, 2H), 1.67 (m, 6H), 1.20 (m, 3H), 0.93 (m, 2H); MS: m/z402.1 (MH⁺).

[0935] Following the procedure described above for Example 35 and theappropriate reagents, starting materials and purification methods knownto those skilled in the art, the following compounds of the presentinvention were prepared: Example MS MS # Compound name (calc) (obs) (36)3-[4-(Benzyl-methyl-amino)-phenyl]-N- 395.5 396.1quinolin-3-yl-propionamide (37) 3-[4-(Methyl-pentyl-amino)-phenyl]-N-375.5 376.2 quinolin-3-yl-propionamide (38)3-[4-(Heptyl-methyl-amino)-phenyl]-N- 403.6 404.2quinolin-3-yl-propionamide (39) 3-[4-(Methyl-propyl-amino)-phenyl]-N-347.5 348.1 quinolin-3-yl-propionamide (40)3-[4-(Cyclohexyl-methyl-amino)-phenyl]- 387.5 388.1N-quinolin-3-yl-propionamide (41) 2-[4-(Methyl-pentyl-amino)-phenyl]-N-361.5 362.1 quinolin-3-yl-acetamide

Example (42)3-[4-(Cyclohexyl-methyl-amino)-phenyl]-N-quinolin-3-yl-acrylamide

[0936]

[0937] A. 3-[4-(Cyclohexyl-methyl-amino)-phenyl]-acrylic acid ethylester. Into a round bottom flask equipped with a stir bar and refluxcondenser was added 30 mL dichloroethane, ethyl 4-aminocinnamate (1.914g, 10.01 mmol), cyclohexanone (1.04 mL, 10.03 mmol) andtetramethylammonium triacetoxyborohydride (5.325 g, 20.2 mmol). Thereaction was heated at reflux overnight, cooled and paraformaldehyde(1.505 g, 50.1 mmol) was added along with additional tetramethylammoniumtriacetoxyborohydride (5.276 g, 20.1 mmol). The reaction was then heatedat reflux overnight. Upon cooling, the reaction mixture was diluted with50 mL dichloromethane, washed twice with 50 mL water, once with 50 mLsaturated NaHCO₃ and once with 50 mL brine. The organics were dried overNa₂SO₄, filtered, evaporated and chromatographed over silica gel elutingwith 0% to 7.5% EtOAc in hexanes. Evaporation of the proper fractionsyielded the product as a thick yellow liquid (1.680 g, 5.85 mmol).

[0938]¹H NMR (CDCl₃): δ 7.62 (d, 1H), 7.40 (d, 2H), 6.70 (d, 2H), 6.21(d, 1H), 4.23 (q, 2H), 3.63 (m, 1H), 2.83 (s, 3H), 1.92-7.66 (m, 5H),1.58-1.23 (m, 7H), 1.16 (m, 1H).

[0939] B. 3-[4-(Cyclohexyl-methyl-amino)-phenyl]-acrylic acid. To around bottom flask equipped with a stir bar was added the cinnamateester obtained in step A, 3-[4-(cyclohexyl-methyl-amino)-phenyl]-acrylicacid ethyl ester (1.672 g, 5.82 mmol), 50 mL THF, 10 mL water andLiOH·H20 (0.252 g, 6.01 mmol). The reaction was stirred for 4 days atroom temperature. The reaction mixture was then heated at refluxovernight, additional LiOH·H2O was added (0.084 g, 2.00 mmol) and therefluxing was continued overnight. The reaction mixture was evaporatedin vacuo to give an aqueous residue which was diluted with 50 mL waterand acidified with 8.0 mL 1N HCl. The precipitated solid was collectedby filtration, rinsed with water and hexanes and dried under vacuum at50° C. The product was obtained as a yellow powder (1.274 g, 4.91 mmol).¹H NMR (DMSO-d₆): 11.92 (s, 1H), 7.48 (m, 3H), 6.78 (d, 2H), 6.22 (d,1H), 3.70 (m, 1H), 2.80 (s, 3H), 1.78 (br d, 2H), 1.65 (br s, 3H),1.58-1.29 (m, 4H), 1.13 (m, 1H); MS: m/z 260.1 (MH⁺).

[0940] C.3-[4-(Cyclohexyl-methyl-amino)-phenyl]-N-quinolin-3-yl-acrylamide. Thecinnamic acid obtained in step B,3-[4-(cyclohexyl-methylamino)-phenyl]-acrylic acid (0.259 g, 1.00 mmol)was dissolved in 5 mL DMF with stirring. To this was added Et₃N (0.16mL, 1.15 mmol), 3-aminoquinoline (0.144 g, 1.00 mmol) and lastly HBTU(0.389 g, 1.03 mmol). The reaction was allowed to stir for 17 days thenpoured into a mixture of Et₂O and NaHCO₃. The solid that formed wascollected by filtration, washed with additional Et₂O and water thendried under vacuum at 40° C. to give the product as an orange powder(0.215 g, 0.56 mmol). ¹H NMR (CDCl₃): δ 8.98 (s, 1H), 8.89 (s, 1H), 8.13(brs, 1H), 8.07 (d, 1H), 7.83 (d, 1H), 7.74 (d, 1H), 7.63 (t, 1H), 7.56(t, 1H), 7.43 (d, 2H), 6.72 (d, 2H), 6.47 (d, 1H), 3.63 (m, 1H), 2.85(s, 3H), 1.93-1.64 (m, 5H), 1.58-1.29 (m, 4H), 1.21 (m, 1H); MS: m/z 386(MH⁺).

[0941] Following the procedure described above for Example 42 and theappropriate reagents, starting materials and purification methods knownto those skilled in the art, the following compounds of the presentinvention were prepared: Example # Compound name MS (calc) MS (obs) (43)3-[4-(Methyl-pentyl-amino)- 373.5 374 phenyl]-N-quinolin-3-yl-acrylamide

Example (44) 3-(4-Dipentylamino-phenyl)-N-quinolin-3-yl-propionamide

[0942]

[0943] A. 3-(4-Dipentylamino-phenyl)-propionic acid ethyl ester. To around bottom flask equipped with a stir bar and reflux condenser wasadded 25 mL dichloroethane, 3-(4-amino-phenyl)-propionic acid ethylester prepared as described above (1.163 g, 6.02 mmol), valeraldehyde(1.30 mL, 12.2 mmol) and tetramethylammonium triacetoxyborohydride (6.34g, 24.1 mmol). The reaction was heated at reflux overnight, cooled anddiluted with 25 mL dichloroethane. The mixture was then washed once with50 mL brine, once with 50 mL saturated NaHCO₃ and once more with 50 mLbrine. The organics were dried over Na₂SO₄, filtered, evaporated invacuo and chromatographed over silica gel eluting with 0% to 5% EtOAc inhexanes. Evaporation of the proper fractions yielded the product as apale yellow oil (1.091 g, 3.27 mmol). ¹H NMR (CDCl₃): δ 7.04 (d, 2H),6.58 (d, 2H), 4.13 (q, 2H), 3.23 (t, 4H), 2.86 (t, 2H), 2.58 (t, 2H),1.58 (m, 4H), 1.43-1.18 (m, 11H), 0.92 (t, 6H); MS: m/z 334.1 (MH⁺).

[0944] B. 3-(4-Dipentylamino-phenyl)-propionic acid. To a round bottomflask equipped with a stir bar was added the propionate ester obtainedin step A, 3-(4-dipentylamino-phenyl)-propionic acid ethyl ester (1.078g, 3.23 mmol), 40 mL THF, 8 mL water and LiOH·H₂O (0.168 g, 4.00 mmol).The reaction was stirred for 48 hours then evaporated in vacuo to anaqueous residue which was diluted with 20 mL water and acidified with4.0 mL 1N HCl. The mixture was then evaporated in vacuo and the oilyresidue triturated with water, decanted and dried under vacuum at 50° C.to give the product as an orange oil (0.965 g, 3.16 mmol). ¹H NMR(CDCl₃): δ 7.08 (br d, 2H), 6.71 (br s, 2H), 3.23 (t, 4H), 2.88 (t, 2H),2.63 (t, 2H), 1.58 (br s, 4H), 1.31 (m, 8H), 0.90 (t, 6H).

[0945] C. 3-(4-Dipentylamino-phenyl)-N-quinolin-3-yl-propionamide. Thecarboxylic acid obtained in step B, 3-(4-dipentylamino-phenyl)-propionicacid (0.318 g, 1.04 mmol) was dissolved in 5 mL DMF with stirring. Tothis was added Et₃N (0.16 mL, 1.15 mmol), 3-aminoquinoline (0.150 g,1.04 mmol) and lastly HBTU (0.405 g, 1.07 mmol). The reaction wasallowed to stir overnight then poured into a mixture of 100 mL aqueousNaHCO₃ containing a small amount of NaOH. The precipitated solid wascollected by filtration, rinsed with 3N NaOH then with water and driedunder vacuum to yield the title product as an orange-brown solid (0.224g, 0.52 mmol). ¹H NMR (CDCl₃): δ 8.73 (s, 1H), 8.55 (d, 1H), 8.02 (d,1H), 7.81 (d, 1H), 7.63 (t, 1H), 7.55 (t 1H), 7.39 (s, 1H), 7.11 (d,2H), 6.62 (d, 2H), 3.25 (t, 4H), 3.02 (t, 2H), 2.75 (t, 2H), 1.57 (m,4H), 1.32 (m, 8H), 0.90 (t, 6H); MS: m/z 432.2 (MH⁺).

[0946] Following the procedure described above for Example 44 and theappropriate reagents, starting materials and purification methods knownto those skilled in the art, the following compounds of the presentinvention were prepared: Example # Compound name MS (calc) MS (obs) (45)2-(4-Dipentylamino-phenyl)-N- 417.6 418.2 quinolin-3-yl-acetamide

Example (46) 3-(4-Pentyl-phenyl)-N-quinolin-3-yl-acrylamide

[0947]

[0948] A. 3-(4-Pentyl-phenyl)-acrylic acid ethyl ester. To a nitrogenflushed round bottom flask equipped with a stir bar and reflux condenserwas added 4pentyl-benzaldehyde (1.782 g, 10.11 mmol) and 25 mL benzene.(Carbethoxymethylene)triphenylphosphorane (3.539 g, 10.16 mmol) wasadded and the solution was heated at reflux overnight. The reactionmixture was evaporated in vacuo. The resulting residue was trituratedwith 50 mL Et₂O and filtered. The filtrate was evaporated in vacuo andchromatographed over silica gel eluting with 0% to 5% EtOAc in hexanes.Evaporation of the proper fractions yielded the product as a colorlessoil (2.126 g, 8.63 mmol). ¹H NMR (CDCl₃): δ 7.68 (d, 1H, J=16.0 Hz),7.45 (d, 2H), 7.20 (d, 2H), 6.41 (d, 1H, J=16.0 Hz), 4.28 (q, 2H), 2.64(t, 2H), 1.62 (m, 2H), 1.33 (m, 7H), 0.89 (t, 3H); MS: m/z 247 (MH⁺).

[0949] B. 3-(4-Pentyl-phenyl)-acrylic acid. To a round bottom flaskequipped with a stir bar was added the cinnamate ester obtained in stepA, 3-(4-pentylphenyl)-acrylic acid ethyl ester (1.052 g, 4.27 mmol), 50mL THF, 10 mL water and LiOH·H₂O (0.187 g,4.46 mmol). The reaction wasstirred overnight then an additional amount of LiOH·H₂O was added (0.179g, 4.27). The reaction was stirred for an additional 5 days thenevaporated in vacuo, diluted with 50 mL water and acidified with 25 mL1N HCl. The precipitated solid was collected by filtration, rinsed withwater and dried under vacuum at 50° C. to give the product as a whitepowder (0.636 g, 2.91 mmol). 1H NMR (DMSO-d₆): 12.32 (s, 1H), 7.60 (m,3H), 7.25 (d, 2H), 6.48 (d, 1H), 2.61 (t, 2H), 1.60 (m, 2H), 1.30 (m,4H), 0.87 (t, 3H); MS: m/z 217.0 (M-H)⁻.

[0950] C. 3-(4-Pentyl-phenyl)-N-quinolin-3-yl-acrylamide. The carboxylicacid obtained in step B, 3-(4-pentyl-phenyl)-acrylic acid (0.220 g, 1.01mmol), was dissolved in 5 mL DMF with stirring. To this was added Et₃N(0.16 mL, 1.15 mmol), 3-aminoquinoline (0.147 g, 1.02 mmol) and lastlyHBTU (0.383 g, 1.01 mmol). The reaction was allowed to stir overnightthen poured into 100 mL aqueous NaHCO₃ containing a small amount ofNaOH. The solid was collected by filtration, rinsed with water andchromatographed over silica gel eluting with 0% to 50% EtOAc in hexanes.Evaporation of the proper fractions yielded the title product as a paletan powder (0.125 g, 0.36 mmol). ¹H NMR (CDCl₃): δ 8.92 (s, 1H), 8.83(d, 1H), 8.05 (d, 1H), 7.82 (m, 3H), 7.65 (t, 1H), 7.57 (t, 1H), 7.48(d, 2H), 7.21 (d, 2H), 6.62 (d, 1H), 2.63 (t, 2H), 1.64 (m, 2H), 1.33(m, 4H), 0.89 (t, 3H); MS: m/z 345.0 (MH⁺).

Example (47) 2-(4-Pentyl-phenyl)-N-quinolin-3-yl-acetamide

[0951]

[0952] A. (4-Pentyl-phenyl)-acetonitrile. Into a 3-neck round bottomflask equipped with a stir bar, reflux condenser and addition funnel wasadded potassium t-butoxide solution (1M in THF, 31 mL, 31 mmol). Theflask was cooled in a dry ice-acetonitrile bath and a solution oftosylmethyl isocyanide (TosMIC) in 15 mL DME was added (3.179 g, 16.3mmol). The reaction was stirred for a few minutes then a solution of4-pentyl-benzaldehyde (2.593 g, 14.7 mmol) in 15 mL DME was addeddropwise over 35 minutes. The reaction was stirred in the ice bath for 2hours then removed and allowed to warm to room temperature. Methanol (40mL) was then added and the solution was heated at reflux for 25 minutes.The reaction mixture was evaporated in vacuo, dissolved in 150 mLdichloromethane, washed twice with 100 mL 5% HOAc, once with 100 mLsaturated NaHCO₃ and finally with 100 mL brine. The organics were driedover Na₂SO₄, filtered, evaporated and chromatographed over silica geleluting with 0% to 7.5% EtOAc in hexanes. Evaporation of the properfractions yielded the product as a brown oil with a distinctive odor(0.949 g, 5.07 mmol). ¹H NMR (CDCl₃): δ 7.22 (m, 4H), 3.72 (s, 2H), 2.60(t, 2H), 1.61 (m, 2H), 1.32 (m, 4H), 0.90 (t, 3H).

[0953] B. (4-Pentyl-phenyl)-acetic acid. Into a round bottom flaskequipped with a stir bar and reflux condenser was added 25 mL EtOH,(4-pentyl-phenyl)-acetonitrile prepared in step A (0.945 g, 5.05 mmol),and NaOH solution (1N, 5 mL, 5 mmol). The reaction was heated at refluxfor 2 days then an additional amount of NaOH solution was added (1N, 5mL, 5 mmol) and reaction mixture was heated at reflux for an additional5 days. The reaction mixture was evaporated in vacuo, dissolved in 50 mLwater then filtered over a pad of celite. The aqueous filtrate wasacidified with 25 mL 1N HCl and the precipitated solid was collected byfiltration. The solid was rinsed with water and dried under vacuum at50° C. to give the product as an orange powder (0.917 g, 4.45 mmol). ¹HNMR (DMSO-d₆): δ 12.25 (s, 1H), 7.13 (m, 4H), 3.52 (s, 2H), 2.54 (t,2H), 1.57 (m, 2H), 1.28 (m, 4H), 0.85 (t, 3H); MS: m/z 205(M-H.)⁻

[0954] C. 2-(4-Pentyl-phenyl)-N-quinolin-3-yl-acetamide. The carboxylicacid obtained in step B (4-pentyl-phenyl)-acetic acid (0.208 g, 1.01mmol) was dissolved in 5 mL DMF with stirring. To this was added Et₃N(0.15 mL, 1.08 mmol), 3-aminoquinoline (0.147 g, 1.02 mmol) and lastlyHBTU (0.390 g, 1.03 mmol). The reaction was allowed to stir overnightthen poured into 100 mL aqueous NaHCO₃ containing a small amount ofNaOH. The precipitated solid was collected by filtration, rinsed withwater and dried under vacuum to yield the product as a tan powder (0.256g, 0.77 mmol). ¹H NMR (CDCl₃): δ 8.74 (d, 1H), 8.58 (d, 1H), 8.02 (d,1H), 7.78 (d, 1H), 7.63 (t, 1H), 7.53 (t, 1H), 7.44 (s, 1H), 7.28 (m,4H), 3.82 (s, 2H), 2.64 (t, 2H), 1.63 (m, 2H), 1.33 (m, 4H), 0.90 (t,3H); MS: m/z 333.0 (MH⁺ ).

Example (48) 4-[(Hexyl-methyl-amino)-methyl]-N-quinolin-3-yl-benzamide

[0955]

[0956] A. 4-[(Hexyl-methyl-amino)-methyl]-benzoic acid methyl ester.Into a round bottom flask equipped with a stir bar was added 25 mLdichloroethane, methyl 4-formylbenzoate (1.235 g, 7.52 mmol),N-methylhexylamine (1.14 mL, 7.52 mmol) and tetramethylammoniumtriacetoxyborohydride (3.975 g, 15.1 mmol). The reaction was stirredovernight then diluted with 25 mL dichloromethane, washed twice with 50mL water, once with 50 mL saturated NaHCO₃ and once with brine. Theorganics were dried over Na₂SO₄, filtered, evaporated and thenchromatographed over silica gel eluting with 0% to 20% EtOAc in hexanes.Evaporation of the proper fractions yielded the product as a colorlessoil (1.386 g, 5.26 mmol). ¹H NMR (CDCl₃): δ 8.01 (d, 2H), 7.42 (d, 2H),3.92 (s, 3H), 3.52 (s, 2H), 2.37 (t, 2H), 2.19 (s, 3H), 1.52 (m, 2H),1.30 (m, 6H), 0.89 (t, 3H); MS: m/z 264.1 (MH⁺).

[0957] B. 4-[(Hexyl-methyl-amino)-methyl]-benzoic acid. To a roundbottom flask equipped with a stir bar was added the benzoate esterprepared in step A, 4-[(hexyl-methyl-amino)-methyl]-benzoic acid methylester (1.386 g, 5.26 mmol), 50 mL THF, 10 mL water and LiOH·H2O (0.252g, 6.01 mmol). The reaction was stirred 48 hours then evaporated invacuo to give an aqueous residue which was diluted with 50 mL water andthen acidified with 6.0 mL 1N HCl. The solution was filtered over a padof celite to remove the turbidity then evaporated in vacuo and driedunder vacuum at 50° C. to give the product as a mixture with LiCl. Nofurther attempts were made to remove the inorganic salt from thecarboxylic acid. 1H NMR (DMSO-d₆): 7.90 (d, 2H), 7.42 (d, 2H), 3.53 (s,2H), 2.32 (t, 2H), 2.12 (s, 3H), 1.46 (m, 2H), 1.25 (m, 6H), 0.83 (t,3H); MS: m/z 250.1 (MH⁺).

[0958] C. 4-[(Hexyl-methyl-amino)-methyl]-benzoyl chloride. Into anitrogen flushed round bottom flask equipped with a stir bar wassuspended the benzoic acid prepared in step B,4-[(hexyl-methyl-amino)-methyl]-benzoic acid (0.298 g, 1.00 mmol) in 20mL dichloromethane. To the suspension was added one drop of DMF followedby oxalyl chloride (0.26 mL, 2.98 mmol). The reaction was stirred forone hour then an additional amount of oxalyl chloride was added (0.26mL, 2.98 mmol) and the reaction was stirred overnight. The reactionmixture was then evaporated in vacuo to give the acid chloride that wascarried on without further purification.

[0959] D. 4-[(Hexyl-methyl-amino)-methyl]-N-quinolin-3-yl-benzamide. Theacid chloride obtained in step C,4-[(hexyl-methyl-amino)-methyl]-benzoyl chloride (1.00 mmol), wasdissolved in 10 mL acetonitrile with stirring. To the solution was addediPr₂NEt (0.38 mL, 2.18 mmol) and 3-aminoquinoline (0.145 g, 1.01 mmol).The reaction was stirred for 2 hours then evaporated in vacuo. Theresulting residue was suspended in 50 mL dichloromethane, washed twicewith 25 mL 1N NaOH, once with 25 mL water and once with 25 mL brine. Theorganics were dried over Na₂SO₄, filtered, evaporated andchromatographed over silica gel eluting with 5% MeOH/NH₃: 95%dichloromethane. Evaporation of the proper fractions yielded the titleproduct as a yellow-tan powder (0.249 g, 0.66 mmol). ¹H NMR (CDCl₃): δ8.94 (s, 1H), 8.88 (d, 1H), 8.20 (s, 1H), 8.07 (d, 1H), 7.91 (d, 2H),7.83 (d, 1H), 7.67 (t, 1H), 7.57 (t, 1H), 7.48 (d, 2H), 3.55 (s, 2H),2.38 (t, 2H), 2.20 (s, 3H), 1.52 (m, 2H), 1.31 (m, 6H), 0.90 (t, 3H);MS: m/z 376.1. (MH⁺)

[0960] Following the procedure described above for Example 48 and theappropriate reagents, starting materials and purification methods knownto those skilled in the art, the following compounds of the presentinvention were prepared: Example # Compound name MS (calc) MS (obs) (49)2-[4-(Cyclohexyl-methyl-amino)- 373.5 374.1phenyl]-N-quinolin-3-yl-acetamide

Example (50) 3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-propionamide

[0961] 4-t-Butylphenylacetic acid To a round bottom flask equipped witha stir bar was added methyl 4-t-butylphenylacetate (5.185 g, 25.13mmol), 125 mL THF, 25 mL water and LiOH·H₂O (1.054 g, 25.12 mmol). Thereaction was stirred overnight then evaporated in vacuo to give anaqueous residue which was diluted with 25 mL water. The solution wasthen filtered over a nylon disk and the filtrate acidified with 50 mL 1NHCl. The precipitated solid that formed was collected by filtration,rinsed with water and dried to yield the product, 4-t-butylphenylaceticacid, as a white powder (4.572 g, 23.8 mmol). ¹H NMR (DMSO-d₆): δ 12.28(br s, 1H), 7.33 (d, 2H), 7.18 (d, 2H), 3.51 (s, 2H), 1.28 (s, 9H); MS:m/z 191.0 (M-H)⁻.

[0962] A. 3-(4-tert-Butyl-phenyl)-propionic acid.3-(4-tert-Butyl-phenyl)-acrylic acid (3.06 g, 15.0 mmol) was dissolvedin 50 mL EtOH along with 10% Pd/C (0.308 g) and hydrogenated at ˜50 psiovernight. Filtration of the reaction mixture over a pad of celite andevaporation of the filtrate gave the title product as a whitecrystalline powder (3.021 g, 14.6 mmol). ¹H NMR (DMSO-d₆): δ 12.11 (brs,1H), 7.30 (d, 2H), 7.14 (d, 2H), 2.78 (t, 2H), 2.52 (t, 2H), 1.27 (s,9H); MS: m/z 205.0 (M-H)⁻.

[0963] B. 3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-propionamide. Thecarboxylic acid obtained in step A, 3-(4-tert-butyl-phenyl)-propionicacid (0.208 g, 1.01 mmol), was dissolved in 5 mL DMF with stirring.Triethylamine (0.16 mL, 1.15 mmol) was then added followed by3-aminoquinoline (0.147 g, 1.02 mmol) and lastly HBTU (0.404 g, 1.07mmol). The reaction mixture was stirred at room temperature for 48 hoursthen poured into 25 mL EtOAc, washed with 25 mL saturated NaHCO₃solution then 25 mL brine. The organics were evaporated in vacuo and theresidue was chromatographed over silica gel eluting with 0% to 60% EtOAcin hexanes. Evaporation of the proper fractions yielded the titleproduct as an off-white powder (0.294 g, 0.88 mmol). ¹H NMR (CDCl₃): δ8.72 (s, 1H), 8.55 (d, 1H), 8.03 (d, 1H), 7.81 (d, 1H), 7.63 (t, 1H),7.53 (t, 1H), 7.37 (d, 2H), 7.21 (m, 3H), 3.09 (t, 2H), 2.78 (t, 2H),1.31 (s, 9H); MS: m/z 333.5 (MH⁺).

[0964] 5-Pentyl-thiophene-2-carboxylic acid. n-Butyllithium (2.0 M incyclohexane, 6.2 mL, 12.4 mmol) was added to a solution of2-pentylthiophene (1.75 g, 11.3 mmol) in diethyl ether (40 mL) at −10°C. The resultant solution was stirred at 0° C. for 30 minutes, thencooled to −10° C. Carbon dioxide was bubbled through the solution at −5to −10° C. for 45 minutes. The solution was washed with 2N hydrochloricacid, then brine and dried over sodium sulfate. The solvent wasevaporated in vacuo to give an oil which crystallized from cold hexane,to give a colorless solid, 0.553 g (25%). MS: m/z 199 (MH⁺). ¹HNMR(CDCl₃): δ 0.90 (t, 3 H), 1.29-1.41 (m, 4 H), 1.65-1.75 (m, 2 H),2.85 (t, 2 H), 6.82 (d, 1H) and 7.72 (d, 1H).

[0965] The preceding carboxylic acids were coupled to 3-aminoquinolinesaccording to the procedure of step B of Example 48.

[0966] Following the procedure described above for Example 50 and theappropriate reagents, starting materials and purification methods knownto those skilled in the art, the following compounds of the presentinvention were prepared: Ex- ample MS MS # Compound name (calc) (obs)(51) 3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl- 330.4 331.4 acrylamide(52) 2-(4-tert-Butyl-phenyl)-N-quinolin-3-yl- 318.4 319.4 acetamide (53)4-tert-Butyl-N-quinolin-3-yl-benzamide 304.4 305.4 (54)N-Quinolin-3-yl-4-trifluoromethyl- 316.28 317.1 benzamide (55)N-Quinolin-3-yl-3-(4-trifluoromethyl- 342.32 342.00 phenyl)-acrylamide(56) 3-(4-Chloro-3-trifluoromethyl-phenyl)-N- 376.77 377.00quinolin-3-yl-acrylamide (57) 3-(3,4-Dichloro-phenyl)-N-quinolin-3-yl-343.21 343.00 acrylamide (342)   (58)N-Quinolin-3-yl-3-(3-trifluoromethyl- 342.31 343.20 phenyl)-acrylamide(59) 5-Butyl-pyridine-2-carboxylic acid 305.38 306 quinolin-3-ylamide(60) 5-Pentyl-thiophene-2-carboxylic acid 324.45 325 quinolin-3-ylamide(61) N-Quinolin-3-yl-3-(4-trifluoromethyl- 344.34 345phenyl)-propionamide (62) 2-Methyl-3-phenyl-N-quinolin-3-yl- 288.35 289acrylamide

Example (63) 4-Butoxy-N-quinolin-3-yl-benzamide

[0967]

[0968] 4-Butoxy-N-quinolin-3-yl-benzamide. 4-Butoxy-benzoyl chloride(0.21 mL, 1.11 mmol), Et₃N (0.16 mL, 1.15 mL) and 3-aminoquinoline(0.153 g, 1.06 mmol) were stirred together in 10 mL acetonitrile in around bottom flask for 4 hours. The reaction mixture was then evaporatedin vacuo and the residue was triturated with 5 mL acetonitrile. Theresulting solid was collected by filtration, rinsed with acetonitrileand dried to yield the title product as a cream-colored powder (0.284 g,0.89 mmol). ¹H NMR (CDCl₃): δ 8.91 (s, 2H), 8.20 (s, 1H), 8.08 (d, 1H),7.94 (d, 2H), 7.84 (d, 1H), 7.67 (t, 1H), 7.57 (t, 1H), 7.01 (d, 2H),4.05 (t, 2H), 1.83 (p, 2H), 1.52 (h, 2H), 1.01 (t, 3H); MS: m/z 321.0(MH⁺ ).

[0969] Methyl-quinolin-3-yl-amine. A solution of quinolin-3-ylamine (5.2g, 36.1 mmol) and trifluoroacetic acid (catalytic) in triethylorthoformate (30 mL) was heated at reflux for 6 hours. The solvent wasevaporated in vacuo, and the residue was dissolved in ethanol (50 mL).Sodium borohydride tablets (2.5 g, 0.203 mol) was added to the solution,and the resultant mixture was stirred at room temperature for 2.5 days.The mixture was partitioned between water and dichloromethane. Theorganic layer was separated, washed with water and dried over sodiumsulfate. The solvent was evaporated in vacuo, to give the product, 5.35g (94%), an oil, which crystallized on standing. MS: m/z 159 (MH⁺). ¹HNMR (CDCl₃): δ 2.90 (d, 3 H), 4.15 (br s, 1H), 6.97 (d, 1H), 7.36-7.47(m, 2 H), 7.55-7.65 (m, 1H), 7.91-7.96 (m, 1H) and 8.42 (d, 1H).

[0970] Following the procedure described above for Example 63 and theappropriate reagents, starting materials and purification methods knownto those skilled in the art, the following compounds of the presentinvention were prepared: Example MS MS # Compound name (calc) (obs) (64)4-Pentyl-N-quinolin-3-yl-benzamide 318.41 319 (65)4-Methyl-N-quinolin-3-yl-benzamide 262.31 263 (66)4-Ethyl-N-quinolin-3-yl-benzamide 276.337 277 (67)4-Propyl-N-quinolin-3-yl-benzamide 290.36 291 (68)4-Butyl-N-quinolin-3-yl-benzamide 304.391 305 (69)4-Hexyl-N-quinolin-3-yl-benzamide 332.44 333 (70)4-Decyl-N-quinolin-3-yl-benzamide 388.552 389 (71)4-Heptyl-N-quinolin-3-yl-benzamide 346.47 347 (72)4-Octyl-N-quinolin-3-yl-benzamide 360.498 361 (73)4-Nonyl-N-quinolin-3-yl-benzamide 374.52 375 (74) Biphenyl-4-carboxylicacid quinolin-3- 324.381 325 ylamide (75)4-Butyl-N-methyl-N-quinolin-3-yl- 318.42 319 benzamide (76)4-Ethoxy-N-quinolin-3-yl-benzamide 292.336 293

[0971] Preparation of Substituted 3-aminoquinolines

[0972] 2-Chloro-quinolin-3-ylamine

[0973] A. 2-Chloro-quinoline-3-carboxylic acid. A suspension of silvernitrate (6.8 g, 40 mmol) in ethanol (100 mL) was added to a solution of2-chloro-quinoline-3-carbaldehyde (4.8 g, 25 mmol) in ethanol (200 mL).A solution of sodium hydroxide (5 g, 125 mmol) in 80% ethanol (100 mL)was added over 15 minutes. The resulting black suspension was stirred atambient temperature for 4 hours. The mixture was filtered through a padof celite, and the pad was washed generously with ethanol. The combinedethanolic solutions were concentrated in vacuo and diluted with water.The aqueous solution was neutralized with concentrated hydrochloricacid, and the product precipitated. The product was collected byfiltration and washed with water. The solid was triturated in hotethanol, cooled and collected by filtration to give a colorless solid,3.5 g (67%). MS: m/z 208 (MH⁺). ¹H NMR(DMSO-d₆): δ 7.74 (d of d, 1 H),7.94 (d of d, 1 H), 8.01 (d, 1 H), 8.18 (d, 1 H), 8.95 (s, 1 H) and13.81 (s, 1 H).

[0974] B. (2-Chloro-quinolin-3-yl)-carbamic acid tert-butyl ester.Diphenyphosphoryl azide (2.72 mL, 12.6 mmol) was added to a mixture of2chloro-quinoline-3-carboxylic acid (2.5 g, 12.0 mmol) and triethylamine(1.84 mL, 13.2 mmol) in tert-butanol (30 mL). The resultant solution washeated at reflux for 2 hours. The solvent was evaporated in vacuo, andthe residue was partitioned between ethyl acetate and water. The organiclayer was washed successively with water (3×), a saturated aqueoussolution of sodium bicarbonate, and brine. The solution was dried oversodium sulfate, and the solvent was evaporated in vacuo. The product waspurified by flash chromatography on silica gel, eluted with 2% to 7.5%ethyl acetate in hexane to give the product, 2.1 g (63%). MS: m/z 279(MH⁺). ¹H NMR(DMSO-d₆): δ 1.58 (s, 9 H), 7.23 (br s, 1 H), 7.51 (d of d,1 H), 7.58 (d of d, 1 H), 7.78 (d, 1 H), 7.93 (d, 1 H) and 8.90 (s, 1H).

[0975] C. 2-Chloro-quinolin-3-ylamine A solution of2-chloro-quinolin-3-yl)carbamic acid tert-butyl ester (2.0 g, 7.18 mmol)in 1,2-dichloroethane (20 mL) and trifluoroacetic acid (12 mL) wasstirred at ambient temperature for 20 hours. The solvents wereevaporated in vacuo, and the residue was triturated in an aqueoussolution of sodium bicarbonate. The product was collected by filtration,washed with water, and dried in vacuo to give the product as a paleyellow solid, 1.2 g (94%). MS: m/z 179 (MH⁺). ¹H NMR(DMSO-d₆): δ 5.8 (brs, 2 H), 7.41 (m, 3 H), 7.71 (m, 2 H).

[0976] 4-Chloro-quinolin-3-ylamine was prepared as described in“Synthesis of Some 3-Nitro- and 3-Amino-4-dialkylaminoquinolineDerivatives” Surrey, A. R.; Cutler, R. A. J. Amer. Chem. Soc. 1951, 73,2413.

[0977] Preparation of Substituted tert-butoxycarbonylamino-benzoic AcidDerivatives.

[0978] 4-tert-Butoxyamino-3-methyl-benzoic acid. A solution ofdi-tert-butyl dicarbonate (18.7 g, 85.8 mmol) in dioxane (50 mL) wasadded to a solution of 4-amino-3-methylbenzoic acid (9.95 g, 65.8 mmol)in 3 N aqueous sodium hydroxide (22 mL, 66 mmol). The resultant solutionwas stirred at ambient temperature, and additional potions ofdi-tert-butyl dicarbonate (14 g and 7 g) were added at 18 and 42 hoursrespectively. The solution was stirred an additional 2 days. Thesolution was diluted with water and neutralized with 1N hydrochloricacid. The precipitate was collected by filtration, washed with water anddried in vacuo, to give the product as a colorless solid, 12.75 g (77%).¹H NMR(DMSO-d₆): δ 1.48 (s, 9 H), 3.47 (s, 3 H), 7.60 (d, 1 H),7.70-7.74 (m, 2 H), 8.70 (s, 1 H) and 12.69 (s, 1 H).

[0979] 4-tert-Butoxyamino-2-chloro-benzoic acid.4-amino-2-chloro-benzoic acid was converted to product in 79% yield,using the procedure described for the synthesis of4-tert-Butoxyamino-3-methyl-benzoic acid. ¹H NMR(DMSO-d₆): δ 1.49 (s, 9H), 7.46 (d of d, 1 H), 7.71 (br s, 1 H), 7.80 (d, 1 H), 9.87 (s, 1 H)and 13.00 (br s, 1 H).

[0980] Preparation of Substituted Nicotinic Acid Derivatives.

[0981] Pyridyl carboxylates were prepared according to the method ofComins, D. L.; Stroud, E. D.; Herrick, J. Heterocyles, 1984, 22, 151.

[0982] 6-Pentyl-6H-pyridine-1,3-dicarboxylic acid 3-methyl ester1-phenyl ester. Phenylchloroformate (1.83 mL, 14.6 mmol) was addeddropwise to a solution of Nicotinic acid methyl ester (2.0 g, 14.6 mmol)in tetrahydrofuran (30 mL) at −20° C., and stirred for ten minutes. Asolution of pentylmagnesium bromide (2 M in diethyl ether, 7.3 mL, 14.6mmol) was added dropwise to the solution and stirred for 30 min at −20°C. The resulting solution was washed successively with saturated aqueousammonium chloride and brine. The solution was dried over sodium sulfate,and the solvent was evaporated in vacuo to give the product mixed withanother isomer. The crude mixture was used without purification in thesubsequent step. MS: m/z 330 (MH⁺).

[0983] 6-Pentyl-nicotinic acid methyl ester. The crude mixture fromabove with naphthalene (27.5 g), and sulfur (0.5 g, 15.6 mmol) washeated for 3 hours. The naphthalene was distilled off in vacuo, and theresidue was partitioned between diethyl ether and 2N hydrochloric acid.The aqueous extracts were combined and made basic with 3N sodiumhydroxide. The product was extracted into dichloromethane andpreabsorbed onto silica gel. The product was separated from its isomerby flash chromatography, using ethyl acetate (15-20%) in hexane as theeluant, to give the product, 0.30 g (10% for 2 steps). MS: m/z 208(MH⁺). ¹H NMR(CDCl₃): δ 0.90 (t, 3 H), 1.31-1.48 (m, 4 H), 1.67-1.78 (m,2 H), 2.85 (t, 2 H), 3.94 (s, 3 H), 7.22 (d, 1 H), 8.18 (d of d, 1 H)and 9.13 (d, 1 H).

Example (77) 4-tert-Butyl-N-(2-chloro-quinolin-3-yl)-benzamide

[0984]

[0985] A solution of trimethylaluminum in toluene (2.0 M, 0.56 mL, 1.12mmol) was added to a solution of 2-chloro-quinolin-3-ylamine (0.2 g,1.12 mmol) and methyl 4-tert-butylbenzoate (0.227 mL, 1.18 mmol) in1,2-dichloroethane (10 mL). The solution was heated at reflux for 6hours, cooled to room temperature and treated with methanol (˜1 mL). Theproduct was preabsorbed onto silica gel, and purified by flashchromatography, using 10% ethyl acetate in hexane as the eluant to givethe product as a colorless solid, 0.32 g (84%). MS: m/z 339 (MH⁺). ¹HNMR(DMSO-d₆): δ 1.34 (s, 9 H), 7.60 (d, 2 H), 7.69 (d of d, 1 H), 7.82(d of d, 1 H), 7.99 (d, 3 H), 8.09 (d, 1 H), 8.67 (s, 1 H) and 10.31 (s,1 H).

[0986] The following compounds were prepared according to the method ofExample 77: Example # Compound name M Wt MH⁺ (78)4-tert-Butyl-N-(2-chloro-quinolin-3-yl)- 338.84 339 benzamide (79)4-tert-Butyl-N-(4-chloro-quinolin-3-yl)- 338.83 339.1 benzamide (80)6-Pentyl-N-quinolin-3-yl-nicotinamide 319.41 320

Example (81)3-(4-tert-Butyl-phenyl)-N-(2-chloro-quinolin-3-yl)-acrylamide

[0987]

[0988] A solution of trimethyaluminum (2.0 M, 0.61 mL, 1.22 mmol) wasadded to a solution of 2-chloro-quinolin-3-ylamine (0.2 g, 1.12 mmol)and methyl 4-tert-butylcinnamate (0.241 g, 1.11 mmol) in1,2-dichloroethane (10 mL). The solution was heated at reflux for 6hours. The solution was cooled and treated with methanol (˜1 mL). Theproduct was preabsorbed on silica gel and eluted with 20% ethyl acetatein hexane, to give the product as a colorless solid, 0.288 g (71%). MS:m/z 365 (MH⁺). ¹H NMR(DMSO-d₆): δ 1.31 (m, 9 H), 7.16 (d, 1 H), 7.50 (d,2 H), 7.59-7.69 (m, 4 H), 7.75 (t, 1 H), 7.95 (d, 1 H), 8.05 (d, 1 H),8.94 (s, 1 H), and 9.97 (s, 1 H).

[0989] The following compounds were prepared according to the method ofExample 81: Ex- ample # Compound name M Wt MH⁺ (82)3-(4-tert-Butyl-phenyl)-N-(4- 364.87 365.00chloro-quinolin-3-yl)-acrylamide (83)3-(4-Cyano-phenyl)-N-quinolin-3-yl- 299.33 300.10 acrylamide (84)3-(4-tert-Butyl-phenyl)-N-(2-chloro- 364.87 365.10quinolin-3-yl)-acrylamide (85) N-(2-Chloro-quinolin-3-yl)-3-[4-(1,1-378.90 379.00 dimethyl-propyl)-phenyl]-acrylamide (86)N-(4-Chloro-quinolin-3-yl)-3-[4-(1,1- 378.90 379.20dimethyl-propyl)-phenyl]-acrylamide (87)3-[4-(1,1-Dimethyl-propyl)-phenyl]-N- 344.46 345.00quinolin-3-yl-acrylamide (87a) 4-tert-Butyl-N-(4-hydroxy-quinolin-320.39 321 3-yl)-benzamide (87b) 3-(4-tert-Butyl-phenyl)-N-(4-hydroxy-346.43 347 quinolin-3-yl)-acrylamide (87c)N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl- 384.53 3855,6,7,8-tetrahydro-naphthalen-2-yl)- acrylamide (87d)N-(4-Chloro-quinolin-3-yl)-3-(5,5,8,8- 418.97 419tetramethyl-5,6,7,8-tetrahydro-naphthalen- 2-yl)-acrylamide (87e)N-(4-Chloro-quinolin-3-yl)-4-(cyclohexyl- 393.92 394methyl-amino)-benzamide (87f) N-(2-Chloro-quinolin-3-yl)-4-(cyclohexyl-393.92 394 methyl-amino)-benzamide (87g)4-tert-Butyl-N-(2-methoxy-quinolin-3-yl)- 334.31 335 benzamide (87h)4-Azepan-1-yl-N-(4-chloro-quinolin-3-yl)- 379.89 380 benzamide (87i)4-Azepan-1-yl-N-(2-chloro-quinolin-3-yl)- 379.89 380 benzamide (87j)4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N- 405.93 406(2-chloro-quinolin-3-yl)-benzamide (87k)4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N- 405.93 406(4-chloro-quinolin-3-yl)-benzamide

Example (88) 4-Phenethylamino-N-quinolin-3-yl-benzamide.

[0990]

[0991] {4-(Quinolin-3-ylcarbamoyl)-phenyl}-carbamic acid tert-butylester. N,N-diisopropylethyl amine (12.1 mL, 69.4 mmol) was added to asolution of 4-tert-butoxycarbonylamino-benzoic acid (9.05 g, 38.1 mmol),quinolin-3-ylamine (5.0 g, 34.7 mmol) andO-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophospate(HBTU) (14.5 g, 38.1 mmol) in acetonitrile (200 mL) and was stirred atambient temperature for ten minutes. The solution was heated at refluxfor approximately 18 hours. Upon cooling to room temperature, theproduct crystallized and was collected by filtration, to give acolorless solid, 7.9 g (63%). MS: m/z 364 (MH⁺). ¹H NMR(DMSO-d₆): δ 1.51(s, 9 H), 7.57-7.70 (m, 4 H), 7.75-8.00 (m, 4 H), 8.83 (d, J=2 Hz, 1 H),9.15 (d, J=2 Hz, 1 H), 9.75 (br s, 1 H) and 10.54 (br s, 1 H).

[0992] 4-Amino-N-quinolin-3-yl-benzamide. A solution of[4-(quinolin-3-ylcarbamoyl)-phenyl]-carbamic acid tert-butyl ester (7.2g, 19.8 mmol) in dichloromethane (70 mL), trifluoroacetic acid (70 mL)and water (7 mL) was stirred at ambient temperature for approximately 18hours. The solvent was evaporated in vacuo, and the resultant residuewas triturated in water (100 mL) and saturated aqueous sodiumbicarbonate (100 mL). The product was collected by filtration, washedwith water and dried in vacuo, to give a colorless solid, 4.36 g (84%).MS: m/z 264 (MH⁺). ¹H NMR(DMSO-d₆): δ 5.87 (br s, 2 H), 6.64 (d, 2 H),7.55-7.67 (m, 2 H), 7.81 (d, 2 H), 7.94 (t, 2 H), 8.81 (d, J=2 Hz, 1 H),9.14 (d, J=2 Hz, 1 H) and 10.22 (br s, 1 H).

[0993] 4-Phenethylamino-N-quinolin-3-yl-benzamide. A solution of4-amino-N-quinolin-3-yl-benzamide (1.0 g, 3.8 mmol), phenylacetaldehyde(0.49 mL, 4.18 mmol), tetramethylammonium triacetoxyborohydride (2.0 g,7.60 mmol) and acetic acid (a catalytic amount) in 1,2-dichloroethane(40 mL) was heated at reflux for approximately 18 hours. The resultantsolution was cooled to room temperature and washed with a saturatedsolution of aqueous sodium bicarbonate. The solution was applied to aflash silica gel column, and the product was eluted with ethyl acetate(40% to 75%) in hexane to give the product, 0.67 g (48%), as a colorlesssolid. MS: m/z 368 (MH⁺). ¹H NMR(DMSO-d₆): δ 2.88(t, 2 H), 3.35 (t, 2H), 6.51 (br t, 1 H), 6.7 (d, 2 H), 7.20-7.27 (m, 1 H), 7.30-7.33 (m, 4H), 7.55-7.67 (m, 2 H), 7.87 (d, 2 H), 7.95 (m, 2 H), 8.82 (d, J=2 Hz, 1H), 9.15 (d, J=2 Hz, 1 H) and 10.25 (s, 1 H).

Example (89) 4-(Methyl-phenethyl-amino)-N-quinolin-3-yl-benzamide.

[0994] A mixture of 4-phenethylamino-N-quinolin-3-yl-benzamide (0.213 g,0.57 mmol), paraformaldehyde (0.17 g, 5.8 mmol) and tetramethylammoniumtriacetoxyborohydride (0.-37 g, 1.42 mmol) in 1,2-dichloroethane (˜10mL) was heated at reflux for 6 hours. The resultant solution was washedwith saturated aqueous sodium bicarbonate and applied to a flash silicagel column. The product was eluted with ethyl acetate (40%) in hexanesto give the product, 0.2 g (92%). MS: m/z 382 (MH⁺). ¹H NMR(DMSO-d₆): δ2.90 (t, 2 H), 2.93 (s, 3 H), 3.66 (t, 2 H), 6.73 (d, 2 H), 7.21-7.35(m, 5 H), 7.53 (d of t, 1 H), 7.63 (d of t, 1 H), 7.80-7.87 (m, 3 H),8.05 (m, 1 H), 8.85 (d, 1 H) and 8.91 (d, 1 H).

Example (90)4-(Cyclohexylmethyl-phenethyl-amino)-N-quinolin-3-yl-benzamide.

[0995] A solution of 4-phenethylamino-N-quinolin-3-yl-benzamide (73 mg,0.199 mmol) cyclohexane carboxaldehyde (0.072 mL, 0.596 mmol),tetramethylammonium triacetoxyborohydride (78 mg, 0.299 mmol) andcatalytic acetic acid in 1,2-dichloroethane was heated at reflux 1 day.Cyclohexane carboxaldehyde (0.15 mL) and tetramethylammoniumtriacetoxyborohydride (0.25 g) was added, and the solution was refluxedan additional 2 days. The reaction was cooled and washed with asaturated solution of aqueous sodium bicarbonate. The solution wasapplied to a flash silica gel column and the product was eluted withethyl acetate in hexane. The product was further purified by preparativereverse phase (C₁₈) chromatography and eluted with a gradient ofacetonitrile in water with 0.1% trifluoroacetic acid, to give theproduct as the trifluoroacetate salt, a colorless solid, 0.040 g (29%).MS: m/z 464 (MH⁺). ¹H NMR(DMSO-d₆): δ 0.91-1.05 (m, 2 H), 1.07-1.19 (m,3 H), 1.57-1.73 (m, 6 H), 2.83 (t, 2 H), 3.15 (d, 2 H), 3.62 (t, 2 H),6.84 (d, 2 H), 7.21-7.35 (m, 5 H), 7.62-7.74 (m, 2 H), 7.93 (d, 2 H),8.01 (d, 2 H), 8.94 (d, 1 H), 9.26 (d, 1 H) and 10.41 (s, 1 H).

[0996] The following compounds were prepared according to the methods ofthe Examples 88-90: Ex- ample # Compound name M Wt MH⁺  (91)4-Dipropylamino-N-quinolin-3-yl-benzamide 347.46 348  (92)4-Dibutylamino-N-quinolin-3-yl-benzamide 375.51 376  (93)4-Benzylamino-N-quinolin-3-yl-benzamide 353.42 354  (94)4-Dibenzylamino-N-quinolin-3-yl-benzamide 443.55 444  (95)4-Amino-N-quinolin-3-yl-benzamide 263.30 264  (96)4-Pentylamino-N-quinolin-3-yl-benzamide 333.43 334  (97)4-Dipentylamino-N-quinolin-3-yl-benzamide 403.57 404  (98)4-Propylamino-N-quinolin-3-yl-benzamide 305.38 306  (99)4-Cyclohexylamino-N-quinolin-3-yl-benzamide 345.44 346 (100)4-Dihexylamino-N-quinolin-3-yl-benzamide 431.62 432 (101)4-(Benzyl-pentyl-amino)-N-quinolin-3-yl- 423.56 424 benzamide (102)4-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl- 359.47 360.3 benzamide(103) 4-(Cyclopentyl-methyl-amino)-N-quinolin-3-yl- 345.44 346 benzamide(104) 4-Cycloheptylamino-N-quinolin-3-yl- 359.47 360 benzamide (105)4-(Cycloheptyl-methyl-amino)-N-quinolin-3-yl- 373.50 374 benzamide (106)4-Phenethylamino-N-quinolin-3-yl-benzamide 367.45 368 (107)4-Cyclopentylamino-N-quinolin-3-yl- 331.42 332 benzamide (108)4-(Cyclohexyl-propyl-amino)-N-quinolin-3-yl- 387.52 388 benzamide (109)4-(Phenethyl-propyl-amino)-N-quinolin-3-yl- 409.53 410 benzamide (110)4-(Cyclohexylmethyl-phenethyl-amino)-N- 463.62 464quinolin-3-yl-benzamide (111) 4-Amino-3-methyl-N-quinolin-3-yl-benzamide277.33 278 (112) 3-Methyl-4-pentylamino-N-quinolin-3-yl- 347.46 348benzamide (113) 3-Methyl-4-(methyl-pentyl-amino)-N-quinolin- 361.49 3623-yl-benzamide (114) 3-Methyl-4-propylamino-N-quinolin-3-yl- 319.41 320benzamide (115) 3-Methyl-4-(methyl-propyl-amino)-N-quinolin- 333.43 3343-yl-benzamide (116) N-Quinolin-3-yl-4-(tetrahydro-pyran-4- 347.42 348ylamino)-benzamide (117) 4-[Methyl-(tetrahydro-pyran-4-yl)-amino]-N-361.44 362 quinolin-3-yl-benzamide (118)4-Amino-2-chloro-N-quinolin-3-yl-benzamide 297.74 298 (119)2-Chloro-4-cyclohexylamino-N-quinolin-3-yl- 379.89 380 benzamide (120)4-(Cyclohexyl-ethyl-amino)-N-quinolin-3-yl- 373.50 374 benzamide (121)2-Chloro-4-pentylamino-N-quinolin-3-yl- 367.88 368 benzamide (122)2-Chloro-4-(cyclohexylmethyl-amino)-N- 393.92 394quinolin-3-yl-benzamide (123) 2-Chloro-4-isopropylamino-N-quinolin-3-yl-339.82 340 benzamide (124) 4-(Cyclohexylmethyl-amino)-3-methyl-N- 373.50374 quinolin-3-yl-benzamide (125)2-Chloro-4-(cyclohexyl-methyl-amino)-N- 393.92 394quinolin-3-yl-benzamide (126) 2-Chloro-4-propylamino-N-quinolin-3-yl-339.82 340 benzamide (127) 4-(Cyclohexylmethyl-methyl-amino)-3-methyl-387.52 388 N-quinolin-3-yl-benzamide (128)4-(Cyclohexyl-methyl-amino)-3-methyl-N- 373.50 374quinolin-3-yl-benzamide (129)2-Chloro-4-(methyl-propyl-amino)-N-quinolin- 353.85 354 3-yl-benzamide(130) 2-Chloro-4-(methyl-pentyl-amino)-N-quinolin- 381.91 3823-yl-benzamide (131) 2-Chloro-4-(cyclohexylmethyl-methyl-amino)- 407.94408 N-quinolin-3-yl-benzamide (132)2-Chloro-4-(isopropyl-methyl-amino)-N- 353.85 354quinolin-3-yl-benzamide (133) 3-(Methyl-pentyl-amino)-N-quinolin-3-yl-347.46 348 benzamide (134) 3-Heptylamino-N-quinolin-3-yl-benzamide361.49 362 (135) 3-Cyclohexylamino-N-quinolin-3-yl-benzamide 345.44 346(136) 3-Propylamino-N-quinolin-3-yl-benzamide 305.38 306 (137)3-Dipropylamino-N-quinolin-3-yl-benzamide 347.46 348 (138)3-Amino-N-quinolin-3-yl-benzamide 263.30 264 (139)3-Pentylamino-N-quinolin-3-yl-benzamide 333.43 334 (140)3-Dipentylamino-N-quinolin-3-yl-benzamide 403.57 404 (141)3-(Methyl-propyl-amino)-N-quinolin-3-yl- 319.41 320 benzamide (142)3-(Heptyl-methyl-amino)-N-quinolin-3-yl- 375.51 376 benzamide (143)3-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl- 359.47 360 benzamide (144)2-(Heptyl-methyl-amino)-N-quinolin-3-yl- 375.51 376 benzamide (145)2-Pentylamino-N-quinolin-3-yl-benzamide 333.43 334 (146)2-Heptylamino-N-quinolin-3-yl-benzamide 361.49 362 (147)2-Amino-N-quinolin-3-yl-benzamide 263.30 264 (148)2-(Methyl-pentyl-amino)-N-quinolin-3-yl- 347.46 348 benzamide (149)4-Amino-N-methyl-N-quinolin-3-yl-benzamide 277.33 278 (150)4-Cyclohexylamino-N-methyl-N-quinolin-3-yl- 359.47 360 benzamide (151)4-(Cyclohexyl-methyl-amino)-N-methyl-N- 373.50 374quinolin-3-yl-benzamide

Example (152) 4-Methylamino-N-quinolin-3-yl-benzamide

[0997]

[0998] 4-(tert-Butoxycarbonyl-methyl-amino)-benzoic acid. A solution ofdi-tert-butyl dicarbonate (8.0 g, 36.7 mmol) in dioxane (15 mL) wasadded, via an addition funnel, to a solution of 4-methylamino-benzoicacid (5.0 g, 33.1 mmol) in 1N aqueous sodium hydroxide (35 mL, 35 mmol)and stirred at ambient temperature for 6 hours. Di-tert-butyldicarbonate (2.7 g, 12.4 mmol) was added and stirring was continued anadditional 18 hours. Di-tert-butyl dicarbonate (1.5 g, 6.8 mmol) wasadded and stirring was continued an additional day. The solution wasdiluted with water (100 mL) and cooled on an ice bath. The solution wasneutralized with 1 N hydrochloric acid, and the resultant precipitatewas collected by filtration, washed with water and dried on the filterfunnel, to give the product as a colorless solid, 7.25 g (87%). ¹HNMR(DMSO-d₆): δ 1.42 (s, 9 H), 3.23 (s, 3 H), 7.42 (d, 2 H), 7.90 (d, 2H) and 12.86 (br s, 1 H).

[0999] Methyl-[4-(quinolin-3-ylcarbamoyl)-phenyl]-carbamic acidtert-butyl ester. A solution of4-(tert-butoxycarbonyl-methyl-amino)-benzoic acid (3.36 g, 13.4 mmol),O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophospate(HBTU) (5.22 g, 13.8 mmol) and N,N-diisopropylethyl(4.8 mL, 27.5 mmol)in acetonitrile (200 mL) was stirred at ambient temperature for tenminutes. Quinolin-3-ylamine (1.93 g, 13.4 mmol) was added, and thesolution was heated at reflux for 20 hours. The solvent was evaporatedin vacuo, and the residue was partitioned between 1 N aqueous sodiumhydroxide and dichloromethane. The product was purified by flash silicagel chromatography, using 67% ethyl acetate in hexane as the eluant togive the product as a colorless solid, 4 g (80%). MS: m/z 378 (MH⁺). ¹HNMR(CDCl₃): δ 1.51 (s, 9 H), 3.29 (s, 3 H), 7.33 (d, 2 H), 7.53 (d of d,1 H), 7.65 (d of d, 1 H), 7.85 (d, 2 H), 8.04 (d, 1 H), 8.70 (br s, 1 H)and 8.86-8.91 (m, 2 H).

[1000] 4-Methylamino-N-quinolin-3-yl-benzamide. A solution ofmethyl-[4(quinolin-3-ylcarbamoyl)-phenyl]-carbamic acid tert-butyl ester(8.5 g, 22.5 mmol) in dichloromethane (100 ml), trifluoroacetic acid(100 mL) and water (10 mL) was stirred at room temperature for 6 hours.The solvent was evaporated in vacuo, and the residue was suspended in 1N aqueous sodium hydroxide (200 mL). The product was collected byfiltration, washed with water and dried in vacuo, to give a colorlesssolid, 5.4 g (87%). MS: m/z 278 (MH⁺). ¹H NMR(DMSO-d₆): δ 2.77 (d, 3 H),6.44 (br d, 1 H), 6.63 (d, 2 H), 7.54-7.67 (m, 2 H), 7.89 (d, 2 H)superimposed on 7.95 (t, 2 H), 8.82 (d, 1 H), 9.16 (d, 1 H) and 10.26(s, 1 H).

Example (153)4-(Cyclohexylmethyl-methyl-amino)-N-quinolin-3-yl-benzamide.

[1001] A solution of 4-methylamino-N-quinolin-3-yl-benzamide (0.075 g,0.27 mmol), cyclohexylcarboxaldehyde (0.049 mL, 0.405 mmol) andtetramethylammonium triacetoxyborohydride (0.213 g, 0.81 mmol) in1,2-dichloroethane was heated to 85° C. in a sealed tube for 18 hours.The solution was cooled to room temperature and washed with a solutionof ammonium hydroxide in water. The product was preabsorbed on silicagel and purified by flash chromatography, using ethyl acetate/hexane(1/1) as the eluant, to give the product as a colorless solid, 0.051 g(51%). MS: m/z 374 (MH⁺). ¹H NMR(DMSO-d₆): δ 0.90-1.05 (m, 2 H),1.10-1.23 (m, 3 H), 1.58-1.77 (m, 6 H), 3.02 (s, 3 H), 3.27 (d, 2 H),6.77 (d, 2 H), 7.54-7.67 (m, 2 H), 7.91 (d, 2 H) superimposed on 7.95(t, 2 H), 8.81 (d, 1 H), 9.15 (d, 1 H) and 10.28 (s, 1 H).

[1002] The following compounds were prepared according to the methods of

Examples 152 and 153:

[1003] Ex- ample # Compound name M Wt MH⁺ (154)4-(Methyl-pentyl-amino)-N-quinolin-3-yl- 347.46 348 benzamide (155)4-[Methyl-(3-methyl-butyl)-amino]-N-quinolin- 347.46 348.13-yl-benzamide (156) 4-[Methyl-(3-phenyl-propyl)-amino]-N- 395.50 396.1quinolin-3-yl-benzamide (157) 4-(Methyl-propyl-amino)-N-quinolin-3-yl-319.41 320 benzamide (158) 4-(Methyl-butyl-amino)-N-quinolin-3-yl-333.43 334 benzamide (159) 4-(Methyl-hexyl-amino)-N-quinolin-3-yl-361.49 362 benzamide (160) 4-(Methyl-nonyl-amino)-N-quinolin-3-yl-403.57 404 benzamide (161) 4-(Methyl-tetradecyl-amino)-N-quinolin-3-yl-473.70 474 benzamide (153) 4-(Cyclohexylmethyl-methyl-amino)-N- 373.50374 quinolin-3-yl-benzamide (162)4-(Methyl-phenethyl-amino)-N-quinolin-3-yl- 381.48 382 benzamide (163)4-[Methyl-(3-phenyl-allyl)-amino]-N-quinolin- 393.49 394 3-yl-benzamide(164) 4-{Methyl-[3-(5-methyl-furan-2-yl)-butyl]- 413.52 414amino}-N-quinolin-3-yl-benzamide (165)4-(Heptyl-methyl-amino)-N-quinolin-3-yl- 375.51 376 benzamide (166)4-(Octyl-methyl-amino)-N-quinolin-3-yl- 389.54 390 benzamide (167)4-[(3,3-Dimethyl-butyl)-methyl-amino]-N- 361.49 362quinolin-3-yl-benzamide (168) 4-(Hept-4-enyl-methyl-amino)-N-quinolin-3-373.50 374 yl-benzamide (169)4-(Methyl-non-6-enyl-amino)-N-quinolin-3-yl- 401.55 402 benzamide (170)4-(Dec-4-enyl-methyl-amino)-N-quinolin-3-yl- 415.58 416 benzamide (171)4-{Methyl-[4-(quinolin-3-ylcarbamoyl)- 389.45 390phenyl]-amino}-but-2-enoic acid ethyl ester (172)4-{Methyl-[4-(quinolin-3-ylcarbamoyl)- 391.47 392 phenyl]-amino}-butyricacid ethyl ester (173) 4-{Methyl-[4-(quinolin-3-ylcarbamoyl)- 363.42 364phenyl]-amino}-butyric acid (174) 4-{Methyl-[4-(quinolin-3-ylcarbamoyl)-361.39 362 phenyl]-amino}-but-2-enoic acid (175)4-(Benzyl-methyl-amino)-N-quinolin-3-yl- 367.45 benzamide (176)R-4-[(3,7-Dimethyl-oct-6-enyl)-methyl- 415.58 416amino]-N-quinolin-3-yl-benzamide (177)S-4-[(3,7-Dimethyl-oct-6-enyl)-methyl- 415.58 416amino]-N-quinolin-3-yl-benzamide

Example (178) 4-(3-Aza-bicyclo[3.3.1]non-3-yl)-N-quinolin-3-yl-benzamide

[1004]

[1005] 4-Fluoro-N-quinolin-3-yl-benzamide. A solution of 4-fluorobenzoicacid (2.57 g, 18.3 mmol), quinolin-3-ylamine (2.5 g, 17.4 mmol),O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophospate(HBTU) (7.3 g, 19.3 mmol) and N,N-diisopropylethylamine (6.4 mL, 36.7mmol) in acetonitrile (75 mL) was stirred at ambient temperature for tenminutes, then heated at reflux for 20 hours. The solution was cooled to0° C., and the product crystallized. The product was collected byfiltration and washed with acetonitrile, to give a colorless solid, 3.86g (79%). MS: m/z 267 (MH⁺). ¹H NMR(DMSO-d₆): δ 7.39-7.46 (m, 2 H),7.58-7.71 (m, 2 H), 7.97-8.01 (m, 2 H), 8.11-8.16 (m, 2 H), 8.85 (d, 1H), 9.15 (d, 1 H) and 10.73 (s, 1 H).

[1006] 4-(3-Aza-bicyclo[3.3.1]non-3-yl)-N-quinolin-3-yl-benzamide. Asolution of 4-fluoro-N-quinolin-3-yl-benzamide (0.080 g, 0.299 mmol),3-azabicyclo[3.3.1]nonane (0.200 g, 1.60 mmol) andN,N-diisopropylethylamine (0.10 mL, 0.57 mmol) in dimethyl sulfoxide (2mL) was heated to 100° C. for 11 days. The DMSO solution was applied toa preparative reverse phase C₁₈ column, and the product was eluted witha gradient of acetonitrile in water with 0.1% trifluoroacetic acid, togive the product as a trifluoroacetate salt, a yellow solid, 0.065 g(36%). MS: m/z 372 (MH⁺). ¹H NMR(DMSO-d₆): δ 1.40-1.50 (m, 1 H),1.58-1.93 (m, 7 H), 2.05 (br s, 2 H), 3.04-3.08 (m, 2 H), 3.85 (d, 2 H),7.00 (d, 2 H), 7.62-7.76 (m, 2 H), 7.96 (d, 2 H), 8.02 (d, 2 H), 8.95(d, 1 H), 9.28 (d, 1 H) and 10.45 (s, 1 H).

[1007] The following compounds were prepared according to the method ofExample 178: Ex- ample # Compound name M Wt MH⁺ (179)4-Pyrrolidin-1-yl-N-quinolin-3-yl-benzamide 317.38 318 (180)4-(4-Benzyl-piperidin-1-yl)-N-quinolin-3-yl- 421.53 422.1 benzamide(181) 4-(3,5-Dimethyl-piperidin-1-yl)-N-quinolin-3- 359.46 360.1yl-benzamide (182) 4-Piperidin-1-yl-N-quinolin-3-yl-benzamide 331.41 332(183) 4-[1,4′]Bipiperidinyl-1′-yl-N-quinolin-3-yl- 414.54 415 benzamide(184) 4-(3-Methyl-piperidin-1-yl)-N-quinolin-3-yl- 345.44 346 benzamide(185) 4-(4-Phenyl-piperidin-1-yl)-N-quinolin-3-yl- 407.51 408 benzamide(186) 1-[4-(Quinolin-3-ylcarbamoyl)-phenyl]- 430.54 431piperidine-3-carboxylic acid diethylamide (187)4-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-N- 389.45 390quinolin-3-yl-benzamide (188) 1-[4-(Quinolin-3-ylcarbamoyl)-phenyl]-375.42 376 piperidine-2-carboxylic acid (189)4-(4-Oxo-piperidin-1-yl)-N-quinolin-3-yl- 345.4 346 benzamide (178)4-(3-Aza-bicyclo[3.3.1]non-3-yl)-N-quinolin-3- 371.47 372 yl-benzamide(190) cis-4-(Octahydro-isoquinolin-2-yl)-N-quinolin- 385.5 386.13-yl-benzamide (191) 4-(4-Benzoyl-piperidin-1-yl)-N-quinolin-3-yl-435.52 436 benzamide (192) 4-(4-Propyl-piperidin-1-yl)-N-quinolin-3-yl-373.49 374 benzamide (193) trans-4-(Octahydro-isoquinolin-2-yl)-N- 385.5386 quinolin-3-yl-benzamide (194)4-Azonan-1-yl-N-quinolin-3-yl-benzamide 373.49 374 (195)4-Azepan-1-yl-N-quinolin-3-yl-benzamide 345.44 346 (196)4-Azepan-1-yl-N-quinolin-3-yl-benzamide 371.47 372 (197)4-Azocan-1-yl-N-quinolin-3-yl-benzamide 359.46 360.1 (198)4-Morpholin-4-yl-N-quinolin-3-yl-benzamide 333.39 334 (199)4-(1,3-Dihydro-isoindol-2-yl)-N-quinolin-3-yl- 365.43 366 benzamide(200) N-Quinolin-3-yl-4-thiomorpholin-4-yl- 349.46 350 benzamide (201)4-(2,6-Dimethyl-morpholin-4-yl)-N-quinolin-3- 361.44 362 yl-benzamide(202) 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-N- 379.46 380quinolin-3-yl-benzamide (203)4-(4-Benzhydryl-piperazin-1-yl)-N-quinolin-3- 498.63 499 yl-benzamide(204) 4-Piperazin-1-yl-N-quinolin-3-yl-benzamide 332.41 333 (205)4-(4-Benzyl-piperazin-1-yl)-N-quinolin-3-yl- 422.53 423 benzamide (206)4-(4-Phenyl-piperazin-1-yl)-N-quinolin-3-yl- 408.50 409 benzamide (207)4-(4-Methyl-piperazin-1-yl)-N-quinolin-3-yl- 346.43 347 benzamide

Example (208) 6-Azocan-1-yl-N-quinolin-3-yl-nicotinamide

[1008]

[1009] 6-Chloro-N-quinolin-3-yl-nicotinamide. A solution of6-chloro-nicotinic acid (2.95 g, 18.7 mmol),O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophospate(HBTU) (7.09 g, 18.7 mmol), quinolin-3-ylamine (2.7 g, 18.7 mmol), andN,N-diisopropylethylamine (8.2 mL, 46.7 mmol) in acetonitrile was heatedat reflux. The resultant mixture was cooled, and the crystalline productwas collected by filtration, to give a colorless solid, 3.1 g (58%). MS:m/z 284 (MH⁺). ¹H NMR(DMSO-d₆): δ 7.61 (t, 1 H), 7.70 (d of t, 1 H),7.77, (d, 1 H), 8.00 (d, 2 H), 8.43 (d of d, 1 H), 8.85 (d, 1 H), 9.05(d, 1 H), 9.14 (d, 1 H) and 10.95 (s, 1 H).

[1010] 6-Azocan-1-yl-N-quinolin-3-yl-nicotinamide. A solution of6-chloro-N-quinolin-3-yl-nicotinamide (0.10 g, 0.35 mmol) andheptamethyleneimine (0.40 mL, 3.17 mmol) in dimethyl sulfoxide (1 mL)was heated to 82° C. for 5 hours. The resultant solution was poured intowater, and the product was extracted with dichloromethane. The organicsolution was washed several times with water, and applied to a flashsilica gel column. The product was eluted with an ethyl acetate/hexanemixture (1/1), to give the product as a colorless solid, 92 mg (72%).MS: m/z 361 (MH⁺). ¹H NMR(DMSO-d₆): δ 1.38-1.57 (m, 6 H), 1.69-1.78 (m,4 H), 3.69 (br s, 4 H), 6.71 (d, 1 H), 7.56-7.68 (m, 2 H), 7.96 (t, 2H), 8.09 (d of d, 1 H), 8.81 (s, 2 H), 9.13 (d, 1 H) and 10.39 (s, 1 H).

[1011] The following compounds were prepared according to the method ofExample 208: Ex- ample # Compound name M Wt MH⁺ (209)3,4,5,6-Tetrahydro-2H-[1,2′]bipyridinyl-5′- 332.41 333 carboxylic acidquinolin-3-ylamide (210) 6-Pentylamino-N-quinolin-3-yl-nicotinamide334.42 335 (211) 6-(Methyl-pentyl-amino)-N-quinolin-3-yl- 348.45 349nicotinamide (212) 6-Azepan-1-yl-N-quinolin-3-yl-nicotinamide 346.43 347(213) 6-Cyclohexylamino-N-quinolin-3-yl- 346.43 347 nicotinamide (214)6-(Cyclohexyl-methyl-amino)-N-quinolin-3- 360.45 361 yl-nicotinamide(215) 6-(3-Aza-bicyclo[3.3.1]non-3-yl)-N-quinolin- 372.47 3733-yl-nicotinamide (216) 6-(Heptyl-methyl-amino)-N-quinolin-3-yl- 376.49377 nicotinamide (208) 6-Azocan-1-yl-N-quinolin-3-yl-nicotinamide 360.46361 (217) 3,4,5,6-Tetrahydro-2H-[1,2′]bipyridinyl-5′- 372.46 373carboxylic acid quinolin-3-ylamide (218)6-(Methyl-phenethyl-amino)-N-quinolin-3-yl- 382.47 383 nicotinamide(219) 4-Propyl-3,4,5,6-tetrahydro-2H- 374.48 375[1,2′]bipyridinyl-5′-carboxylic acid quinolin- 3-ylamide (220)4-Benzyl-3,4,5,6-tetrahydro-2H- 422.53 423[1,2′]bipyridinyl-5′-carboxylic acid quinolin- 3-ylamide (221)6-(Benzyl-methyl-amino)-N-quinolin-3-yl- 368.43 369 nicotinamide (222)cis-6-(Octahydro-isoquinolin-2-yl)-N- 386.50 387quinolin-3-yl-nicotinamide (223) trans-6-(Octahydro-isoquinolin-2-yl)-N-386.50 387 quinolin-3-yl-nicotinamide

Example (224) 1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid(4-chloro-quinolin-3-yl)-amide

[1012]

[1013] 5-Bromo-1-cyclohexyl-2,3-dihydro-1H-indole. A solution of5-bromo-2,3-dihydro-1 H-indole (94.0 g, 20.2 mmol), cyclohexanone (4.6mL, 44.4 mmol) and sodium cyanoborohydride (1.6 g, 25.5 mmol) inmethanol (100 mL) was heated at reflux for 16 hours. More cyclohexanone(2.3 mL, 22.2 mmol) and sodium cyanoborohydride (1.6 g, 25.5 mmol) wereadded. Heating was continued for 1 day. The solvent was evaporated invacuo, and the residue was treated with ammonium hydroxide in water. Theproduct was extracted into dichloromethane, and dried over sodiumsulfate. The solvent was evaporated in vacuo, and the product waspurified by flash silica gel chromatography, eluted with ethyl acetate(1% to 2%) in hexane to give an oil, 7.49 g (37%). MS: m/z 280 (MH⁺). ¹HNMR(CDCl₃): δ 1.08-1.20 (m, 1 H), 1.25-1.42 (m, 4 H), 1.64-1.74 (m, 1H), 1.76-1.88 (m, 4 H), 2.91 (t, 2 H), 3.24-3.32 (m, 1 H), 3.36 (t, 2H), 6.23 (d, 1 H) and 7.08-7.11 (m, 2 H).

[1014] 1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid methylester. In a steel pressure reactor, pressurized with carbon monoxide(250 psi), a solution of 5-bromo-1-cyclohexyl-2,3-dihydro-1H-indole (2.1g, 7.49 mmol), bis(triphenylphosphine)palladium(II)chloride (0.263 g,0.375 mmol), triphenylphosphine (0.196 g, 0.749 mmol) andN,N-diisopropylethylamine (2.9 mL, 16.5 mmol) in methanol (40 mL) washeated to 100° C. for 3 days. The reactor was cooled, and the gas wascarefully vented. Insoluble material was removed by filtration, and thesolvent was evaporated in vacuo. The residue was purified by flashsilica gel chromatography, eluted with 5% ethyl acetate in heptane, togive the product, 1.56 g (80%), a colorless oil. ¹H NMR(CDCl₃): δ1.08-1.20 (m, 1 H), 1.27-1.47 (m, 4 H), 1.68-1.76 (m, 1 H), 1.80-1.89(m, 4 H), 2.97 (t, 2 H), 3.34-3.45 (m, 1 H), 3.51 (t, 2 H), 3.83 (s, 3H), 6.29 (d, 1 H), 7.65 (d, 1 H) and 7.78 (d of d, 1 H).

[1015] 1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid(4-chloroquinolin-3-yl)-amide. Trimethylaluminum (2.0 M in toluene, 0.6mL, 1.2 mmol) was added to a solution of1-cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid methyl ester (0.14g, 0.54 mmol) and 4-chloro-quinolin-3-ylamine (0.097 g, 0.543 mmol) in1,2-dichloroethane. The resultant solution was heated at reflux for 4hours. Methanol (˜1 mL) was added and the product was preabsorbed ontosilica gel and purified by flash chromatography, using 30% ethyl acetatein heptane as the eluant. The product was further purified by reversephase (C₁₈) chromatography using a gradient of acetonitrile in waterwith 0.1% trifluoroacetic acid as the eluant, to give the product asit's trifluoroacetate salt, 0.090 g (32%). MS: m/z 406 (MH⁺). ¹HNMR(DMSO-d₆): δ 1.07-1.23 (m, 1 H), 1.29-1.49 (m, 4 H), 1.62-1.84 (m, 5H), 3.51 (t, 2 H), 3.45 (m, 3 H), 6.52 (d, 1 H), 7.72 (s, 1 H),7.77-7.88 (m, 3 H), 8.11 (d, 1 H), 8.23 (d, 1 H), 9.00 (s, 1 H) and10.02 (s, 1 H).

Example (225)3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide

[1016]

[1017] 3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-acrylic-acid methylester. In a sealed tube, a solution of5-bromo-1-cyclohexyl-2,3-dihydro-1H-indole (2.2 g, 7.85 mmol), methylacrylate (0.848 mL, 9.42 mmol) and palladium(II)acetate in triethylamine(4.7 mL, 33.8 mmol) was heated to 100° C. for 2 hours. The resultantsuspension was diluted with methanol and transferred into a round bottomflask. The solvents were evaporated in vacuo, and the residue waspartitioned between dichloromethane and saturated aqueous sodiumbicarbonate. The product was preabsorbed onto silica gel and purified byflash chromatography, using ethyl acetate (5% to 10%) in heptane as theeluant, to give the product as a yellow solid, 1.86 g (83%). MS: m/z 286(MH⁺). ¹H NMR(CDCl₃): δ 1.17-1.22 (m, 1 H), 1.28-1.45 (m, 4 H),1.64-1.74 (m, 1 H), 1.77-1.99 (m, 4 H), 2.96 (t, 2 H), 3.29-3.44 (m, 1H), 3.49 (t, 2 H), 3.76 (s, 3 H), 6.14 (d, 1 H), 6.31 (d, 1 H), 7.19 (brd, 1 H), 7.25 (d, 1 H) and 7.59 (d, 1 H).

[1018]3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide Asolution of trimethylaluminum (2.0 M in toluene, 1.05 mL, 2.1 mmol) wasadded to a solution of quinolin-3-ylamine (0.15 g, 1.04 mmol) and3-(1-cyclohexyl-2,3-dihydro-1H-indol-5-yl)-acrylic acid methyl ester(0.30 g, 1.04 mmol) in 1,2-dichloroethane (10 mL). The resultantsolution was heated at reflux for 2 hours. The solution was cooled andtreated with methanol (˜1 mL). The product was preabsorbed onto silicagel and eluted with ethyl acetate (35% to 50%) in heptane, to give theproduct as a yellow solid, 0.35 g (85%). MS: m/z 398 (MH⁺). ¹HNMR(DMSO-d₆): δ 1.03-1.20 (m, 1 H), 1.29-1.47 (m, 4 H), 1.60-1.81 (m, 5H), 2.50 (t, 2 H), 3.38-3.51 (m, 3 H), 6.47 (d, 1 H), 6.53 (d, 1 H),7.27 (d, 1 H) superimposed on 7.29 (s, 1 H), 7.51 (d, 1 H), 7.57-7.66(m, 2 H), 7.92 (d, 1 H), 7.95 (d, 1 H), 8.80 (d, 1 H), 8.97 (d, 1 H) and10.43 (s, 1H).

Example (226)3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-propionamide

[1019] 3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-propionic acid methylester. A solution of 3-(1-cyclohexyl-2,3-dihydro-1H-indol-5-yl)-acrylicacid methyl ester (1.60 g, 5.61 mmol) in methanol (30 mL) with 10%palladium on carbon (0.16 g) was hydrogenated at 55 psi and roomtemperature for 20 hours. The catalyst was removed by filtration, andthe solvent was evaporated in vacuo. The crude product was purified byflash chromatography, using 7.5% ethyl acetate in hexane as the eluant,to give the product, 1.36 g (84%), an oil. MS: m/z 288 (MH⁺). ¹HNMR(CDCl₃): δ 1.04-1.21 (m, 1 H), 1.26-1.43 (m, 4 H), 1.64-1.73 (m, 1H), 1.78-1.86 (m, 4 H), 2.82 (t, 2 H), 2.84-2.92 (m, 4 H), 3.29 (m, 1 H)super imposed on 3.34 (t, 2 H), 3.66 (s, 3 H), 6.31 (d, 1 H), 6.85 (d, 1H) and 6.87 (s, 1 H).

[1020]3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-propionamide.A solution of trimethyaluminum (2.0 M in toluene, 0.26 mL, 0.52 mmol)was added to a solution of3-(1-cyclohexyl-2,3-dihydro-1H-indol-5-yl)-propionic acid methyl ester(0.147 g, 0.511 mmol) and quinolin-3-ylamine (0.074 g, 0.511 mmol) in1,2-dichloroethane (2 mL). The resultant solution was heated to 85° C.in a sealed tube for 2 hours. The cooled solution was treated withseveral drops of methanol. The product was preabsorbed onto silica geland purified via flash chromatography, using ethyl acetate/hexane (1/1)as the eluant. The product was dissolved in tetrahydrofuran and treatedwith ethereal hydrogen chloride. The solvents were evaporated in vacuoto give the product as the hydrochloride salt, 0.110 g (46%), acolorless solid. MS: m/z 400 (MH⁺). ¹H NMR(DMSO-d₆): δ 1.01-1.47 (m, 5H), 1.56-1.80 (m, 5 H), 2.79 (t, 2 H), 3.00 (t, 2 H), 3.10 (t, 2 H),3.62-3.77 (m, 3 H), 7.29-7.32 (m, 3 H), 7.73 (t, 1 H), 7.81 (d of t, 1H), 8.12 (d, 2 H), 8.99 (d, 1 H), 9.22 (d, 1 H) and 11.09 (s, 1H).

[1021] The following compounds were prepared according to the method ofExample 226: Ex- ample # Compound name M Wt MH⁺ (227)1-Pentyl-2,3-dihydro-1H-indole- 359.47 360 5-carboxylic acid quinolin-3-ylamide (228) 3-(1-Cyclohexylmethyl-2,3- 413.55 414dihydro-1H-indol-5-yl)-N- quinolin-3-yl-propionamide (229)1-Propyl-2,3-dihydro-1H-indole- 331.41 332 5-carboxylic acid quinolin-3-ylamide (230) 1-Cyclohexyl-2,3-dihydro-1H- 371.47 372indole-5-carboxylic acid quinolin-3-ylamide (231)1-Methyl-2,3-dihydro-1H-indole- 303.36 304 5-carboxylic acid quinolin-3-ylamide (226) 3-(1-Cyclohexyl-2,3-dihydro-1H- 399.53 400indol-5-yl)-N-quinolin-3- yl-propionamide (232)3-(1-Propyl-2,3-dihydro-1H-indol- 359.47 360.15-yl)-N-quinolin-3-yl-propionamide (233)1-Cyclohexyl-2,3-dihydro-1H-indole-5- 405.93 406.2 carboxylicacid(4-chloro-quinolin-3- yl)-amide (234)3-(1-Cyclohexyl-2,3-dihydro-1H-indol- 397.51 398.35-yl)-N-quinolin-3-yl-acrylamide (234a)3-(1-Cyclohexyl-2,3-dihydro-1H-indol- 397.52 3985-yl)-N-quinolin-3-yl-acrylamide (234b)1-Cyclohexyl-2,3-dihydro-1H-indole-5- 405.93 406 carboxylicacid(2-chloro-quinolin-3- yl)-amide (234c)N-(2-Chloro-quinolin-3-yl)-3-(1- 431.97 432 cyclohexyl-2,3-dihydro-1H-indol-5-yl)-acrylamide

Example (235) 1-Pentyl-1H-indole-5-carboxylic acid quinolin-3-ylamide

[1022]

[1023] 1-Pentyl-1H-indole-5-carboxylic acid methyl ester. Methylindole-5-carboxylate (0.875 g, 5.0 mmol) was added to a suspension ofsodium hydride (60% in oil, 0.22 g, 5.5 mmol) in N,N-dimethylformamide(15 mL) at 0° C. The resultant solution was stirred at room temperaturefor 30 min. Bromopentane (0.706 mL, 5.69 mmol) was added to thesolution, and stirring was continued for 4 hours. The solution waspoured into ice water (100 mL), and the product was extracted intodichloromethane. The organic solution was washed several times withwater and dried over sodium sulfate. The solvent was evaporated invacuo, and the residue was purified by flash silica gel chromatographyusing 5% ethyl acetate in hexane as the eluant, to give the product,0.975 g (79%), as an oil. MS: m/z 280 (MH⁺). ¹H NMR(CDCl₃): δ 0.87 (t, 3H), 1.22-1.40 (m, 4 H), 1.77-1.87 (m, 2 H), 3.92 (s, 3 H), 4.11 (t, 2H), 6.58 (d, 1 H), 7.14 (d, 1 H), 7.32 (d, 1 H), 7.90 (d of d, 1 H) and8.40 (d, 1 H).

[1024] 1-Pentyl-1H-indole-5-carboxylic acid. Aqueous sodium hydroxide(1N, 3.4 mL, 3.4 mmol) was added to a solution of1-pentyl-1H-indole-5-carboxylic acid methyl ester (0.79 g, 3.09 mmol) inmethanol (30 mL). The resultant solution was heated at reflux for 4hours. Additional aqueous sodium hydroxide (3.4 mL) was added andheating was continued for 4 hours. The solution was cooled, neutralizedwith 1N hydrochloric acid. The solvent was evaporated in vacuo. Theresidue was partitioned between water dichloromethane. The organicsolution was dried over sodium sulfate and the solvent was evaporated invacuo, to give the product, 0.715 g (100%). MS: m/z 232 (MH⁺). ¹HNMR(CDCl₃): δ 0.88 (t, 3 H), 1.24-1.42 (m, 4 H), 1.80-1.89 (m, 2 H),4.14 (t, 2 H), 6.61 (d, 1 H), 7.16 (d, 1 H), 7.36 (d, 1 H), 7.99 (d ofd, 1 H) and 8.50 (s, 1 H).

[1025] 1-Pentyl-1H-indole-5-carboxylic acid quinolin-3-ylamide. Asolution of 1-pentyl-1H-indole-5-carboxylic acid (0.687, 2.97 mmol),O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophospate(HBTU) (1.18 g, 3.11 mmol) and N,N-diisopropylethyl(1.14 mL, 6.53 mmol)in acetonitrile (20 mL) was stirred at ambient temperature for 5minutes. Quinolin-3-ylamine (1.93 g, 13.4 mmol) was added, and thesolution was heated at reflux for 18 hours. The solvent was evaporatedin vacuo, and the residue was partitioned between dichloromethane andwater. The product was preabsorbed-onto silica gel and purified by flashchromatography using ethyl acetate in hexane as the eluant, to give theproduct, 0.40 g (38%). MS: m/z 358 (MH⁺). ¹H NMR(DMSO-d₆): δ 0.84 (t, 3H), 1.23-1.34 (m, 4 H), 1.73-1.83 (m, 2 H), 4.24 (t, 2 H), 6.64 (d, 1H), 7.53 (d, 1 H), 7.56-7.69 (m, 3 H), 7.86 (d, 1 H), 7.98 (t, 2 H),8.37 (s, 1 H), 8.89 (d, 1 H), 9.21 (d, 1 H) and 10.60 (s, 1 H).

[1026] The following compounds were prepared according to the method ofExample 235: Ex- ample # Compound name M Wt MH⁺ (235)1-Pentyl-1H-indole-5-carboxylic acid 357.46 358 quinolin-3-ylamide (236)1-Propyl-1H-indole-5-carboxylic 363.85 364acid(2-chloro-quinolin-3-yl)-amide (237) 1-Propyl-1H-indole-5-carboxylic363.85 364 acid(4-chloro-quinolin-3-yl)-amide (238)1-Propyl-1H-indole-5-carboxylic acid 329.40 330 quinolin-3-ylamide(238a) 3-(1-Cyclohexyl-1H-indol-5-yl)-N- 395.51 396quinolin-3-yl-acrylamide (238b) N-(4-Chloro-quinolin-3-yl)-3-(1- 429.95430 cyclohexyl-1H-indol-5-yl)- acrylamide (238c)1-Cyclohexyl-1H-indole-5-carboxylic 403.92 404acid(4-chloro-quinolin-3-yl)-amide (238d)1-Cyclohexyl-1H-indole-5-carboxylic 369.47 370 acid quinolin-3-ylamide(238e) 1-Cyclohexyl-1H-indole-5-carboxylic 403.92 404acid(2-chloro-quinolin-3-yl)-amide (238f)N-(2-Chloro-quinolin-3-yl)-3-(1- 429.95 430cyclohexyl-1H-indol-5-yl)-acrylamide

Example (239) 3-(4-Azepan-1-yl-phenyl)-N-quinolin-3-yl-acrylamide

[1027]

[1028] 4-Azepan-1-yl-benzaldehyde. A solution of 4-fluoro-benzaldehyde(2.59 mL, 24.2 mmol) and hexamethyleneimine (8.2 mL, 72 mmol) inacetonitrile (40 mL) was heated at reflux for 16 hours. The product waspreabsorbed onto silica gel and purified by flash silica gelchromatography, using ethyl acetate (10-15%) in hexane as the eluant, togive the product, 5.0 g (100%). MS: m/z 204 (MH⁺). ¹H NMR(CDCl₃): δ1.53-1.59 (m, 4 H), 1.78-1.82 (m, 4 H), 3.53 (t, 4 H), 6.70 (d, 2 H),7.70 (d, 2 H) and 9.70 (s, 1 H).

[1029] 3-(4-Azepan-1-yl-phenyl)-acrylic acid ethyl ester. Triethylphosphonoacetate (2.4 mL, 12.1 mmol) was added to a solution of4-azepan-1 -yl-benzaldehyde (2.05 g, 10.1 mmol),1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (1.81 mL, 12.1 mmol) andlithium chloride (0.641 g, 15.1 mmol) in acetonitrile (40 mL) was heatedat reflux for 2 hours. Triethyl phosphonoacetate (0.24 mL, 1.2 mmol),1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (0.18 mL, 1.2 mmol) and lithiumchloride (0.065 g, 1.5 mmol) was added, and the solution was refluxed anadditional 18 hours. The solvent was evaporated in vacuo. The productwas preabsorbed onto silica gel and purified by flash chromatography,using ethyl acetate (5%) in hexane as the eluant, to give the product,1.941 g (70%), as a yellow crystalline solid. MS: m/z 274 (MH⁺). ¹HNMR(CDCl₃): δ 1.32 (t, 3 H), 1.52-1.56 (m, 4 H), 1.78 (m, 4 H), 3.49 (t,4 H), 4.23 (q, 2 H), 6.19 (d, 1 H), 6.65 (d, 2 H), 7.39 (d, 2 H) and7.61 (d, 1 H).

[1030] 3-(4-Azepan-1-yl-phenyl)-N-quinolin-3-yl-acrylamide. A solutionof trimethylaluminum (2.0 M in toluene, 0.274 mL, 0.54 mmol) was addedto a solution of (3-(4-azepan-1-yl-phenyl)-acrylic acid ethyl ester(0.15 g, 0.55 mmol) and quinolin-3-ylamine (0.072 g, 0.49 mmol) in1,2-dichloroethane. The solution was sealed in a tube and heated to 80°C. for 6 hours. The solution was cooled, and the product was preabsorbedonto silica gel. The product was eluted with methanol (3%) indichloromethane. Further purification by reverse phase (C₁₈)chromatography, using a gradient of acetonitrile (30-90%) in water with0.1% trifluoroacetate, gave the product as the bis-trifluoroacetatesalt, an orange solid, 0.045 g (14%). MS: m/z 372 (MH⁺). ¹HNMR(DMSO-d₆): δ 1.46 (m, 4 H), 1.73 (m, 4 H), 3.51 (t, 4 H), 6.58 (d, 1H), 6.75 (d, 2 H), 7.45 (d, 2 H), 7.54-7.66 (m, 3 H), 7.94 (t, 2 H),8.81(d, 1 H), 8.98 (d, 1 H) and 10.48 (s, 1 H).

Example (240) 3-(4-Azepan-1-yl-phenyl)-N-quinolin-3-yl-propionamide

[1031] 3-(4-Azepan-1-yl-phenyl)-propionic acid ethyl ester. A solutionof 3(4-azepan-1-yl-phenyl)-acrylic acid ethyl ester (1.0 g, 3.65 mmol)in ethanol (20 Ml) was hydrogenated at 55 psi over 10% palladium (0.1 g)for 18 hours. The catalyst was removed by filtration, and the solventwas evaporated in vacuo. The crude product was purified by flash silicagel chromatograpy, using 5% ethyl acetate in hexane as the eluant, togive the product, 1.0 g (99%), a color less oil. MS: m/z 276 (MH⁺). ¹HNMR(CDCl₃): δ 1.24 (t, 3 H), 1.48-1.61 (m, 4 H), 1.76 (m, 4 H), 2.56 (t,2 H), 2.84 (t, 2 H), 3.42 (t, 4 H), 4.13 (q, 2 H), 6.61 (d, 2 H) and7.03 (d, 2 H).

[1032] 3-(4-Azepan-1-yl-phenyl)-N-quinolin-3-yl-propionamide. A solutionof trimethylaluminum (2.0 M in toluene, 0.50 mL, 1.0 mmol) was added toa solution of 3-(4-Azepan-1-yl-phenyl)-propionic acid ethyl ester (0.20g, 0.73 mmol) and quinoline-3-ylamine (0.087 g, 0.61 mmol) in1,2-dichloroethane (2 mL). The resultant solution was heated to 85° C.in a sealed tube. The solution was cooled and treated with several dropsof methanol. The product was preabsorbed onto silica gel and purified byflash chromatography, using ethyl acetate/hexane (1/2) as the eluant.The product was dissolved in tetrahydrofuran and treated with 1Nethereal hydrogen chloride. The solvents were evaporated in vacuo togive the product as the hydrochloride salt, 0.23 g (70%). MS: m/z 374(MH⁺). ¹H NMR(DMSO-d₆): δ 1.57-1.72 (m, 4 H), 1.87-2.03 (m, 4 H), 2.80(t, 2 H), 2.97 (t, 2 H), 3.47-3.62 (m, 4 H), 7.34 (br s, 2 H)superimposed on 7.45 (br s, 1 H), 7.77 (d of d, 1 H), 7,87 (d of d, 1H), 8.17 (d, 2 H), 9.07 (d, 1 H), 9.30 (d, 1 H) and 11.25 (s, 1 H).

[1033] The following compounds were prepared according to the method ofExample 240: Example # Compound name M Wt MH⁺ (241)3-(4-Azepan-1-yl-phenyl)-N-quinolin-3-yl- 371.48 372 acrylamide (242)3-(4-Azepan-1-yl-phenyl)-N-(4-chloro- 405.927 406quinolin-3-yl)-acrylamide (243) 3-(4-Azepan-1-yl-phenyl)-N-(2-chloro-405.93 406 quinolin-3-yl)-acrylamide (240)3-(4-Azepan-1-yl-phenyl)-N-quinolin-3-yl- 373.5 374 propionamide

Example (244) 4-tert-Butyl-N-(1-oxy-quinolin-3-yl)-benzamide

[1034]

[1035] 4-tert-Butyl-N-(1-oxy-quinolin-3-yl)-benzamide.meta-Chloroperbenzoic acid (50-87%, 0.578 g, ˜2.2 mmol) was added to asolution of 4-tert-butyl-N-quinolin-3-yl-benzamide (0.51 g, 1.68 mmol)in dichloromethane (10 mL) and stirred at room temperature for 20 hours.The product was preabsorbed onto silica gel and purified by flashchromatography, using methanol (3-5%) in dichloromethane as the eluant,to give the product, 0.411 g (76%), an off white solid. MS: m/z 321(MH⁺). ¹H NMR(DMSO-d₆): δ 1.34 (s, 9 H), 7.60 (d, 2 H), 7.69-7.74 (m, 2H), 7.94 (d, 2 H), 8.05-8.08 (m, 1 H), 8.42 (br s, 1 H), 8.45-8.48 (m, 1H), 9.02 (d, 1 H) and 10.60 (s, 1 H). 15 The following compounds wereprepared according to the method of

Example 244:

[1036] Example # Compound name M Wt MH⁺ (245)N-(1-Oxy-quinolin-3-yl)-4-trifluoromethyl- 332.28 333 benzamide (244)4-tert-Butyl-N-(1-oxy-quinolin-3-yl)- 320.39 321 benzamide

Example (246) 3-(4-Piperidin-1-yl-phenyl)-N-quinolin-3-yl-propionamide

[1037]

[1038] A. 3-(4-Amino-phenyl)-propionic acid ethyl ester. Ethyl4-nitrocinnamate (6.66 g, 30.1 mmol) was dissolved in 60 mL EtOH alongwith 5% Pd/C (0.667 g) and hydrogenated at ˜50 psi for 1.5 hours.Filtration over a pad of celite and evaporation of the filtrate gave theproduct as a pale peach colored liquid (5.776 g, 29.9 mmol).

[1039] B. 3-(4-Piperidin-1-yl-phenyl)-propionic acid ethyl ester. Into anitrogen flushed round bottom flask equipped with a stir bar was addedthe aniline from step A, 3-(4-amino-phenyl)-propionic acid ethyl ester,(1.342 g, 6.94 mmol) and 13 mL of dichloroethane. The flask was cooledon an ice bath and into an addition funnel was introduced an aqueoussolution of glutaraldehyde (4.0 mL, 50 wt. % aqueous solution), sulfuricacid (3M, 12 mL), 19 mL MeOH and 13 mL THF. A 0.4 g tablet of NaBH₄ wasintroduced to the solution of the aniline and at the same time theglutaraldehyde mixture was added dropwise to the reaction mixture over aperiod of 6 minutes. An additional 0.4 g tablet of NaBH₄ was added andthe reaction mixture was allowed to warm up overnight. The reactionmixture was then partitioned between 100 mL Et₂O and 100 mL 10% aqueousNa₂CO₃ solution. The organics were separated and washed with 100 mLbrine. The organics were dried over Na₂SO₄, filtered and evaporated invacuo. The residue was purified by chromatography over silica geleluting with 0% to 10% EtOAc in hexanes. Evaporation of the properfractions yielded the product as a colorless oil (0.693 g, 2.65 mmol).¹H NMR (CDCl₃): δ 7.09 (d, 2H), 6.88 (d, 2H), 4.13 (q, 2H), 3.11 (t,4H), 2.88 (t, 2H), 2.58 (t, 2H), 1.71 (m, 4H), 1.57 (m, 2H), 1.24 (t,3H); MS: m/z 262.1 (MH⁺).

[1040] C. 3-(4-Piperidin-1-yl-phenyl)-propionic acid. To a round bottomflask equipped with a stir bar was added the propionate ester IR (0.687g, 2.63 mmol), 25 mL THF, 5 mL water and LiOH·H₂O (0.126 g, 3.00 mmol).The reaction was stirred for 48 hours then evaporated in vacuo to anaqueous residue which was diluted with 10 mL water and acidified with3.0 mL 1N HCl. Evaporation of the clear solution in vacuo yielded asolid residue theoretically containing 83% product and 17% LiCl byweight. ¹H NMR (DMSO-d₆): δ 12.08 (s, 1H), 7.06 (d, 2H), 6.83 (d, 2H),3.08 (br s, 4H), 2.72 (t, 2H), 2.46 (t, 2H), 1.71-1.43 (m, 6H); MS: m/z234.1 (MH⁻).

[1041] D. 3-(4-Piperidin-1-yl-phenyl)-propionyl chloride. Into anitrogen flushed round bottom flask equipped with a stir bar3-(4-piperidin-1-yl-phenyl)-propionic acid, obtained in step C, wassuspended (0.286 g, 1.02 mmol) in 20 mL DCM. To the suspension was addedone drop of DMF followed by oxalyl chloride (0.30 mL, 3.4 mmol). Thereaction was stirred overnight then evaporated in vacuo to give the acidchloride which was carried on without further purification.

[1042] E. 3-(4-Piperidin-1-yl-phenyl)-N-quinolin-3-yl-propionamide. Theacid chloride obtained in step D, 3-(4-piperidin-1-yl-phenyl)-propionylchloride, (1.02 mmol) was dissolved in 10 mL acetonitrile with stirring.To the solution was added iPr₂NEt (0.39 mL, 2.24 mmol) and3-aminoquinoline (0.119 g, 0.83 mmol). The reaction was stirred for 5hours, evaporated in vacuo and suspended in 50 mL Et₂O. The ethersuspension was washed twice with 25 mL 1N NaOH and twice with 25 mLbrine. At this point a solid had formed. Both the solid and organicextract were combined and evaporated in vacuo to yield a residue thatwas purified by silica gel chromatography eluting with 3% MeOH/NH₃: 97%DCM. Evaporation of the proper fractions yielded the product as a tanpowder (0.148 g, 0.412 mmol). ¹H NMR (CDCl₃): δ 8.74 (s, 1H), 8.53 (d,1H), 8.02 (d, 1H), 7.80 (d, 1H), 7.63 (t, 1H), 7.53 (t, 1H), 7.23 (m,1H), 7.17 (d, 2H), 6.89 (d, 2H), 3.12 (t, 4H), 3.04 (t, 2H) 2.74 (t,2H), 1.71 (m, 4H), 1.58 (m, 2H); MS: m/z 360.1 (MH⁺).

Example (247)3-[4-(Methyl-phenethyl-amino)-phenyl]-N-quinolin-3-yl-propionamide

[1043] Synthesis of 3-phenylpropionic & 3-phenyacrylic esters

[1044] 3-[4-(Methyl-phenethyl-amino)-phenyl]-N-quinolin -3-yl-propionamide

[1045] 3-[4-(Phenethyl-amino)-phenyl]-propionic acid ethyl ester.Tetramethylammonium triacetoxyborohydride (4.9 g, 18.6 mmol) was addedto a solution of 3-(4-aminophenyl)-propionic acid ethyl ester (3.0 g,15.5 mmol) and phenylacetaldehyde (1.08 mL, 15.5 mmol) in1,2-dichloroethane (50 mL). The resultant solution was stirred at roomtemperature for ten minutes, then heated at reflux overnight. Thesolution was treated with a 1:1 solution of water:ammonium hydroxide.The organic layer was applied to a silica gel column and eluted withethyl acetate/hexane (1/9) to give the product as an oil, 1.3 g (28%).MS: m/z 298 (MH⁺). ¹H NMR(CDCl₃): δ 1.24 (t, 3 H), 2.58 (t, 2 H), 2.86(s, 3 H), 3.53 (t, 2 H), 3.67 (t, 2 H), 4.13 (q, 2 H), 4.32 (t, 2 H),6.67 (d, 2 H), 7.09 (d, 2 H), 7.19-7.32 (m, 5 H).

[1046] 3-[4-(Methyl-phenethyl-amino)-phenyl]-propionic acid ethyl ester.Paraformaldehyde (0.89 g, 30.5 mmol) was added to a solution of3-[4(Phenethyl-amino)-phenyl]-propionic acid ethyl ester (1.3 g, 4.37mmol) in 1,2-dichloroethane (25 mL). The resultant suspension wasstirred at room temperature for 15 minutes. Tetramethylammoniumtriacetoxyborohydride (2.0 g, 8.74 mmol) was added, and the suspensionwas heated at reflux for 6 hours. The mixture was cooled to roomtemperature and treated with ammonium hydroxide (20 mL). The organiclayer was separated and applied to a silica gel column. The product waseluted with ethyl acetate/hexane (1/20) to give an oil, 0.80 g (59%).MS: m/z 312 (MH⁺). ¹H NMR(CDCl₃): δ 1.23 (t, 3 H), 2.55 (t, 2 H), 2.90(t, 2 H), 3.37 (t, 2 H), 3.59 (br s, 1 H), 4.11 (q, 2 H), 6.55 (d, 2 H),7.01 (d, 2 H), 7.20-7.37 (m, 5 H).

[1047] 3-(2,2-Dimethyl-chroman-6-yl)-acrylic acid ethyl ester. A mixtureof 2,2-Dimethyl-chroman-6-carbaldehyde (1.87 g, 9.82 mmol), lithiumchloride (0.73 g, 17.2 mmol), triethyl phosphonoacetate (2.92 mL, 14.7mmol) and 1,8diazabicyclo[5.4.0]undec-7-ene (DBU) (2.2 mL, 14.7 mmol) inacetonitrile (30 mL) was heated at reflux for 2 hours. The solvent wasevaporated in vacuo, and the residue was partitioned betweendichloromethane and water. The product was preabsorbed onto silica geland purified by flash chromatography, using 5-10% ethyl acetate inhexane as the eluant to give 2.2 g (86%). MS: m/z 261 (MH⁺). ¹HNMR(CDCl₃): δ 1.32 (t, 3 H), 1.34 (s, 6 H), 1.81 (t, 2 H), 2.77 (t, 2H), 4.24 (q, 2 H), 6.26 (d, 1 H), 6.77 (d, 1 H), 7.24-7.30 (m, 2 H) and7.60 (d, 1 H).

[1048] 3-(2,2-Dimethyl-chroman-6-yl)-propionic acid ethyl ester. Asuspension of 3-(2,2-Dimethyl-chroman-6-yl)-acrylic acid ethyl ester(1.2 g, 4.61 mmol) in methanol (25 mL) was hydrogenated with 10%palladium on carbon at 60 psi of hydrogen for 6 hours. The catalyst wasremoved by filtration, and the solvent was evaporated in vacuo to givethe product 0.95 g (79%). MS: m/z 263 (MH⁺). ¹H NMR(CDCl₃): δ 1.15 (t, 3H), 1.24 (s, 6 H), 1.70 (t, 2 H), 2.49 (t, 2 H), 2.65 (t, 2 H), 2.76 (t,2 H), 4.04 (q, 2 H), 6.62 (d, 1 H) and 6.81-6.86 (m, 2 H).

[1049] The esters above were converted to the following productsaccording to the conditions set forth in scheme AA: Example Compoundname M Wt MH⁺ (247) 3-[4-(Methyl-phenethyl-amino)- 409.53 410phenyl]-N-quinolin-3-yl-propionamide (248)3-(2,2-Dimethyl-chroman-6-yl)-N- 358.44 359 quinolin-3-yl-acrylamide(249) 3-(2,2-Dimethyl-chroman-6-yl)-N- 360.45 361quinolin-3-yl-propionamide

Example (250)4-(4-Phenylacetyl-piperazin-1-yl)-N-quinolin-3-yl-benzamide

[1050] 4-Piperazin-1-yl-N-quinolin-3-yl-benzamide. A solution of4-fluoro-N-quinolin-3-yl-benzamide (2.0 g, 3.76 mmol) and piperazine(6.2 g, 72 mmol) in methylsulfoxide (30 mL) was heated 100° C. for 1.5days, to give the product 2.53 g (100%).

[1051] 4-(4-Phenylacetyl-piperazin-1-yl)-N-quinolin-3-yl-benzamide. Asolution of 4-piperazin-1-yl-N-quinolin-3-yl-benzamide (75 mg, 0.284mmol), phenylacetic acid (51 mg, 0.375 mmol),O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate(HBTU)(118 mg, 0.30 mmol) and N,N-N,N-diisopropylethylamine (0.110 mL,0.626 mmol) in acetonitrile (2 mL) was heated to 80° C. The solution wascooled to room temperature and the product crystallized. The product wascollected by filtration washed with acetonitrile to give 63 mg (49%).MS: m/z 451 (MH⁺). ¹H NMR(DMSO-d₆): δ 3.24-3.34 (m, 4 H), 3.63-3.69 (m,4 H), 3.79 (s, 2 H), 7.05 (d, 2 H), 7.22-7.46 (m, 5 H), 7.54-7.67 (m, 2H), 7.92-7.99 (m, 4 H), 8.82 (d, 1 H), 9.15 (d, 1 H) and 10.40 (s, 1 H).

Example (251) 2,3-Dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide

[1052] 5-Bromo-2,3-dihydro-indole-1-carboxylic acid tert-butyl ester. Asolution of 5-bromo-2,3-dihydro-1H-indole (4.97 g, 25.1 mmol),di-tert-butyl dicarbonate (6.0 g, 27.5 mmol) and 4-dimethylaminopyridine(catalytic) in dichloromethane (70 mL) was stirred at room temperatureuntil the starting material was consumed. The solvent was evaporated invacuo, and the residue was purified by flash chromatography on silicagel, eluted with ethyl acetate/hexane to give the product, 4.1 g (55%).¹H NMR(CDCl₃): δ 1.55 (s, 9 H), 3.06 (t, 2 H), 3.97 (t, 2 H), 7.23-7.27(m, 2 H) and 7.72 (br m, 1 H).

[1053] 2,3-Dihydro-indole-1,5-dicarboxylic acid 1-tert-butyl ester5-methyl ester. A solution of 5-bromo-2,3-dihydro-indole-1-carboxylicacid tert-butyl ester (4.0 g, 13.5 mmol), tributylamine andbis-triphenylphosphinopalladium(II) chloride (0.65 g, 0.926 mmol) inmethanol was sealed in a Parr pressure apparatus and pressurized with600 psi of carbon monoxide. The solution was heated at 100° C. for oneweek. The vessel was cooled to room temperature and the gas vented. Thesolution was filtered, and the solvent was evaporated in vacuo. Theresidue was purified by flash chromatography, on silica gel eluted with10-40% ethyl acetate in hexane to give the product mixed withtributylamine, 2.5 g (67%). The product was used without furtherpurification in the subsequent step.

[1054] 2,3-Dihydro-indole-1,5-dicarboxylic acid 1-tert-butyl ester. Asolution of 2,3-dihydro-indole-1,5-dicarboxylic acid 1-tert-butyl ester5-methyl ester (2.3 g, 8.29 mmol) in methanol (30 mL) was treated with 3N aqueous sodium hydroxide (2.77 mL, 8.29 mmol) and heated at reflux for4 hours. An additional portion of 3N aqueous sodium hydroxide (1.38 mL,4.14 mmol) was added and the solution was heated at reflux for anadditional 28 hours. The solution was concentrated in vacuo and thendiluted with water. The resultant solution was neutralized with 2Nhydrochloric acid (6.3 mL). The product precipitated and was collectedby filtration and washed with water, to give the product 1.5 g (69%). ¹HNMR(DMSO-d₆): δ 1.51 (s, 9 H), 3.10 (t, 2 H), 3.95 (t, 2 H), 7.53-7.82(m, 3 H) and 12.59 (s, 1 H).

[1055] 5-(Quinolin-3-ylcarbamoyl)-2,3-dihydro-indole-1-carboxylic acidtert-butyl ester. A solution of 2,3-dihydro-indole-1,5-dicarboxylic acid1-tert-butyl ester (1.5 g, 5.70 mmol),O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluorophosphate(HBTU) (2.37 g, 6.27 mmol), N,N-diisopropylethylamine (2.41 mL, 13.8mmol) and 3-aminoquinoline (0.904 g, 6.27 mmol) in acetonitrile washeated to reflux for 20 hours. The solvent was evaporated in vacuo andthe residue was partitioned between water and dichloromethane. Theorganic layer was separated, and the solvent was evaporated. The residuewas purified by flash chromatography on silica gel eluted with ethylacetate/hexane to give the product, 1.43 g (64%). MS: m/z 390 (MH⁺). ¹HNMR(DMSO-d₆): δ 1.54 (s, 9 H), 3.16 (t, 2 H), 4.00 (t, 2 H), 7.57-7.83(m, 3 H), 7.88-8.00 (m, 4 H), 8.84 (d, 1 H), 9.15 (d, 1 H) and 10.53 (s,1 H).

[1056] 2,3-Dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide. Asolution of 5-(Quinolin-3-ylcarbamoyl)-2,3-dihydro-indole-1-carboxylicacid tert-butyl ester (1.4 g, 3.59 mmol) in trifluoroacetic acid (9 mL),water (1 mL) and dichloromethane (20 mL) was stirred at room temperaturefor 18 hours. The solvents were evaporated in vacuo and the residue wastriturated in aqueous sodium bicarbonate. The product was collected byfiltration and washed with water, to give an off white solid 1.03 g(99%). MS: m/z 290 (MH⁺). ¹H NMR(DMSO-d₆): δ 3.02 (t, 2 H), 3.56 (t, 2H), 6.27 (br s, 1 H), 6.54 (d, 1 H), 7.56 (t, 1 H), 7.64 (t, 1 H),7.71-7.76 (m, 2 H), 7.94 (m, 2 H), 8.82 (d, 1 H), 9.14 (d, 1 H) and10.23 (s, 1 H).

Example (252) 1-Acetyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide.

[1057] A solution of 2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide (77 mg, 0.266 mmol) and N,N-diisopropylethylamine(0.060 mL, 0.345 mmol) in 1,2-dichloroethane (2 mL) was treated withacetyl chloride (0.020 mL, 0.292 mmol). The resultant solution wasstirred at room temperature overnight. The solvent was evaporated andthe residue was triturated in water (1 mL) and saturated aqueous sodiumbicarbonate (1 mL). The product was collected by filtration, to give theproduct 74 mg (84%). MS: m/z 332 (MH⁺). ¹H NMR(DMSO-d₆): δ 2.21 (s, 3H),3.24 (t, 2 H), 4.18 (t, 2 H), 7.59 (t, 1 H), 7.67 (t, 1 H), 7.89-7.98(m, 4 H), 8.15 (d, 1 H), 8.84 (s, 1 H), 9.14 (s, 1 H) and 10.566 (s, 1H).

[1058] The following compounds were prepared according to the method ofExamples 251 and 252: Example No. Compound name M Wt MH⁺ (253)1-Butyryl-2,3-dihydro-1H-indole- 359.43 360 5-carboxylic acidquinolin-3- ylamide (254) 1-Cyclohexanecarbonyl-2,3- 399.49 400dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide (255)1-Benzoyl-2,3-dihydro-1H-indole- 393.44 394 5-carboxylic acidquinolin-3- ylamide

Example (256)4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(6-fluoro-quinolin-3-yl)-benzamide

[1059]

[1060] 2-[(4-Fluoro-phenylamino)-methylene]-malonic acid diethyl ester.A mixture of 4-fluoro-phenylamine (5.1 mL, 54.4 mmol) and diethylethoxymethylenemalonate (10 mL, 49.5 mmol) was heated at 100° C. for 4hours, an oil which solidified on cooling. The solid was triturated inheptane, collected by filtration and washed with heptane, to give theproduct as a colorless solid, 10.5 g (75%). MS: m/z 282.1 (MH⁺).

[1061] 6-Fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethylester. 2-[(4-Fluoro-phenylamino)-methylene]-malonic acid diethyl ester(11.5 g, 40.9 mmol)) was added in portions to hot diphenyether (80 mL),while heating at reflux. The resultant mixture was heated an additional2 hours, then allowed to cool to room temperature. A solid whiteprecipitate developed. The mixture was diluted with heptanes, and theproduct was collected by filtration, washed with heptane, to give theproduct as a colorless crystalline solid, 3.0 g (31%). MS: m/z 235.9(MH⁺).

[1062] 4-Chloro-6-fluoro-quinoline-3-carboxylic acid ethyl ester. Amixture of 6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethylester (4.4 g, 18.7 mmol) in thionyl chloride (50 mL) was heated atreflux for 3 hours (at 30 min. mixture changed to a clear solution). Theresultant solution was cooled to room temperature, and the excessthionyl chloride was evaporated in vacuo. The residue was added toammonium hydroxide on ice (note: highly exothermic). Let resultantmixture stir for 15 minutes, and the product was collected by filtrationand washed generously with water. The solid was purified by flashchromatography, on silica gel, eluted with a gradient of ethyl acetate(0% to 30%) in heptane, to give the product, 4.24 g (89%) as a colorlesssolid. MS: m/z 253.8 (MH⁺).

[1063] 6-Fluoro-quinoline-3-carboxylic acid ethyl ester. A solution of4chloro-6-fluoro-quinoline-3-carboxylic acid ethyl ester (4.2 g, 16.6mmol) and diisopropylethylamine (8.7 mL, 50 mmol) in ethanol (50 mL) washydrogenated over 10% palladium on carbon (0.2 g) at 1 atmosphere ofhydrogen for 1 day. Additional catalyst (0.3 g) was added and thehydrogenation was continued at 50 psi of hydrogen for 2 hours. Thecatalyst was removed by filtration. The solvent was evaporated in vacuo,and the residue was partitioned between water and dichloromethane. Theorganic layer was dried over sodium sulfate. The product was preabsorbedonto silica gel and purified by flash chromatography, using a gradientof ethyl acetate (0% to 30%) in heptanes as the eluant, to give theproduct as a yellow solid, 2.2 g (60%). MS: m/z 219.9 (MH⁺).

[1064] 6-Fluoro-quinoline-3-carboxylic acid. 3 N aqueous sodiumhydroxide (5 mL, 15 mmol) was added to a solution of6-fluoro-quinoline-3-carboxylic acid ethyl ester (2.2 g, 10 mmol) inmethanol (50 mL). A heavy precipitate developed, and the mixture wasdiluted with an additional 50 mL of methanol to facilitate stirring. Themixture was stirred for 3 hours, then neutralized with of 1Nhydrochloric acid (15 mL). The methanol was evaporated in vacuo, and theslurry diluted with water. The product was collected by filtration andwashed with water, to give the product, 1.76 g (92%) as a colorlesssolid. MS: m/z 192.1 (MH⁺).

[1065] (6-Fluoro-quinolin-3-yl)-carbamic acid tert-butyl ester. Asolution of 6-fluoro-quinoline-3-carboxylic acid (1.7 g, 8.89 mmol),diphenylphosphoryl azide (2.3 mL, 10.7 mmol) and diisopropylethylamine(4.65 mL, 26.67 mmol) in t-butanol (40 mL) was heated at reflux for 1hour. The solution was cooled to room temperature, and the solvent wasevaporated in vacuo. The residue was partitioned between aqueous sodiumbicarbonate and dichloromethane. The organic layer was dried over sodiumsulfate, and the product was preabsorbed onto silica gel. Purificationby flash chromatography, using a gradient of ethyl acetate (0% to 30%)in heptane as the eluant, to give the product as a colorless solid, 1.3g (56%). MS: m/z 263.0 (MH⁺).

[1066] 6-Fluoro-quinolin-3-ylamine. A solution of(6-fluoro-quinolin-3-yl)carbamic acid tert-butyl ester (1.3 g, 4.95mmol) in 1,2-dichloroethane (15 mL) was treated with trifluoroaceticacid (15 mL) and water (1 mL). The resultant solution was stirred atroom temperature for 6 hours. The solvents were evaporated in vacuo, andthe residue was triturated in diethyl ether. The solid was purified byflash chromatography using a gradient of 2 N ammonia in methanol (0% to3%) in dichloromethane as the eluant, to give the product as a colorlesssolid, 0.47 g (59%). MS: m/z 162.9 (MH⁺).

[1067]4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(6-fluoro-quinolin-3-yl)-benzamide.In a sealed tube, a solution of trimethylaluminum in toluene (3N, 0.41mL, 1.23 mmol) was added to a solution of 6-fluoro-quinolin-3-ylamine(90 mg, 0.56 mmol) and 4-(3-aza-bicyclo[3.2.2]non-3-yl)-benzoic acidethyl ester (180 mg, 0.65 mmol) in 1,2-dichloroethane (2 mL). Thesolution was allowed to stir at room temperature for 15 minutes, andthen heated at 83° C. for 16 hours. The tube was cooled and carefullyopened. Methanol (0.5 mL) was added and the resultant mixture wasallowed to stir at room temperature for several hours. The mixture wasdiluted with dichloromethane and preabsorbed onto silica gel. Flashchromatography, using a gradient of methanol (0% to 3%) indichloromethane as the eluant, gave the product, 60 mg (28%), as acolorless solid. MS: m/z 390.0 (MH⁺). ¹HNMR(DMSO-d₆): δ 1.67 (m, 8 H),2.14 (m, 2 H), 3.56 (d, 2 H), 6.97 (d, 2 H), 7.54 (d of t, 1 H), 7.77 (dof d, 1 H), 7.92 (d, 2 H), 8.04 (d of d, 1 H), 8.85 (d, 1 H), 9.13 (d, 1H) and 10.3 (s, 1 H).

[1068] The following compounds were prepared according to the method ofExamples 256: Example No. Compound name M Wt MH⁺ (257)4-(Cyclohexyl-methyl-amino)-N-(8-fluoro-quinolin-3-yl)- 377.47 378benzamide (258) 4-Azocan-1-yl-N-(8-fluoro-quinolin-3-yl)-benzamide377.47 378 (259)4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-fluoro-quinolin-3- 389.48 399yl)-benzamide (260)4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-trifluoromethyl- 439.48 440quinolin-3-yl)-benzamide (261)4-(Cyclohexyl-methyl-amino)-N-(8-trifluoromethyl- 427.47 428quinolin-3-yl)-benzamide (262)4-(Cyclohexyl-methyl-amino)-N-(6-fluoro-quinolin-3-yl)- 377.47 378benzamide (263) 4-Azocan-1-yl-N-(6-fluoro-quinolin-3-yl)-benzamide377.47 378 (264)4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(6-fluoro-quinolin-3- 389.48 390yl)-benzamide (265)4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(7-trifluoromethyl- 439.48 440quinolin-3-yl)-benzamide (266)4-Azocan-1-yl-N-(7-trifluoromethyl-quinolin-3-yl)- 427.47 428 benzamide(267) 4-(Cyclohexyl-methyl-amino)-N-(7-trifluoromethyl- 427.47 428quinolin-3-yl)-benzamide (268)4-Azocan-1-yl-N-(5-fluoro-quinolin-3-yl)-benzamide 377.47 378 (269)4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(5-fluoro-quinolin-3- 389.48 390yl)-benzamide

Example (270) 3-(4-tert-Butyl-phenyl)-propynoic acid quinolin-3-ylamide

[1069]

[1070] A solution of (4-tert-butyl-phenyl)-propynoic acid ethyl ester(0.23 g, 1.0 mmol) and 3-aminoquinoline (0.144 g, 1.0 mmol) in1,2-dichloroethane (15 mL) was treated with a 2N solution oftrimethylaluminum in toluene (0.75 mL, 1.5 mmol). The resultant solutionwas stirred at room temperature for 15 minutes, then heated at refluxfor 18 h. The solution was cooled and treated with methanol (0.50 mL).The product was preabsorbed onto silica gel and purified by flashchromatography, using a gradient of methanolin dichloromethane as theeluant. The product was isolated, after trituration in diethyl ether, asa colorless solid, 0.17 g (52%). MS: m/z 329.2 (MH⁺). ¹HNMR(DMSO-d₆): δ1.31 (s, 9 H), 7.54-7.72 (m, 6 H), 7.97 (d, 1 H), 8.72 (d, 1 H), 8.96(d, 1 H) and 11.3 (s, 1 H).

[1071] The following compounds were prepared according to the method ofExamples 270: Example No. Compound name M Wt MH⁺ (271)3-Phenyl-propynoic acid quinolin-3-ylamide 272.31 273 (272)trans-2-Phenyl-cyclopropanecarboxylic acid quinolin-3- 288.35 289ylamide (273) 3-(4-tert-Butyl-phenyl)-propynoic acid quinolin-3- 328.41329 ylamide (274) 2-(4-tert-Butyl-phenyl)-cyclopropanecarboxylic acid307.79 308 quinolin-3-ylamide

BIOLOGICAL EXAMPLES Example 275 Human or Rat VR₁ Binding Assay

[1072] Compounds of the present invention were tested for their abilityto inhibit the binding of [³H] RTX to hVR1 receptors in a [³H] RTXbinding assay as previously described (Zhang, Sui-Po. Improved ligandbinding assays for vanilloid receptors. PCT Int. Appl. (2002), 29 pp.CODEN: PIXXD2 WO 0233411 A1 20020425 AN 2002:315209; Grant, Elfrida R.;Dubin, Adrienne E.; Zhang, Sui-Po; Zivin, Robert A.; Zhong, ZhongSimultaneous intracellular calcium and sodium flux imaging in humanvanilloid receptor 1 (VR1)-transfected human embryonic kidney cells: amethod to resolve ionic dependence of VR1-mediated cell death. Journalof Pharmacology and Experimental Therapeutics (2002), 300(1), 9-17.)

[1073] HEK293 cells were transfected with human VR1 vanilloid receptorsand washed with Hank's Balanced Salt Solution, dissociated with celldissociation buffer (Sigma), and then centrifuged at 1000×g for 5 min.Cell pellets were homogenized in cold 20 mM HEPES buffer, pH 7.4,containing 5.8 mM NaCl, 320 mM sucrose, 2 mM MgCl₂, 0.75 CaCl₂ and 5 mMKCl and centrifuged at 1000×g for 15 min. The resultant supernate wasthen centrifuged at 40000×g for 15 min. The pelleted membranes were keptin an −80° C. freezer.

[1074] Approximately 120 μg protein/ml from membranes were incubatedwith indicated concentrations of [³H] RTX in 0.5 ml of the HEPES buffer(pH 7.4) containing 0.25 mg/mL fatty acid-free bovine serum albumin at37° C. for 60 min. The reaction mixture was then cooled to 4° C., added0.1 mg α₁-acid glycoprotein to each sample and incubated at 4° C. for 15min. The samples were centrifuged at 18500×g for 15 min. The tip of themicrocentrifuge tube containing the pellet was cut off. Boundradioactivity was quantified by scintillation counting. Non-specificbinding was tested in the presence of 200 nM unlabeled RTX.

[1075] Alternatively, a binding assay using rat tissue was used. Ratspinal cord was homogenized twice with a Polytron and centrifuged at3000 rpm for 10 min in HEPES buffer containing 20 mM HEPES, pH 7.4, NaCl5.8 mM, sucrose 320 mM, MgCl₂ 2 mM, CaCl₂ 0.75 mM and KCl 5 mM. Thesupernatant was then centrifuged at 18,000 rpm for 20 min. The pelletwas saved in a tube and 10 ml assay buffer was added into the tube. Thepellet and buffer were mixed with a Polytron. The assay contained 120μg/ml membrane protein and 0.3-0.6 nM [³H]-RTX (NEN, Boston) in a totalvolume of 0.5 ml HEPES buffer. Following-incubation for 60 min at 37°C., the samples were cooled down on ice, and 100 mg of a-acidglycoprotein were added into the samples. After centrifugation at 13,000rpm for 15 min, the supernatant was aspirated and the tips of tubes werecut off and placed into 6 ml vials. Data were calculated according tothe equation: % inhibition=(total binding−binding)*100/(totalbinding−non specific binding). Ki value values were calculated using aPrism program.

Example 276 Human VR₁ Functional Assay

[1076] The functional activity of the test compounds was determined bymeasuring changes in intracellular calcium concentration using aCa⁺⁺-sensitive fluorescent dye and FLIPR™ technology. Increases in Ca⁺⁺concentration were readily detected upon challenge with capsaicin.

[1077] HEK293 Cells expressing human VR1 were grown on poly-D-lysinecoated 96 well black-walled plates (BD 354640) and 2 days later loadedwith Fluo-3/AM for 1 hour and subsequently tested for agonist-inducedincreases in intracellular Ca²⁺ levels using FLIPR™ technology. Cellswere challenged with test compounds (at varying concentrations) andintracellular Ca⁺⁺ was measured for 3 min prior to the addition ofcapsaicin to all wells to achieve a final concentration of 0.015 μMeliciting ˜80% maximal response. EC₅₀ or IC₅₀ values were determinedfrom dose-response studies.

[1078] Alternatively, a rat electrophysiological assay was used.Compounds were tested for their activity on VR1 expressed endogenouslyon small rat dorsal root ganglion (DRG) neurons. DRG neurons from normalrats were dissociated and whole cell currents mediated by VR1 wererecorded using the whole cell patch clamp technique. The estimatedpotency of the compounds was determined by measuring the shift in thecapsaicin-induced dose response in the presence of compound underconditions of limited capsaicin-induced VR1 desensitization (i.e., using0 Ca²⁺-containing saline solutions). pA₂ values were determined. TABLE 2Vanilloid In vitro assay data ³H-RTX binding assay FLIPR functionalassay % Inhibition Ki hVR1 IC₅₀ hVR1 IC₅₀ hVR1 Compound Name @ 1 μM (nM)(nM) 60 min (nM) 1-Acetyl-2,3-dihydro-1H-indole- 1 3.15 × 10³5-carboxylic acid quinolin-3- ylamide 1-Benzoyl-2,3-dihydro-1H- 3 1.45 ×10³ indole-5-carboxylic acid quinolin-3-ylamide1-Butyryl-2,3-dihydro-1H-indole- 2 1.80 × 10³ 5-carboxylic acidquinolin-3- ylamide 1-Cyclohexanecarbonyl-2,3- 25 1.50 × 10³dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide1-Cyclohexyl-2,3-dihydro-1H- 103 4.87 × 10⁰ 4.40 × 10¹ 7.40 × 10¹indole-5-carboxylic acid quinolin-3-ylamide1-Isopropyl-2-trifluoromethyl- 3.64 × 10² 8.00 × 10³1H-benzoimidazole-5-carboxylic acid quinolin-3-ylamide1-Methyl-1,2,3,4-tetrahydro- 79 3.41 × 10² 6.90 × 10²quinoline-6-carboxylic acid quinolin-3-ylamide1-Methyl-2,3-dihydro-1H-indole- 12 9.00 × 10² 5-carboxylic acidquinolin-3- ylamide 1-Pentyl-1,2,3,4-tetrahydro- 93 3.91 × 10¹ 1.60 ×10³ 4.70 × 10² quinoline-6-carboxylic acid quinolin-3-ylamide1-Pentyl-1H-indole-5-carboxylic 95 6.31 × 10¹ 1.50 × 10² acidquinolin-3-ylamide 1-Pentyl-2,3-dihydro-1H-indole- 98 2.41 × 10¹ 8.40 ×10¹ 1.06 × 10² 5-carboxylic acid quinolin-3- ylamide1-Propyl-2,3-dihydro-1H-indole- 93 1.56 × 10¹ 4.10 × 10² 5-carboxylicacid quinolin-3- ylamide 2-(4-Dipentylamino-phenyl)-N- 5.08 × 10²quinolin-3-yl-acetamide 2-(4-Pentyl-phenyl)-N-quinolin- 2.20 × 10³3-yl-acetamide 2-(4-tert-Butyl-phenyl)-N- 5.76 × 10³quinolin-3-yl-acetamide 2-(Heptyl-methyl-amino)-N- 0quinolin-3-yl-benzamide 2-(Methyl-pentyl-amino)-N- 21quinolin-3-yl-benzamide 2,3-Dihydro-1H-indole-5- 1 1.05 × 10⁴ carboxylicacid quinolin-3- ylamide 2-{4-(Methyl-pentyl-amino)- 1.35 × 10³phenyl}-N-quinolin-3-yl- acetamide 2-Chloro-4-(cyclohexylmethyl- 65 1.13× 10³ amino)-N-quinolin-3-yl- benzamide 2-Chloro-4-pentylamino-N- 401.00 × 10⁴ quinolin-3-yl-benzamide 2-Heptylamino-N-quinolin-3-yl- 791.12 × 10³ 1.60 × 10³ 5.00 × 10³ benzamide2-Pentylamino-N-quinolin-3-yl- 23 benzamide3-(1-Cyclohexyl-2,3-dihydro-1H- indol-5-yl)-N-quinolin-3-yl-propionamide 3-(1-Cyclohexylmethyl-2,3- 61 5.12 × 10² 1.20 × 10³dihydro-1H-indol-5-yl)-N- quinolin-3-yl-propionamide3-(1-Propyl-1H-indol-5-yl)-N- 59 2.64 × 10² 4.80 × 10²quinolin-3-yl-propionamide 3-(1-Propyl-2,3-dihydro-1H- 51 1.07 × 10³1.06 × 10³ indol-5-yl)-N-quinolin-3-yl- propionamide3-(2,2-Dimethyl-chroman-6-yl)- N-quinolin-3-yl-acrylamide3-(2,2-Dimethyl-chroman-6-yl)- N-quinolin-3-yl-propionamide3-(4-Azepan-1-yl-phenyl)-N- quinolin-3-yl-acrylamide3-(4-Azepan-1-yl-phenyl)-N- quinolin-3-yl-propionamide3-(4-Cyclohexylmethyl-phenyl)- 9.41 × 10¹ 6.70 × 10² 3.50 × 10¹N-quinolin-3-yl-propionamide 3-(4-Dipentylamino-phenyl)-N- 1.53 × 10²quinolin-3-yl-propionamide 3-(4-Pentyl-phenyl)-N-quinolin- 4.28 × 10²5.20 × 10³ 3-yl-acrylamide 3-(4-Pentyl-phenyl)-N-quinolin- 1.81 × 10²5.90 × 10² 3-yl-propionamide 3-(4-sec-Butyl-phenyl)-N- 1.39 × 10¹ 1.20 ×10³ quinolin-3-yl-propionamide 3-(4-tert-Butyl-phenyl)-N- 1.11 × 10⁰quinolin-3-yl-acrylamide 3-(4-tert-Butyl-phenyl)-N- 2.03 × 10⁰quinolin-3-yl-propionamide 3-(Cyclohexyl-methyl-amino)-N- 89 9.82 × 10¹quinolin-3-yl-benzamide 3-(Heptyl-methyl-amino)-N- 82 1.42 × 10² 8.80 ×10³ quinolin-3-yl-benzamide 3-(Methyl-pentyl-amino)-N- 72 2.62 × 10²5.00 × 10² quinolin-3-yl-benzamide 3,4,5,6-Tetrahydro-2H- 1[1,2′]bipyridinyl-5′-carboxylic acid quinolin-3-ylamide3,4,5,6-Tetrahydro-2H- 100 2.05 × 10¹ 4.30 × 10³ 1.40 × 10²{1,2′}bipyridinyl-5′-carboxylic acid quinolin-3-ylamide3-[4-(Methyl-phenethyl-amino)- 90 1.92 × 10² 1.80 × 10²phenyl]-N-quinolin-3-yl- propionamide 3-{4-(1,1-Dimethyl-3-phenyl- 1.59× 10¹ propyl)-phenyl}-N-quinolin-3-yl- propionamide3-{4-(1,1-Dimethyl-pentyl)-2,6- 96 1.06 × 10¹ 1.00 × 10³dimethoxy-phenyl}-N-quinolin-3- yl-propionamide3-{4-(1,1-Dimethyl-pentyl)- 4.03 × 10¹ 1.14 × 10²phenyl}-N-quinolin-3-yl 3-{4-(1,1-Dimethyl-propyl)-2,6- 93 5.20 × 10¹3.20 × 10² dimethoxy-phenyl}-N-quinolin-3- yl-propionamide3-{4-(1,1-Dimethyl-propyl)- 5.24 × 10⁰ 3.67 × 10¹ 3.00 × 10¹phenyl}-N-quinolin-3-yl- propionamide 3-{4-(1-Cyclohexyl-1-methyl- 3.15× 10¹ 5.70 × 10² ethyl)-phenyl}-N-quinolin-3-yl- propionamide3-{4-(1-Methyl-pentyl)-phenyl}- 1.32 × 10¹ 1.10 × 10³N-quinolin-3-yl-propionamide 3-{4-(1-Methyl-pentyl)-phenyl}- 1.50 × 10¹1.00 × 10⁴ N-quinolin-3-yl-propionamide 3-{4-(Benzyl-methyl-amino)- 1.11× 10² 3.54 × 10² phenyl}-N-quinolin-3-yl- propionamide3-{4-(Cyclohexyl-methyl-amino)- 91 1.31 × 10² 4.00 × 10²phenyl}-N-quinolin-3-yl- acrylamide 3-{4-(Cyclohexyl-methyl-amino)- 511.17 × 10³ 3.90 × 10³ phenyl}-N-quinolin-3-yl- propionamide3-{4-(Cyclohexylmethyl-methyl- 8.15 × 10¹ 2.60 × 10² 3.90 × 10²amino)-phenyl}-N-quinolin-3-yl- propionamide 3-{4-(Methyl-pentyl-amino)-65 1.22 × 10² phenyl}-N-quinolin-3-yl- acrylamide3-{4-(Methyl-pentyl-amino)- 1.78 × 10² 1.10 × 10³ 1.90 × 10²phenyl}-N-quinolin-3-yl- propionamide 3-{4-(Methyl-propyl-amino)- 1.96 ×10² 5.00 × 10² phenyl}-N-quinolin-3-yl- propionamide3-{5-(1,1-Dimethyl-propyl)- 1.42 × 10¹ thiophen-2-yl}-N-quinolin-3-yl-propionamide 3-Cyclohexylamino-N-quinolin- 1 3.20 × 10³ 3-yl-benzamide3-Dipentylamino-N-quinolin-3-yl- 93 1.07 × 10² 2.60 × 10² benzamide3-Heptylamino-N-quinolin-3-yl- 20 1.00 × 10⁴ benzamide3-Indan-5-yl-N-quinolin-3-yl- 1.58 × 10² 1.00 × 10⁴ propionamide3-Methyl-4-(methyl-pentyl- 107 3.79 × 10¹ 5.40 × 10¹amino)-N-quinolin-3-yl- benzamide 3-Methyl-4-pentylamino-N- 81 7.35 ×10¹ 7.80 × 10² 1.20 × 10¹ quinolin-3-yl-benzamide3-Pentylamino-N-quinolin-3-yl- 12 2.70 × 10³ benzamide4-(1,3-Dihydro-isoindol-2-yl)-N- 1 quinolin-3-yl-benzamide4-(1,4-Dioxa-8-aza- 9 spiro[4.5]dec-8-yl)-N-quinolin-3- yl-benzamide4-(2,6-Dimethyl-morpholin-4-yl)- 18 1.00 × 10⁴ N-quinolin-3-yl-benzamide4-(3,5-Dimethyl-piperidin-1-yl)- 91 8.61 × 10¹ 1.80 × 10³N-quinolin-3-yl-benzamide 4-(3-Aza-bicyclo{3.3.1}non-3- 99 5.15 × 10⁰1.70 × 10² 1.27 × 10² yl)-N-quinolin-3-yl-benzamide4-(3-Methyl-piperidin-1-yl)-N- 78 quinolin-3-yl-benzamide4-(4-Benzoyl-piperidin-1-yl)-N- 61 2.76 × 10² quinolin-3-yl-benzamide4-(4-Benzyl-piperidin-1-yl)-N- 99 1.76 × 10¹ 3.57 × 10²quinolin-3-yl-benzamide 4-(4-Phenylacetyl-piperazin-1- 1.00 × 10^(s)1.00 × 10⁴ yl)-N-quinolin-3-yl-benzamide 4-(4-Phenyl-piperidin-1-yl)-N-34 2.93 × 10⁴ quinolin-3-yl-benzamide 4-(4-Propyl-piperidin-1-yl)-N- 921.03 × 10² 1.60 × 10⁴ 1.70 × 10² quinolin-3-yl-benzamide4-(Acetyl-cyclohexyl-amino)-N- 1 1.00 × 10⁴ quinolin-3-yl-benzamide4-(Benzyl-methyl-amino)-N- 98 7.53 × 10¹ 2.30 × 10³ 3.70 × 10²quinolin-3-yl-benzamide 4-(Benzyl-pentyl-amino)-N- 67 1.69 × 10²quinolin-3-yl-benzamide 4-(Cycloheptyl-methyl-amino)- 100 1.40 × 10¹4.00 × 10² N-quinolin-3-yl-benzamide 4-(Cyclohexanecarbonyl-methyl-amino)-N-quinolin-3-yl- benzamide 4-(Cyclohexyl-ethyl-amino)-N-1.26 × 10¹ 3.00 × 10² quinolin-3-yl-benzamide4-(Cyclohexylmethyl-amino)-3- 111 8.70 × 10¹ methyl-N-quinolin-3-yl-benzamide 4-(Cyclohexyl-methyl-amino)-3- 2.20 × 10¹ 5.60 × 10² 2.30 ×10¹ methyl-N-quinolin-3-yl- benzamide 4-(Cyclohexyl-methyl-amino)-N- 122.00 × 10³ methyl-N-quinolin-3-yl- benzamide4-(Cyclohexyl-methyl-amino)-N- 1.03 × 10¹ 4.65 × 10² 2.20 × 10¹quinolin-3-yl-benzamide 4-(Cyclohexylmethyl-methyl- 6.83 × 10¹ 1.00 ×10⁴ amino)-3-methyl-N-quinolin-3- yl-benzamide4-(Cyclohexylmethyl-methyl- 104 1.57 × 10¹ 1.70 × 10³amino)-N-quinolin-3-yl- benzamide 4-(Cyclohexylmethyl-phenethyl- 87 1.62× 10² amino)-N-quinolin-3-yl- benzamide 4-(Cyclohexyl-propyl-amino)-N-8.46 × 10¹ 1.00 × 10⁴ quinolin-3-yl-benzamide4-(Cyclopentyl-methyl-amino)- 2.79 × 10¹ 1.85 × 10²N-quinolin-3-yl-benzamide 4-(Dec-4-enyl-methyl-amino)-N- 104 2.31 × 10¹6.60 × 10¹ quinolin-3-yl-benzamide 4-(Hept-4-enyl-methyl-amino)- 1042.98 × 10¹ 1.90 × 10³ 4.60 × 10¹ N-quinolin-3-yl-benzamide4-(Heptyl-methyl-amino)-N- 101 2.45 × 10¹ 1.00 × 10⁴ 1.16 × 10²quinolin-3-yl-benzamide 4-(Methyl-butyl-amino)-N- 97 8.33 × 10¹ 7.86 ×10² 1.00 × 10² quinolin-3-yl-benzamide 4-(Methyl-hexyl-amino)-N- 98 7.01× 10¹ 1.30 × 10³ 8.60 × 10¹ quinolin-3-yl-benzamide4-(Methyl-non-6-enyl-amino)-N- 101 3.65 × 10¹ 4.80 × 10¹quinolin-3-yl-benzamide 4-(Methyl-nonyl-amino)-N- 101 2.32 × 10¹ 1.50 ×10² quinolin-3-yl-benzamide 4-(Methyl-pentyl-amino)-N- 1.03 × 10² 4.30 ×10² 1.32 × 10² quinolin-3-yl-benzamide 4-(Methyl-phenethyl-amino)-N-101.500000 2.73 × 10¹ 1.90 × 10³ 7.20 × 10¹ quinolin-3-yl-benzamide4-(Methyl-propyl-amino)-N- 91 2.67 × 10² 8.80 × 10³ 3.90 × 10²quinolin-3-yl-benzamide 4-(Methyl-tetradecyl-amino)-N- 23 1.47 × 10³1.00 × 10⁴ quinolin-3-yl-benzamide 4-(Octyl-methyl-amino)-N- 105 1.47 ×10¹ 1.90 × 10² quinolin-3-yl-benzamide 4-(Phenethyl-propyl-amino)-N- 1057.16 × 10¹ 3.60 × 10² quinolin-3-yl-benzamide4-[1,4′]Bipiperidinyl-1′-yl-N- 8 quinolin-3-yl-benzamide4-{(3,3-Dimethyl-butyl)-methyl- 99 2.09 × 10¹ 1.00 × 10⁴ 1.30 × 10³amino}-N-quinolin-3-yl- benzamide 4-{4-(1,1-Dimethyl-pentyl)- 80 1.94 ×10² phenyl}-but-3-enoic acid quinolin-3-ylamide4-{4-(1,1-Dimethyl-pentyl)- 82 2.21 × 10² 1.00 × 10⁴phenyl}-N-quinolin-3-yl- butyramide 4-{4-(1,1-Dimethyl-propyl)- 55 1.37× 10² 1.00 × 10⁴ phenyl}-but-3-enoic acid quinolin-3-ylamide4-{4-(1,1-Dimethyl-propyl)- 65 5.27 × 10² phenyl}-N-quinolin-3-yl-butyramide 4-{Methyl-(3-methyl-butyl)- 90 5.54 × 10² 2.80 × 10²amino}-N-quinolin-3-yl- benzamide 4-{Methyl-(3-phenyl-allyl)- 79 1.25 ×10² amino}-N-quinolin-3-yl- benzamide 4-{Methyl-(3-phenyl-propyl)- 977.41 × 10¹ 1.00 × 10⁴ 1.56 × 10² amino}-N-quinolin-3-yl- benzamide4-{Methyl-(tetrahydro-pyran-4- 19 yl)-amino}-N-quinolin-3-yl- benzamide4-{Methyl-{3-(5-methyl-furan-2- 102 3.12 × 10¹ 1.50 × 10³yl)-butyl}-amino}-N-quinolin-3-yl- benzamide4-Azepan-1-yl-N-quinolin-3-yl- 96 1.79 × 10¹ 2.30 × 10³ 2.10 × 10²benzamide 4-Azepan-1-yl-N-quinolin-3-yl- 5.90 × 10⁰ 5.31 × 10³ 1.11 ×10² benzamide 4-Azocan-1-yl-N-quinolin-3-yl- 1.85 × 10¹ 2.90 × 10²benzamide 4-Azonan-1-yl-N-quinolin-3-yl- 1.18 × 10¹ 9.20 × 10¹ benzamide4-Benzyl-3,4,5,6-tetrahydro-2H- 100 2.56 × 10¹ 4.40 × 10²{1,2′}bipyridinyl-5′-carboxylic acid quinolin-3-ylamide4-Butoxy-N-quinolin-3-yl- 1.55 × 10² 1.00 × 10⁴ benzamide4-Butyl-cyclohexanecarboxylic 81 1.24 × 10² 1.70 × 10² acidquinolin-3-ylamide 4-Butyl-cyclohexanecarboxylic 81 1.24 × 10² 1.70 ×10² acid quinolin-3-ylamide 4-Cycloheptylamino-N-quinolin- 7.30 × 10²3-yl-benzamide 4-Cyclohexylamino-N-methyl-N- 2.16 × 10³ 1.00 × 10⁴quinolin-3-yl-benzamide 4-Cyclohexylamino-N-quinolin- 77 1.56 × 10²3-yl-benzamide 4-Cyclopentylamino-N-quinolin- 32 3.20 × 10³3-yl-benzamide 4-Dibenzylamino-N-quinolin-3- 51 4.41 × 10² 4.20 × 10³yl-benzamide 4-Dibutylamino-N-quinolin-3-yl- 2.41 × 10² 4.60 × 10³ 2.70× 10² benzamide 4-Dihexylamino-N-quinolin-3-yl- 74 1.85 × 10² 2.90 × 10³benzamide 4-Dipentylamino-N-quinolin-3-yl- 1.58 × 10² benzamide4-Dipropylamino-N-quinolin-3- 2.19 × 10² 6.10 × 10² 1.66 × 10²yl-benzamide 4-Morpholin-4-yl-N-quinolin-3-yl- 4 benzamide4-Pentylamino-N-quinolin-3-yl- 8.76 × 10² 8.10 × 10³ 3.00 × 10⁴benzamide 4-Phenethylamino-N-quinolin-3- 31 9.20 × 10³ yl-benzamide4-Piperazin-1-yl-N-quinolin-3-yl- 1 7.40 × 10² benzamide4-Piperidin-1-yl-N-quinolin-3-yl- 60 6.12 × 10¹ benzamide4-Propyl-3,4,5,6-tetrahydro-2H- 93 1.17 × 10² 4.90 × 10²{1,2′}bipyridinyl-5′-carboxylic acid quinolin-3-ylamide4-Pyrrolidin-1-yl-N-quinolin-3-yl- 27 benzamide 4-tert-Butyl- 97 6.49 ×10¹ 1.00 × 10⁴ cyclohexanecarboxylic acid quinolin-3-ylamide4-tert-Butyl- 97 6.49 × 10¹ 1.00 × 10⁴ cyclohexanecarboxylic acidquinolin-3-ylamide 5,5,8,8-Tetramethyl-5,6,7,8- 3.04 × 10¹tetrahydro-naphthalene-2- carboxylic acid quinolin-3- ylamide5,6,7,8-Tetrahydro- 6.23 × 10¹ 1.00 × 10⁴ naphthalene-2-carboxylic acidquinolin-3-ylamide 5-Chloro-1H-indole-2-carboxylic 36 2.80 × 10³ acidquinolin-3-ylamide 5-Pentyl-thiophene-2-carboxylic 57 6.47 × 10² 9.00 ×10² acid quinolin-3-ylamide 6-(3-Aza-bicyclo{3.3.1}non-3- 80 9.86 × 10⁰3.70 × 10³ 2.79 × 10² yl)-N-quinolin-3-yl-nicotinamide6-(Benzyl-methyl-amino)-N- 43 3.90 × 10² quinolin-3-yl-nicotinamide6-(Cyclohexyl-methyl-amino)-N- 99 3.59 × 10¹ 3.00 × 10²quinolin-3-yl-nicotinamide 6-(Cyclohexyl-methyl-amino)-N- 2.18 × 10²2.45 × 10² quinolin-3-yl-nicotinamide 6-(Heptyl-methyl-amino)-N- 90 9.73× 10¹ 1.50 × 10³ quinolin-3-yl-nicotinamide 6-(Methyl-pentyl-amino)-N-91 1.22 × 10² 4.00 × 10² quinolin-3-yl-nicotinamide6-(Methyl-phenethyl-amino)-N- 97 2.43 × 10² 1.20 × 10³ 5.40 × 10²quinolin-3-yl-nicotinamide 6-Azepan-1-yl-N-quinolin-3-yl- 44 1.24 × 10²2.15 × 10² nicotinamide 6-Azocan-1-yl-N-quinolin-3-yl- 102 3.04 × 10¹5.16 × 10³ 2.50 × 10² nicotinamide 6-Cyclohexylamino-N-quinolin- 1 9.90× 10² 3-yl-nicotinamide 6-Pentylamino-N-quinolin-3-yl- 57 2.81 × 10⁵8.00 × 10³ nicotinamide cis-4-(Octahydro-isoquinolin-2- 105 4.56 × 10¹1.85 × 10² 2.20 × 10² yl)-N-quinolin-3-yl-benzamidecis-6-(Octahydro-isoquinolin-2- 99 3.68 × 10¹ 4.20 × 10²yl)-N-quinolin-3-yl-nicotinamide N-Quinolin-3-yl-3-(3-trifluoromethyl-phenyl)- acrylamide N-Quinolin-3-yl-3-(4- 1.76 × 10²1.90 × 10³ tricyclo{5.3.1.13,9}dodec-1-yl- phenyl)-propionamideN-Quinolin-3-yl-3-(4- trifluoromethyl-phenyl)- acrylamideN-Quinolin-3-yl-3-(5,5,8,8- 1.30 × 10¹ 7.00 × 10¹tetramethyl-5,6,7,8-tetrahydro- naphthalen-2-yl)-propionamideN-Quinolin-3-yl-3-(5,6,7,8- 2.00 × 10² 1.00 × 10⁴tetrahydro-naphthalen-2-yl)- propionamide N-Quinolin-3-yl-4-(tetrahydro-9 pyran-4-ylamino)-benzamide N-Quinolin-3-yl-4-thiomorpholin- 414-yl-benzamide R-4-{(3,7-Dimethyl-oct-6-enyl)- 105 1.11 × 10¹methyl-amino}-N-quinolin-3-yl- benzamide S-4-{(3,7-Dimethyl-oct-6-enyl)-105 1.29 × 10¹ 1.50 × 10² methyl-amino}-N-quinolin-3-yl- benzamidetrans-4-(Octahydro-isoquinolin- 104 2.92 × 10¹2-yl)-N-quinolin-3-yl-benzamide trans-6-(Octahydro-isoquinolin- 104 3.32× 10¹ 8.50 × 10¹ 2-yl)-N-quinolin-3-yl- nicotinamide1-Cyclohexyl-1H-indole-5- 1.66 × 10² carboxylic acid (4-chloro-quinolin-3-yl)-amide N-(4-Chloro-quinolin-3-yl)-4- 1.07 × 10²(cyclohexyl-methyl-amino)- benzamide N-Quinolin-3-yl-3-(5,5,8,8- 6.50 ×10¹ tetramethyl-5,6,7,8-tetrahydro- naphthalen-2-yl)-acrylamideN-(4-Chloro-quinolin-3-yl)-3- 3.00 × 10¹ (5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)- acrylamide 3-(4-tert-Butyl-phenyl)- 6.60 ×10¹ propynoic acid quinolin-3- ylamide 1-Cyclohexyl-1H-indole-5- 7.40 ×10¹ carboxylic acid quinolin-3- ylamide

Example 277

[1079] Carrageenan Paw-Induced Thermal Hyperalgesia

[1080] The hot-plate test originally described by Eddy and Leimbach (J.Pharmacol. Exp. Ther. 107:385-393, 1953) with minor modifications (e.g.,O'Callaghan and Holtzman, J. Pharmacol. Exp. Ther. 192: 497-505,1975) isused to ascertain the analgesic potential of compounds. Generally thisprocedure is most sensitive to centrally-acting analgesics (e.g.,opioids) in that other compounds are inactive in this test. Thus, anyactivity demonstrated by a compound in this test which is shown to benonopioid-like (i.e., not naloxone reversible) represents a potentiallynovel analgesic agent.

[1081] Generally, male, Swiss-derived albino mice (CRS-CD1®; CharlesRiver Laboratories), weighing 18-24 g at the time of testing or maleSprague Dawley rats (CD1, Charles River Laboratories) 100-300 g areused. The animals are weighed, placed in a plastic box with wood chips(typically 10 mice or 4-6 rats per box) and allowed to acclimate beforetesting. The hot-plate (e.g., Technilab instruments, Inc.) is maintainedat some preset temperature, usually 48±0.5° C., 52.5±0.5° C. or 55±0.5°C. for mice and 51±0.5° C. for rats.

[1082] An animal is placed on the heated surface and the time intervalbetween placement and a shaking, licking or tucking of the hindpaw isrecorded as the control reaction time (RTc). The reaction time ofdrug-treated animals is compared to the reaction time of untreatedanimals or to the animals own predrug latency. A ‘cut-off’ time isestablished to prevent injury to the animals tail: 90 sec for the 48° C.test (based on control reaction times generally between 25 and 40 sec)and 60 sec for the 55° C. test (based on control reaction timesgenerally between 10 and 20 sec). A reaction time for drug-treatedanimals greater than 3 SD from the mean of the control reaction time forall the animals in the group is the criterion for an analgesic response(% analgesia) according to the formula:

% analgesia=100×(No. of animals at criterion)/(No. animals in group).

[1083] A percent maximum possible effect (% MPE) can also be calculatedfrom the following formula:

% MPE=100×(RTdc−RTc)/(CO−RTc),

[1084] where RTdc and RTc are drug-treated and control reaction times,respectively, and CO is cut-off time.

[1085] As a screen, the largest possible nontoxic dose of test drug isadministered. If activity is detected, and if appropriate, generally 3-5doses (usually 10 mice or 6-8 rats per dose) are used to construct adose response curve or time course. Appropriate computer-assistedanalysis (e.g., SAS Probit Analysis for quantal data or EDPLOT forgraded data) is used to calculate ED50 values and 95% confidenceinterval (C.I.). The ED50 value is determined at the time of peakeffect. Representative ED50 values for some reference compounds in miceare listed below: Compound Route Pre-treat time (min) ED50 (95% C.I.)Morphine i.p. 30 4.1(2.7-6.9) Codeine i.p. 30 16.5(11.2-25.2)Pentazocine i.p. 30 32.7(10.8-91.9) Zomepirac i.p. 30 inactive

[1086] Results dose % Compound (mg/kg) route Recovery4-(Methyl-pentyl-amino)-N- 10 sc 83 quinolin-3-yl-benzamide4-(Cyclohexyl-methyl-amino)-N- 30 po 55 quinolin-3-yl-benzamide3-{4-(Methyl-pentyl-amino)- 30 po 58 phenyl}-N-quinolin-3-yl-propionamide 4-(Methyl-phenethyl-amino)-N- 10 po 42quinolin-3-yl-benzamide 4-(4-Benzyl-piperidin-1-yl)-N- 10 po 64quinolin-3-yl-benzamide 3-{4-(Cyclohexylmethyl- 20 po 87methyl-amino)-phenyl}-N- quinolin-3-yl-propionamide4-Azepan-1-yl-N-quinolin-3- 1 po 46 yl-benzamide3-{4-(1,1-Dimethyl-propyl)- 30 po 47 phenyl}-N-quinolin-3-yl-propionamide 1-Pentyl-2,3-dihydro-1H-indole- 10 po 52 5-carboxylic acidquinolin-3- ylamide 3-(4-Chloro-3-trifluoromethyl- 10 po 58phenyl)-N-quinolin-3-yl- acrylamide 3-(4-tert-Butyl-phenyl)-N-(4- 10 po70 chloro-quinolin-3-yl)-acrylamide

Example (278) Intraplantar Inflammatory Hyperalgesia Testing

[1087] Rats and mice are allowed to become familiar with the conduct ofthe testing protocol and the experimental equipment. Thispreconditioning is meant to reduce the confounding effect of stress andnovelty on the behavioral assessments being undertaken. Followingpreconditioning, baseline behavioral responses to either thermal(radiant light or hot/cold plate) or mechanical (paw pressure or vonFrey filament) stimulation are recorded. Additionally, to minimizeanimal number requirements non-noxious passive measures (paw volume,weight bearing, activity monitoring) may be collected where they do notinterfere with the evoked sensory endpoints. The subjects then receive aunilateral intraplantar injection of inflammogen (e.g. carrageenan,zymosan, or Freund's Complete Adjuvant) or neuronal sensitizing agent(e.g., capsaicin, inflammatory cytokine, neuropeptide or neurokinin) toinitiate a localized inflammatory/sensitization response in a singlehind paw. Following a defined period, behavioral responses are againassessed to verify shortened thermal latencies or reduced mechanicalthresholds indicative of hyperalgesia and/or increased paw volumeassociated with edema. Test compound or vehicle administration isfollowed by behavioral assessment at defined times (e.g., one or twohours). The test may also be run using prophylactic dosing to assess theability of test compounds to prevent the development of inflammatoryhyperalgesia. Note that the incubation period relating to the time ofpeak hyperalgesia ranges from minutes following capsaicin, to ˜4 hoursfollowing carrageenan or zymosan. The hyperalgesia produced by theseinflammogens is self-limiting and resolves by 6-8 hours post-injection.Freund's Complete Adjuvant (CFA), which has a more lengthily course ofaction, may be studied over a longer time period, especially forrepeated dose studies.

[1088] Thermal sensitivities: each animal's latency to respond (bylifting or licking of foot or jumping) is assessed when placed on aheated surface (up to 55° C.) or cooled surface (down to 1C). Inexperiments where comparisons between individual hind paws are required,a radiant thermal stimulus (beam of light) focused on the sole of eachhind paw in turn is utilized. Mechanical sensitivities: responsethresholds to mechanical pressure are determined using theRandall-Selitto method wherein a Paw Pressure Instrument applies agradually increasing force to the subject's hind paw. A deliberate pawwithdrawal or vocalization is considered a positive response, at whichtime the test is stopped and the gram-force is recorded. A reducedresponse threshold to this graded stimulus following inflammation isconsidered mechanical hyperalgesia. Alternatively, von Frey filaments (aset of fibers providing a graduated series of bending forces) or anelectronic version thereof may be applied to the sole of the foot todetect alterations in mechanical response thresholds below the noxiouslevel. Mechanical allodynia is defined as the perception of painascribed to a normally non-noxious mechanical stimulus.

[1089] Passive measures: 1) paw volume measurements are obtained usingan automated volume displacement device wherein the subject is heldelevated above a small fluid reservoir and each hind paw is submerged inturn providing a direct digital readout of paw volume (mL).Post-inflammation paw volumes are compared to baseline and contralateralpaw volumes to determine the level of edema. 2) weight-bearing test(rats only) utilizes the “incapacitence meter” (Stoelting) tosimultaneously measure the distribution of body weight on the two hindpaws. Postural favoring of the inflamed paw can thusly be quantified ingrams. 3) open field ambulatory activity is a measure of willingness touse an inflamed paw. Automated activity monitoring boxes count photocellbeam interruptions to quantitate both horizontal and vertical (rearing)activity levels.

[1090] Test compound administration: compounds are typicallyadministered orally, however under special circumstances other routes ofadministration (s.c., i.p., i.m., i.v., i.t., i.c.v, topical) orcombinations of agents are utilized.

Example 279 Guinea Pig Bronchial Ring Constriction

[1091] Two mm rings of bronchial tissue obtained from male guinea pigswere suspended in normal Krebs solution between two wire hooks under aninitial loading tension of 1 gram. The saline was maintained in a 5% CO₂and 95% O₂ atmosphere at 37° C. in the presence of indomethacin (5 μM).A sub-maximal dose of 5-methylfurmethide (5Mef, 1 μM) was added to eachtissue to determine responsiveness using an isometric force transducer.After washout, tissues were exposed to compounds or vehicle for 30 minand treated with thiorphan (10 μM, 5% Na₂CO₃). A concentration-responsecurve was then constructed using capsaicin (10 nM-10 μM) increasing in0.5 log unit increments. The dose response curve was calculated as % maxof the 5-Mef response and estimated pA₂ were determined. As shown inFIG. 7, 4-(3-Aza-bicyclo[3.3.1]non-3-yl)-N-quinolin-3-yl-benzamideshifted the capsaicin dose-response curve to the right, indicative ofits antagonism of the capsaicin-induced response.

Example 280 Mouse Colitis Model

[1092] Dextran Sulfate Sodium Induced Colitis.

[1093] The dextran sulfate sodium model of experimental colitis ischaracterized by a discontinuous pattern of mucosal epithelial damage inthe distal colon, shrinkage of the colon's length, decreases in the wetweight of the colon, infiltration of inflammatory cells that includemacrophages and neutrophils into the mucosa and submucosa, and diarrhea(Blumberg, R. S., Saubermann, L. J., and Strober, W., Current Opinion inImmunology, 11: 648-656, 1999; Okayasu, I.et al., Gastroenterology, 98:694-702, 1990; Cooper, H. et al., Lab Invest., 69: 238-249, 1993; Egger,B., et al., Digestion, 62: 240-248, 2000; Stevceva, L., et al., BMCClinical Pathology, 1: 3-13, 2001). These are similar to what occurs inhuman colitis.

[1094] Balb/c female mice are provided with a solution of tap watercontaining 5% DSS (ICN chemicals) ad libitum over a 7-day period. Duringthis same time, test animals are administered a preparation of4-(Cyclohexyl-methylamino)-N-quinolin-3-yl-benzamide. This material maybe administered orally or intraperitoneally, once or twice daily. At theend of this period, the animals are euthanized and their colons arecollected for further analysis. Among the parameters analyzed are thelength of the colon starting from 1 cm above the anus to the top of thececum, the weight of the colon, the consistency of any stools foundwithin the colon, and the gross macroscopic appearance of the colon. Thedistal colon between the 1st and the 4th centimeter are dissected intotwo halves. One half is placed in 10% neutral buffered formalin forlater histological analysis if desired. The other half is cleaned in abath of physiological buffer, patted dry, weighed and then placed in asolution of 0.5% hexadecyltrimethylammonium bromide (HTAB; Sigma)dissolved in 50 mM phosphate buffer, adjusted to pH 5.4. The tissuesample thus treated is then frozen at −80° C.

[1095] For the following parameters, colon length, colon weight, stoolconsistency and appearance and macroscopic damage a scoring system isused to describe the changes. The 4 scores for each animal are added toprovide a Total Score. Thus,

[1096] Stool Score:

[1097] 0=normal (well-formed fecal pellets);

[1098] 1=loosely-shaped moist pellets;

[1099] 2=amorphous, moist, sticky pellets;

[1100] 3=bloody diarrhea. Presence of blood in stool: add 1 to scores <3

[1101] Colon Damage Score:

[1102] 0=no inflammation;

[1103] 1=reddening mild inflammation;

[1104] 2=moderate inflammation or more widely distributed;

[1105] 3=severe inflammation and/or extensively distributed

[1106] Colon Weight Score:

[1107] 0=<5% weight loss;

[1108] 1=5-14% weight loss;

[1109] 2=15-24% weight loss;

[1110] 3=25-35% weight loss; 4=>35% weight loss.

[1111] Colon Length Score:

[1112] 0=<5% shortening;

[1113] 1=5-14% shortening;

[1114] 2=15-24% shortening;

[1115] 3=25-35% shortening;

[1116] 4=>35% shortening.

[1117] Colon weight changes and colon length changes are also directlymeasured and the net changes compared to DSS and untreated controls areused to calculate a % inhibition of colon weight loss or colon shrinkageinduced by DSS treatment.

[1118] Myeloperoxidase Assay

[1119] The tissue sample previously frozen at −80° C. in 0.5% solutionof HTAB is thawed, homogenized twice for 15 seconds using a BrinkmanPolytron homogenizer fitted with a TS10 generator. The crude homogenateis next sonicated at 60 watts for two 5-second bursts and thencentrifuged for 20 minutes at 15000×g. The supernatant of thishomogenate is collected, aliquoted and frozen at −70° C. for futureanalysis for myeloperoxidase analysis (MPO). MPO is an intracellularenzyme found in neutrophils and can be considered a surrogate marker forneutrophil infiltration into tissues, including those afflicted withcolitis (Diaz-Granados, et al., 2000).

[1120] Results

[1121] For FIGS. 1-6, data are from 3 experiments for animals given 5%DSS in their dringing water and dosed with4-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide twice daily,orally at 0.05 mg/kg (n=10), 0.5 mg/kg (n=20), 5 mg/kg (n=30), 10 mg/kig(n=30), or 30 mg/kg (n=20) and are compared to animals administered only5% DSS (n=30) and animals not administered 5% DSS (n=29).

[1122] Statistical analyses were performed by ANOVA using MultipleComparisons Test and Tukey's test.

[1123] The data in FIG. 1 show that there was significant (p<0.05)inhibition of colon weight loss by treatment with4-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide. The prevention orreversal of colon weight loss suggests that the tissues retained normalamounts of water and that the stools are more solid and are retainedwithin the colon. This is thus an indirect measure of correctingincreased motility that occurs during colitis.

[1124]FIG. 2 shows that there was significant (p<0.05) inhibition ofcolon shrinkage after treatment with4-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide. Colon shrinkageinduced by DSS is an indication of neuronally mediated smooth musclecontraction in the intestine that may be stimulated by inflammation.

[1125] Colon Damage Score was diminished (p>0.05), but not statisticallysignificantly, after treatment with4-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide, as shown in FIG.3. A decrease in a colon damage score indicates that there was decreasedinflammation (reddening) of the tissues, and decreases in the extent ofthe tissue damage. A lower score indicates improvement compared to DSSalone.

[1126] Stool Score was decreased (p>0.05), but not statisticallysignificantly, after treatment with4-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide, as shown in FIG.4. A decrease in a stool score indicates that there was decreasedevidence of diarrhea or softened stools contained within the colon andincreases in firmness of the stool contained therein. This is also anindicator of changes in motility that occurs during colitis and thecorrection of those changes. A lower score indicates improvementcompared to DSS alone.

[1127] There was significant (p<0.05) inhibition of Total Score aftertreatment with 4-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide, asshown in FIG. 5. The total score is the sum of the individual scores andprovides an overall assessment of the health or disease state of thesubject. A lower score indicates improvement compared to DSS alone.

[1128] Myleoperoxidase (MPO) inhibition (p>0.05) after treatment with4(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide is shown in FIG. 6.MPO is an enzyme contained within neutrophils. Increases in MPOcorrelate with increased tissue neutrophil numbers. This represents ameasure of inflammatory cell recruitment into the tissues and a decreasewould indicate a reduction in inflammatory cell presence.

1. A compound of Formula (I):

wherein: R¹ is a substituent independently selected from the groupconsisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionallysubstituted with one or more substituents independently selected fromthe group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy;C₁₋₈alkanyloxy optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl;C₁₋₈alkanylthio optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy;nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino;C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl;C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl;C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;wherein the heteroatom contained in the quinoline ring of Formula (I) isoptionally substituted with an oxo substituent; m is 0, 1 or 2; R² ishydrogen or C₁₋₈alkanyl; L is a direct bond or C₁₋₄alkyldiyl optionallysubstituted with a substituent selected from the group consisting ofC₁₋₈alkanyl, C₃₋₈cycloalkanyl and phenyl optionally substituted with oneto three substituents independently selected from the group consistingof C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl,fluorinated alkanyloxy, amino, di(C₁₋₃)alkanylamino, andC₁₋₃alkanylamino; R³ is selected from the group consisting of pyrrolyl,pyridyl, furyl, thienyl, phenyl and cyclohexyl; R⁴ is independentlyselected from the group consisting of C₁₋₁₂alkanyl, C₄₋₈alkanyloxy,C₃₋₈cycloalkanyloxy, C₁₋₈alkanylamino, C₃₋₈cycloalkanylamino, C₃₋₁₄cyclic heteroalkanyl, C₁₋₆fluorinated alkanyl and —N(R⁵)(R⁶); or when nis 2 or 3, optionally two R⁴ substituents taken together form a C₃₋₁₄cyclic heteroalkyl or C₃₋₁₄ cyclic alkanyl; R⁵ is hydrogen, C₁₋₁₆alkyl,alkanylcarbonyl or arylcarbonyl; R₆ is C₄₋₁₆ alkyl, alkanylcarbonyl,C₁₋₃alkyl substituted with a substituent selected from the groupconsisting of pyrrolyl, pyridyl, furyl, thienyl, phenyl, and furyl, orarylcarbonyl; or optionally R⁶ and one of R⁴ taken together form asaturated or partially unsaturated cyclic heteroalkyl or a heteroaryl;or R⁵ and R⁶ optionally taken together form a bridged or non-bridgedcyclic heteroalkanyl, wherein said heteroalkanyl is optionallysubstituted with C₁₋₆alkanylcarbonyl; wherein the alkanyls in any of theforegoing alkanyl-containing substituents of R⁴, R⁵ or R⁶ are optionallyand independently substituted with pyrrolyl, pyridyl, furyl, thienyl,phenyl, furyl, C₁₋₄alkylpyrrolyl, C₁₋₄alkylpyridyl, C₁₋₄alkylthienyl,C₁₋₄alkylphenyl, or C₁₋₄alkylfuryl; n is 1, 2 or 3; Z is O or S; andenantiomers, diastereomers, tautomers, solvates, and pharmaceuticallyacceptable salts thereof.
 2. The compound according to claim 1 wherein Lis a direct bond.
 3. The compound according to claim 1 wherein L isC₁₋₄alkyldiyl.
 4. The compound according to claim 1 wherein R³ isphenyl.
 5. The compound according to claim 1 wherein R³ is pyridyl. 6.The compound according to claim 1 wherein R³ is thienyl.
 7. The compoundaccording to claim 1 wherein n is
 1. 8. The compound according to claim1 wherein n is 2 or 3 and R⁴ is C₁₋₁₂alkanyl.
 9. The compound accordingto claim 1 wherein R⁴ is —N(R⁵)(R⁶).
 10. The compound according to claim9 wherein R⁵ and R⁶ are different.
 11. The compound according to claim 1wherein L is Cl-4alkyldiyl, R³ is phenyl, n is 1 and R⁴ is C₁₋₁₂alkanyl.12. The compound according to claim 1 wherein R³ is phenyl, n is 1 andR⁴ is —N(R⁵)(R⁶).
 13. The compound according to claim 1 wherein R³ isphenyl, n is 2 or 3, and two R⁴ substituents taken together form a C₃₋₁₄cyclic heteroalkyl or C₃₋₁₄ cyclic alkyl.
 14. The compound according toclaim 1 wherein Z is O.
 15. The compound according to claim 1 wherein mis
 0. 16. The compound according to claim 1 wherein R² is hydrogen. 17.A compound of Formula (I):

wherein: R¹ is a substituent independently selected from the groupconsisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionallysubstituted with one or more substituents independently selected fromthe group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy;C₁₋₈alkanyloxy optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl;C₁₋₈alkanylthio optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy;nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino;C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl;C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl;C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;wherein the heteroatom contained in the quinoline ring of Formula (I) isoptionally substituted with an oxo substituent; m is 0, 1 or 2; R² ishydrogen or C₁₋₈alkanyl; L is a C₁₋₄alkyldiyl optionally substitutedwith a substituent selected from the group consisting of C₁₋₈alkanyl,C₃₋₈cycloalkanyl and phenyl optionally substituted with one to threesubstituents independently selected from the group consisting ofC₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl,fluorinated alkanyloxy, amino, di(C₁₋₃)alkanylamino, andC₁₋₃alkanylamino; R³ is selected from the group consisting of pyrrolyl,pyridyl, furyl, thienyl, phenyl and cyclohexyl; R⁴ is independentlyselected from the group consisting of C₁₋₁₂alkanyl, C₄₋₈alkanyloxy,C₃₋₈cycloalkanyloxy, C₁₋₈alkanylamino, C₃₋₈cycloalkanylamino, C₃₋₁₄cyclic heteroalkanyl, C₁₋₆ fluorinated alkanyl, and —N(R⁵)(R⁶); or whenn is 2 or 3, optionally two R⁴ substituents taken together form a C₃₋₁₄cyclic heteroalkyl or C₃₋₁₄ cyclic alkanyl; R⁵ is hydrogen, C₁₋₁₆alkyl,alkanylcarbonyl or arylcarbonyl; R₆ is C₄₋₁₆ alkyl, alkanylcarbonyl,C₁₋₃alkyl substituted with a substituent selected from the groupconsisting of pyrrolyl, pyridyl, furyl, thienyl, phenyl, and furyl, orarylcarbonyl; or optionally R⁶ and one of R⁴ taken together form asaturated or partially unsaturated cyclic heteroalkyl or a heteroaryl;or R⁵ and R⁶ optionally taken together form a bridged or non-bridgedcyclic heteroalkanyl, wherein said heteroalkanyl is optionallysubstituted with C₁₋₆alkanylcarbonyl; wherein the alkanyls in any of theforegoing alkanyl-containing substituents of R⁴, R⁵ or R⁶ are optionallyand independently substituted with pyrrolyl, pyridyl, furyl, thienyl,phenyl, furyl, C₁₋₄alkylpyrrolyl, C₁₋₄alkylpyridyl, C₁₋₄alkylthienyl,C₁₋₄alkylphenyl, or C₁₋₄alkylfuryl; n is 1, 2 or 3; Z is O or S; andenantiomers, diastereomers, tautomers, solvates, and pharmaceuticallyacceptable salts thereof.
 18. The compound according to claim 17 whereinR³ is phenyl.
 19. The compound according to claim 17 wherein R³ ispyridyl.
 20. The compound according to claim 17 wherein R³ is thienyl.21. The compound according to claim 17 wherein n is
 1. 22. The compoundaccording to claim 17 wherein n is 2 or 3 and R⁴ is C₁₋₁₂alkanyl. 23.The compound according to claim 17 wherein R⁴ is —N(R⁵)(R⁶).
 24. Thecompound according to claim 23 wherein R⁵ and R⁶ are different.
 25. Thecompound according to claim 17 wherein L is C₁₋₄alkyldiyl, R³ is phenyl,n is 1 and R⁴ is C-₁₋₁₂alkanyl.
 26. The compound according to claim 17wherein R³ is phenyl, n is 1 and R⁴ is —N(R⁵)(R⁶).
 27. The compoundaccording to claim 17 wherein R³ is phenyl, n is 2 or 3, and two R⁴substituents taken together form a C₃₋₁₄ cyclic heteroalkyl or C₃₋₁₄cyclic alkyl.
 28. The compound according to claim 17 wherein Z is O. 29.The compound according to claim 17 wherein m is
 0. 30. The compoundaccording to claim 17 wherein R² is hydrogen.
 31. A compound of Formula(I):

wherein: R¹ is a substituent independently selected from the groupconsisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionallysubstituted with one or more substituents independently selected fromthe group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy;C₁₋₈alkanyloxy optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl;C₁₋₈alkanylthio optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy;nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino;C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl;C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl;C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;wherein the heteroatom contained in the quinoline ring of Formula (I) isoptionally substituted with an oxo substituent; m is 0, 1 or 2; R² ishydrogen or C₁₋₈alkanyl; L is a direct bond or C₁₋₄alkyldiyl optionallysubstituted with a substituent selected from the group consisting ofC₁₋₈alkanyl, C₃₋₈cycloalkanyl and phenyl optionally substituted with oneto three substituents independently selected from the group consistingof C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl,fluorinated alkanyloxy, amino, di(C₁₋₃)alkanylamino, andC₁₋₃alkanylamino; R³ is selected from the group consisting of pyrrolyl,pyridyl, furyl, thienyl, phenyl and cyclohexyl; R⁴ is independentlyselected from the group consisting of C₁₋₈alkanyl, C₄₋₈alkanyloxy,C₃₋₈cycloalkanyloxy, C₁₋₈alkanylamino, C₃₋₈cycloalkanylamino, C₃₋₁₄cyclic heteroalkanyl, C₁₋₆ fluorinated alkanyl, and —N(R⁵)(R⁶); or bothR⁴ substituents taken together form a C₃₋₁₄ cyclic heteroalkyl or C₃₋₁₄cyclic alkanyl; R⁵ is hydrogen, C₁₋₁₆alkyl, alkanylcarbonyl orarylcarbonyl; R₆ is C₄₋₁₆ alkyl, alkanylcarbonyl, C₁₋₃alkyl substitutedwith a substituent selected from the group consisting of pyrrolyl,pyridyl, furyl, thienyl, phenyl, and furyl, or arylcarbonyl; oroptionally R⁶ and one of R⁴ taken together form a saturated or partiallyunsaturated cyclic heteroalkyl or a heteroaryl; or R⁵ and R⁶ optionallytaken together form a bridged or non-bridged cyclic heteroalkanyl,wherein said heteroalkanyl is optionally substituted withC₁₋₆alkanylcarbonyl; wherein the alkanyls in any of the foregoingalkanyl-containing substituents of R⁴, R⁵ or R⁶ are optionally andindependently substituted with pyrrolyl, pyridyl, furyl, thienyl,phenyl, furyl, C₁₋₄alkylpyrrolyl, C₁₋₄alkylpyridyl, C₁₋₄alkylthienyl,C₁₋₄alkylphenyl, or C₁₋₄alkylfuryl; n is 2 or 3; Z is O or S; andenantiomers, diastereomers, tautomers, solvates, and pharmaceuticallyacceptable salts thereof.
 32. The compound according to claim 31 whereinL is a direct bond.
 33. The compound according to claim 31 wherein L isC₁₋₄alkyldiyl.
 34. The compound according to claim 31 wherein R³ isphenyl.
 35. The compound according to claim 31 wherein R³ is pyridyl.36. The compound according to claim 31 wherein R³ is thienyl.
 37. Thecompound according to claim 31 wherein R⁴ is C₁₋₁₂alkanyl.
 38. Thecompound according to claim 31 wherein R⁴ is —N(R⁵)(R⁶).
 39. Thecompound according to claim 38 wherein R⁵ and R⁶ are different.
 40. Thecompound according to claim 31 wherein L is C₁₋₄alkyldiyl, R³ is phenyl,and one R⁴ is C₁₋₁₂alkanyl.
 41. The compound according to claim 31wherein R³ is phenyl, and one R⁴ is —N(R⁵)(R⁶).
 42. The compoundaccording to claim 31 wherein R³ is phenyl and two R⁴ substituents takentogether form a C₃₋₁₄ cyclic heteroalkyl or C₃₋₁₄ cyclic alkyl.
 43. Thecompound according to claim 31 wherein Z is O.
 44. The compoundaccording to claim 31 wherein m is
 0. 45. The compound according toclaim 31 wherein R² is hydrogen.
 46. A compound of Formula (I):

wherein: R¹ is a substituent independently selected from the groupconsisting of hydroxy; halogen; C₁₋₈alkanyl optionally substituted withone or more substituents independently selected from the groupconsisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy;C₁₋₈alkanyloxy optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl;C₁₋₈alkanylthio optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy;nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino;C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl;C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl;C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;wherein the heteroatom contained in the quinoline ring of Formula (I) isoptionally substituted with an oxo substituent; m is 1 or 2; R² ishydrogen or C₁₋₈alkanyl; L is a direct bond or C₁₋₄alkyldiyl optionallysubstituted with a substituent selected from the group consisting ofC₁₋₈alkanyl, C₃₋₈cycloalkanyl and phenyl optionally substituted with oneto three substituents independently selected from the group consistingof C₁₋₈alkanyl, halogen, C₁₋₈alkanyloxy, hydroxy, fluorinated alkanyl,fluorinated alkanyloxy, amino, di(C₁₋₃)alkanylamino, andC₁₋₃alkanylamino; R³ is selected from the group consisting of pyrrolyl,pyridyl, furyl, thienyl, phenyl and cyclohexyl; R⁴ is independentlyselected from the group consisting of C₁₋₈alkanyl, C₄₋₈alkanyloxy,C₃₋₈cycloalkanyloxy, C₁₋₈alkanylamino, C₃₋₈cycloalkanylamino, C₃₋₁₄cyclic heteroalkanyl, C₁₆ fluorinated alkanyl, and —N(R⁵)(R⁶); or bothR⁴ substituents taken together form a C₃₋₁₄ cyclic heteroalkyl or C₃₋₁₄cyclic alkanyl; R⁵ is hydrogen, C₁₋₁₆alkyl, alkanylcarbonyl orarylcarbonyl; R₆ is C₄₋₁₆ alkyl, alkanylcarbonyl, C₁₋₃alkyl substitutedwith a substituent selected from the group consisting of pyrrolyl,pyridyl, furyl, thienyl, phenyl, and furyl, or arylcarbonyl; oroptionally R⁶ and one of R⁴ taken together form a saturated or partiallyunsaturated cyclic heteroalkyl or a heteroaryl; or R⁵ and R⁶ optionallytaken together form a bridged or non-bridged cyclic heteroalkanyl,wherein said heteroalkanyl is optionally substituted withC₁₋₆alkanylcarbonyl; wherein the alkanyls in any of the foregoingalkanyl-containing substituents of R⁴, R⁵ or R⁶ are optionally andindependently substituted with pyrrolyl, pyridyl, furyl, thienyl,phenyl, furyl, C₁₋₄alkylpyrrolyl, C₁₋₄alkylpyridyl, C₁₋₄alkylthienyl,C₁₋₄alkylphenyl, or C₁₋₄alkylfuryl; n is 1, 2 or 3; Z is O or S; andenantiomers, diastereomers, tautomers, solvates, and pharmaceuticallyacceptable salts thereof.
 47. The compound according to claim 46 whereinL is a direct bond.
 48. The compound according to claim 46 wherein L isC₁₋₄alkyldiyl.
 49. The compound according to claim 46 wherein R³ isphenyl.
 50. The compound according to claim 46 wherein R³ is pyridyl.51. The compound according to claim 46 wherein R³ is thienyl.
 52. Thecompound according to claim 46 wherein R⁴ is C₁₋₁₂alkanyl.
 53. Thecompound according to claim 46 wherein R⁴ is —N(R⁵)(R⁶).
 54. Thecompound according to claim 46 wherein R⁵ and R⁶ are different.
 55. Thecompound according to claim 46 wherein L is C₁₋₄alkyldiyl, R³ is phenyl,and one R⁴ is C₁₋₁₂alkanyl.
 56. The compound according to claim 46wherein R³ is phenyl, and one R⁴ is —N(R⁵)(R⁶).
 57. The compoundaccording to claim 46 wherein R³ is phenyl and two R⁴ substituents takentogether form a C₃₋₁₄ cyclic heteroalkyl or C₃₋₁₄ cyclic alkyl.
 58. Thecompound according to claim 46 wherein Z is O.
 59. The compoundaccording to claim 46 wherein m is
 0. 60. The compound according toclaim 46 wherein R² is hydrogen.
 61. A compound of Formula (I):

wherein: R¹ is a substituent independently selected from the groupconsisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionallysubstituted with one or more substituents independently selected fromthe group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy;C₁₋₈alkanyloxy optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl;C₁₋₈alkanylthio optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy;nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino;C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl;C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl;C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;wherein the heteroatom contained in the quinoline ring of Formula (I) isoptionally substituted with an oxo substituent; m is 0, 1 or 2; R² ishydrogen or C₁₋₈alkanyl; L is ethen-1,2-diyl; R³ is selected from thegroup consisting of pyrrolyl, pyridyl, furyl, thienyl, phenyl andcyclohexyl; R⁴ is independently selected from the group consisting ofC₁₋₁₂alkanyl, C₄₋₈alkanyloxy, C₃₋₈cycloalkanyloxy, C₁₋₈alkanylamino,C₃₋₈cycloalkanylamino, C₃₋₁₄ cyclic heteroalkanyl, C₁₋₆ fluorinatedalkanyl, halogen, and —N(R⁵)(R⁶); or when n is 2 or 3, optionally two R⁴substituents taken together form a C₃₋₁₄ cyclic heteroalkyl or C₃₋₁₄cyclic alkanyl; R⁵ is hydrogen, C₁₋₁₆alkyl, alkanylcarbonyl orarylcarbonyl; R₆ is C₄₋₁₆ alkyl, alkanylcarbonyl, C₁₋₃alkyl substitutedwith a substituent selected from the group consisting of pyrrolyl,pyridyl, furyl, thienyl, phenyl, and furyl, or arylcarbonyl; oroptionally R⁶ and one of R⁴ taken together form a saturated or partiallyunsaturated cyclic heteroalkyl or a heteroaryl; or R⁵ and R⁶ optionallytaken together form a bridged or non-bridged cyclic heteroalkanyl,wherein said heteroalkanyl is optionally substituted withC₁₋₆alkanylcarbonyl; wherein the alkanyls in any of the foregoingalkanyl-containing substituents of R⁴, R⁵ or R⁶ are optionally andindependently substituted with pyrrolyl, pyridyl, furyl, thienyl,phenyl, furyl, C₁₋₄alkylpyrrolyl, C₁₋₄alkylpyridyl, C₁₋₄alkylthienyl,C₁₋₄alkylphenyl, or C₁₋₄alkylfuryl; n is 1, 2 or 3; Z is O or S; andenantiomers, diastereomers, tautomers, solvates, and pharmaceuticallyacceptable salts thereof.
 62. The compound according to claim 61 whereinR³ is phenyl.
 63. The compound according to claim 61 wherein R³ ispyridyl.
 64. The compound according to claim 61 wherein R³ is thienyl.65. The compound according to claim 61 wherein n is
 1. 66. The compoundaccording to claim 61 wherein n is 2 or 3 and R⁴ is C₁₋₁₂alkanyl. 67.The compound according to claim 61 wherein n is 2, one R⁴ is halogen,and the other R⁴ is C₁₋₆ fluorinated alkanyl.
 68. The compound accordingto claim 61 wherein R⁴ is C₁₋₆ fluorinated alkanyl.
 69. The compoundaccording to claim 61 R⁴ is halogen.
 70. The compound according to claim61 wherein R⁴ is —N(R⁵)(R⁶).
 71. The compound according to claim 67wherein R⁵ and R⁶ are different.
 72. The compound according to claim 61wherein L is C₁₋₄alkyldiyl, R³ is phenyl, n is 1 and R⁴ is C₁₋₁₂alkanyl.73. The compound according to claim 61 wherein R³ is phenyl, n is 1 andR⁴ is —N(R⁵)(R⁶).
 74. The compound according to claim 61 wherein R³ isphenyl, n is 2 or 3, and two R⁴substituents taken together form a C₃₋₁₄cyclic heteroalkyl or C₃₋₁₄ cyclic alkyl.
 75. The compound according toclaim 61 wherein Z is O.
 76. The compound according to claim 61 whereinm is
 0. 77. The compound according to claim 61 wherein R² is hydrogen.78. A compound of Formula (I):

wherein: R¹ is a substituent independently selected from the groupconsisting of hydrogen; hydroxy; halogen; C₁₋₈alkanyl optionallysubstituted with one or more substituents independently selected fromthe group consisting of halogen, fluorinated alkanyl and C₁₋₈alkanyloxy;C₁₋₈alkanyloxy optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl;C₁₋₈alkanylthio optionally substituted with one or more substituentsindependently selected from the group consisting of halogen, fluorinatedalkanyl and C₁₋₈alkanyloxy; C₃₋₈cycloalkanyl; C₃₋₈cycloalkanyloxy;nitro; amino; C₁₋₈alkanylamino; C₁₋₈dialkanylamino;C₃₋₈cycloalkanylamino; cyano; carboxy; C₁₋₇alkanyloxycarbonyl;C₁₋₇alkanylcarbonyloxy; C₁₋₇alkanylaminocarbonyl;C₁₋₇alkanylcarbonylamino; diC₁₋₇alkanylaminocarbonyl; and formyl;wherein the heteroatom contained in the quinoline ring of Formula (I) isoptionally substituted with an oxo substituent; m is 0, 1 or 2; R² ishydrogen or C₁₋₈alkanyl; L is a direct bond; R³ is selected from thegroup consisting of pyrrolyl, pyridyl, furyl, thienyl, and cyclohexyl;R⁴ is selected from the group consisting of C₁₋₁₂alkanyl,C₄₋₈alkanyloxy, C₃₋₈cycloalkanyloxy, C₁₋₈alkanylamino,C₃₋₈cycloalkanylamino, C₃₋₁₄ cyclic heteroalkanyl, C₁₋₆ fluorinatedalkanyl, and —N(R⁵)(R⁶), wherein the alkanyls in any of the foregoingalkanyl-containing substituents of R⁴ is optionally substituted withthienyl or phenyl; or when n is 2 or 3, optionally two R⁴ substituentstaken together form a C₃₋₁₄ cyclic heteroalkyl or C₃₋₁₄ cyclic alkanyl;R⁵ is hydrogen, C₁₋₁₆alkyl, alkanylcarbonyl or arylcarbonyl; R₆ is C₄₋₁₆alkyl, alkanylcarbonyl, C₁₋₃alkyl substituted with a substituentselected from the group consisting of pyrrolyl, pyridyl, furyl, thienyl,phenyl, and furyl, or arylcarbonyl; or optionally R⁶ and one of R⁴ takentogether form a saturated or partially unsaturated cyclic heteroalkyl ora heteroaryl; or R⁵ and R⁶ optionally taken together form a bridged ornon-bridged cyclic heteroalkanyl, wherein said heteroalkanyl isoptionally substituted with C₁₋₆alkanylcarbonyl; wherein the alkanyls inany of the foregoing alkanyl-containing substituents of R⁴, R⁵ or R⁶ areoptionally and independently substituted with pyrrolyl, pyridyl, furyl,thienyl, phenyl, furyl, C₁₋₄alkylpyrrolyl, C₁₋₄alkylpyridyl,C₁₋₄alkylthienyl, C₁₋₄alkylphenyl, or C₁₋₄alkylfuryl; n is 1, 2 or 3; Zis O or S; and enantiomers, diastereomers, tautomers, solvates, andpharmaceutically acceptable salts thereof.
 79. The compound according toclaim 78 wherein L is a direct bond.
 80. The compound according to claim78 wherein R³ is pyridyl.
 81. The compound according to claim 78 whereinR³ is thienyl.
 82. The compound according to claim 78 wherein R³ isfuryl.
 83. The compound according to claim 78 wherein R³ is cyclohexyl.84. The compound according to claim 78 wherein n is
 1. 85. The compoundaccording to claim 78 wherein n is 2 or 3 and R⁴ is C₁₋₁₂alkanyl. 86.The compound according to claim 78 wherein R⁴ is —N(R⁵)(R⁶).
 87. Thecompound according to claim 86 wherein R⁵ and R⁶ are different.
 88. Thecompound according to claim 78 wherein Z is O.
 89. The compoundaccording to claim 78 wherein m is
 0. 90. The compound according toclaim 78 wherein R² is hydrogen.
 91. A compound selected from the groupconsisting of 1-Acetyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide; 1-Benzoyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide; 1-Butyryl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide;1-Cyclohexanecarbonyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide; 1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide;1-Isopropyl-2-trifluoromethyl-1H-benzoimidazole-5-carboxylic acidquinolin-3-ylamide; 1-Methyl-1,2,3,4-tetrahydro-quinoline-6-carboxylicacid quinolin-3-ylamide; 1-Methyl-2,3-dihydro-1H-indole-5-carboxylicacid quinolin-3-ylamide;1-Pentyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acidquinolin-3-ylamide; 1-Pentyl-1H-indole-5-carboxylic acidquinolin-3-ylamide; 1-Pentyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide; 1-Propyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide;2-(4-Dipentylamino-phenyl)-N-quinolin-3-yl-acetamide;2-(4-Pentyl-phenyl)-N-quinolin-3-yl-acetamide;2-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-acetamide;2-(Heptyl-methyl-amino)-N-quinolin-3-yl-benzamide;2-(Methyl-pentyl-amino)-N-quinolin-3-yl-benzamide;2,3-Dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;2-{4-(Methyl-pentyl-amino)-phenyl}-N-quinolin-3-yl-acetamide;2-Chloro-4-(cyclohexylmethyl-amino)-N-quinolin-3-yl-benzamide;2-Chloro-4-pentylamino-N-quinolin-3-yl-benzamide;2-Heptylamino-N-quinolin-3-yl-benzamide;2-Pentylamino-N-quinolin-3-yl-benzamide;3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-propionamide;3-(1-Cyclohexylmethyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-propionamide;3-(1-Propyl-1H-indol-5-yl)-N-quinolin-3-yl-propionamide,3-(1-Propyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-propionamide;3-(2,2-Dimethyl-chroman-6-yl)-N-quinolin-3-yl-acrylamide;3-(2,2-Dimethyl-chroman-6-yl)-N-quinolin-3-yl-propionamide;3-(4-Azepan-1-yl-phenyl)-N-quinolin-3-yl-acrylamide;3-(4-Azepan-1-yl-phenyl)-N-quinolin-3-yl-propionamide;3-(4-Cyclohexylmethyl-phenyl)-N-quinolin-3-yl-propionamide;3-(4-Dipentylamino-phenyl)-N-quinolin-3-yl-propionamide;3-(4-Pentyl-phenyl)-N-quinolin-3-yl-acrylamide;3-(4-Pentyl-phenyl)-N-quinolin-3-yl-propionamide;3-(4-sec-Butyl-phenyl)-N-quinolin-3-yl-propionamide;3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-acrylamide;3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-propionamide;3-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide;3-(Heptyl-methyl-amino)-N-quinolin-3-yl-benzamide;3-(Methyl-pentyl-amino)-N-quinolin-3-yl-benzamide;3,4,5,6-Tetrahydro-2H-[1,2′]bipyridinyl-5′-carboxylic acidquinolin-3-ylamide;3,4,5,6-Tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylic acidquinolin-3-ylamide;3-[4-(Methyl-phenethyl-amino)-phenyl]-N-quinolin-3-yl-propionamide;3-{4-(1,1-Dimethyl-3-phenyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(1,1-Dimethyl-pentyl)-2,6-dimethoxy-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(1,1-Dimethyl-pentyl)-phenyl}-N-quinolin-3-yl;3-{4-(1,1-Dimethyl-propyl)-2,6-dimethoxy-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(1,1-Dimethyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(1-Cyclohexyl-1-methyl-ethyl)-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(1-Methyl-pentyl)-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(1-Methyl-pentyl)-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(Benzyl-methyl-amino)-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(Cyclohexyl-methyl-amino)-phenyl}-N-quinolin-3-yl-acrylamide;3-{4-(Cyclohexyl-methyl-amino)-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(Cyclohexylmethyl-methyl-amino)-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(Methyl-pentyl-amino)-phenyl}-N-quinolin-3-yl-acrylamide;3-{4-(Methyl-pentyl-amino)-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(Methyl-propyl-amino)-phenyl}-N-quinolin-3-yl-propionamide;3-{5-(1,1-Dimethyl-propyl)-thiophen-2-yl}-N-quinolin-3-yl-propionamide;3-Cyclohexylamino-N-quinolin-3-yl-benzamide;3-Dipentylamino-N-quinolin-3-yl-benzamide;3-Heptylamino-N-quinolin-3-yl-benzamide;3-Indan-5-yl-N-quinolin-3-yl-propionamide;3-Methyl-4-(methyl-pentyl-amino)-N-quinolin-3-yl-benzamide;3-Methyl-4-pentylamino-N-quinolin-3-yl-benzamide;3-Pentylamino-N-quinolin-3-yl-benzamide;4-(1,3-Dihydro-isoindol-2-yl)-N-quinolin-3-yl-benzamide;4-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-N-quinolin-3-yl-benzamide;4-(2,6-Dimethyl-morpholin-4-yl)-N-quinolin-3-yl-benzamide;4-(3,5-Dimethyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;4-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-benzamide;4-(3-Methyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;4-(4-Benzoyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;4-(4-Benzyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;4-(4-Phenylacetyl-piperazin-1-yl)-N-quinolin-3-yl-benzamide;4-(4-Phenyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;4-(4-Propyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;4-(Acetyl-cyclohexyl-amino)-N-quinolin-3-yl-benzamide;4-(Benzyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Benzyl-pentyl-amino)-N-quinolin-3-yl-benzamide;4-(Cycloheptyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Cyclohexanecarbonyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Cyclohexyl-ethyl-amino)-N-quinolin-3-yl-benzamide; 4-(Cyclohexylmethyl-amino)-3-methyl-N-quinolin-3-yl-benzamide;4-(Cyclohexyl-methyl-amino)-3-methyl-N-quinolin-3-yl-benzamide;4-(Cyclohexyl-methyl-amino)-N-methyl-N-quinolin-3-yl-benzamide;4-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide; 4-(Cyclohexylmethyl-methyl-amino)-3-methyl-N-quinolin-3-yl-benzamide; 4-(Cyclohexylmethyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Cyclohexylmethyl-phenethyl-amino)-N-quinolin-3-yl-benzamide;4-(Cyclohexyl-propyl-amino)-N-quinolin-3-yl-benzamide;4-(Cyclopentyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Dec-4-enyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Hept-4-enyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Heptyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Methyl-butyl-amino)-N-quinolin-3-yl-benzamide;4-(Methyl-hexyl-amino)-N-quinolin-3-yl-benzamide;4-(Methyl-non-6-enyl-amino)-N-quinolin-3-yl-benzamide;4-(Methyl-nonyl-amino)-N-quinolin-3-yl-benzamide;4-(Methyl-pentyl-amino)-N-quinolin-3-yl-benzamide;4-(Methyl-phenethyl-amino)-N-quinolin-3-yl-benzamide;4-(Methyl-propyl-amino)-N-quinolin-3-yl-benzamide;4-(Methyl-tetradecyl-amino)-N-quinolin-3-yl-benzamide;4-(Octyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Phenethyl-propyl-amino)-N-quinolin-3-yl-benzamide;4-[1,4′]Bipiperidinyl-1′-yl-N-quinolin-3-yl-benzamide;4-{(3,3-Dimethyl-butyl)-methyl-amino}-N-quinolin-3-yl-benzamide;4-{4-(1,1-Dimethyl-pentyl)-phenyl}-but-3-enoic acid quinolin-3-ylamide;4-{4-(1,1-Dimethyl-pentyl)-phenyl}-N-quinolin-3-yl-butyramide;4-{4-(1,1-Dimethyl-propyl)-phenyl}-but-3-enoic acid quinolin-3-ylamide;4-{4-(1,1-Dimethyl-propyl)-phenyl}-N-quinolin-3-yl-butyramide;4-{Methyl-(3-methyl-butyl)-amino}-N-quinolin-3-yl-benzamide;4-{Methyl-(3-phenyl-allyl)-amino}-N-quinolin-3-yl-benzamide;4-{Methyl-(3-phenyl-propyl)-amino}-N-quinolin-3-yl-benzamide;4-{Methyl-(tetrahydro-pyran4-yl)-amino}-N-quinolin-3-yl-benzamide;4-{Methyl-{3-(5-methyl-furan-2-yl)-butyl}-amino}-N-quinolin-3-yl-benzamide;4-Azepan-1-yl-N-quinolin-3-yl-benzamide;4-Azepan-1-yl-N-quinolin-3-yl-benzamide;4-Azocan-1-yl-N-quinolin-3-yl-benzamide;4-Azonan-1-yl-N-quinolin-3-yl-benzamide;4-Benzyl-3,4,5,6-tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylic acidquinolin-3-ylamide; 4-Butoxy-N-quinolin-3-yl-benzamide;4-Butyl-cyclohexanecarboxylic acid quinolin-3-ylamide;4-Butyl-cyclohexanecarboxylic acid quinolin-3-ylamide;4-Cycloheptylamino-N-quinolin-3-yl-benzamide;4-Cyclohexylamino-N-methyl-N-quinolin-3-yl-benzamide;4-Cyclohexylamino-N-quinolin-3-yl-benzamide;4-Cyclopentylamino-N-quinolin-3-yl-benzamide;4-Dibenzylamino-N-quinolin-3-yl-benzamide;4-Dibutylamino-N-quinolin-3-yl-benzamide;4-Dihexylamino-N-quinolin-3-yl-benzamide;4-Dipentylamino-N-quinolin-3-yl-benzamide;4-Dipropylamino-N-quinolin-3-yl-benzamide;4-Morpholin-4-yl-N-quinolin-3-yl-benzamide;4-Pentylamino-N-quinolin-3-yl-benzamide;4-Phenethylamino-N-quinolin-3-yl-benzamide;4-Piperazin-1-yl-N-quinolin-3-yl-benzamide;4-Piperidin-1-yl-N-quinolin-3-yl-benzamide;4-Propyl-3,4,5,6-tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylic acidquinolin-3-ylamide; 4-Pyrrolidin-1-yl-N-quinolin-3-yl-benzamide;4-tert-Butyl-cyclohexanecarboxylic acid quinolin-3-ylamide;4-tert-Butyl-cyclohexanecarboxylic acid quinolin-3-ylamide;5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carboxylic acidquinolin-3-ylamide; 5,6,7,8-Tetrahydro-naphthalene-2-carboxylic acidquinolin-3-ylamide; 5-Chloro-1H-indole-2-carboxylic acidquinolin-3-ylamide; 5-Pentyl-thiophene-2-carboxylic acidquinolin-3-ylamide;6-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-nicotinamide;6-(Benzyl-methyl-amino)-N-quinolin-3-yl-nicotinamide;6-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-nicotinamide;6-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-nicotinamide;6-(Heptyl-methyl-amino)-N-quinolin-3-yl-nicotinamide;6-(Methyl-pentyl-amino)-N-quinolin-3-yl-nicotinamide;6-(Methyl-phenethyl-amino)-N-quinolin-3-yl-nicotinamide;6-Azepan-1-yl-N-quinolin-3-yl-nicotinamide;6-Azocan-1-yl-N-quinolin-3-yl-nicotinamide;6-Cyclohexylamino-N-quinolin-3-yl-nicotinamide;6-Pentylamino-N-quinolin-3-yl-nicotinamide;cis-4-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-benzamide;cis-6-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-nicotinamide;N-Quinolin-3-yl-3-(3-trifluoromethyl-phenyl)-acrylamide;N-Quinolin-3-yl-3-(4-tricyclo{5.3.1.13,9}dodec-1-yl-phenyl)-propionamide;N-Quinolin-3-yl-3-(4-trifluoromethyl-phenyl)-acrylamide;N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propionamide;N-Quinolin-3-yl-3-(5,6,7,8-tetrahydro-naphthalen-2-yl)-propionamide;N-Quinolin-3-yl-4-(tetrahydro-pyran4-ylamino)-benzamide;N-Quinolin-3-yl-4-thiomorpholin-4-yl-benzamide;R-4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;S4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;trans-4-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-benzamide;trans-6-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-nicotinamide;4-tert-Butyl-N-(4-hydroxy-quinolin-3-yl)-benzamide;3-(4-tert-Butyl-phenyl)-N-(4-hydroxy-quinolin-3-yl)-acrylamide;N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-acrylamide;N-(4-Chloro-quinolin-3-yl)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-acrylamide;N-(4-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;N-(2-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;4-tert-Butyl-N-(2-methoxy-quinolin-3-yl)-benzamide;4-Azepan-1-yl-N-(4-chloro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(2-chloro-quinolin-3-yl)-benzamide;4-Azepan-1-yl-N-(2-chloro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(4-chloro-quinolin-3-yl)-benzamide;3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid(2-chloro-quinolin-3-yl)-amide;N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-2,3-dihydro-1H-indol-5-yl)-acrylamide;3-(1-Cyclohexyl-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;N-(4-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;1-Cyclohexyl-1H-indole-5-carboxylic acid (4-chloro-quinolin-3-yl)-amide;1-Cyclohexyl-1H-indole-5-carboxylic acid quinolin-3-ylamide;1-Cyclohexyl-1H-indole-5-carboxylic acid (2-chloro-quinolin-3-yl)-amide;N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;4-(Cyclohexyl-methyl-amino)-N-(8-fluoro-quinolin-3-yl)-benzamide;4-Azocan-1-yl-N-(8-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;4-(Cyclohexyl-methyl-amino)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;4-(Cyclohexyl-methyl-amino)-N-(6-fluoro-quinolin-3-yl)-benzamide;4-Azocan-1-yl-N-(6-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(6-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;4-Azocan-1-yl-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;4-(Cyclohexyl-methyl-amino)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;4-Azocan-1-yl-N-(5-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(5-fluoro-quinolin-3-yl)-benzamide;3-Phenyl-propynoic acid quinolin-3-ylamide;trans-2-Phenyl-cyclopropanecarboxylic acid quinolin-3-ylamide;3-(4-tert-Butyl-phenyl)-propynoic acid quinolin-3-ylamide; and2-(4-tert-Butyl-phenyl)-cyclopropanecarboxylic acid quinolin-3-ylamide.92. A compound selected from the group consisting of1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;1-Pentyl-1,2,3,4-tetrahydro-quinoline-6-carboxylic acidquinolin-3-ylamide; 1-Pentyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide; 1-Propyl-2,3-dihydro-1H-indole-5-carboxylic acidquinolin-3-ylamide; 3-(4-sec-Butyl-phenyl)-N-quinolin-3-yl-propionamide;3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-acrylamide;3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-propionamide;3,4,5,6-Tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylic acidquinolin-3-ylamide;3-{4-(1,1-Dimethyl-3-phenyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(1,1-Dimethyl-pentyl)-2,6-dimethoxy-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(1,1-Dimethyl-pentyl)-phenyl}-N-quinolin-3-yl;3-{4-(1,1-Dimethyl-propyl)-2,6-dimethoxy-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(1,1-Dimethyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(1-Cyclohexyl-1-methyl-ethyl)-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(1-Methyl-pentyl)-phenyl}-N-quinolin-3-yl-propionamide;3-{5-(1,1-Dimethyl-propyl)-thiophen-2-yl}-N-quinolin-3-yl-propionamide;4-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-benzamide;4-(4-Benzyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;4-(Cycloheptyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Cyclohexyl-ethyl-amino)-N-quinolin-3-yl-benzamide;4-(Cyclohexyl-methyl-amino)-3-methyl-N-quinolin-3-yl-benzamide;4-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Cyclohexylmethyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Cyclopentyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Dec-4-enyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Hept-4-enyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Heptyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Methyl-non-6-enyl-amino)-N-quinolin-3-yl-benzamide;4-(Methyl-nonyl-amino)-N-quinolin-3-yl-benzamide;4-(Methyl-phenethyl-amino)-N-quinolin-3-yl-benzamide;4-(Octyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-{(3,3-Dimethyl-butyl)-methyl-amino}-N-quinolin-3-yl-benzamide;4-{Methyl-{3-(5-methyl-furan-2-yl)-butyl}-amino}-N-quinolin-3-yl-benzamide;4-Azepan-1-yl-N-quinolin-3-yl-benzamide;4-Azepan-1-yl-N-quinolin-3-yl-benzamide;4-Azocan-1-yl-N-quinolin-3-yl-benzamide;4-Azonan-1-yl-N-quinolin-3-yl-benzamide;4-Benzyl-3,4,5,6-tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylic acidquinolin-3-ylamide;5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carboxylic acidquinolin-3-ylamide;6-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-nicotinamide;6-Azocan-1-yl-N-quinolin-3-yl-nicotinamide;cis-4-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-benzamide;cis-6-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-nicotinamide;N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propionamide;R-4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;S4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;trans-4-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-benzamide;trans-6-(Octahydro-isoquinolin-2-yl)-N-quinolin-3-yl-nicotinamide;4-tert-Butyl-N-(4-hydroxy-quinolin-3-yl)-benzamide;3-(4-tert-Butyl-phenyl)-N-(4-hydroxy-quinolin-3-yl)-acrylamide;N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-acrylamide;N-(4-Chloro-quinolin-3-yl)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-acrylamide;N-(4-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;N-(2-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;4-tert-Butyl-N-(2-methoxy-quinolin-3-yl)-benzamide;4-Azepan-1-yl-N-(4-chloro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(2-chloro-quinolin-3-yl)-benzamide;4-Azepan-1-yl-N-(2-chloro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(4-chloro-quinolin-3-yl)-benzamide;3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid(2-chloro-quinolin-3-yl)-amide;N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-2,3-dihydro-1H-indol-5-yl)-acrylamide;3-(1-Cyclohexyl-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;N-(4-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;1-Cyclohexyl-1H-indole-5-carboxylic acid (4-chloro-quinolin-3-yl)-amide;1-Cyclohexyl-1H-indole-5-carboxylic acid quinolin-3-ylamide;1-Cyclohexyl-1H-indole-5-carboxylic acid (2-chloro-quinolin-3-yl)-amide;N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;4-(Cyclohexyl-methyl-amino)-N-(8-fluoro-quinolin-3-yl)-benzamide;4-Azocan-1-yl-N-(8-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;4-(Cyclohexyl-methyl-amino)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;4-(Cyclohexyl-methyl-amino)-N-(6-fluoro-quinolin-3-yl)-benzamide;4-Azocan-1-yl-N-(6-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(6-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;4-Azocan-1-yl-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;4-(Cyclohexyl-methyl-amino)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;4-Azocan-1-yl-N-(5-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(5-fluoro-quinolin-3-yl)-benzamide;3-Phenyl-propynoic acid quinolin-3-ylamide;trans-2-Phenyl-cyclopropanecarboxylic acid quinolin-3-ylamide;3-(4-tert-Butyl-phenyl)-propynoic acid quinolin-3-ylamide; and2-(4-tert-Butyl-phenyl)-cyclopropanecarboxylic acid quinolin-3-ylamide.93. A compound selected from the group consisting of1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;1-Pentyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;1-Propyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;3-(4-sec-Butyl-phenyl)-N-quinolin-3-yl-propionamide;3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-acrylamide;3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-propionamide;3,4,5,6-Tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylic acidquinolin-3-ylamide;3-{4-(1,1-Dimethyl-3-phenyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(1,1-Dimethyl-pentyl)-2,6-dimethoxy-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(1,1-Dimethyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(1-Methyl-pentyl)-phenyl}-N-quinolin-3-yl-propionamide;3-{5-(1,1-Dimethyl-propyl)-thiophen-2-yl}-N-quinolin-3-yl-propionamide;4-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-benzamide;4-(4-Benzyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;4-(Cycloheptyl-methyl-amino)-N-quinolin-3-yl-benzamide;;4-(Cyclohexyl-ethyl-amino)-N-quinolin-3-yl-benzamide;4-(Cyclohexyl-methyl-amino)-3-methyl-N-quinolin-3-yl-benzamide;4-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Cyclohexylmethyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Cyclopentyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Dec4-enyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Heptyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Methyl-nonyl-amino)-N-quinolin-3-yl-benzamide;4-(Methyl-phenethyl-amino)-N-quinolin-3-yl-benzamide;4-(Octyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-{(3,3-Dimethyl-butyl)-methyl-amino}-N-quinolin-3-yl-benzamide;4-Azepan-1-yl-N-quinolin-3-yl-benzamide;4-Azepan-1-yl-N-quinolin-3-yl-benzamide;4-Azocan-1-yl-N-quinolin-3-yl-benzamide;4-Azonan-1-yl-N-quinolin-3-yl-benzamide;4-Benzyl-3,4,5,6-tetrahydro-2H-{1,2′}bipyridinyl-5′-carboxylic acidquinolin-3-ylamide;6-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-nicotinamide;N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propionamide;R⁴-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;S-4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;4-tert-Butyl-N-(4-hydroxy-quinolin-3-yl)-benzamide;3-(4-tert-Butyl-phenyl)-N-(4-hydroxy-quinolin-3-yl)-acrylamide;N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-acrylamide;N-(4-Chloro-quinolin-3-yl)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-acrylamide;N-(4-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;N-(2-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;4-tert-Butyl-N-(2-methoxy-quinolin-3-yl)-benzamide;4-Azepan-1-yl-N-(4-chloro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(2-chloro-quinolin-3-yl)-benzamide;4-Azepan-1-yl-N-(2-chloro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(4-chloro-quinolin-3-yl)-benzamide;3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid(2-chloro-quinolin-3-yl)-amide;N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-2,3-dihydro-1H-indol-5-yl)-acrylamide;3-(1-Cyclohexyl-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;N-(4-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;1-Cyclohexyl-1H-indole-5-carboxylic acid (4-chloro-quinolin-3-yl)-amide;1-Cyclohexyl-1H-indole-5-carboxylic acid quinolin-3-ylamide;1-Cyclohexyl-1H-indole-5-carboxylic acid (2-chloro-quinolin-3-yl)-amide;N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;4-(Cyclohexyl-methyl-amino)-N-(8-fluoro-quinolin-3-yl)-benzamide;4-Azocan-1-yl-N-(8-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;4-(Cyclohexyl-methyl-amino)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;4-(Cyclohexyl-methyl-amino)-N-(6-fluoro-quinolin-3-yl)-benzamide;4-Azocan-1-yl-N-(6-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(6-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;4-Azocan-1-yl-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;4-(Cyclohexyl-methyl-amino)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;4-Azocan-1-yl-N-(5-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(5-fluoro-quinolin-3-yl)-benzamide;3-Phenyl-propynoic acid quinolin-3-ylamide;trans-2-Phenyl-cyclopropanecarboxylic acid quinolin-3-ylamide;3-(4-tert-Butyl-phenyl)-propynoic acid quinolin-3-ylamide; and2-(4-tert-Butyl-phenyl)-cyclopropanecarboxylic acid quinolin-3-ylamide.94. A compound selected from the group consisting of1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;1-Propyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;3-(4-sec-Butyl-phenyl)-N-quinolin-3-yl-propionamide;3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-acrylamide;3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-propionamide;3-{4-(1,1-Dimethyl-3-phenyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(1,1-Dimethyl-pentyl)-2,6-dimethoxy-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(1,1-Dimethyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;3-{4-(1-Methyl-pentyl)-phenyl}-N-quinolin-3-yl-propionamide;3-{5-(1,1-Dimethyl-propyl)-thiophen-2-yl}-N-quinolin-3-yl-propionamide;4-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-benzamide;4-(4-Benzyl-piperidin-1-yl)-N-quinolin-3-yl-benzamide;4-(Cycloheptyl-methyl-amino)-N-quinolin-3-yl-benzamide;;4-(Cyclohexyl-ethyl-amino)-N-quinolin-3-yl-benzamide;4-(Cyclohexyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Cyclohexylmethyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-(Octyl-methyl-amino)-N-quinolin-3-yl-benzamide;4-Azepan-1-yl-N-quinolin-3-yl-benzamide;4-Azepan-1-yl-N-quinolin-3-yl-benzamide;4-Azocan-1-yl-N-quinolin-3-yl-benzamide;4-Azonan-1-yl-N-quinolin-3-yl-benzamide;6-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-nicotinamide;N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-propionamide;R-4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide;S4-{(3,7-Dimethyl-oct-6-enyl)-methyl-amino}-N-quinolin-3-yl-benzamide; 54-tert-Butyl-N-(4-hydroxy-quinolin-3-yl)-benzamide;3-(4-tert-Butyl-phenyl)-N-(4-hydroxy-quinolin-3-yl)-acrylamide;N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-acrylamide;N-(4-Chloro-quinolin-3-yl)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-acrylamide;N-(4-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;N-(2-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;4-tert-Butyl-N-(2-methoxy-quinolin-3-yl)-benzamide;4-Azepan-1-yl-N-(4-chloro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(2-chloro-quinolin-3-yl)-benzamide;4-Azepan-1-yl-N-(2-chloro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(4-chloro-quinolin-3-yl)-benzamide;3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid(2-chloro-quinolin-3-yl)-amide;N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-2,3-dihydro-1H-indol-5-yl)-acrylamide;3-(1-Cyclohexyl-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;N-(4-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;1-Cyclohexyl-1H-indole-5-carboxylic acid (4-chloro-quinolin-3-yl)-amide;1-Cyclohexyl-1H-indole-5-carboxylic acid quinolin-3-ylamide;1-Cyclohexyl-1H-indole-5-carboxylic acid (2-chloro-quinolin-3-yl)-amide;N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;4-(Cyclohexyl-methyl-amino)-N-(8-fluoro-quinolin-3-yl)-benzamide;4-Azocan-1-yl-N-(8-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;4-(Cyclohexyl-methyl-amino)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;4-(Cyclohexyl-methyl-amino)-N-(6-fluoro-quinolin-3-yl)-benzamide;4-Azocan-1-yl-N-(6-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(6-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;4-Azocan-1-yl-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;4-(Cyclohexyl-methyl-amino)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;4-Azocan-1-yl-N-(5-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(5-fluoro-quinolin-3-yl)-benzamide;3-Phenyl-propynoic acid quinolin-3-ylamide;trans-2-Phenyl-cyclopropanecarboxylic acid quinolin-3-ylamide;3-(4-tert-Butyl-phenyl)-propynoic acid quinolin-3-ylamide; and2-(4-tert-Butyl-phenyl)-cyclopropanecarboxylic acid quinolin-3-ylamide.95. A compound selected from the group consisting of1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid quinolin-3-ylamide;3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-acrylamide;3-(4-tert-Butyl-phenyl)-N-quinolin-3-yl-propionamide;3-{4-(1,1-Dimethyl-propyl)-phenyl}-N-quinolin-3-yl-propionamide;4-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-benzamide;4-Azepan-1-yl-N-quinolin-3-yl-benzamide;6-(3-Aza-bicyclo{3.3.1}non-3-yl)-N-quinolin-3-yl-nicotinamide;4-tert-Butyl-N-(4-hydroxy-quinolin-3-yl)-benzamide;3-(4-tert-Butyl-phenyl)-N-(4-hydroxy-quinolin-3-yl)-acrylamide;N-Quinolin-3-yl-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-acrylamide;N-(4-Chloro-quinolin-3-yl)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-acrylamide;N-(4-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;N-(2-Chloro-quinolin-3-yl)-4-(cyclohexyl-methyl-amino)-benzamide;4-tert-Butyl-N-(2-methoxy-quinolin-3-yl)-benzamide;4-Azepan-1-yl-N-(4-chloro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(2-chloro-quinolin-3-yl)-benzamide;4-Azepan-1-yl-N-(2-chloro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(4-chloro-quinolin-3-yl)-benzamide;3-(1-Cyclohexyl-2,3-dihydro-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;1-Cyclohexyl-2,3-dihydro-1H-indole-5-carboxylic acid(2-chloro-quinolin-3-yl)-amide;N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-2,3-dihydro-1H-indol-5-yl)-acrylamide;3-(1-Cyclohexyl-1H-indol-5-yl)-N-quinolin-3-yl-acrylamide;N-(4-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;1-Cyclohexyl-1H-indole-5-carboxylic acid (4-chloro-quinolin-3-yl)-amide;1-Cyclohexyl-1H-indole-5-carboxylic acid quinolin-3-ylamide;1-Cyclohexyl-1H-indole-5-carboxylic acid (2-chloro-quinolin-3-yl)-amide;N-(2-Chloro-quinolin-3-yl)-3-(1-cyclohexyl-1H-indol-5-yl)-acrylamide;4-(Cyclohexyl-methyl-amino)-N-(8-fluoro-quinolin-3-yl)-benzamide;4-Azocan-1-yl-N-(8-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;4-(Cyclohexyl-methyl-amino)-N-(8-trifluoromethyl-quinolin-3-yl)-benzamide;4-(Cyclohexyl-methyl-amino)-N-(6-fluoro-quinolin-3-yl)-benzamide;4-Azocan-1-yl-N-(6-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(6-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;4-Azocan-1-yl-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;4-(Cyclohexyl-methyl-amino)-N-(7-trifluoromethyl-quinolin-3-yl)-benzamide;4-Azocan-1-yl-N-(5-fluoro-quinolin-3-yl)-benzamide;4-(3-Aza-bicyclo[3.2.2]non-3-yl)-N-(5-fluoro-quinolin-3-yl)-benzamide;3-Phenyl-propynoic acid quinolin-3-ylamide;trans-2-Phenyl-cyclopropanecarboxylic acid quinolin-3-ylamide;3-(4-tert-Butyl-phenyl)-propynoic acid quinolin-3-ylamide; and2-(4-tert-Butyl-phenyl)-cyclopropanecarboxylic acid quinolin-3-ylamide.96. A pharmaceutical composition comprising a compound, salt or solvateaccording to claim 1 admixed with a pharmaceutically acceptable carrier,excipient or diluent.
 97. A veterinary composition comprising acompound, salt or solvate according to claim 1 admixed with aveterinarily acceptable carrier, excipient or dilluent.
 98. A method oftreating or preventing a disease or condition in a mammal which diseaseor condition is affected by the modulation of one or more vanilloidreceptors, which method comprises administering to a mammal in need ofsuch treatment or prevention a therapeutically effective amount of acompound, salt or solvate of claim
 1. 99. A method for preventing ortreating a chronic-pain causing disease or condition, an acute-paincausing disease or condition, or a pulmonary dysfunction comprising thestep of administering to a mammal in need of such treatment atherapeutically effective amount of a compound, salt or solvate ofclaim
 1. 100. A method for preventing or treating a disease orcondition, wherein said disease or condition causes inflammatory pain,burning pain, itch urinary incontinence, or chronic obstructivepulmonary disease, said method comprising the step of administering to amammal in need of such treatment a therapeutically effective amount of acompound, salt or solvate of claim
 1. 101. A method for preventing ortreating a disease or condition selected from the group consisting ofosteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache,toothache, burn, sunburn, snake bite (in particular, venomous snakebite), spider bite, insect sting, neurogenic bladder, benign prostatichypertrophy, interstitial cystitis, urinary tract infection, coughasthma, pharyngitis, mucositis, pancreatitis, enteritis, cellulites,peripheral neuropathy, bilateral peripheral neuropathy, diabeticneuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia,sciatic neuritis, mandibular joint neuralgia, peripheral neuritis,polyneuritis, stump pain, phantom limb pain, bony fractures,post-operative ileus, Irritable Bowel Syndrome, Crohn's Disease,ulcerative colitis, cholecystitis, pancreatitis, postmastectomy painsyndrome, oral neuropathic pain, Charcot's pain, reflex sympatheticdystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouthsyndrome, optic neuritis, postfebrile neuritis, migrating neuritis,segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachialneuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngialneuralgia, migrainous neuralgia, idiopathic neuralgia, intercostalsneuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia,occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatineneuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache,tension headache, labor, childbirth, intestinal gas, menstrual cramps,cancer, and trauma, said method comprising the step of administering toa mammal in need of such treatment a therapeutically effective amount ofa compound, salt or solvate of claim
 1. 102. The method of claim 101wherein the disease or condition is ulcerative colitis.
 103. The methodof claim 101 wherein said therapeutically effective amount comprises adose range of from about 0.001 mg to about 1,000 mg.
 104. The method ofclaim 101 wherein said therapeutically effective amount comprises a doserange of from about 0.1 mg to about 500 mg.
 105. The method of claim 101wherein said therapeutically effective amount comprises a dose range offrom about 1 mg to about 250 mg.
 106. A kit comprising in one or morecontainers an amount of the composition of claim 1 effective to treat orprevent a disease or condition selected from the group consisting ofosteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache,toothache, burn, sunburn, snake bite (in particular, venomous snakebite), spider bite, insect sting, neurogenic bladder, benign prostatichypertrophy, interstitial cystitis, urinary tract infection, coughasthma, pharyngitis, mucositis, pancreatitis, enteritis, cellulites,peripheral neuropathy, bilateral peripheral neuropathy, diabeticneuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia,sciatic neuritis, mandibular joint neuralgia, peripheral neuritis,polyneuritis, stump pain, phantom limb pain, bony fractures,post-operative ileus, Irritable Bowel Syndrome, Crohn's Disease,ulcerative colitis, cholecystitis, pancreatitis, postmastectomy painsyndrome, oral neuropathic pain, Charcot's pain, reflex sympatheticdystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouthsyndrome, optic neuritis, postfebrile neuritis, migrating neuritis,segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachialneuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngialneuralgia, migrainous neuralgia, idiopathic neuralgia, intercostalsneuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia,occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatineneuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache,tension headache, labor, childbirth, intestinal gas, menstrual cramps,cancer, and trauma.
 107. A pharmaceutical composition comprising acompound, salt or solvate according to claim 17 admixed with apharmaceutically acceptable carrier, excipient or diluent.
 108. Aveterinary composition comprising a compound, salt or solvate accordingto claim 17 admixed with a veterinarily acceptable carrier, excipient ordilluent.
 109. A method for preventing or treating a disease orcondition selected from the group consisting of osteoarthritis,rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn,sunburn, snake bite (in particular, venomous snake bite), spider bite,insect sting, neurogenic bladder, benign prostatic hypertrophy,interstitial cystitis, urinary tract infection, cough asthma,pharyngitis, mucositis, pancreatitis, enteritis, cellulites, peripheralneuropathy, bilateral peripheral neuropathy, diabetic neuropathy,postherpetic neuralgia, trigeminal neuralgia, causalgia, sciaticneuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis,stump pain, phantom limb pain, bony fractures, post-operative ileus,Irritable Bowel Syndrome, Crohn's Disease, ulcerative colitis,cholecystitis, pancreatitis, postmastectomy pain syndrome, oralneuropathic pain, Charcot's pain, reflex sympathetic dystrophy,Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome,optic neuritis, postfebrile neuritis, migrating neuritis, segmentalneuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia,cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia,migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia,mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipitalneuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia,supraorbital neuralgia, vidian neuralgia, sinus headache, tensionheadache, labor, childbirth, intestinal gas, menstrual cramps, cancer,and trauma, said method comprising the step of administering to a mammalin need of such treatment a therapeutically effective amount of acompound, salt or solvate of claim
 17. 110. The method of claim 109wherein the disease or condition is ulcerative colitis.
 111. The methodof claim 109 wherein said therapeutically effective amount comprises adose range of from about 0.001 mg to about 1,000 mg.
 112. The method ofclaim 109 wherein said therapeutically effective amount comprises a doserange of from about 0.1 mg to about 500 mg.
 113. The method of claim 109wherein said therapeutically effective amount comprises a dose range offrom about 1 mg to about 250 mg.
 114. A kit comprising in one or morecontainers an amount of the composition of claim 17 effective to treator prevent a disease or condition selected from the group consisting ofosteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache,toothache, burn, sunburn, snake bite (in particular, venomous snakebite), spider bite, insect sting, neurogenic bladder, benign prostatichypertrophy, interstitial cystitis, urinary tract infection, coughasthma, pharyngitis, mucositis, pancreatitis, enteritis, cellulites,peripheral neuropathy, bilateral peripheral neuropathy, diabeticneuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia,sciatic neuritis, mandibular joint neuralgia, peripheral neuritis,polyneuritis, stump pain, phantom limb pain, bony fractures,post-operative ileus, Irritable Bowel Syndrome, Crohn's Disease,ulcerative colitis, cholecystitis, pancreatitis, postmastectomy painsyndrome, oral neuropathic pain, Charcot's pain, reflex sympatheticdystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouthsyndrome, optic neuritis, postfebrile neuritis, migrating neuritis,segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachialneuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngialneuralgia, migrainous neuralgia, idiopathic neuralgia, intercostalsneuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia,occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatineneuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache,tension headache, labor, childbirth, intestinal gas, menstrual cramps,cancer, and trauma.
 115. A pharmaceutical composition comprising acompound, salt or solvate according to claim 31 admixed with apharmaceutically acceptable carrier, excipient or diluent.
 116. Aveterinary composition comprising a compound, salt or solvate accordingto claim 31 admixed with a veterinarily acceptable carrier, excipient ordilluent.
 117. A method for preventing or treating a disease orcondition selected from the group consisting of osteoarthritis,rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn,sunburn, snake bite (in particular, venomous snake bite), spider bite,insect sting, neurogenic bladder, benign prostatic hypertrophy,interstitial cystitis, urinary tract infection, cough asthma,pharyngitis, mucositis, pancreatitis, enteritis, cellulites, peripheralneuropathy, bilateral peripheral neuropathy, diabetic neuropathy,postherpetic neuralgia, trigeminal neuralgia, causalgia, sciaticneuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis,stump pain, phantom limb pain, bony fractures, post-operative ileus,Irritable Bowel Syndrome, Crohn's Disease, ulcerative colitis,cholecystitis, pancreatitis, postmastectomy pain syndrome, oralneuropathic pain, Charcot's pain, reflex sympathetic dystrophy,Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome,optic neuritis, postfebrile neuritis, migrating neuritis, segmentalneuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia,cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia,migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia,mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipitalneuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia,supraorbital neuralgia, vidian neuralgia, sinus headache, tensionheadache, labor, childbirth, intestinal gas, menstrual cramps, cancer,and trauma, said method comprising the step of administering to a mammalin need of such treatment a therapeutically effective amount of acompound, salt or solvate of claim
 31. 118. The method of claim 117wherein the disease or condition is ulcerative colitis.
 119. The methodof claim 117 wherein said therapeutically effective amount comprises adose range of from about 0.001 mg to about 1,000 mg.
 120. The method ofclaim 117 wherein said therapeutically effective amount comprises a doserange of from about 0.1 mg to about 500 mg.
 121. The method of claim 117wherein said therapeutically effective amount comprises a dose range offrom about 1 mg to about 250 mg.
 122. A kit comprising in one or morecontainers an amount of the composition of claim 31 effective to treator prevent a disease or condition selected from the group consisting ofosteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache,toothache, burn, sunburn, snake bite (in particular, venomous snakebite), spider bite, insect sting, neurogenic bladder, benign prostatichypertrophy, interstitial cystitis, urinary tract infection, coughasthma, pharyngitis, mucositis, pancreatitis, enteritis, cellulites,peripheral neuropathy, bilateral peripheral neuropathy, diabeticneuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia,sciatic neuritis, mandibular joint neuralgia, peripheral neuritis,polyneuritis, stump pain, phantom limb pain, bony fractures,post-operative ileus, Irritable Bowel Syndrome, Crohn's Disease,ulcerative colitis, cholecystitis, pancreatitis, postmastectomy painsyndrome, oral neuropathic pain, Charcot's pain, reflex sympatheticdystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouthsyndrome, optic neuritis, postfebrile neuritis, migrating neuritis,segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachialneuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngialneuralgia, migrainous neuralgia, idiopathic neuralgia, intercostalsneuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia,occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatineneuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache,tension headache, labor, childbirth, intestinal gas, menstrual cramps,cancer, and trauma.
 123. A pharmaceutical composition comprising acompound, salt or solvate according to claim 61 admixed with apharmaceutically acceptable carrier, excipient or diluent.
 124. Aveterinary composition comprising a compound, salt or solvate accordingto claim 61 admixed with a veterinarily acceptable carrier, excipient ordilluent.
 125. A method for preventing or treating a disease orcondition selected from the group consisting of osteoarthritis,rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn,sunburn, snake bite (in particular, venomous snake bite), spider bite,insect sting, neurogenic bladder, benign prostatic hypertrophy,interstitial cystitis, urinary tract infection, cough asthma,pharyngitis, mucositis, pancreatitis, enteritis, cellulites, peripheralneuropathy, bilateral peripheral neuropathy, diabetic neuropathy,postherpetic neuralgia, trigeminal neuralgia, causalgia, sciaticneuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis,stump pain, phantom limb pain, bony fractures, post-operative ileus,Irritable Bowel Syndrome, Crohn's Disease, ulcerative colitis,cholecystitis, pancreatitis, postmastectomy pain syndrome, oralneuropathic pain, Charcot's pain, reflex sympathetic dystrophy,Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome,optic neuritis, postfebrile neuritis, migrating neuritis, segmentalneuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia,cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia,migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia,mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipitalneuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia,supraorbital neuralgia, vidian neuralgia, sinus headache, tensionheadache, labor, childbirth, intestinal gas, menstrual cramps, cancer,and trauma, said method comprising the step of administering to a mammalin need of such treatment a therapeutically effective amount of acompound, salt or solvate of claim
 61. 126. The method of claim 125wherein the disease or condition is ulcerative colitis.
 127. The methodof claim 125 wherein said therapeutically effective amount comprises adose range of from about 0.001 mg to about 1,000 mg.
 128. The method ofclaim 125 wherein said therapeutically effective amount comprises a doserange of from about 0.1 mg to about 500 mg.
 129. The method of claim 125wherein said therapeutically effective amount comprises a dose range offrom about 1 mg to about 250 mg.
 130. A kit comprising in one or morecontainers an amount of the composition of claim 61 effective to treator prevent a disease or condition selected from the group consisting ofosteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache,toothache, burn, sunburn, snake bite (in particular, venomous snakebite), spider bite, insect sting, neurogenic bladder, benign prostatichypertrophy, interstitial cystitis, urinary tract infection, coughasthma, pharyngitis, mucositis, pancreatitis, enteritis, cellulites,peripheral neuropathy, bilateral peripheral neuropathy, diabeticneuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia,sciatic neuritis, mandibular joint neuralgia, peripheral neuritis,polyneuritis, stump pain, phantom limb pain, bony fractures,post-operative ileus, Irritable Bowel Syndrome, Crohn's Disease,ulcerative colitis, cholecystitis, pancreatitis, postmastectomy painsyndrome, oral neuropathic pain, Charcot's pain, reflex sympatheticdystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouthsyndrome, optic neuritis, postfebrile neuritis, migrating neuritis,segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachialneuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngialneuralgia, migrainous neuralgia, idiopathic neuralgia, intercostalsneuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia,occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatineneuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache,tension headache, labor, childbirth, intestinal gas, menstrual cramps,cancer, and trauma.
 131. A pharmaceutical composition comprising acompound, salt or solvate according to claim 78 admixed with apharmaceutically acceptable carrier, excipient or diluent.
 132. Aveterinary composition comprising a compound, salt or solvate accordingto claim 78 admixed with a veterinarily acceptable carrier, excipient ordilluent.
 133. A method for preventing or treating a disease orcondition selected from the group consisting of osteoarthritis,rheumatoid arthritis, fibromyalgia, migraine, headache, toothache, burn,sunburn, snake bite (in particular, venomous snake bite), spider bite,insect sting, neurogenic bladder, benign prostatic hypertrophy,interstitial cystitis, urinary tract infection, cough asthma,pharyngitis, mucositis, pancreatitis, enteritis, cellulites, peripheralneuropathy, bilateral peripheral neuropathy, diabetic neuropathy,postherpetic neuralgia, trigeminal neuralgia, causalgia, sciaticneuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis,stump pain, phantom limb pain, bony fractures, post-operative ileus,Irritable Bowel Syndrome, Crohn's Disease, ulcerative colitis,cholecystitis, pancreatitis, postmastectomy pain syndrome, oralneuropathic pain, Charcot's pain, reflex sympathetic dystrophy,Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome,optic neuritis, postfebrile neuritis, migrating neuritis, segmentalneuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia,cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia,migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia,mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipitalneuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia,supraorbital neuralgia, vidian neuralgia, sinus headache, tensionheadache, labor, childbirth, intestinal gas, menstrual cramps, cancer,and trauma, said method comprising the step of administering to a mammalin need of such treatment a therapeutically effective amount of acompound, salt or solvate of claim
 78. 134. The method of claim 133wherein the disease or condition is ulcerative colitis.
 135. The methodof claim 133 wherein said therapeutically effective amount comprises adose range of from about 0.001 mg to about 1,000 mg.
 136. The method ofclaim 133 wherein said therapeutically effective amount comprises a doserange of from about 0.1 mg to about 500 mg.
 137. The method of claim 133wherein said therapeutically effective amount comprises a dose range offrom about 1 mg to about 250 mg.
 138. A kit comprising in one or morecontainers an amount of the composition of claim 133 effective to treator prevent a disease or condition selected from the group consisting ofosteoarthritis, rheumatoid arthritis, fibromyalgia, migraine, headache,toothache, burn, sunburn, snake bite (in particular, venomous snakebite), spider bite, insect sting, neurogenic bladder, benign prostatichypertrophy, interstitial cystitis, urinary tract infection, coughasthma, pharyngitis, mucositis, pancreatitis, enteritis, cellulites,peripheral neuropathy, bilateral peripheral neuropathy, diabeticneuropathy, postherpetic neuralgia, trigeminal neuralgia, causalgia,sciatic neuritis, mandibular joint neuralgia, peripheral neuritis,polyneuritis, stump pain, phantom limb pain, bony fractures,post-operative ileus, Irritable Bowel Syndrome, Crohn's Disease,ulcerative colitis, cholecystitis, pancreatitis, postmastectomy painsyndrome, oral neuropathic pain, Charcot's pain, reflex sympatheticdystrophy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouthsyndrome, optic neuritis, postfebrile neuritis, migrating neuritis,segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachialneuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngialneuralgia, migrainous neuralgia, idiopathic neuralgia, intercostalsneuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia,occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatineneuralgia, supraorbital neuralgia, vidian neuralgia, sinus headache,tension headache, labor, childbirth, intestinal gas, menstrual cramps,cancer, and trauma.